{"title": "PDF", "author": "PDF", "url": "https://www.db-thueringen.de/servlets/MCRFileNodeServlet/dbt_derivate_00051341/dissdoerfer.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "id": "PDF", "license": "PDF", "body": "PDF", "comments": "PDF", "commentsbody": "PDF", "raw_text": "PDF", "text": " \n \nUntersuchung\nen zu Struktur-Aktivit\u00e4tsbeziehungen  \nund zum Wirkmechanismus der Melleolid-Antibiotika \n \n \n \nDissertation \nzur Erlangung des akademischen Grades  \n\u201edoctor rerum naturalium\u201c (Dr. rer. nat.) \n \n \n \n \nvorgelegt dem Rat der Fakult\u00e4t f\u00fcr Biowissenschaften  \nder Friedrich-Schiller-Universit\u00e4t Jena \n \n \n \n \n \nvon Dipl.-Pharm. Maximilian D\u00f6rfer, \n \n \ngeboren am 15.09.1989  \nin Gera   \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nTag der Einreichung:  12.12.2019  \nGutachter:   Prof. Dr. Dirk Hoffmeister  \n    Friedrich -Schiller -Universit\u00e4t, Jena  \n    Prof. Dr. Oliver Werz  \n    Friedrich -Schiller -Universit\u00e4t, Jena  \n   Prof. Dr. Gabriele M. K\u00f6nig \n    Rheinische Friedrich -Wilhelms-Universit\u00e4t, Bonn  \n \nTag der Disputation:  15.07.2020   \n \n \n \n \n \n \nF\u00dcR M\nEINE FAMILIE \n   1. Einleitung   I \nInhalts\nverzeichnis \nINHALTSVERZEICHNIS ........................................................................................................................................ I  \n1. EINLEITUNG .................................................................................................................................................. 2  \n1.1. DIE GATTUNG A RMILLARIA  ................................................................................................................................ . 2 \n1.2. CHEMISCHE VIELFALT UND METABOLISCHE DIVERSIT\u00c4T VON NATURSTOFFEN  ................................................................  4 \n1.3. NATURSTOFFE AUS PILZEN  .................................................................................................................................. 6  \n1.3.1. Naturstoffe aus Aminos\u00e4ure-abgeleiteten Bausteinen ........................................................................ 6  \n1.3.2. Polyketide ............................................................................................................................................. 6  \n1.3.3. Terpene ................................................................................................................................................. 8  \n1.3.4. Hybride Naturstoffe ............................................................................................................................  11 \n1.4. MELLEOLID -ANTIBIOTIKA - NATURSTOFFE AUS ARMILLARIA MELLEA  ......................................................................... 11 \n1.5. KLASSIFIZIERUNG BEKANNTER ANTIBIOTIKA  .......................................................................................................... 14 \n1.5.1. Einteilung der Zytostatika ................................................................................................................... 14 \n1.5.2. Einteilung der Antimykotika ............................................................................................................... 15 \n1.6. FORSCHUNGSBEDARF  ....................................................................................................................................... 16 \n2. ZIELSETZUNG DER ARBEIT ...........................................................................................................................  17 \n3. PUBLIKATIONEN ......................................................................................................................................... 18 \n3.1. PUBLIKATION 1 \u2013 MELLEOLIDES IMPACT FUNGAL TRANSLATION VIA ELONGATION FACTOR 2 .......................................... 18 \n3.2. PUBLIKATION 2  \u2013 MELLEOLIDES FROM HONEY MUSHROOM INHIBIT  5-LIPOXYGENASE VIA CYS 159 ...............................  50 \n3.3. PUBLIKATION 3  \u2013 DIVERSITY AND BIOACTIVITY OF ARMILLARIA  SESQUITERPENE ARYL ESTER NATURAL PRODUCT  ................. 73 \n4. UNVER\u00d6FFENTLICHTE ERGEBNISSE ............................................................................................................. 85 \n4.1. RAPID CELL DEATH INDUCTION BY THE HONEY MUSHROOM MYCOTOXIN DEHYDROARMILLYL -ORSELLINATE THROUGH COVALENT \nREACTION WITH MEMBRANE PHOSPHATIDYLETHANOLAMINES  ......................................................................................... 85 \n5. DISKUSSION .............................................................................................................................................. 120 \n5.1. VOM NATURSTOFF ZUM ARZNEIMITTEL AM BEISPIEL DES MELLEOLIDS DAO  ............................................................  120 \n5.1.1. Die Entdeckung des molekularen Wirkziels ...................................................................................... 120 \n5.1.2. Synthese einer Sonde f\u00fcr eine affinit\u00e4tsgesteuerte Proteinaufreinigung ......................................... 121 \n5.2. MELLEOLIDE IM VERGLEICH ZU ANDEREN ANTIBIOTIKA  .........................................................................................  123 \n5.2.1. Melleolide im Vergleich zu anderen Zytostatika ............................................................................... 123 \n5.2.2. Melleolide im Vergleich zu anderen Antimykotika ........................................................................... 126 \n5.3. ZUK\u00dcNFTIGE ANWENDUNGEN VON MELLEOLIDEN  ...............................................................................................  129 \n6. AUSBLICK .................................................................................................................................................. 132 \n7. ZUSAMMENFASSUNG ...............................................................................................................................  133 \n8. SUMMARY ................................................................................................................................................ 134 \n9. LITERATURVERZEICHNIS ...........................................................................................................................  135 \n10. ANHANG ................................................................................................................................................. 146 \n10.1.EIGENST\u00c4NDIGKEITSERKL\u00c4RUNG ......................................................................................................... 146 \n10.2. ABK\u00dcRZUNGSVERZEICHNIS ................................................................................................................. 147 \n10.3. VER\u00d6FFENTLICHUNGEN ....................................................................................................................... 148 \n10.3.1. Publikationen .................................................................................................................................. 148 \n10.3.2. Poster .............................................................................................................................................. 148 \n10.4. WISSENSCHAFTLICHER WERDEGANG .................................................................................................. 149 \n10.5. DANKSAGUNG ..................................................................................................................................... 150 \n 1. Einleitung   2 \n1. Einleitung\n \n1.1. Die Gattung Armillaria  \nDie Basidiomycet en (St\u00e4nderpilze) sind mit ca. 30000 Arten die gr\u00f6\u00dfte Klasse der Pilze. Ihr \nHauptmerkmal ist ein Sporenst\u00e4nder (Basidiophor), welcher die Basidiosporen beherbergt. Die \nBasidiomyceten-Gattung Armillaria, zu der auch der honiggelbe Hallimasch ( Armillaria mellea ) \ngeh\u00f6rt , z\u00e4hlt weltweit ca. 40 Art en in fast allen Klimazonen, vom Regenwald bis hin zum \nborealen Nadelwald (Baumgartner et al., 2011; Hood, 1991; Shaw und Kile, 1991). \n \nAbbildung 1. A Fru chtk\u00f6rper von A. mellea . (Dirk Hoffmeister Big Woods State Park, Nerstrand, \nMinnesota)  B Rhizomorphe von A. mellea. (Schmitt und Tatum, 2008)  C von A. mellea  infiziertes \nWaldareal. (Schmitt und Tatum, 2008)  \nBereits im sp\u00e4ten 19. Jahr hundert war A. mellea  als Pflanzenpathogen bekannt (Smith, 1894). \nHeute sind Vertreter der Gattung Armillaria  nicht nur als \u00f6kologisch wertvolle Saprophyten , \nsondern auch parasitische Besiedler von \u00fcber 500 verschiedenen Nadel- und Obstgeh\u00f6lzen \nbekannt (Raabe, 1962; Williams und Wargo, 1989). Der Hallimasch  z\u00e4hlt in unseren Breiten \nneben dem Borkenk\u00e4fer zu den prominentesten Forstsch\u00e4dlingen (Petercord et al., 2009) .  \nDoch was macht die Gattung Armillaria  so erfolgreich in seiner Ausbreitung?   \nZun\u00e4chst erm\u00f6glichen Rhizomorphen (siehe Abbildung 1 B), eine mit pflanzlichen Wurzeln \nvergleichbare morphologische Differenzierungsform des Myzels, die Erschlie\u00dfung neuer \nLebens r\u00e4ume (Lamour et al., 2007). Die 1 - 3 mm dicken Gebilde sind in der \u00e4u\u00dferen Schicht \nstark melanisiert und somit gut vor \u00e4u\u00dferen Einfl\u00fcssen wie oxidativen Effekten oder UV-\nStrahlung gesch\u00fctzt (Ribera et al., 2019). Die Rhizomorphen eigen sich somit bestens f\u00fcr den \nTransport von Wasser oder N\u00e4hrstoffen \u00fcber weite Strecken (Boddy et al., 2009), dienen aber \nauch als \u00dcberdauerungsorgan und zur Erschlie\u00dfung neuer Lebensr\u00e4ume.  \nDas gr\u00f6\u00dfte Lebewesen der Welt, ein Vertreter der Armillaria ostoyae , besiedelt im US-\nBundesstaat Oregon aktuell eine Fl\u00e4che von ca. 9,6 km\u00b2 \u00fcber ein dicht verzweigtes Netzwerk \n1. Einleitung   3 \naus Rhi\nzomorphen und Mycel (Schmitt und Tatum, 2008). Mit einem Alter von 1900 bis zu \n8650 Jahren ist es eines der \u00e4ltesten Lebewesen auf unserem Planeten (Ferguson et al., \n2003) . Ein weiterer, ca. 2500 Jahre alter Vertreter, Armillaria gallica,  besiedelt in Michigan eine \nFl\u00e4che von 3,7 km\u00b2. Das Genom beider Organismen ist trotz des hohen Alters sehr robust und \nunterlag nur wenigen Ver\u00e4nderungen (Anderson et al., 2018). Armillaria  scheint in seiner \ngenetischen Entwicklung gegen\u00fcber \u00e4u\u00dferen Einfl\u00fcssen also sehr resistent zu sein. \nSein \u00dcberleben sichert der Hallimasch aber auch durch seine hohe morphologische \nVariabilit\u00e4t, welche er sowohl in freier Natur als auch in Kultur innehat:  \nBasidiomyceten sind in ihrer vegetativen Phase normalerweise dikaryotisch. Einige Armillarien  \nk\u00f6nnen hier jedoch diploid sein. Die meiotischen Basidiosporen der Fruchtk\u00f6rper keimen zu \nhaploidem, monokaryotischem Myzel aus (Korhonen und Hintikka, 1974). Kompatible Partner \nk\u00f6nnen sich kreuzen und kurzzeitig dikaryotische Zellen bilden. Deren Kerne verschmelzen \nnach kurzer Zeit zu diploidem Sekund\u00e4rmyzel, welches monokaryotisch ist (Korhonen, 1978). \nUnter Laborbedingungen l\u00e4sst sich diploides und haploides Myzel z\u00fcchten. Auf festem \nMedium bilden die stark pigmentierten, haploiden St\u00e4mme Rhizomorphen, diploide St\u00e4mme \nsind meist frei von Pigmenten, somit schneewei\u00df (Hintikka, 1973) und bilden deutlich weniger \nRhizomorphen aus. \nNeben den morphologischen und reproduktiven Besonderheiten, besitzen Armillarien ein \nbreites Arsenal an bioaktiven Sekund\u00e4rstoffen . Zu besonderer Bedeutung gelangten neben \nden ebenfalls bioaktiven Emestrinen und Cephalosporoliden (Herath et al., 2013) vor allem die \nMelleolide. Es wird vermutet, dass der Pilz diese hochdiverse Stoffgruppe zur Kommunikation \nmit anderen Organismen bzw. als Selektionsvorteil zur chemischen Abwehr verwendet , (Peipp \nund Sonnenbichler, 1992). Die genauen Wirkmechanismen sind jedoch noch unbekannt, \ngenauso, wie der Umgang mit reaktiven Sauerstoff-Spezies (ROS). D ie ROS k\u00f6nnten vom Pilz \nsekretiert werden, um aromatische Polymere wie Lignin in H\u00f6lzern zu zersetzen, oder aber \ngegen Nahrungskonkurrenten eingesetzt werden (Collins et al., 2017). \nVersuche, Sch\u00e4den durch Armillarien  in Nutzw\u00e4ldern und Obstplantagen mit Hilfe nat\u00fcrlicher \nAntagonisten zu begrenzen, scheiterten bisher. Mit Trichoderma  spec. wie T. asperellum , \nT. gamsii  oder T. harzianum  hoffte man , eine biologische Kontrolle gegen die durch Armillarien  \nverursachte Stumpf- und Wurzelf\u00e4ule gefunden zu haben, da diese zu den Ascomyceten \nz\u00e4hlenden, filament\u00f6sen Pilze eine Resistenz gegen Armillarien  zeigen (Schnabel et al., 2011; \nTarus et al., 2003). Der Sch\u00e4dling ist dennoch h\u00e4ufig so potent, dass es seiner Abschw\u00e4chung \nbedarf, bevor der biologische Antagonist wirksam werden kann (Ohr und Munnecke, 1974; \nOhr et al., 1973). 1. Einleitung   4 \nVermut\nlich um sich selbst vor ROS zu sch\u00fctzen, sind viele Armillarien  zur Biolumineszen z \nbef\u00e4higt (Mogil\u2019naya et al., 2015) . Hierbei wird zun\u00e4chst ein Luciferin-Precursor durch \nNAD(P)H-abh\u00e4ngige Enzyme in Luciferin \u00fcberf\u00fchrt und dieses katalytisch durch eine \nLuciferase unter Verwendung von Sauerstoff oxidiert (Purtov et al., 201 5). Dabei wird gr\u00fcnes \nLicht (520 \u2013 530 nm) emittiert. Die Luciferin-Synthese ist in den Fruchtk\u00f6rpern blockiert. Sie \nproduzieren keine ROS, vor denen sie sich sch\u00fctzen m\u00fcssten, k\u00f6nnen somit auch kein Holz \nzersetzen (Purtov et al., 2017). Die eukaryotische Biolumineszenz in Pilzen auf genetischer \nEbene wurde erst vor kurzem eingehend untersucht und beschrieben (Kotlobay et al., 2018). \nDie Fruchtk\u00f6rper (siehe Abbildung 1 A) sind nicht nur unf\u00e4hig zur Lumineszenz, sie \nproduzieren auch (fast) keine Melleolide. Das macht den Hallimasch zu einem potenziellen \nSpeisepilz f\u00fcr all jene, die nach dem Genuss gr\u00fcndlich gekochter, junger Fruchtk\u00f6rper keine \nUnvertr\u00e4glichkeitsreaktionen zeigen. In der traditionellen chinesischen Medizin (TCM) werden \nvor allem A. mellea  verschiedenste Heilwirkungen u. a. gegen L\u00e4hmung, Schwindel, \nBluthochdruck, Kopfschmerzen und Schlaflosigkeit zugeschrieben. Zusammen mit dem \nparasitischen Wirt Gastrodia elata  ist A. mellea in der TCM auch als \u201eTianma\u201c mit \nvergleichbaren Wirkungen bekannt (Chen et al., 2016). Wissenschaftlich erforscht werden \nzurzeit die antitumoralen Wirkungen der beiden Tianma-Bestandteile (Chang et al., 2016; \nChen et al., 2016; Heo et al., 2007). \n1.2. Chemische Vielfalt und metabolische Diversit\u00e4t von Naturstoffen \nDie Natur hat eine Vielzahl komplexer Verbindungen hervorgebracht, welche noch heute nur \nmit unverh\u00e4ltnism\u00e4\u00dfigem Aufwand in Vollsynthesen nachzubilden sind. Dies betrifft vor allem \nsogenannte Sekund\u00e4rmetaboliten, welche im Gegensatz zu Prim\u00e4rmetaboliten wie \nKohlenhydraten, Lipiden und Aminos\u00e4uren nicht lebensnotwendig sind, aber h\u00e4ufig zu einem \nSelektionsvorteil f\u00fcr Organismen einer Gruppe oder sogar Art f\u00fchren.  \nDer Mensch hat gelernt, sich die Wirkungen einiger Sekund\u00e4rstoffe, wie Erythromycin , \nVinblastin oder Paclitaxel (Abbildung 2 ) pharmazeutisch zu erschlie\u00dfen und diese medizinisch \nals Wirkstoff zu nutzen. \n \nAbbildung 2. Ausgew\u00e4hlte Naturstoffe aus Bakterien und Pflanzen \n1. Einleitung   5 \nDas 1949\n entdeckte Makrolidantibiotikum Erythromycin wurde erstmals 1981 in einer 50-\nstufigen Vollsynthese hergestellt. Zeit- und Kostenaufwand der Synthese rechtfertigten keine \ngro\u00dftechnischen Gewinnung (Woodward et al., 1981). Noch heute wird das biosynthetisch auf \neinem Polyketid basierende Antibiotikum biotechnologisch durch den Actinomyceten \nSaccharopolyspora erythraea  (ehemals Streptomyces erythreus ) in gro\u00dfen Fermentern \nproduziert (Hamedi et al., 2005; Martin und Bushell, 1996) .  \nDas Chemotherapeutik um Vinblastin (Abbildung 2) wurde urspr\u00fcnglich im Madagaskar-\nImmergr\u00fcn ( Catharanthus roseus)  entdeckt. Biosynthetisch entsteht das terpenoide Alkaloid \ndurch die Dimerisierung der Vorl\u00e4ufermolek\u00fcle Tabersonin und Catharanthin (Caputi et al., \n2018) , welche ihren Ursprung in Stemmadeninacetat, bestehend aus Tryptamin (Shikimat-\nWeg) und Secologanin (Terpen) haben (Zhu et al., 2015). Bisher wird Vinblastin ausschlie\u00dflich \naus der Pflanze isoliert (Heijden et al., 2004). Der Verbrauch von 15 t der Pflanze zur Isolation \nvon 28,35 g (Meyers, 2007) , spiegelt sich auch im Preis von ca. 2 Mio $ pro kg (Alam und \nSharaf-Eldin, 2016). Die erste, 17-stufige Totalsynthese ist auch hier ein wichtiger Schritt f\u00fcr \ndie zuk\u00fcnftige Bedarfssicherung des antitumoralen Wirkstoffes (Kuehne et al., 1991), welcher \ndie Mikrotubuli-Polymerisierung durch kovalentes Binden an Tubulin hemmt (Wilson et al., \n1975) . \nDas 1971 entdeckte Zytostatikum Paclitaxel (Taxol) (Abbildung 2) aus der pazifischen Eibe \n(Taxus brevifolia ) hemmt ebenfalls die Mikrotubuli-Polymerisierung und so die Zellteilung \n(Schiff et al., 1979; Wani et al., 1971). Gewann man zun\u00e4chst aus 1 kg Rinde nur 138 mg \nPaclitaxel, wurde mit der halbsynthetischen Herstellung aus der nat\u00fcrlichen Vorstufe \nBaccatin III eine Produktion von 1 g Taxol aus 1 kg Nadeln m\u00f6glich (Denis et al., 1988) . Mit \nden Totalsynthesen, welche Mitte der 1990er Jahre erarbeitet wurden, konnte der Bedarf \nebenfalls nicht gedeckt werden, da diese zu komplex und unwirtschaftlich sind (Bartsch, 2004; \nHolton et al., 1994; Nicolaou und Guy, 1994). Bis heute ist die 2002 zugelassene \u201ePlant Cell \nFermentation\u201c (PCF) die ausschlie\u00dfliche Methode zur Deckung des Weltbedarfs . Hier werden \nPflanzenzellen in Suspension \u00fcber 8 Monate kultiviert (Bartsch, 2004). Final lassen sich laut \nHersteller (Phyton Biotech, Ahrensburg, Deutschland) bis zu 1000 kg pro 200.000 L Charge \nherstellen ( \u2259 5 g/L). \nDie Beispiele belegen, wie gut der Mensch Naturstoffe erforscht hat und sich diese zu Nutze \nmacht. Im Laufe der Zeit entdeckte man, dass die Biosynthese von Naturstoffen gegen\u00fcber \neiner Totalsynthese wirtschaftlich sinnvoll ist, da sie Zeit und Geld spart. Doch wie genau \nentsteht diese Diversit\u00e4t und warum sind viele Naturstoffe so schwer durch den Menschen \nreproduzierbar? Diese Fragen sollen im folgenden Abschnitt am Beispiel pilzlicher Naturstoffe \ngekl\u00e4rt werden. 1. Einleitung   6 \n1.3. N\naturstoffe aus Pilzen \nW\u00e4hrend der Gro\u00dfteil der Pflanzen (ca. 80%) mittlerweile als bekannt gilt, wurden nur ca. 5% \nder gesch\u00e4tzt 1,5 Mio Pilz-Arten identifiziert (Hawksworth, 2001). Das Reich der Pilze \nverspricht also einen reichen Fundus an neuen Sekund\u00e4rstoffen. Vor allem pilzliche \nSekund\u00e4rstoffe sind hier von gro\u00dfer Bedeutung f\u00fcr die Pharmazie. Die Sekund\u00e4rstoffe lassen \nsich in Abh\u00e4ngigkeit von ihrem Biosyntheseweg grob in drei Gruppen einteilen: Aminos\u00e4ure-\nabgeleitete Stoffe, Polyketide und Terpene. Auf die Synthese der Polyketide und Terpene wird \naufgrund ihrer Bedeutung f\u00fcr diese Arbeit nachfolgend detaillierter eingegangen. \n1.3.1. Naturstoffe aus Aminos\u00e4ure-abgeleiteten Bausteinen \nZun\u00e4chst soll nicht unerw\u00e4hnt bleiben, dass Bakterien und Pilze bei der Synthese von \nkleineren Peptiden aus Aminos\u00e4uren eine Besonderheit aufweisen. Sie besitzen \nnichtribosomale Peptidsynthetasen (NRPS). Bei NRPS handelt es sich um gro\u00dfe \nEnzymkomplexe aus verschiedenen Dom\u00e4nen. Sie dienen als Matrize und legen somit die \nAminos\u00e4uresequenz, sowie Modifizierungen am fertigen Peptid fest. Im Vergleich zu \nribosomalen Proteinen mit Kettenl\u00e4ngen von teilweise mehr als 10.000 Aminos\u00e4uren ist die \nL\u00e4nge der NRPS-Produkte im Schnitt auf 2-15 Aminos\u00e4urereste begrenzt (Mootz und \nMarahiel, 1999). NRPSen produzieren Peptide unabh\u00e4ngig von den Ribosomen. Als Substrat \nf\u00fcr NRPSen, sowie NRPS-\u00e4hnliche Enzyme dienen Aminos\u00e4uren . Im Gegensatz zur R NA-\nabh\u00e4ngigen, ribosomalen Peptidsynthese, k\u00f6nnen NRPS und NRPS-artige neben den 20 \nproteinogenen L- Aminos\u00e4uren weitere Substrate wie D- Amino- , \u03b1-Keto-, \u03b1-Hydroxy- oder \nandere nicht proteinogene Aminos\u00e4uren miteinander verkn\u00fcpfen und sogar Fetts\u00e4uren als \nStartereinheiten nutzen (Marahiel, 2016; Marahiel et al., 1997). Dies f\u00fchrt zu einzigartigen \npharmazeutischen Leitstrukturen wie den Penicillinen oder Ciclosporinen und zeigt die \ndiversit\u00e4tsorientierte Strategie der Naturstoffbildung auf. \n1.3.2. Polyketide  \nDie Polyketide sind eine Gruppe oft stark mit Sauerstoff angereicherter Substanzen. Ihre \nBildung erfolgt \u00e4hnlich der Fetts\u00e4uresynthasen an gro\u00dfen Enzymkomplexen, den Polyketid-\nsynthasen (PKS). Man unterscheidet hierbei zwischen nicht-reduzierenden PKS (NR- PKS) , \nden stark (highly)-reduzieren den (HR)- PKS und den teilweise (partially)-reduzierenden (PR)-\nPKS. Der Aufbau der Polyketide erfolgt aus thioesteraktivierten Carbons\u00e4urebausteinen wie \nAcetyl-CoA oder Mal onyl-CoA. Durch die schrittweise Verbindung von Acyl-CoA-Bausteinen \ndurch eine KS-Dom\u00e4nen-vermittelte Claisen-Kondensation (C-C-Bindung ) wird das Produkt \nverl\u00e4ngert (Staunton und Weissman, 2001) .  \nEine minimal-PKS besteht aus den drei Dom\u00e4nen Ketoacylsynthase- (KS), Acyltransferase- \n(AT) und einer Acyl Carrier Protein-Dom\u00e4ne (ACP). Je nach Modul k\u00f6nnen reduzierende 1. Einleitung   7 \nDom\u00e4nen w\nie Dehydratasen (DH), Enoyl-Reduktasen (ER) oder Ketoreduktasen (KR) \nvorhanden sein (Abbildung 3). Bei NR-PKS fehlen diese reduzierenden Dom\u00e4nen. \n Abbildung 3 Vereinfachte Darstellung eines PKS-\nModuls. D\nas Modul enth\u00e4lt eine Ketosynthase (KS), \neine Acyltransferase (AT), ein Acyl Carrier Protein \n(ACP), an welchem ein Phosphopantetheinylat-Rest \n(Ppant) gebunden ist, sowie optional eine \nDehydratase (DH), eine Enoylreduktase (ER) und \neine Ketoreduktase (KR).  \nDie modifizierenden Dom\u00e4nen (DH, ER, KR) reduzieren \u03b2-Ketoeinh eiten zu \u03b2 -Hydroxy-\neinheiten (KR), dehydrieren diese zu konjugierten Alkenen (DH) und k\u00f6nnen diese final \nabs\u00e4ttigen (ER). Durch diese partiell reduktiven Ver\u00e4nderungen entsteht im Vergleich zur \nFetts\u00e4uresynthese eine hohe Diversit\u00e4t an PKS-Produkten (Hertweck, 2009). Bei der \nSynthese von Fetts\u00e4uren erfolgt immer eine komplette Reduktion bei jedem \nVerl\u00e4ngerungsschritt. Bei PKS erfolgt diese nur graduell und in jedem Schritt unterschiedlich \nstark. Die Abspaltung der fertigen Produkte erfolgt meist \u00fcber eine Thioesterasedom\u00e4ne (TE). \nDie L\u00e4nge der PKS-Produkte wird bei pilzlichen NR-PKS durch die Produkttemplate (PT)-\nDom\u00e4ne bestimmt, welche \u00fcber ihre Hot-Dog-Struktur nicht nur die Anzahl der \nKondensationszyklen bestimmt, sondern auch die Art der Zyklisierungsreaktion des finalen \naromatischen Systems (Crawford et al., 2009) .   \nPilzliche PKS-Synthasen sind meistens vom Typ I und arbeiten iterativ, d. h. eine KS-Dom\u00e4ne \nkatalysiert mehr als einen Elongationszyklus. Die modifizierenden Dom\u00e4nen k\u00f6nnen in jeder \nRunde, in welcher d as Produkt verl\u00e4ngert wird, am \u03b2 -Keto-Kohlenstoff eingreifen und die \nMolek\u00fcldiversit\u00e4t beeinflussen (Hertweck, 2009). Es gibt aber auch nicht-iterative Typ I-\nSynthasen, welche vor allem in Bakterien vorkommen. Diese synthetisieren beispielsweise \nMakrolid-Antibiotika wie Erythromycin (Abbildung 2). Typ II PKS findet man ausschlie\u00dflich in \nBakterien. Hier wird ausschlie\u00dflich Malonyl-CoA zur Kettenverl\u00e4ngerung durch einen Satz \niterativ arbeitender Enzymuntereinheiten benutzt (Hertweck et al., 2007). Typ III-Synthasen, \nhaupts\u00e4chlich in Pflanzen und teilweise in Bakterien und selten in Pilzen vorkommend, \nverwenden Acyl-CoA unabh\u00e4ngig von einer ACP-Dom\u00e4ne (Hertweck, 2009). Heute wei\u00df man, \ndass PKS je nach genetischer Ausstattung ebenfalls in der Lage sind, verschiedenste \nCarboxyl-Startereinheiten wie Fetts\u00e4uren oder Aryls\u00e4uren zu verarbeiten und somit die \nDiversit\u00e4t dieser Stoffklasse zu erh\u00f6hen (Ray und Moore, 2016).  \nEine der aufgrund des pharmazeutischen Interesses am besten erforschten pilzlichen PKS ist \ndie nicht-reduzierende Lovastatin-Nonaketidsynthase (LNKS, LovA). Lovastatin (Abbildung 4) , \nist ein Hemmstoff der 3-Hydroxy-3-methylglutaryl-CoA (HMG-CoA)-Reduktase. Es wurde u m \n1. Einleitung   8 \n1970 i\nn Aspergillus terreus  entdeckt (Alberts et al., 1980) und 1987 zur Behandlung von \nHypercholesterin\u00e4mie zugelassen. Der weltweite Jahresbedarf von ca. 300 Tonnen (Sch\u00e4fer, \n2010)  wird heute immer noch fermentativ erzeugt (P\u00e9rez-S\u00e1nchez et al., 2017) . \nStereoselektive Totalsynthese n sind wegen aufw\u00e4ndiger Aufreinigungen und der Verwendung \nungew\u00f6hnlicher Edukte ineffektiv (Clive et al., 1990; Heathcock et al., 1987; Hirama und \nIwashita, 1983). Biosynthetisch handelt es sich bei Lovastatin um das ver esterte Produkt \nzweier Polyketide, der LNKS (C18), LovA und einer Lovastatin-Diketid-(C4)-synthase (LDKS, \nLovB).  \nDer Nutzen der Statin-Produktion f\u00fcr den Pilz selbst ist bis heute nicht vollst\u00e4ndig aufgekl\u00e4rt. \nVermutlich bieten Statine einen Vorteil gegen\u00fcber  Konkurrenten (Cabral et al., 2010) .  \n \nAbbildung 4 Strukturen von Polyketiden. Der HMG- CoA-Inhibitor Lovastatin (auch Mevinolin oder \nMonacolin-K) und das Tetraketid Orsellins\u00e4ure  \nEin weit verbreitetes PKS-Produkt ist Orsellins\u00e4ure (Abbildung 4). Das Tetraketid kom mt in \nvielen Pilzen wie Aspergillus - oder Penicillium- Arten vor (Cox, 2007), findet sich aber auch in \nFlechten (Parrot et al., 2015). Aufgrund seiner Einfachheit gilt Orsellins\u00e4ure als ein evolution\u00e4r \nsehr fr\u00fch entstandenes Tet raketid, dessen Funktion in vielen Organismen noch v\u00f6llig \nunbekannt ist (Schroeckh et al., 2009) .   \nIn Armillaria spp.  ist Orsellins\u00e4ure ein wichtiger Bestandteil s\u00e4mtlicher Melleolid-Antibiotika, \nauf welche in dieser Arbeit noch detaillierter eingegangen werden soll. Die Orsellins\u00e4ure wird \nhier von einer PKS auf verschiedene Sesquiterpenalkohole \u00fcbertragen (Lackner et al., 2013). \n1.3.3. Terpene \nDie Terpene bieten mit \u00fcber 80.000 bekannten Verbindungen die gr\u00f6\u00dfte Diversit\u00e4t der hier \ngenannten Naturstoffklassen (Christianson, 2017). Die meisten Terpene sind pflanzlicher \nHerkunft, da sie als Duft-, Signal- oder Abwehrstoffe bisher gr\u00fcndlich erforscht wurden \n(Balandrin et al., 1985; Gershenzon und Dudareva, 2007). Als ein prominentes Beispiel eines \nnichtfl\u00fcchtigen Terpens sei hier das Zytostatikum Paclitaxel (Abbildung 2 ) genannt.  \nWie in Abbildung 5 gezeigt, werden Terpene aus den C5-Bausteinen Isopentenylpyrophosphat \n(IPP) und Dimethylallylpyro phosphate (DMAPP) aufgebaut, welche wiederum bei allen \n1. Einleitung   9 \npilzli\nchen Vertretern aus Acetyl-CoA \u00fcber den Mevalonat-Biosyntheseweg erzeugt werden \n(Xiao und Zhong, 2016) . Durch eine 1\u2018 -4-Kopf-zu-Schwanz-Kondensation werden ein bis drei \nIPP-Verl\u00e4ngerungseinheiten durch eine all-trans -Isoprenylpyrophosphat-Synthase (IPPS) , \neine Terpen-Synthase, an DMAPP gebunden. So entstehen diphosphorylierte Isoprene \nunterschiedlicher L\u00e4nge. Produkte sind Monoterpene aus Geranyldiphosphat (GPP, C 10), \nSesquiterpene aus Farnesyldiphosphat (FPP, C 15) oder Diterpene aus Geranylgeranyl-\ndiphosphat (GGPP, C 20). L\u00e4ngere Ketten werden durch 1\u2018 -1-Kopf- an-Kopf Kondensation \nzweier FPPs \u00fcber eine Squalen-Synthase zu Triterpenen (C 30) oder zweier GPPs \u00fcber eine \nPhyto en-Synthase zu Tetraterpenen (C 40) katalysiert (Schmidt-Dannert, 2015). \nDie linearen Substrate werden durch unterschiedliche Enzyme umgewandelt. \nPrenyltransferasen \u00fcbertragen beispielsweise eine Prenylkette auf bevorzugt aromatische \nStrukturen, Terpenzyklasen zyklisieren die Ketten zu einer Vielzahl neuer Molek\u00fcle \n(Christianson, 2017). Monooxygenasen, vor allem Cytochrom P450-Enzyme f\u00fchren \nHydroxylgruppen ins Molek\u00fcl ein. \n \nAbbildung 5 . Biosynth ese des Terpen-Grundger\u00fcstes . Ausgehend von Isopentenyldiphosphat (IPP) \nund Dimethylallyldiphosphat (DMAPP) wird das Produkt immer um eine weitere IPP-Einheit verl\u00e4ngert. \nDurch enzymatische Modifikationen entstehen z. B. das Sesquiterpen 6-Protoilluden oder das Diterpen \nSordaricin, welches das Aglycon von Sordarin darstellt.  \nMonoterpene sind in Pilzen nur \u00e4u\u00dferst selten zu finden, Sesquiterpene, Diterpene und \nTriterpe\nne hingegen sehr h\u00e4ufig. Beispielhaft sollen hier nur die antifungalen Trichothecene \naus Trichothecium roseum , phytomodulatorische Gibberelline aus Gibberella fujikuroi  und das \nin Pilzen weit verbreitete Ergosterol, ein wichtiger Angriffspunkt f\u00fcr Antimykotika, als Vertreter \ngenannt werden (Hanson, 2008). \nAuf das Sesquiterpen 6-Protoilluden und das Diterpen Sordaricin soll hier etwas genauer \neingegangen werden, da diese Molek\u00fcle in abgewandelter Form im Fokus dieser Arbeit \nstehen :  \n1. Einleitung   10 \nSordaricin i\nst das Aglycon des Antibiotikums Sordarin. Dieses Diterpen wird unter anderem \nvon dem auf Tierdung wachsenden (coprophilen) Pilz Sordaria araneosa  gebildet . GGP P wird \nhierf\u00fcr durch eine Terpenzyklase zu einem 5-8-5 Trizyklus umgebaut. Nach zahlreichen \nModifikationen durch CYP P450 Monooxygenasen wird das Molek\u00fcl am Octazyklus oxygeniert \nund der Ring in einem noch unbekannten Mechanismus ge\u00f6ffnet und neu geschlossen. So \nergibt sich das komplexe in Abbildung 5 gezeigte \u00fcberbr\u00fcckte Ringsystem. Durch eine \nGlycosyltransferase wird Desoxyaltrose aus GDP-6-deoxy- D-altrose auf das Terpenger\u00fcst \n\u00fcbertragen und bildet das Sordarin (Kudo et al., 2016).   \nSordarin wurde 1969 unter dem Namen SL 2266 von der Schweizer Firma Sandoz patentiert \n(Odds, 2001) und die antifungale Wirkung erstmals 1971 beschrieben (Hauser und Sigg, \n1971) . Schnell gab es einen Wettbewerb der Pharmafirmen Merck und Glaxo Wellcome um \ndie Etablierung eines neuen, nebenwirkungsarmen, antifungalen Medikaments am Pharma-\nMarkt (Vicente et al., 2003) . Eigentlich auf der Suche nach einem selektiven Inhibitor gegen \nden Translations-Elongationsfaktor 3 (EF3) (Odds, 2001), welcher nur in Pilzen vorkommt \n(Sturtevant, 2002) , zeigte sich Sordarin als ein sehr spezifischer Inhibitor des eukaryotischen \nElongationsfaktors 2 (eEF2) (Dom\u00ednguez und Mart\u00edn, 1998; Justice et al., 1998). Sordarin \ninhibiert dessen GTPase Aktivit\u00e4t, wodurch die Translokation blockiert wird (Dom \u0131\u0301nguez et al., \n1999) .   \nBisher ist Sordarin immer noch nicht als Medikament auf dem Markt. Sordarin und seine \nDerivate zeigten im Tiermodell gute Wirkungen und Vertr\u00e4glichkeit, jedoch eine zu geringe \nPlasma-Halbwertszeit (Odds, 2001). Derivate der Substanz werden deshalb weiterhin \nerforscht, um weitere Antimykotika mit diesem Wirkprinzip zu finden (Herreros et al., 1998 ; \nLiang, 2008; S\u00f8e et al., 2007; Vicente et al., 2003). In dieser Arbeit dient Sordarin als gut \nerforschte Referenzsubstanz zur Untersuchung der ribosomalen Translationshemmung, \nspeziell bedingt durch die Inhibierung des eEF2. \nF\u00fcr diese Arbeit ebenfalls von Relevanz ist das Sesquiterpen 6-Protoilluden, dessen \nges\u00e4ttigtes Derivat auch als Protoilludan bezeichnet wird. Das Molek\u00fcl wird \u00fcber eine \nProtoilluden-Synthase aus FPP zyklisiert. Protoilluden stellt i. d. R. nur ein Zwischenprodukt \ndar, aus welchem enzymatisch Sekund\u00e4rmetabolite wie Illudine, Formannosine oder \nMarasmane abgeleitet werden (Abraham, 2001; Schmidt-Dannert, 2015).   \nProtoilluden-Alkohole wie Illudol wurden zuerst in Fomitopsis insularis  entdeckt (Hanson, \n2008) . Ebenso wie Illudine (Illudin M & S) oder Marasmane (Marasmans\u00e4ure) haben sie \nantibakterielle Eigenschaften, um den Produzenten vor Bakterien zu sch\u00fctzen (Arnone et al., \n1989) . Die Totalsynthesen dieser recht kleinen Protoilluden-Molek\u00fcle zeig en, wie effektiv \nnat\u00fcrliche Enzyme neue, komplexe Verbindungen schaffen, wof\u00fcr Menschen aufw\u00e4ndige \nSynthesen entwickeln m\u00fcssen (Hovey et al., 2017; Oppolzer und Nakao, 1986) . Deshalb lohnt \nsich der Aufwand, die Biosynthese und Struktur-Aktivit\u00e4tsbeziehungen (SAR) zu ergr\u00fcnden. 1. Einleitung   11 \nPr\notoilludenalkohole sind ein Hauptbestandteil der Melleolid-Antibiotika. \u00c4nderungen am \nProtoilludan-Grundger\u00fcst durch Armillaria -eigene Enzyme, bieten eine Vielzahl an \nM\u00f6glichkeiten, das Molek\u00fcl durch Hydroxylgruppen oder Doppelbindungen zu modifizieren. \n1.3.4. Hybride Naturstoffe \nWie eingangs angedeutet gibt es in der Natur nicht nur eindeutig klassifizierbare \nSekund\u00e4rstoffe, welche ausschlie\u00dflich aus Produkten der vorangestellten drei \nNaturstoffgruppen bestehen. Durch eine Kombination der verschiedenen Substanzklassen \nkommt es zur Bildung von \u201eHybriden\u201c.  Naturstoffe, welche aus Bausteinen derselben \nbiosynthetischen Herkunft zusammengesetzt sind, wie z. B. Lovastatin aus zwei \nunterschiedlichen Polyketiden, werden hier nicht als Hybride bezeichnet.  \nHybride Naturstoffe k\u00f6nnen durch eine Kondensation von Produkten z. B. aus einer PKS und \neiner NRPS , wie bei den Echinocandinen aus A. nidulans  bestehen. Diese Stoffe bilden die \nneueste Gruppe derzeit bekannter Antimykotika. Sie hemmen durch die Blockade der \u03b2-(1,3)-\nD-Glucan-Synthase den pilzlichen Zellwandaufbau (Sucher et al., 2009). Bei der \nEchinocandin-Biosynthese wird die von einer PKS erzeugte Myristins\u00e4ure als Startermolek\u00fcl \nauf die T-Dom\u00e4ne einer NRPS mit 6 Modulen geladen (Cacho et al., 2012). Durch schrittweise \nVerl\u00e4ngerung einer sich bildenden Peptidkette entsteht final ein Hexapeptid mit einer stark \nreduzierten Polyketid-Seitenkette (H\u00fcttel et al., 2016). Durch die Verwendung verschiedener \nlangkettiger S\u00e4uren als Starter, sowie den Einbau unterschiedlicher Aminos\u00e4uren ergibt sich \nauch unter den Echinocandinen eine hohe Diversit\u00e4t (H\u00fcttel, 2017).  \nDoch keine der bisher genannten Sekund\u00e4rstoffgruppen bietet eine \u00e4hnlich hohe Diversit\u00e4t \nwie die Melleolide \u2013 PKS/Terpen Hybride aus Armillaria spp ., die im nachfolgenden Kapitel \ngenauer beleuchtet werden sollen. \n1.4. Melleolid-Antibiotika - Naturstoffe aus Armillaria mellea \nDie Einzelbausteine Protoilluden (Sesquiterpen) und Orsellins\u00e4ure (Polyketid) sind weit \nverbreitete Metaboliten verschiedener Organismen. Die Kombination der Bausteine in \nVertretern der Gattung Armillaria  gilt bisher als einzigartig (Misiek und Hoffmeister, 2012). \nHeute sind mehr als 70 verschiedene Metabolite bekannt. Dies spricht f\u00fcr eine diversit\u00e4ts-\norientierte Biosynthese. Die PKS ArmB bildet hierbei das Polyketid Orsellins\u00e4ure (Lackner et \nal., 2012). Des Weiteren ist ArmB in der Lage, die Veresterung der Orsellins\u00e4ure mit einem \nProtoilludenalkolhol zu katalysieren. ArmB funktioniert daher nicht nur als Polyketid-Synthase \nsondern auch als intermolekulare Transferase (Lackner et al., 2013). Eine \u00e4hnliche Reaktion \nwurde bisher auch f\u00fcr die Orsellins\u00e4uresynthase OrsA aus A. nidulans  beobachtet. Das Enzym \nbildet hier neben Orsellins\u00e4ure auch Lecanors\u00e4ure, welches ein transesterifiziertes \nOrsellins\u00e4uredimer darstellt (Gressler et al., 2015).  1. Einleitung   12 \n \nAbbildung 6 . Variation sm\u00f6glichkeiten am Melleolid-Grundger\u00fcst. Ver\u00e4nderungen wie die Lage \neiner m\u00f6glichen Doppelbindung, potenzielle Hydroxylierungsstellen am Protoilludan oder eine \nMethylierungsstelle, sowie eine Position zur Halogenierung an der Orsellins\u00e4ure, sind links in Rot \ndargestellt. Rechts sind zwei f\u00fcr diese Arbeit wichtige Vertreter, n\u00e4mlich Dehydroarmillylorsellinat (DAO) \nund Arnamial dargestellt. \nDie Protoilludenalkohole werden durch eine Protoilludensynthase gebildet (Engels et al., \n2011) . Ar\nmB verestert die Orsellins\u00e4ure mit dem Alkohol eines Protoilludenderivates. Hier \nentsteht die hohe Diversit\u00e4t: Die Charakterisierung der Substrat-Derivate f\u00fcr ArmB scheint f\u00fcr \ndie Veresterung keine wesentliche Rolle zu spielen. Protoilludene mit unterschiedlichsten \nSubstitutionsmustern werden mit dem Polyketid verestert. Sechs verschiedene Kohlenstoffe \n(C1, C3, C4, C10, C13, C15) k\u00f6nnen hierbei in allen m\u00f6glichen Kombinationen hydroxyliert \nsein. Ebenso ergeben sich je nach Substitutionsmuster bis zu sechs Stereozentren. Am \nKohlenstoff C1 kann anstelle eines Alkohols auch ein Aldehyd vorliegen. Des Weiteren \nunterscheidet sich der Terpenk\u00f6rper regioselektiv anhand der Lage und dem Vorhandensein \neiner Doppelbindung: Diese kann entweder komplett fehlen oder zwischen den Kohlenstoffen \nC2 und C 4 (\u03942,4) bzw. zwischen C2 und C3 (\u03942,3) liegen.  \n1. Einleitung   13 \n \nAbbildung 7. Melleolid N und Armellid A , Esterbi ndung der Orsellins\u00e4ure an C1 des Protoilludans  \nDie PKS ArmB verbindet die beiden Bausteine bevorzugt, aber nicht v\u00f6llig selektiv \u00fcber die  \nHydroxygruppe am C5 des Protoilludans , denn es wurden auch Veresterungen \u00fcber den \nAlkohol an C1 z. B. bei Armellid A (Arnone et al., 1988) oder Melleolid N gefunden (Chen et \nal., 2011). Nach der Verbindung der beiden Bausteine ist eine Halogenierung am Kohlenstoff \nC6\u00b4 der Orsellins\u00e4ure m\u00f6glich. Hier wurden bisher neben Chlorierungen  auch eine artifizielle \nBromierung in vitro  beobachtet (Wick et al., 2016). Au\u00dferdem wird vermutet, dass die C5\u00b4-\nHydroxylgruppe nachtr\u00e4glich von einer Methyltransferase methyliert wird.  \nDie kombinatorische Ausstattung einer gro\u00dfen Anzahl von Molek\u00fclen mit verschiedenen \nstrukturellen Merkmalen entlang eines einzelnen Stoffwechselweges gilt als hoch effizient und \nunterst\u00fctzt die sogenannte \u201eScreening -Hypothese\u201c (Bohnert et al., 2014a). Diese Hypothese \nbesagt, dass eine h\u00f6here Wahrscheinlichkeit f\u00fcr Bioaktivit\u00e4t dann erreicht wird, wenn eine \nSpezies m\u00f6glichst viele struktur\u00e4hnliche Produkte bildet (Firn und Jones, 2003). So wird die \nWahrscheinlichkeit erh\u00f6ht, ein zellul\u00e4res Ziel bei Konkurrenten zu treffen, um sich selbst einen \nVorteil zu schaffen (Firn und Jones, 2009).  \nDie Diversit\u00e4t der Melleolide ist f\u00fcr den Pharmazeuten hierbei Segen und Fluch zugleich. \nProblematisch bei der F\u00fclle an sich stark \u00e4hnelnden Metaboliten ist die Isolierung und \nAufreinigung einzelner Substanzen. Sehr vorteilhaft ist jedoch, dass sich die SAR der \nMelleolide allein anhand isolierter Derivate aufkl\u00e4ren lassen. Synthetische Derivatisierungen \nsind aufgrund der vielen bereits bekannten und isolierten Melleolide nicht notwendig. \nBisher wurden verschiedene SAR beobachtet: Melleolide mit einem Aldehyd am C1 und einer \n\u03942,4-Doppelbindung haben eine antifungale Wirkung. Die antifungale Wirkung geht verloren, \nwenn sich die Doppelbindung in \u03942,3-Position befindet oder g\u00e4nzlich fehlt (Bohnert et al., \n2014a) . Vorarbeiten zeigten f\u00fcr die antifungale Wirkung der Melleolide keine urs\u00e4chliche \nErkl\u00e4rung. Es wurde aber herausgefunden, dass Melleolide die Transkription von A. nidulans  \nbeeinflussen.  \nDer Hauptteil dieser Arbeit besch\u00e4ftigte sich mit der Identifikation des zellul\u00e4ren Wirkziels am \n1. Einleitung   14 \nModell\norganismus A. nidulans . Speziell wurden hier \u03942,4-unges\u00e4ttigte Melleolid-Derivate wie \nDehydroarmillylorsellinat (DAO) und Arnamial untersucht (Abbildung 6). \nIn weiteren Untersuchungen zeigten sich viele Melleolide als zytotoxisch gegen humane \nKrebszelllinien (Chang et al., 2016; Chen et al., 2015; Li et al., 2016; Misiek et al., 2009) . \nInteressanterweise ist die Lage der Doppelbindung f\u00fcr die zytotoxische Wirkung kaum \nrelevant. Entscheidend ist vielmehr die Anzahl an Hydroxylierungen (Bohnert et al., 2011; \nBohnert et al., 2014b).  \nIn Vorarbeiten zeigte sich, dass der Zelltod humaner Zellen durch Melleolide besonders \nschnell herbeigef\u00fchrt wird. Im Gegensatz zu g\u00e4ngigen Vergleichssubstanzen f\u00fcr \nZellviabilit\u00e4tsassays wie Staurosporin oder Pretubulysin, deren Wirkung nach mehreren \nStunden einsetzt, zeigten einige Melleolide schon nach 15 Minuten erste zytotoxische Effekte \nmit apoptotischen und nekrotischen Merkmalen (Bohnert et al., 2014b) . Beobachtet wurde \nauch eine starke Abnahme der ribosomalen Translation, welche ebenfalls nicht den Grund f\u00fcr \neinen so raschen Zelltod darstellen kann (Bohnert et al., 2011).   \nDa die Doppelbindungsposition f\u00fcr die zytotoxische Wirkung nicht entscheidend ist, wird bisher \nvon zwei verschiedenen Wirkmechanismen ausgegangen. Ein Teil dieser Arbeit besch\u00e4ftigt \nsich deshalb mit dem Wirkmechanismus der Melleolid-Antibiotika an menschlichen Zellen. \n1.5. Klassifizierung bekannter Antibiotika \nAntibiotika sind dem Ursprung des Wortes nach (von griechich \u1f00\u03bd\u03c4\u03af- anti- \u201egegen\u201c und \u03b2\u03af\u03bf\u03c2 \nbios- \u201eLeben\u201c) Stoffe, welche das Wachstum anderer Organismen behindern, oder diese \nabt\u00f6ten. Im heutigen Sprachgebrauch meint man mit Antibiotika aber vor allem \nniedermolekulare Stoffe, urspr\u00fcnglich meist aus Bakterien oder Pilzen, welche ihre Wirkung \ngegen andere Mikroorganismen, vor allem Bakterien aus\u00fcben (Mutschler, 2013). Wirkstoffe, \nwelche sich gezielt gegen menschliche Zellen, im pharmazeutischen Sinne vor allem gegen \nschnell proliferierendes Gewebe wie Krebszellen richten, bezeichnet man als Zytostatika oder \nChemotherapeutika. Wirkstoffe mit einem wachstumshemmenden oder zerst\u00f6renden Einfluss \nauf Pilzzellen kennt man als Antimykotika. Nachfolgend werden Melleolid-Antibiotika mit \nZytostatika und Antimykotika verglichen. \n1.5.1. Einteilung der Zytostatika \nZytostatika lassen sich grob in vier gro\u00dfe Gruppen einteilen:  \nZun\u00e4chst gibt es Quervernetzende Substanzen , welche die Basen der DNA (meist \nPurinbasen) vernetzen. Die einzelnen DNA-Str\u00e4nge werden kovalent miteinander verbunden. \nDie codierte Information kann nicht mehr abgelesen werden (Mutschler, 2013). Zu dieser \nGruppe z\u00e4hlen zahlreiche Wirkstoffe der N-Lost-Verbindungen, der Alkylsulfonate, der \nNitroharnstoff-Derivate, der Platinsalze, oder der Triazene.  1. Einleitung   15 \nEine \nweitere Zytostatika-Gruppe stellen die Antimetaboliten  dar. Diese hemmen die DNA \noder RNA-Synthese durch Unterdr\u00fcckung der de novo  Synthese von Nukleotiden oder durch \nden Einbau falscher Nukleotide (Peters, 2014). G\u00e4ngige Wirkstoffe sind \nDihydrofolatreduktase-Hemmer wie Methotrexat, Pyrimidinanaloga oder Purinanalog a.  \nAu\u00dferdem gro\u00dfen Absatz finden Mitosehemmstoffe  wie Vincaalkaloide, oder Taxole, welche \ndurch eine Hemmung der Polymerisierung von Tubulinen den Auf-/Abbau des \nSpindelapparates und somit einen Kernprozess der Zellteilung behindern.  \nAuch Antibiotika wie Mitomycine, Anthrazykline, Actinomycine oder Bleomycin finden \nVerwendung als Zytostatika. Diese Stoffe sind DNA -Interkalatoren. Die Substanzen f\u00fchren \ndurch eine Einlagerung in die DNA Doppelhelix zu Strangbr\u00fcchen, zur Hemmung von \nTopoisomerasen oder von RNA/DNA Polymerasen (Mutschler, 2013)  \nNeben den genannten Haupt-Wirkmechanismen sind noch hormonelle Therapeutika  zu \nnennen, welche meist antagonistisch bei Hormon-abh\u00e4ngigen Tumoren eingesetzt werden \n(Riemsma et al., 2010).   \nSeit einigen Jahren auf dem Vormarsch sind die sogenannten Biological Response Modifiers, \nwelche \u00fcber einen Eingriff in die Signaltransduktion die Zellproliferation beeinflussen (Liu et \nal., 2016). Auch die individualisierte Tumortherapie zum Beispiel \u00fcber eine gentechnische \nVer\u00e4nderung von T-Zellen des Patienten bietet eine innovative Alternative zu den \n\u201eklassischen\u201c Zytostatika -Gruppen (Androulla und Lefkothea, 2018), soll hier aber nicht n\u00e4her \nthematisiert werden. \n1.5.2. Einteilung der Antimykotika \nDie meisten Antimykotika interagieren mit der Bildung der pilzlichen Zellwand bzw. \u2013membran. \nAzole  wirken durch eine Hemmung der pilzlichen Lanosterol- 14\u03b1-Demethylase (CYP51A) \nfungistatisch bis fungizid. Dadurch kommt es zum einen zur Akkumulation toxischer \nVorl\u00e4ufermolek\u00fcle der Zellmembran, als auch zur St\u00f6rung des Membranaufbaus (Zonios und \nBennett, 2008). Als neuer Wirkmechanismus wird auch eine \u00dcberproduktion von Zellwand-\nKohlenhydrat-Patches postuliert, welche durch Penetration der Plasmamembran zum Tod \neines Pilzes f\u00fchren (Geissel et al., 2018) . Allylamine  hemmen ebenfalls die Ergosterol-\nBiosynthese, speziell die Squalenepoxidase, und somit den Aufbau der Zellmembran (Petranyi \net al., 1984) . Polyene  integrieren sich in die Ergosterol-haltige Zellmembran, f\u00fchren zur \nBildung durchl\u00e4ssiger Poren und somit zum Zelltod (Hamilton-Miller, 1974; Holz, 1974) . \nEchinocandine st\u00f6ren durch eine Hemmung der \u03b2 -1,3-D-Glucan Synthase den Aufbau der \nZellwand und f\u00fchren \u00fcber eine osmotische Instabilit\u00e4t zur Zelllyse (Denning, 1997; \nGeorgopapadakou, 2001) .   \nEin weiterer Angriffspunkt ist die Ausbildung von Mikrotubuli. \u00c4hnlich der Wirkung des \nVinblastins wird durch eine Interaktion mit Griseofulvin  die pilzliche Mitose gehemmt \n(Rathinasamy et al., 2010) .   1. Einleitung   16 \nAu\u00dferdem si\nnd Hemmstoffe der Nucleins\u00e4uresynthese (DNA/RNA) bekannt. Beispielsweise \nhemmt Flucytosin  die pilzliche Thymidylat Synthase und somit die DNA Synthese. Als \nProdrug wird es in 5-Fluorodeoxyuridin umgewandelt in die RNA eingebaut, was zus\u00e4tzlich \neine Hemmung der Proteinbiosynthese bewirkt (Vermes et al., 2000). \n1.6. Forschungsbedarf \nBisher war unklar, welche Funktion die Melleolide f\u00fcr ihren Wirt einnehmen. Zwar war schon \nsehr fr\u00fch bekannt, dass Melleolide antibiotisch wirksam sind (Oduro et al., 1976) , \u00fcber die \nNutzung dieser bioaktiven Sekund\u00e4rstoffe als Selektionsvorteil gegen\u00fcber Konkurrenten \nwurde erst sp\u00e4ter spekuliert (Misiek und Hoffmeister, 2012) . Bohnert et al. entdeckten neben \ncytotoxischen Effekten auf humane Zelllinien erstmals konkretere Wirkziele an Pilzen, n\u00e4mlich \ndie pilzliche Transkription (Bohnert et al., 2014a; Bohnert et al., 2014b), jedoch fehlte es auch \nhier an Nachweisen f\u00fcr molekulare Angriffspunkte f\u00fcr die jeweils entdeckten Effekte.  \nIn dieser Arbeit sollen erstmals konkrete Wirkmechanismen ausgew\u00e4hlter Melleolide \nhinsichtlich einer cytotoxischen und antifungalen Wirkung aufgedeckt werden. \n \n 2. Zielsetzung der Arbeit   17 \n2. Zielsetzung de\nr Arbeit \nDas Substitutionsmuster v.a. des Terpens und die Lage der darin befindlichen Doppelbindung \n(\u03942,3, \u03942,4) tragen ma\u00dfgeblich zur Diversit\u00e4t der antibiotischen Wirkung gegen verschiedenste \nOrganismen bei . Daraus ergab sich die Fragestellungen und Zielsetzung dieser Arbeit: \n1. Welches ist das molekulare Ziel, \u00fcber das die antimykotische Wirkung der Melleolide \nerfolgt?  \n2. Ist es m\u00f6glich, am Beispiel von DAO durch eine chemische Synthese eine Sonde zu \nerzeugen, um dieses Wirkziel aus einem pilzlichen Modellorganismus ( A. nidulans)  und aus \nmenschlichen Zellen zu isolieren und zu identifizieren? \n3. Welche Mechanismen f\u00fchren in humanen Zelllinien zur raschen Zytotoxizit\u00e4t? Worin \nbestehen die Unterschiede zu antifungalen Wirkzielen? \n \n 3. Publikationen   18 \n3. Publik\nationen \n \n3.1. Publikation 1 \u2013 Melleolides impact fungal translation via elongation \nfactor 2  \nMaximilian D\u00f6rfer , Daniel Heine, Stefanie K\u00f6nig, Sagar Gore , Oliver Werz, Christian \nHertweck, Markus Gressler, Dirk Hoffmeister \nOrganic & Biomolecular Chemistry , 2019, Volume 17, 4906-4 916. \nZusammenfassung \nIn dieser Arbeit ist es gelungen, mit DAO, einem Naturstoff aus der Stoffgruppe der Melleolide \naus der Gattung Armillaria,  eine Zielstruktur von \u03942,4-unges\u00e4ttigten Melleoliden in \nAspergillus nidulans zu identifizieren. In einer chemischen Synthese wurde DAO an Biotin \ngekoppelt, um eine Streptavidin-basierte, affinit\u00e4tschromatographische Proteinextraktion am \nModell A. nidulans durchzuf\u00fchren. Die MALDI-TOF-basierte Peptidanalyse der angereicherten \nProteine identifizierte den eukaryotischen Elongationsfaktor eEF2 als Wirkziel von DAO, was \n\u00fcber Western Blot best\u00e4tigt werden konnte. Die Inhibition der Proteinproduktion und der damit \neinhergehenden antifungalen Wirkung von \u03942,4-unges\u00e4ttigten Melleoliden konnte in vivo  mittels \ntransgener mCherry-St\u00e4mme nachgewiesen werden. \u00dcber in silico Protein-Modellierung \nwurden putative Bindestellen identifiziert und diese mit DAO-sensitiven bzw. resistenten Hefen \nverglichen. \nEigenanteil 50%: \nMaximilian D\u00f6rfer:  Kultivierung von A. mellea , Isolation und Analyse der Naturstoffe, \n     Synthese von Sonden f\u00fcr Pull-Down Assays , Target Fishing, Western \n    Blotting, in vivo -Translationsassay in A. nidulans , Wachstums-  \n    experimente mit Hefen, Verfassen des Manuskripts  \n \n \n \n \n \n \n \nJena, den \n \n____________________  \nProf. Dr. Dirk Hoffmeister Organic &\nBiomolecular Chemistry\nPAPER\nCite this: Org. Biomol. Chem. , 2019,\n17,\n4906\nReceived 8th March 2019,\nAccepted 24th April 2019\nDOI: 10.1039/c9ob00562e\nrsc.li/obcMelleolides impact fungal translation via\nelongation factor 2 \u2020\nMaximilian D\u00f6rfer,aDaniel Heine,bStefanie K\u00f6nig,cSagar Gore,dOliver Werz,c\nChristian Hertweck,bMarkus Gressler*aand Dirk Ho \ufb00meister *a\nMelleolides from the honey mushroom Armillaria mellea represent a structurally diverse group of poly-\nketide-sesquiterpene hybrids. Among various bioactivites, melleolides show antifungal e \ufb00ects against\nAspergillus and other fungi. This bioactivity depends on a \u03942,4-double bond present in dihydroarmillylor-\nsellinate (DAO) or arnamial, for example. Yet, the mode of action of \u03942,4-unsaturated, antifungal melleo-\nlides has been unknown. Here, we report on the molecular target of DAO in the fungus Aspergillus nidu-\nlans. Using a combination of synthetic chemistry to create a DAO-labelled probe, protein pulldown\nassays, MALDI-TOF-based peptide analysis and western blotting, we identify the eukaryotic translation\nelongation factor 2 (eEF2) as a binding partner of DAO. We con \ufb01rm the inhibition of protein biosynthesis\nin vivo with an engineered A. nidulans strain producing the red \ufb02uorescent protein mCherry. Our work\nsuggests a binding site dissimilar from that of the protein biosynthesis inhibitor sordarin, and highlights\ntranslational elongation as a valid antifungal drug target.\nIntroduction\nThe fungal genus Armillaria (honey mushrooms) includes\nnotorious and globally distributed tree pathogens that cause\nsevere butt and root rot, thus impacting timber production,\nfruit and crop trees, and ornamentals.1A physiological hall-\nmark of these fungi is the production of numerous hybrid\npolyketide-sesquiterpene antibiotics, referred to as the melleo-\nlides.2From a chemical perspective, they are intriguing for two\nreasons. Firstly, the tricyclic protoilludene-type sesquiterpe-\nnoid secondary alcohol that is esterified to an orsellinic acid\n(or derivatives thereof) makes them structurally unique among\nnatural products, even though protoilludenes and orsellinic\nacid \u2013as separate entities \u2013are common fungal compounds.3,4\nSecondly, with more than 70 known structural congeners, themelleolides form one of the largest classes of fungal natural\nproducts. From a pharmaceutical perspective it is remarkable\nthat numerous melleolides exert potent antifungal e \ufb00ects\nagainst Aspergilli and various other fungi.5Yet, the bioactivity\nof these compounds reaches further and also includes\nphytotoxicity and toxicity on human monocytes and cancer\ncells.2,6\u20138Human 5-lipoxygenase, i.e., the key enzyme in the\nbiosynthesis of pro-inflammatory leukotrienes, was identified\nas molecular target of dihydroarmillylorsellinate (DAO, 1)\nwhose \u03b1,\u03b2-unsaturated aldehyde represents a Michael acceptor\nthat selectively reacts with the 5-lipoxygenase surface cysteine\n159.9Remarkably, the structural prerequisites for the antifun-\ngal and the cytotoxic activities are incongruent. Thus, the mel-\nleolides unite completely dissimilar structure \u2013activity-relation-\nships, which adds to the uniqueness of this class of natural\nproducts.10Previous work identified the protoilludene \u03942,4-\ncarbon \u2013carbon double bond as being critical for antifungal\nactivity. Conversely, those compounds that possess a \u03942,3-\ndouble bond are inactive, even though an \u03b1,\u03b2-unsaturated car-\nbonyl moiety is still present, suggesting that the spatial confor-\nmation of the sesquiterpene as consequence of the shifted\ndouble bond impacts bioactivity.10\nWhile the mode of action on human cells has been estab-\nlished, the cellular target that mediates antifungal activity\nremained elusive. Here, we show that 1interferes with protein\nbiosynthesis and interacts with Aspergillus eukaryotic trans-\nlation elongation factor 2 (eEF2). The findings were confirmed\nbyin vivo translation inhibition with arnamial ( 2), another\nmelleolide that possesses a \u03942,4-double bond. 1adds to the\u2020Electronic supplementary information (ESI) available. See DOI: 10.1039/\nC9OB00562EaDepartment Pharmaceutical Microbiology at the Hans Kn\u00f6ll Institute,\nFriedrich-Schiller-University, Beutenbergstrasse 11a, 07745 Jena, Germany.\nE-mail: dirk.ho \ufb00meister@hki-jena.de, markus.gressler@hki-jena.de;\nFax: +49-3641-949852; Tel: +49-3641-949851\nbDepartment Biomolecular Chemistry, Leibniz Institute for Natural Product Research\nand Infection Biology \u2013Hans Kn\u00f6ll Institute, Beutenbergstrasse 11a, 07745 Jena,\nGermany\ncDepartment Pharmaceutical and Medicinal Chemistry, Friedrich-Schiller-University\nJena, Philosophenweg 14, 07743 Jena, Germany\ndDepartment Systems Biology and Bioinformatics, Leibniz Institute for Natural\nProduct Research and Infection Biology \u2013Hans Kn\u00f6ll Institute,\nBeutenbergstrasse 11a, 07745 Jena, Germany\n4906 |Org. Biomol. Chem. ,2 0 1 9 ,17 , 4906\u2013 4916 This journal is \u00a9 The Royal Society of Chemistry 2019Published on 24 April 2019. Downloaded by Thueringer Universitats Landesbibliothek Jena on 11/24/2019 1:13:08 PM. View Article Online\nView Journal  | View Issuevery few mushroom metabolites whose modes of action are\nunderstood and r\nepresents a unique scenario of a natural\nproduct that exerts bioactivity viadissimilar targets in human\nversus fungal cells, yet acting highly selectively in either case.\nResults and discussion\nFor more profound insight into the antifungal mode of action\nof the melleolides, we used the model fungus Aspergillus\nnidulans and relied on a combined approach that included\n(i) design and synthesis of a DAO-coupled a \ufb03nity matrix,\n(ii) pulldown assays and western blots to enrich, identify and\nverify protein targets in vitro and subsequently (iii) a recombi-\nnant A. nidulans strain producing the fluorescent protein\nmCherry to monitor translational activity of the fungal cells\nin vivo .\n\u03942,4-Unsaturated melleolides confer antifungal activity against\nAspergillus nidulans\nThe antifungal activity of three unsaturated melleolides, 1,2\nand melleolide D ( 3) was tested against the filamentous model\nfungus A. nidulans (Fig. 1). Consistent with previous data, we\nobserved antifungal activity for 1and 2. Both compounds\nbelong to the \u03942,4-unsaturated aldehyde melleolides, whose\ndouble bond is predicted to be critical for antifungal activity.10\nIn contrast, 3harboring a \u03942,3-double bond and a hydroxyl\ngroup in place of the aldehyde, was inactive.Synthesis of a DAO-coupled chemical probe\nTo identify putative fungal target proteins for \u03942,4-unsaturated\nmelleolides by an unbiased a \ufb03nity-based protein fishing\napproach, we synthesized DAO probes with covalently bound\nbiotin. In order to leave the terpenoid pharmacophore intact,\nbiotin was coupled viaan alkynyl linker and cycloaddition to\nthe 5 \u2032-hydroxy group of the orsellinic acid. Initial attempts to\nintroduce the alkynyl moiety using propargyl halides under\nbasic conditions (Cs 2CO3or K 2CO3) led to degraded 1.\nSimilarly, coupling of propiolic acid to the 5 \u2032-hydroxy group\nusing benzotriazol-1-yl-oxytripyrrolidinophosphonium hexa-\nfluorophosphate (PyBOP) or 4-dimethylaminopyridine (DMAP)\nin the presence of 1-ethyl-3-(3-dimethylaminopropyl)carbodi-\nimide (EDC) or N,N\u2032-dicyclohexylcarbodiimide (DCC), sup-\nported by H\u00fcnig \u2019s base, pyridine or trimethylamine, were not\ne\ufb00ective either. Eventually, 5-hexynoic acid was successfully\ncoupled using EDC and H\u00fcnig \u2019s base (Scheme 1).\nEsterification of 5-hexynoic acid with the 5 \u2032-hydroxy group was\nconfirmed by13C-NMR spectroscopy. The signals of C-4 \u2032and\nC-6 \u2032(\u03b4C102.3 ppm (C-4 \u2032),\u03b4C113.1 ppm (C-6 \u2032)) in 1were shifted\ndownfield in dihydroarmillylorsellinate-5 \u2032-O-hexynoylester ( 4)\ndue to deshielding of the aromatic ring system ( \u03b4C108.2 ppm\n(C-4 \u2032),\u03b4C116.6 ppm (C-6 \u2032)) (ESI, Fig. S1 \u2013S5, Table S1 \u2020). Besides\nthe characteristic signals for 1, six additional carbon signals\n(C-1 \u2032\u2013C-6 \u2032) were observed (ESI, Fig. S2 \u2020), thus indicating\ncorrect 5 \u2032-O-esterification. The unaltered signal of C-1 at \u03b4C\n192.6 ppm confirmed that the highly reactive aldehyde has\nremained intact and not been reduced to a primary alcohol.\nThe reaction on position 5 \u2032was preferred, leading to 4\n(Scheme 1) as the major product (yield: 72%, 2.7 mg), most\nlikely due to an unfavourable steric environment around\nhydroxy groups on positions 3 and 3 \u2032. Ascorbate served as\nreducing agent in a subsequent copper-catalyzed Huisgen 1,3-\ncycloaddition with azide-PEG 3-biotin, yielding the desired\nprobe 5(yield: 34%, 1.0 mg) (Scheme 1). A parallel coupling\nreaction of 3with 5-hexynoic acid (to create a negative control\nfor subsequent protein pull-down assays) showed poor regio-\nselectivity. Consequently, we synthesized a compound ( 6, yield:\n92%, 11.8 mg) in which 1was replaced by butylparabene (ESI,\nScheme S1 \u2020). The structures of 5and 6were confirmed by\nHR-MS spectrometry and NMR spectroscopy (ESI, Fig. S6 \u2013S10,\nTable S2 \u2020).\nDAO binds to Aspergillus nidulans eEF2\nCompounds 5(probe) and 6(control) were bound to streptavi-\ndin-coated beads viathe biotin moiety. These a \ufb03nity matrices\nwere used for protein fishing experiments that were performed\nwith cell-free total protein extracts from A. nidulans as target\nsource. Proteins binding to the a \ufb03nity matrix were eluted,\nelectrophoretically separated by SDS-polyacrylamide electro-\nphoresis, and visualised by Coomassie staining (Fig. 2). Using\n5as bait, we identified two enriched protein bands at 28 kDa\n(band 1) and 95 kDa (band 2) that were absent in pulldowns\nwith the negative control 6. Both bands were cut out and sub-\njected to trypsin digestion and subsequent MALDI-TOF ana-\nFig. 1 Growth inhibition of A. nidulans by unsaturated\nmelleolides. A. Structures of unsaturated melleolides. B. Solid medium\nwith germinating A. nidulans conidia which were exposed to 1,2, and 3\n(20 \u00b5g per well). Methanol served as negative solvent control (NC).Organic & Biomolecular Chemistry Paper\nThis\njournal is \u00a9 The Royal Society of Chemistry 2019 Org. Biomol . Chem. ,2 0 1 9 ,17 , 4906\u2013 4916 | 4907Published on 24 April 2019. Downloaded by Thueringer Universitats Landesbibliothek Jena on 11/24/2019 1:13:08 PM. View Article Onlinelyses (ESI, Table S3 \u2020). Peptides fr om band 1 revealed the\neukaryotic elongation factor 1 \u03b1(eEF1 \u03b1) as a candidate.\nHowever, due to only five short peptide fragments (4 \u20136 amino\nacids), low abundance of the peptides, and a band position(28 kDa) that deviated from the expected size (50.8 kDa),\nprotein identification remained ambiguous. In contrast, band\n2 was identified as eEF2 by 19 peptide fragments and a\nsequence coverage of 29.4% (ESI, Fig. S11 \u2020). Therefore, we con-\nScheme 1 Chemical synthesis of biotin-labelled DAO probe 5and control probe 6. For detailed information on the synthesis of 6, see also ESI,\nScheme S1.\u2020\nFig. 2 Identi \ufb01cation of eEF2 as molecular target of 1. (A) SDS-polyacrylamide electrophoresis of fractions of the protein pulldown assay.\nStreptavidin beads were incubated with DMSO (solvent control), 6(negative control), or 5(probe). A total protein lysate of A. nidulans was applied\n(total cell lysate). The beads were washed with bu \ufb00er (wash) and eluted with Laemmli bu \ufb00er (elution). Indicated bands were digested with trypsin,\nand peptides were analysed by MALDI-TOF (ESI, Table S3\u2020 ). (B) Western blot analyses of protein elution fractions from protein pull-down assays\nusing rabbit anti-human eEF2 IgG. The upper panel shows the loading control (Coomassie stained SDS-PAGE), while the lower panel shows the\nmembrane using IRDye\u00ae 800CW goat anti-rabbit IgG as secondary antibody. Indicated values represent relative \ufb02uorescence intensities (exposure \u03bb\n= 778 nm; emission \u03bb= 795 nm).Paper Organic & Biomolecular Chemistry\n4908 |Org.Biom ol. Chem. ,2 0 1 9 , 17,4 9 0 6 \u20134916 This journal is \u00a9 The Royal Society of Chemistry 2019Published on 24 April 2019. Downloaded by Thueringer Universitats Landesbibliothek Jena on 11/24/2019 1:13:08 PM. View Article Onlinecluded that 1interacts with the 93.8 kDa eEF2 in A. nidulans .\nTo independently test this hypothesis, we performed a western\nblot analysis with the pulled-down proteins. Since no antibody\nagainst fungal eEF2 was available and since the N-terminal\neEF2 epitope of A. nidulans is 78% identical to the human\neEF2, we used a rabbit anti-human eEF2 IgG to detect fungal\neEF2 in the fractions. Western blot analysis clearly con-\nfirmed the enrichment of the protein and, thus, the binding\nof eEF2 to the probe 5but not to the corresponding negative\ncontrol. These results indicate that eEF2 directly binds\n\u03942,4-unsaturated melleolides which may compromise its\nactivity, leading to inhibited translation, and hence, to anti-\nfungal activity.\nIn silico blind docking studies revealed a putative binding\npocket\nSimilar to the melleolides 1and2, the diterpene glycoside sor-\ndarin ( 7) targets translational elongation in fungi viaeEF2,11\nwhereas other pharmaceutically relevant antifungals, such as\nazoles, allylamines, echinocandins, or polyenes, interfere with\ncell wall or membrane biosynthesis or integrity.12Specifically,\n7selectively binds to eEF2 of Saccharomyces cerevisiae in a well-\ndefined binding pocket (517CVLTYMSE524) which is located in\nclose vicinity to the GDP/GTP binding site of eEF2.13By stabi-\nlising the eEF2-80S ribosome complex, 7-bound eEF2 is kept\nin a GTPase activation state and prevents the tRNA-mediated\ntranslocation reaction.14Prior studies showed that the\ndi\ufb00erent susceptibility to 7in various yeast species is due to\nmutations in this 7binding pocket.13,15However, in silico\nmolecular fingerprint similarity values between 1and 7indi-\ncated structural and chemical di \ufb00erences between both mole-\ncules (ESI, Table S4 \u2020). Thus, we compared the sensitivity and\nresistance profile of 1in various yeast species to those of 7and\nfound that both profiles di \ufb00er strongly (Fig. 3A). We observed\ngrowth inhibition by 1forCandida albicans ,Candida parapsilo-\nsisand Candida lusitaniae , while Candida glabrata and\nS. cerevisiae were resistant. In contrast, S. cerevisiae and\nC. albicans are susceptible to 7, while no inhibition by 7was\ndetected for the other yeast species. Similarly, A. nidulans is\ninhibited by 1, but not by 7. From these results and given the\ndi\ufb00erent chemistry of the molecules (ESI, Table S4 \u2020)w e\nhypothesised that 1and 7might target dissimilar sites in\neEF2. To corroborate our assumption and to obtain first\ninsight into the potential place of binding, we relied on\nin silico methods: 3D modelling of S. cerevisiae and C. albicans\neEF2 revealed highly conserved amino acid residues in the\nbinding pockets for 7(Y521 and S523), as shown in Fig. 3B.\nDi\ufb00erences in the binding pocket for 7inA. nidulans eEF2\n(M522 and N524) may alter the binding pocket shape and van\nder Waals interactions (Fig. 3B) and hence may cause resis-\ntance to 7(Fig. 3A). In contrast, the highly hydrophobic bulky\nterpenoid moiety of 1does not fit into the binding pocket of 7.\nBlind docking studies with 3D structural model of A. nidulans\neEF2, built with template crystal structure of S. cerevisiae eEF2\nrevealed possible binding sites for 1(ESI, Table S5 \u2020).16\nHowever, in some cases, these are buried inside the proteinand hence are not accessible to 1. The most likely binding site\ndepicts a proper orientation of the protoilludene moiety inside\neEF2 and is located next to the GTP binding domain of\nA. nidulans eEF2 (Fig. 3C). In addition, binding of 1can be\nmodelled into eEF2 of the 1sensitive C. albicans and of the 1\nresistant yeast S. cerevisiae , although their amino acid\nsequence in the binding region di \ufb00ers from that of A. nidulans\neEF2 at positions 170, 249, and 261 \u2013265. Interestingly, the two\n1resistant organisms S. cerevisiae and C. glabrata , share an\naltered amino acid sequence in the binding pocket which may\nlead to insensitivity to 1(T170, F249, T262). Specifically, the\nside-chain amino group of K262 in C. albicans eEF2 may\ninteract with the 5 \u2032hydroxy group of 1, whereas T262 in both\nresistant strains faces away from the metabolite and seems\nnot to interact (Fig. 3A and C). Similarly, eEF2 from all tested\n1susceptible strains exhibit a Y249 whose hydroxy group\nmay stabilize the ester (C-1 \u2032) or the aldehyde (C-1) of 1.I n\ncontrast, in both resistant strains, Y249 is replaced by F249\nlacking this important hydroxy group (Fig. 3A). Although\nother resistance mechanisms cannot be ruled out, the pro-\nposed binding pocket is fully consistent with the observed\nsusceptibility profile. For a more comprehensive perspective,\na phylogenetical survey of eEF2 \u2013an indispensable com-\nponent of the fungal translational machinery \u2013revealed a\nhigh degree of conservation both in Mucoromycota ( \u201clower\nfungi \u201d) and in Asco- and Basidiomycota (\u201c higher fungi \u201d,e.g.,\nmushrooms) (ESI, Fig. S12 \u2020). Resistance towards \u03942,4-unsatu-\nrated melleolides is not congruent with a particular evol-\nutionary group of fungi and may have evolved independently\nseveral times.\nArnamial inhibits the protein biosynthesis in A. nidulans\nin vivo\nUnbiased target fishing and blind docking experiments\nsuggested binding of \u03942,4-unsaturated melleolides to\nA. nidulans eEF2. This elongation factor is essential for GTP-\ndependent translocation of the ribosome during protein bio-\nsynthesis but not involved in other cellular processes.\nTherefore, if eEF2 is compromised due to small molecule\nbinding, we expected selective inhibition of translation while\ntranscription remains intact. To test if the translation, but not\ntranscription, is inhibited in vivo , we constructed A. nidulans\nstrain tMD03 that expresses a gene encoding the easily detect-\nable red fluorescent protein mCherry under control of the\nstrongly inducible promoter P alcA (Fig. 4A).17In contrast to\nother fluorescent proteins, mCherry is highly stable and sup-\nports a quick in situ read-out that does not require an addition\nof substrates.18Both wild type A. nidulans and the strain\ntMD03 are susceptible to the translational inhibitor hygromy-\ncin B ( 8), which is widely used as antifungal agent against\nAspergillus species (Fig. 4B).19,20In contrast to wild type,\ntMD03 shows a strong fluorescent emission signal at 595 nm\nin the mycelium (Fig. 4A). As expected from prior studies on\nthe alcA promoter,21production of mCherry is repressed by\nD-glucose, yet induced by ethanol, and its production rate can\nbe monitored from cell-free protein extracts. When D-glucose isOrganic & Biomolecular Chemistry Paper\nThis\njournal is \u00a9 The Royal Society of Chemistry 2019 Org. Biomol. C hem. ,2 0 1 9 ,17 , 4906\u2013 4916 | 4909Published on 24 April 2019. Downloaded by Thueringer Universitats Landesbibliothek Jena on 11/24/2019 1:13:08 PM. View Article OnlineFig. 3 Predicted binding sites of 7and1in eEF2. (A) Structural formulas and antifungal activities of 7and1. Susceptible and resistant strains are indi-\ncated by \u201cS\u201dand \u201cR\u201d, respectively. C. albicans and S. cerevisiae are susceptible to 7, while C. glabrata ,C. parapsilosis and C. lusitaniae are resistant.\nNote the incongruent resistance pattern against 7and1. Putative binding sites for 7and1are indicated. Amino acid exchanges in comparison to\nA. nidulans eEF2 are colour coded: red, acidic; blue, basic; green, hydrophobic; orange, hydrophilic. Initial optical densities (OD 600) of 0.02 (*) or\n0.1 (**) were used for yeast strains. Plates with A. nidulans were initially inoculated with 1 \u00d7 106conidia per mL (***). (B) Close-up views of the 7\nbinding pocket in eEF2 of S. cerevisiae (brown peptide backbone), C. albicans (blue), and A. nidulans (violet). 7bound S. cerevisiae eEF2 (PDB\nID:1N0U) was used to model the 3D structure of C. albicans eEF2 and A. nidulans eEF2. 7was subsequently transferred to the binding pocket.\nHydrogen bonding interactions are shown in black lines. Important residues of the binding pocket are shown in stick representations. eEF2 from\nS. cerevisiae ,C. albicans ,A. nidulans were superimposed onto each other. Residue positions that di\ufb00 er in eEF2 from A. nidulans (M522 and N524) in\ncomparison to S. cerevisiae orC. albicans (both Y521 and S523) are depicted and may lead to 7resistance. (C) Close-up view of the predicted 1\nbinding pocket by Achilles blind docking server with 3D structural model of A. nidulans eEF2 (violet peptide backbone) . C. albicans (blue) and\nS. cerevisiae (PDB ID:1N0V, brown) protein structures were superimposed onto A. nidulans eEF2 to compare predicted binding pocket residues.\nResidues that might be crucial for 1binding and that also di \ufb00er between A. nidulans ,C. albicans , and S. cerevisiae are shown in stick representations.\nFigures in panels 3B and 3C were generated with UCFSF Chimera.32Paper Organic & Biomolecular Chemistry\n4910 |Org. Biomol. Chem. ,2 0 1 9 ,17 , 4906\u2013 4916 This journal is \u00a9 The Royal Society of Chemistry 2019Published on 24 April 2019. Downloaded by Thueringer Universitats Landesbibliothek Jena on 11/24/2019 1:13:08 PM. View Article Onlinecompletely exhausted, the fungus metabolises ethanol as\ncarbon source which\nthen induces transgene expression.\nOptimum mCherry production was observed in an autoinduc-\ntion medium with 10 mM D-glucose and 100 mM ethanol (ESI,\nFig. S13 \u2020). Both 1and2are antifungally active, share an identi-\ncal pharmacophore and a near-identical overall structure\n(Fig. 1). However, for this subsequent in vivo translation inhi-\nbition assay, only 2was obtained in su\ufb03 cient quantities from\nA. mellea cultures in order to perform the experiment. After\npre-cultivation of the test strain for 16 h, translation was inhib-\nited by adding 10 \u00b5g mL\u221212or 25 \u00b5g mL\u221218(positive control)\n(Fig. 4C). Untreated mycelium served as internal fluorescence\nreference. The fluorescent signals of the protein crude extracts\nwere determined over a total cultivation time of 48 h. The treat-\nment with both inhibitors did not alter the expression levels of\nthemCherry gene or the intrinsic alcA gene, as determined by\nqRT-PCR (ESI, Fig. S14 \u2020). However, at early stages of treatment,\neither inhibitor induced the expression of genes encoding\nribosomal structural proteins 2-fold, most likely to compensatetranslational inhibition (ESI, Fig. S14 \u2020). In the untreated\ncontrol, mCherry production began 15 h after inoculation and\nreached its maximum after 24 h. In contrast, cultures treated\nwith 8showed a weak, slowly increasing fluorescent signal\n(20\u201340% of the control), indicating a strong translational inhi-\nbition. This is in agreement with the described mode of action\nof8to inhibit peptide chain elongation by preventing eEF2-\ndependent translocation on eukaryotic ribosomes.20mCherry\nproduction in cultures treated with 2was moderately, but sig-\nnificantly inhibited (40 \u201380%). After 48 h, the fluorescence\nreached values similar to those of the untreated control.\nTreatment with 2 \u00b5g mL\u22121of2did not inhibit the translation\nin vivo (ESI, Fig. S15\u2020 ). These results indicate that 2exerts tran-\nsient e\ufb00 ects, probably as it acts as a fungistatic agent rather\nthan representing a fungicide, such as 8, under the tested con-\nditions. This is supported by the observation that cultures\ntreated with 1or2recover over time (ESI, Fig. S16 \u2020). However,\nunder natural conditions, A. mellea produces a complex\nmixture of melleolides which may increase or prolong antifun-\nFig. 4 In vivo inhibition of pr otein biosynthesis in A. nidulans FGSC A4_tMD03. (A) Growth comparison between tMD03 and its parental strain FGSC\nA4. tMD03 is pyrithiamine (Pt) resistant but it is susceptible towards the translational inhibitor hygromycin B ( 8) as the wild type. Note that the\nmutant produces the red \ufb02uorescent protein mCherry after induction with ethanol (right panel). (B) Chemical structure of 8. (C) Decreased pro-\nduction rates of mCherry by 2and8treatments in A. nidulans . tMD03 was pre-cultivated in 100 mM ethanol and 10 mM glucose and subsequently\n10 \u00b5g mL\u221212or 10 \u00b5g mL\u221218.P-Value signi\ufb01 cance levels are given with *( p< 0.05) and **( p< 0.01).Organic & Biomolecular Chemistry Paper\nThis\njournal is \u00a9 The Royal Society of Chemistry 2019 Org. Biomol. C hem. ,2 0 1 9 ,17 , 4906\u2013 4916 | 4911Published on 24 April 2019. Downloaded by Thueringer Universitats Landesbibliothek Jena on 11/24/2019 1:13:08 PM. View Article Onlinegal properties.5Resistance to fungicidal drugs, such as echino-\ncandins or 5-flucytosine, usually requires multiple cell gener-\nations and is a long-term resistance mechanism.12In contrast,\nresistance against fungistatic azoles is mediated by over-pro-\nduction of the target enzyme, the lanosterol 14- \u03b1-demethylase\nErg11 or by e\ufb03 cient drug e\ufb04 ux mediated by multi-drug trans-\nporters.12However, in the case of 2, the expression of target\nprotein eEF2 is not a \ufb00ected (ESI, Fig. S14 \u2020). Therefore, the\nobserved recovery after initial inhibition may reflect increasing\nclearance from Aspergillus cells or, alternatively, intracellular\nmodification to inactivate the pharmacophore.\nConclusions\nExploiting an unbiased target fishing approach using a bio-\nactive melleolide as bait, we have identified eEF2 as molecular\ntarget for one of the largest families of fungal metabolites pro-\nduced by the globally distributed fungal genus Armillaria . Our\nwork has elucidated the mechanism of the antifungal activity\nof the melleolides that is conferred by interference with eEF2-\nmediated translation. A binding site dissimilar from that of\nthe protein biosynthesis inhibitor 7was identified as most\nplausible area of interaction, which underscores translational\nelongation as a valid antifungal drug target. This work at the\ninterface of chemistry and biology should encourage further\nresearch on the melleolides for pharmaceutical purposes. As\nArmillaria is a long-lived organism competing with other fungi\nfor nutritional supply in its natural habitat, antifungal melleo-\nlides represent an alternative, but e \ufb00ective defence mechanism\ncompared to known antifungals. Therefore, our results also\ncontribute to the chemical ecology of this important pathogen.\nExperimental\nMaterials, and general microbiological procedures\nChemicals, reagents, solvents, and media components were\npurchased from Carl Roth, Sigma-Aldrich, and VWR.\nArmillaria mellea FR-P75 was cultured in glucose minimal\nmedium (GMM).10A. nidulans FGSC A4 and tMD03 were main-\ntained on Aspergillus minimal medium (AMM) agar plates22or\non malt extract \u2013peptone (MEP) solid medium (per litre: 30 g\nmalt extract, 3 g soy peptone, 1.8% agar, pH 5.6 with acetic\nacid). Antifungal agents were 8at 5, 10, or 100 \u00b5g mL\u22121,o r\npyrithiamine hydrobromide at 0.1 \u00b5g mL\u22121. Plasmid propa-\ngation was carried out in E. coli XL1 blue strains cultivated in\nLB medium supplemented with 50 \u00b5g mL\u22121carbenicillin.\nPreparative and analytical chemistry\nMetabolite extraction and isolation. 16 L of culture broth\nfrom A. mellea was extracted as described.10The crude extract\nwas initially fractionated viasolid phase extraction on a\nSepPak Vac C-18, 35 cc, 10 g column (Waters). A step gradient\n(40, 60, 80, and 100% methanol) was applied that yielded four\nfractions which were analyzed by UHPLC-MS (method 1). 1and 2were detected in the 80% fraction by MS ( m/z423 and\nm/z461 [M + Na]+, respectively), which were further separated\nby preparative HPLC (method 2). Fractions were again analysed\nby method 1. Final work-up of 1- and 2-containing fractions\nwas accomplished by semi-preparative HPLC (method 3).\nStructures of purified 1and 2were confirmed by NMR spec-\ntroscopy in comparison to described data.6\nHPLC and LC-MS methods. Method 1 was carried out on an\nAgilent 1290 Infinity II chromatograph equipped with a Zorbax\nEclipse C18 2.1 \u00d7 50 mm column (1.8 \u00b5m particle size) and\ninterfaced to a 6130 quadrupole mass spectrometer using\nelectrospray ionization for molecular ionization. The flow\nwas 1 mL min\u22121using 0.1% formic acid in water (solvent A)\nand acetonitrile (ACN, solvent B). Initially, 5% B was held for\n2 min, then increased to 100% B within 5 min.\nMethod 2 was run on a preparative Agilent 1260 Infinity\nHPLC instrument, connected to a Phenomenex Luna C18\ncolumn (250 \u00d7 21.2 mm, 10 \u00b5m particle size), using water (A)\nand ACN (B). Initially, 50% B was held for 2 min, then\nincreased to 85%, held for 2 min, again increased within\n9 min to 100%. The flow rate was 20 mL min\u22121.\nSemi-preparative methods (methods 3 through 7) were per-\nformed on an Agilent 1200 instrument using a Zorbax Eclipse\ncolumn (C18, 9.4 \u00d7 250 mm; 10 \u00b5m particle size). Method 3\nwas run with water (A) and ACN (B) at a flow rate of 1.7 mL\nmin\u22121and with a Zorbax Eclipse Plus column (C18, 9.4 \u00d7\n250 mm; 5 \u00b5m particle size). Methods 4 \u20137 were run with 0.1%\ntrifluoroacetic acid in water (A) and ACN (B) at a flow of\n4 mL min\u22121.\nMethod 3 included an isocratic run of 85% B for 25 min,\nfollowed by an increase to 100% within 2 min. Method 4 was\na gradient of initially 10% B for 1 min, linear increase to 40%\nwithin 2 min and to 90% in further 15 min, then held for\n4m i n ,a n di n c r e a s e dt o1 0 0 %Bw i t h i n1m i n .M e t h o d5w a s\ninitially 10% B for 1 min, linear increase to 65% within 2 min\nand to 90% in further 13 min, then held for 4 min, increased\nto 100% B within 4 min. Method 6 was initially 10% of B for\n1 min, linear increase to 70% within 2 min, further increase\nto 90% within 13 min and to 100% B in 0.5 min. Method 7\nwas 5% B for 1 min, linear increase to 20% in 4 min and\nfurther to 90% within 5 min, terminal linear increase to\n100% in 1 min. High resolution mass spectrometry was per-\nformed on a Q Exactive Plus mass spectrometer (Thermo\nScientific).\nStructure elucidation. One- and two-dimensional NMR\nspectra of purified compounds were recorded in CD 3OD on\nBruker Avance III spectrometers, operating at 500 and\n600 MHz (1H spectra) or at 125 and 150 MHz (13C spectra),\nrespectively. Chemical shifts were referenced to residual\nCH 3OH ( \u03b4H3.31 ppm; \u03b4C49.1 ppm).\nMALDI-TOF-based peptide analysis. Peptide samples\nembedded in an \u03b1-cyano-4-hydroxycinnamic acid (HCCA)\nmatrix for peptides (Bruker) were measured on a Bruker\nUltraflextreme instrument using a Smartbeam II Laser and\nMTP Standard AnchorChip Target (800 \u00b5m) in positive reflec-\ntor-mode (MS and MS-MS).Paper Organic & Biomolecular Chemistry\n4912 |Org. Biomol. Chem. ,2 0 1 9 ,17, 4906\u2013 4916 This journal is \u00a9 The Royal Society of Chemistry 2019Published on 24 April 2019. Downloaded by Thueringer Universitats Landesbibliothek Jena on 11/24/2019 1:13:08 PM. View Article OnlineChemical synthesis\nSynthesis of 5. One equivalent\nhexynoic acid (7.1 \u00b5mol;\n0.87 mg) and 1.05 equivalents of 1(7.5 \u00b5mol; 3 mg) were\nmixed with 1.2 equivalents of N-(3-dimethylaminopropyl)- N\u2032-\nethylcarbodiimide (EDC) (8.5 \u00b5mol; 0.46 mg) in water-free di-\nchloromethane (DCM). The solvent was evaporated to dryness\nand 0.5 equivalents of H\u00fcnig \u2019s base (3.6 \u00b5mol; 0.46 mg) in\n300 \u00b5L dried DCM were subsequently added. The mixture was\nstirred at room temperature for 67 h and the final product ( 4)\nwas purified via HPLC method 4. One equivalent of 4\n(3.2 \u00b5mol; 1.59 mg) and 1.2 equivalents of azide-PEG 3-biotin\n(Jena Bioscience) (3.9 \u00b5mol; 1.72 mg) were mixed in a final\nvolume of 400 \u00b5L DCM. 5 \u00b5L of 0.5 M CuSO 4and 15 \u00b5L of 0.5\nM sodium ascorbate solution were added every 24 h while stir-\nring. After 62 h, 5was purified viaHPLC method 5. The struc-\nture of 5was elucidated by NMR spectroscopy and high resolu-\ntion mass spectrometry (ESI, Fig. S1 \u2013S5, Table S1 \u2020).\nSynthesis of 6. A reaction mixture with one equivalent of\nn-butyl 4-hydroxybenzoate (51.5 \u00b5mol; 10 mg), 1.15 equivalents\nof 5-hexynoic acid (59.2 \u00b5mol; 6.64 mg), 0.7 equivalents of tri-\nmethylamine (36.0 \u00b5mol; 2.55 mg) and 1.15 equivalents of\nEDC (59.2 \u00b5mol; 11.35 mg) was stirred in a total volume of\n500 \u00b5L DCM for 72 h at ambient temperature. The reaction\nproduct (intermediate 9, ESI, Scheme S1 \u2020) was purified via\nHPLC method 6. For the final click reaction, one equivalent of\n9(17.3 \u00b5mol; 5 mg) was added to 1.15 equivalents of azide-\nPEG 3-biotin (19.9 \u00b5mol; 8.87 mg) with 8 \u00b5L of a 0.5 M CuSO 4\nsolution and 50 \u00b5L of a 0.5 M sodium ascorbate solution in a\ntotal volume of 370 \u00b5L DCM. After incubation for 36 h at\nambient temperature, purification carried out via HPLC\nmethod 7 resulted in product 6. The structure of 6was eluci-\ndated by NMR spectroscopy and high resolution mass spec-\ntrometry (ESI, Fig. S6 \u2013S10, Table S1 \u2020). The reaction is shown\nin Scheme S1 (ESI \u2020).\nCell biology\nProduction of cell lysate. A. nidulans FGSC A4 at a final con-\ncentration of 1 \u00d7 106conidia per mL was inoculated in 50 mL\nof liquid AMM22supplemented with 0.1% (m/v) yeast extract.\nAfter incubation at 180 rpm and 37 \u00b0C for 16 h, the mycelium\nwas filtered and washed with phosphate bu \ufb00ered saline (PBS;\n137 mM NaCl, 2.7 mM KCl, 10 mM Na 2HPO 4, 1.8 mM\nKH 2PO4, pH 7.4), supplemented with 0.1% D-glucose. The\nmycelium was frozen in liquid nitrogen, ground to a powder,\nand resuspended in 10 ml PBS. After centrifugation (1 h,\n10 621 g, 4 \u00b0C) and size exclusion filtration (Amicon, 10 kDa cut\no\ufb00, 550 g, 20 min, 4 \u00b0C), the supernatant was used for biotin/\nstreptavidin a \ufb03nity chromatography (below).\nA\ufb03nity chromatography. A\ufb03nity chromatography was per-\nformed according to the protocol of the Pierce Pull-Down\nBiotinylated Protein:Protein Interaction Kit (Thermo\nScientific). In brief, 100 \u00b5L of streptavidin beads were washed\nwith Tris-bu \ufb00ered saline (TBS; 25 mM Tris-HCl, 150 mM NaCl,\npH 7.0) and pretreated for 30 min either with probe 5, control\n6, or equivalent amounts of DMSO as negative control. Afterblocking with biotin-blocking solution (Thermo Scientific), the\nbeads were washed with TBS and then incubated with 200 \u00b5L\ncell lysate (1 \u201310 mg mL\u22121protein) for 16 h at 4 \u00b0C. After a sub-\nsequent wash step with TBS, proteins were eluted with 50 \u00b5L\nof SDS loading bu \ufb00er (50 mM Tris-HCl, 2% SDS, 10% glycerol,\n1%\u03b2-mercaptoethanol, 12.5 mM EDTA, 0.02% bromophenol\nblue, pH 6.8). Samples were loaded on a 10% SDS polyacryl-\namide gel, electrophoresed, and subsequently stained with\nCoomassie Brilliant Blue.23For further protein identification,\nprotein bands were cut out with a scalpel, digested with\ntrypsin as described,24and subjected to MALDI-TOF peptide\nanalysis.\nWestern blot. Proteins separated by SDS polyacrylamide gels\nwere transferred to a nitrocellulose membrane as\ndescribed.25,26The membrane was stained with Ponceau red\nand washed with water, TBS with 0.1% (v/v) tween 20, and\nagain with water. The membrane was blocked by 5% milk\npowder in TBS for 1 h. The primary antibody (rabbit anti-\nhuman eEF2 antibody; Cell Signaling) was diluted 1 : 1000 in\nTBS + 5% milk powder and applied to the membrane. After\nincubation overnight at 4 \u00b0C, the membrane was washed three\ntimes with 0.1% (v/v) tween 20 in TBS, followed by a final wash\nwith TBS for 5 min. The secondary antibody (IRDye\u00ae 800CW\ngoat anti-rabbit IgG, Li-Cor) was diluted 1 : 10 000 with 5%\nmilk powder in TBS and applied to the membrane. After incu-\nbation for 30 min, the membrane was washed three times with\nTBS + 0.1% (v/v) Tween 20 for 5 min and dried at 37 \u00b0C prior\nto detection of the fluorescent signal on an Odyssey CLx\nImaging System (excitation 778 nm, emission 795 nm).\nAntifungal assays. Antifungal activity tests against yeast\nstrains were performed with Candida albicans SC5314,\nSaccharomyces cerevisiae ATCC9763, Candida glabrata\nATCC2001, Candida parapsilosis GA1-wt, and Candida lusita-\nniae 10-09-05-73/5169.13Prior to pouring plates, 50 \u00b0C warm\nliquid YPD agar was inoculated with an overnight YPD culture\nof the respective strain to a final OD 600= 0.1 or OD 600= 0.02.\nHoles were punched with a cork borer, and 20 \u00b5L of an 1solu-\ntion (in methanol) or 7(aqueous) at a concentration of 1000,\n200, or 40 \u00b5g mL\u22121were applied. Pure methanol served as\nnegative control. Plates were incubated for 24 h at 30 \u00b0C.\nMolecular biology\nConstruction of Aspergillus nidulans tMD03. The\nMagnaporthe oryzae pRP27 promoter in plasmid pMS01 con-\ntaining the mCherry protein coding sequence under control of\nthe RP27 promoter was replaced by the ethanol inducible\nA. nidulans alcA promoter (P alcA) using the Fast Cloning\nmethod.27PalcA was amplified from genomic DNA of\nA. nidulans FGSCA4 using oligonucleotide primers oMG234\nund oMG235 (Table 1), the vector backbone was amplified\nfrom pMS01 with primers oMG233 and oMG170 using\nPhusion DNA polymerase according to the supplier \u2019s protocol\n(Thermo Scientific). Both fragments were purified, mixed in an\nequimolar ratio and used for transformation of. E. coli XL1\nblue. 10 \u00b5g of the resulting plasmid pMD03 (containing the\nmCherry gene downstream of the alcA promoter) were used forOrganic & Biomolecular Chemistry Paper\nThis\njournal is \u00a9 The Royal Society of Chemistry 2019 Org. Biomol. C hem. ,2 0 1 9 ,17 , 4906\u2013 4916 | 4913Published on 24 April 2019. Downloaded by Thueringer Universitats Landesbibliothek Jena on 11/24/2019 1:13:08 PM. View Article Onlinetransformation of A. nidulans FGSC A4 wild type according to a\npublished procedure.28Transformants were streaked out on\nAMM22plates containing 0.1 \u00b5g ml\u22121pyrithiamine and were\nthen checked by PCR using primers oMG234 and oMG171.\nPrior to the translational inhibition assay, 40 transformants\nwere screened by fluorescence microscopy (Zeiss Imager M2\nAXIO, excitation 550 \u00b1 25 nm, emission 605 \u00b1 70 nm, laserlight\nirradiation time 2000 ms, brightfield 3 ms) to identify the\ntransformant with strongest fluorescence intensity (tMD03).\nThe wild type served as control.\nQuantitative real time-PCR (qRT-PCR). RNA from mycelium\nofA. nidulans tMD03 grown for 0, 14 and 36 h in the presence\nof translation inhibitors (see below) was isolated using the SV\nTotal RNA Isolation System (Promega). Genomic DNA was\ndigested by Baseline ZERO DNase (Biozyme), and 500 ng RNA\nwas reverse transcribed to cDNA by RevertAid Reverse\nTranscriptase (Thermo Scientific). To assess transcription\ne\ufb03ciency, qPCR experiments were performed with a\nQuantStudio 3 thermal cycler (Thermo Scientific) using the\nprimer in Table 1. Expression levels were normalized using\nenoA and gpdA transcription levels as reference.29To determine\nprimer e\ufb03 ciencies, 12 \u00b5L of MyTaq \u2122HS mix (Bioline) were\nmixed with 1 \u00b5L of Biotium EvaGreen\u00ae Dye (20\u00d7 stock solu-\ntion, 25 \u00b5M) for each test reaction. 1 \u00b5L of water and 4 \u00b5L of a\nmixture of corresponding oligonucleotide primer pairs\n(forward/reverse; 10 \u00b5M), were added, as well as 2 \u00b5L of a 1 : 10\ndilution of template cDNA.\nTranslation inhibition of A. nidulans .AMM plates contain-\ning 5, 10, or 100 \u00b5g mL\u221218and MEP plates (positive control)\nwere inoculated with 2 \u00d7 105conidia and incubated for 72 h at\n37 \u00b0C.\nFor translation inhibition in liquid media, 100 mL AMM\ncontaining 10 mM D-glucose and 100 mM ethanol were inocu-lated with A. nidulans FGSC A4 (wild type, fluorescent blank\ncontrol) or tMD03 (1 \u00d7 106conidia per mL) and pre-incubated\nfor 16 h at 37 \u00b0C and 180 rpm. After adding 50 mM ethanol,\ntranslation was inhibited by addition of 25 \u00b5g mL\u221218,o r\n2\u00b5 gm L\u22121or 10 \u00b5g mL\u221212(solved in methanol). Pure metha-\nnol served as negative control. After further cultivation at\n37 \u00b0C, 180 rpm for 0, 3, 6, 9, 14, 24, 30, and 48 h, mycelium\nwas harvested and lyophilised. 10 \u201320 mg mycelium was sus-\npended in 500 \u00b5L of LET bu \ufb00er (100 mM LiCl, 20 mM EDTA,\n10 mM Tris HCl, pH 8.0) and ground with 0.25 \u20130.5 mm glass\nbeads for 4.5 m s\u22121for 60 s in a cell disruptor. The mycelium\nwas removed by centrifugation at 16 595 gfor 30 min. 150 \u00b5L\nsupernatant or dilutions thereof (1 : 2 and 1 : 4) were trans-\nferred to black 96-well plates. Fluorescence was detected (exci-\ntation at 544 nm; emission at 595 nm) with a BMG FluoStar\nGalaxy microplate reader (gain 80). Relative fluorescence (RF)\nwas determined as follows:\nRF\u00bcfluorescence \u00f0tMD03; treated \u00de\nbiomass \u00f0tMD03; treated \u00de/C0fluorescence \u00f0WT\u00de\nbiomass \u00f0WT\u00de\nfluorescence \u00f0tMD03; control \u00de\nbiomass \u00f0tMD03; control \u00de/C0fluorescence \u00f0WT\u00de\nbiomass \u00f0WT\u00de\nInsilico modelling and blind\ndocking studies\nMolecular fingerprint (FP) comparison between 1 and 7.\nSimplified molecular-input line-entries (SMILE) for 1(CID\n51351608) and 7(CID 485851) were obtained from the\nPubchem database. SMILE strings were encoded into Morgan\nand 2D pharmacophore FP for structural comparisons.30\nMorgan FP considers circular neighbourhood of atoms while\n2D pharmacophore FP combines two-dimensional topological\ndistances of atoms with chemical features. Morgan FPs with\nfeature-based atomic environment definitions were used. After\nencoding them into FPs Tanimoto and Dice similarities were\ncalculated, which are listed in Table S4 (ESI \u2020). Tanimoto\n(Jaccard) and Dice are widely used similarity coe \ufb03cients to\ncompare molecular structures which take into account shared\nsubstructures or chemical features.\n3D structural modelling of A. nidulans and C. albicans eEF2.\nTemplate based structural modelling of A. nidulans and\nC. albicans eEF2 was accomplished using MODELLER\n(mod9.21).31Since eEFs are highly conserved, S. cerevisiae\neEF2 crystal structures (PDB ID 1N0U & 1N0V) were selected as\ntemplates for the modelling purpose. PDB ID:1N0U structure\nharbours 7in the binding pocket, hence it was transferred to\nmodelled C. albicans eEF2 for binding interaction compari-\nsons. The A. nidulans eEF2 3D model obtained using PDB\nID:1N0V ( 7unbound structure) was subsequently used as an\ninput for blind docking studies for 1. Figures of 3D structural\nmodels were generated with UCSF Chimera.32\nPrediction of binding pockets for 1 on A. nidulans eEF2 by\nblind docking. 3D coordinates of model constructed through\ncomparative modelling (PDB ID:1N0V) were used as an input\nfor blind docking servers. The mol2 formatted structure of 1\nfrom Pubchem and A. nidulans eEF2 model were submitted to\nthe Achilles blind docking server (http://bio-hpc.ucam.edu/Table 1 Oligonucleotides used in this study. Underlined: Overlapping\n\ufb02anks to the vector backbone\nOligonucleotide 5 \u2032\u20133\u2032-Sequence Target\noMG234 T \u0332T \u0332A \u0332C \u0332G \u0332C \u0332C \u0332G \u0332G \u0332C \u0332G \u0332C \u0332G \u0332C \u0332C \u0332GTAG P alcA\n(FGSCA4 gDNA) ATATTTTCGAAGGGATTC\noMG235 G \u0332C \u0332C \u0332C \u0332T \u0332T \u0332G \u0332C \u0332T \u0332C \u0332A \u0332C \u0332C \u0332A \u0332T \u0332TTTGA P alcA\n(FGSCA4 gDNA) GGCGAGGTGATAGGATTG\noMG170 ATGGTGAGCAAGGGCGAGGAG pMS01\noMG233 GGCGCGCCGGCGTAATCATGGTC pMS01\noMG171 TTACTTGTACAGCTCGTCCATGC mCherry\noMD01 CCTGAAGGGCGAGATCAAGC mCherry (qPCR)\noMD02 GTTCCACGATGGTGTAGTCC mCherry (qPCR)\noMD03 CTTTCGCTGAGGACGACTGG enoA (qPCR)\noMD04 CTTGAGAAGGAGAGCGTTGC enoA (qPCR)\noMD05 TACGACCAGATCAAGGATGC gpdA (qPCR)\noMD06 CATCGAAGATGGAAGAGCGG gpdA (qPCR)\noMD09 GTTGAGATGCACCACCAGC eef1\u03b1(qPCR)\noMD10 CCTGACCAGGGTGGTTAAGG eef1\u03b1(qPCR)\noMD13 GACGAGAAGGACCTTACTGG eef2(qPCR)\noMD14 GTCACGGATACCAGCGAAGG eef2(qPCR)\noMD17 GTGAGCCTCACTCTCTGCC 40sS2 (qPCR)\noMD18 TGTAGGCATCCTGGACACC 40sS2 (qPCR)\noMD19 GCTCAACCTCCTTCAACTCG 60sL4 (qPCR)\noMD20 GAAGAGTTGATAAGGCGGGC 60sL4 (qPCR)\noMD21 TCAGAGAAGCCCTTCCAGC alcA (qPCR)\noMD22 CGAAGAAGTCCAGAGCCTCG alcA (qPCR)Paper Organic & Biomolecular Chemistry\n4914 |Org. Biomol. C hem. ,2 0 1 9 ,17 , 4906\u2013 4916 This journal is \u00a9 The Royal Society of Chemistry 2019Published on 24 April 2019. Downloaded by Thueringer Universitats Landesbibliothek Jena on 11/24/2019 1:13:08 PM. View Article Onlineachilles/).33Binding poses for 1were rank-ordered based upon\ntheir predicted free energies of binding. Top seven binding\nposes with corresponding binding residues showing lowest\nbinding free energies and high number of clustered poses are\nlisted in Table S5 (ESI \u2020).\nStatistics. Significance levels in translational inhibition\nassays were estimated by the Wilcoxon \u2013Mann \u2013Whitney\n(WMW) test.34Significance levels of expression levels obtained\nfrom qRT-PCR analyses were calculated using the independent\ntwo-sample student \u2019st-test.\nCon\ufb02icts of interest\nThere are no conflicts of interest to declare.\nAcknowledgements\nPlasmid pMS01 was kindly provided by M. Samalova (Central\nEuropean Institute of Technology, Brno, Czech Republic).\nYeast strains for antifungal tests were kindly provided by\nS. Brunke (Leibniz Institute for Natural Product Research and\nInfection Biology \u2013Hans Kn\u00f6ll Institute (HKI), Jena). The\nauthors are grateful to A. Perner and H. Heinecke for\nrecording mass and NMR spectra, respectively, and to\nT. Kindel (all HKI Jena) for supporting MALDI-TOF-based\npeptide analyses. M. D. and M. G. thank N. Stefani and\nT. Heinekamp (both HKI, Jena) for introduction in fluo-\nrescence microscopy. The groups of O. W., C. H., and\nD. H. are supported by the DFG Collaborative Research\nCentre SFB1127 (ChemBioSys).\nReferences\n1 K. Baumgartner, M. P. Coetzee and D. Ho \ufb00meister, Mol.\nPlant Pathol. , 2011, 12, 515 \u2013534.\n2 M. Misiek, J. Williams, K. Schmich, W. Huttel, I. Merfort,\nC. E. Salomon, C. C. Aldrich and D. Ho\ufb00 meister, J. Nat.\nProd. , 2009, 72, 1888 \u20131891.\n3 I. Schmitt, S. Kautz and H. T. Lumbsch, Mycol. Res., 2008,\n112, 289 \u2013296.\n4 W. R. Abraham, Curr. Med. Chem. , 2001, 8, 583 \u2013606.\n5 M. Misiek and D. Ho \ufb00meister, Mycol. Prog., 2012, 11,7\u201315.\n6 M. Bohnert, S. Miethbauer, H. M. Dahse, J. Ziemen,\nM. Nett and D. Ho \ufb00meister, Bioorg. Med. Chem. Lett. , 2011,\n21, 2003 \u20132006.\n7 M. Bohnert, O. Scherer, K. Wiechmann, S. K\u00f6nig,\nH. M. Dahse, D. Ho \ufb00meister and O. Werz, Bioorg. Med.\nChem., 2014, 22, 3856 \u20133861.\n8 H. Kobori, A. Sekiya, T. Suzuki, J. H. Choi, H. Hirai and\nH. Kawagishi, J. Nat. Prod. , 2015, 78, 163 \u2013167.\n9 S. K\u00f6nig, E. Romp, V. Krauth, M. Ruhl, M. D\u00f6rfer,\nS. Liening, B. Hofmann, A. K. Hafner, D. Steinhilber,\nM. Karas, U. Garscha, D. Ho\ufb00 meister and O. Werz, Cell\nChem. Biol. , 2019, 26,6 0 \u201370.10 M. Bohnert, H. W. N\u00fctzmann, V. Schroeckh, F. Horn,\nH. M. Dahse, A. A. Brakhage and D. Ho \ufb00meister,\nPhytochemistry , 2014, 105, 101 \u2013108.\n11 L. Capa, A. Mendoza, J. L. Lavandera, F. G\u00f3mez de\nlas Heras and J. F. Garc\u00eda-Bustos, Antimicrob. Agents\nChemother. , 1998, 42, 2694 \u20132699.\n12 A. Srinivasan, J. L. Lopez-Ribot and\nA. K. Ramasubramanian, Drug Discovery Today: Technol.,\n2014, 11,6 5 \u201371.\n13 M. Shastry, J. Nielsen, T. Ku, M. J. Hsu, P. Liberator,\nJ. Anderson, D. Schmatz and M. C. Justice, Microbiology ,\n2001, 147, 383 \u2013390.\n14 C. M. Spahn, M. G. Gomez-Lorenzo, R. A. Grassucci,\nR. Jorgensen, G. R. Andersen, R. Beckmann, P. A. Penczek,\nJ. P. Ballesta and J. Frank, EMBO J., 2004, 23, 1008 \u20131019.\n15 J. M. Dominguez, V. A. Kelly, O. S. Kinsman, M. S. Marriott,\nF. Gomez de las Heras and J. J. Martin, Antimicrob. Agents\nChemother. , 1998, 42, 2274 \u20132278.\n16 M. G. Gomez-Lorenzo, C. M. T. Spahn, R. K. Agrawal,\nR. A. Grassucci, P. Penczek, K. Chakraburtty,\nJ. P. G. Ballesta, J. L. Lavandera, J. F. Garcia-Bustos and\nJ. Frank, EMBO J., 2000, 19, 2710 \u20132718.\n17 Y. M. Chiang, C. E. Oakley, M. Ahuja, R. Entwistle,\nA. Schultz, S. L. Chang, C. T. Sung, C. C. Wang and\nB. R. Oakley, J. Am. Chem. Soc. , 2013, 135, 7720 \u20137731.\n18 A. P. Siegel, M. A. Baird, M. W. Davidson and R. N. Day,\nInt. J. Mol. Sci., 2013, 14, 20340 \u201320358.\n19 P. J. Punt and C. A. van den Hondel, Methods Enzymol. ,\n1992, 216, 447 \u2013457.\n20 A. Gonz\u00e1lez, A. Jim\u00e9nez, D. V\u00e1zquez, J. E. Davies and\nD. Schindler, Biochim. Biophys. Acta , 1978, 521, 459 \u2013469.\n21 C. Bailey and H. N. Arst Jr., Eur. J. Biochem. , 1975, 51,\n573 \u2013577.\n22 G. Pontecorvo, J. A. Roper, L. M. Hemmons, K. D. Macdonald\nand A. W. Bufton, Adv. Genet. , 1953, 5, 141\u2013 238.\n23 D. H. Kang, Y. S. Gho, M. K. Suh and C. H. Kang, Bull.\nKorean Chem. Soc. , 2002, 23, 1511 \u20131512.\n24 A. Shevchenko, H. Tomas, J. Havlis, J. V. Olsen and\nM. Mann, Nat. Protoc. , 2006, 1, 2856 \u20132860.\n25 O. Salinovich and R. C. Montelaro, Anal. Biochem. , 1986,\n156, 341 \u2013347.\n26 H. Towbin, T. Staehelin and J. Gordon, Proc. Natl. Acad.\nSci. U. S. A. , 1979, 76, 4350 \u20134354.\n27 C. Li, A. Wen, B. Shen, J. Lu, Y. Huang and Y. Chang, BMC\nBiotechnol. , 2011, 11, 92.\n28 E. Brandenburger, M. Gressler, R. Leonhardt, G. Lackner,\nA. Habel, C. Hertweck, M. Brock and D. Ho\ufb00 meister, Appl.\nEnviron. Microbiol. , 2017, 83, e01478-17.\n29 M. Gressler, F. Meyer, D. Heine, P. Hortschansky,\nC. Hertweck and M. Brock, eLife , 2015, 4.\n30 A. Gobbi and D. Poppinger, Biotechnol. Bioeng. , 1998, 61,\n47\u201354.\n31 N. Eswar, B. Webb, M. A. Marti-Renom,\nM. S. Madhusudhan, D. Eramian, M. Y. Shen, U. Pieper\nand A. Sali, Curr Protoc Bioinformatics , 2006, ch. 5,\nunit-5.6.Organic & Biomolecular Chemistry Paper\nThis\njournal is \u00a9 The Royal Society of Chemistry 2019 Org. Biomol. C hem. ,2 0 1 9 ,17 , 4906\u2013 4916 | 4915Published on 24 April 2019. Downloaded by Thueringer Universitats Landesbibliothek Jena on 11/24/2019 1:13:08 PM. View Article Online3 2 E .F .P e t t e r s e n ,T .D .G o d d a r d ,C .C .H u a n g ,\nG. S. Co\nuch, D. M. Greenblatt, E. C. Meng\na n dT .E .F e r r i n , J. Comput. Chem. , 2004, 25, 1605\u2013\n1612.33 I. Sanchez-Linares, H. Perez-Sanchez, J. M. Cecilia and\nJ. M. Garcia, BMC Bioinf. , 2012, 13(Suppl 14), S13.\n34 A. Marx, C. Backes, E. Meese, H. P. Lenhof and A. Keller,\nGenomics, Proteomics Bioinf. , 2016, 14,5 5 \u201361.Paper Organic & Biomolecul ar Chemistry\n4916 |Org.Biomol. C hem. ,2 0 1 9 , 17,4 9 0 6 \u20134916 This journal is \u00a9 The Royal Society of Chemistry 2019Published on 24 April 2019. Downloaded by Thueringer Universitats Landesbibliothek Jena on 11/24/2019 1:13:08 PM. View Article Online1Melleolides impact fungal translation via Elongation Factor 2 \nMaximilian D\u00f6r\nfer,a Daniel Heine,b Stefanie K\u00f6nig,c Sagar Gore,d Oliver Werz,c Christian Hertweck,b Markus \nGressler,a Dirk Hoffmeistera,*\na Department Pharmaceutical Microbiology at the Hans Kn\u00f6ll Institute, Friedrich-Schiller-University, Beutenbergstrasse 11a, 07745 Jena, Germany\nb Department Biomolecular Chemistry, Leibniz Institute for Natural Product Chemistry and Infection Biology - Hans Kn\u00f6ll Institute, Beutenbergstrasse \n11a, 07745 Jena, Germany\nc Department Pharmaceutical and Medicinal Chemistry, Friedrich-Schiller-University Jena, Philosophenweg 14, 07743 Jena, Germany\nd Department Systems Biology and Bioinformatics, Leibniz Institute for Natural Product Chemistry and Infection Biology - Hans Kn\u00f6ll Institute, \nBeutenbergstrasse 11a, 07745 Jena, Germany  \n*Correspondence: Dirk Hoffmeister, Markus Gressler, Department Pharmaceutical Microbiology at the Hans Kn\u00f6ll Institute, Friedrich-Schiller-\nUniversity, Beutenbergstrasse 11a, 07745 Jena, Germany; Phone: +49-3641-949851; Fax: +49-3641-949852; e-mail: dirk.hoffmeister@hki-jena.de , \nmarkus.gressler@hki-jena.de.\nElectronic supplementary information \nTable of contents\nTable S1: NMR data of 5 .......................................................................................................................................... 2\nTable S2: NMR data of 6 .......................................................................................................................................... 3\nTable S3: MALDI-TOF-based peptide identification of eEF1 \uf061 and eEF2 .................................................................4\nTable S4:  Molecular fingerprint similarity analysis with 1 and 7.................................................................................4\nTable S5:  Predicted binding pocket for 1 in A. nidulans eEF2 .................................................................................5\nFigure S1 : 1H NMR spectrum of 5............................................................................................................................6\nFigure S2 : 13C NMR spectrum of 5 ...........................................................................................................................7\nFigure S3 : 1H,1H COSY spectrum of 5.......................................................................................................................8\nFigure S4: 1H,13C HMBC spectrum of 5....................................................................................................................9\nFigure S5 : ESI-MS data of 5 ...................................................................................................................................... 10\nFigure S6 : 1H NMR spectrum of 6............................................................................................................................11\nFigure S7 : 13C NMR spectrum of 6 ...........................................................................................................................12\nFigure S8 : 1H,1H COSY spectrum of 6.......................................................................................................................13\nFigure S9: 1H,13C HMBC spectrum of 6....................................................................................................................14\nFigure S10 : ESI-MS data of 6.................................................................................................................................... 15\nFigure S11 : MALDI-TOF-based peptide fingerprinting of eEF2................................................................................16\nFigure S12 : Phylogenetic analysis of fungal eEF2s ..................................................................................................17\nFigure S13 : Optimization of cultivation conditions of reporter strain A. nidulans tMD03......................................18\nFigure S14 : Expression analyses by qRT-PCR...........................................................................................................18\nFigure S15 : In vivo inhibition of protein biosynthesis in A. nidulans .......................................................................19\nFigure S16 : Recovery of A. nidulans in the presence of 1 and 2  .............................................................................19\nScheme S1: Synthesis route for compound 6..........................................................................................................20\nReferences ............................................................................................................................................................... 20Electronic Supplementary Material (ESI) for Organic & Biomolecular Chemistry.\nThis journal is \u00a9\nThe Royal Society of Chemistry 20192Table S1. NMR data of 5 in CD 3OD . a3-OH and 3\u2019-OH not observed; b not assigned due to signal overlap.\nno. \u03b4C, type \u03b4H (J in Hz) HMBC\n1 192.6,  CH 9.86 s 1, 2, 3, 4\n2 134.6,  qC\n3 73.3,   CHa4.31 dd (2.3; 7.3) 2, 4, 9\n4 169.5,  qC\n5 71.3,   CH 6.33 m 2, 4, 6\n6 46.3,   CH 2a: 2.15 dd  (5.8; 9.4) \nb: 2.7\n4 dd  (6.9; 9.3)b: 4, 8, (1')\na: 5,\n 6\n7 41.1,   qC\n8 21.3,   CH 3 1.20 4, 6, 7\n9 47.6,   CH 2.48 m 8, (3), (6), (11)\n10 41.9,   CH 2 1.53-1.42 m 10, 13, 14, 15\n11 40.6,   qC\n12 47.4,   CH 2a: 1.24 dd (9.0; 10.3)\nb: 1.8\n4 mb: 9, 15\na: 3,\n 15\n13 50.2,   CH 2.34-2.38 m 3, 12\n14 29.9,   CH 3 1.12 s 9, 11, 15\n15 27.6,   CH 3 1.00 s 9, 11, 14\n1' 169.8, qC\n2' 114.9, qC\n3' 161.8, qCa\n4' 108.8, CH 6.52 d (2.0) 3', 5', 6'\n5' 155.3, qC\n6' 116.7, CH 6.49 d (1.9) 2', 4', 5', 8'\n7' 142.4, qC\n8' 22.3,   CH 3 2.40 s 6', 7'\n1'' 172.7, qC\n2\" 34.2,   CH 2 2.61 1\", 3\", 4\"\n3\" 25.5,   CH 2 2.07 1\", 2\", 4\", 5\"\n4\" 25.6,   CH 2 2.81 2\", 3\", 5\", 6\"\n5\" 147.9, qC\n6\" 124.4, CH 7.83 s\nI 41.2,   CH 2a) 2.66 m\nb) 2.88\n dd (4.3; 10.6)II, VII, VI\nII 61.6,   CH 4.45 m I, IV, VII\nIII NH 6.20\nIV 166.1, qC\nV NH 6.16\nVI 63.3,   CH 4.25 m I, IV, VII\nVII 57.0,   CH 3.15 m IX, X\nVIII 26.8,   CH 2 1.62 m VI, IX, X, XI\nIX 29.8,   CH 2 1.40 m VII, XI\nX 29.5,   CH 2 1.67-1.72 m IX, (VII)\nXI 36.7,   CH 2 2.18 t (6.0)\nXII 176.1, qC\nXIII NH 8.45\nXIV 40.3,   CH 2 3.31 m XVI-XIX, XII\nXV 70.6,   CH 2 3.48 t(4.63) XIV, XVI-XIX\nXVIb\nXVIIb\nXVIIIb\nXIXb71.5 \u2013 71.2, 4 x CH 2 3.54-3.59 m XVI-XIX\nXX 70.4,   CH 2 3.85 m XXI, XIX\nXXI 51.4,   CH 2 4.55 m XX, C6\u201c\n3Table S2. NMR data of 6 in CD 3OD . anot assigned due to signal overlap.\nno. \u03b4C, type \u03b4H (J in Hz) HMBC\n1 14.1, CH 3 0.98 t (7.4) 2, 3\n2 19.8, CH 2 1.47 sext (7.5) 3, 4, 1\n3 31.3, CH 2 1.74 quin (6.6) 1, 2, 4\n4 65.5, CH 2 4.30 t (6.6) 2, 3, 1'\n1' 166.3, qC\n2' 128.8, qC\n3' 131.5, CH 8.05 d (8.7) 7', 6', 4', 5', 2'\n4' 122.2, CH 7.17 d (8.7) 6', 2', 5', 1', (1'')\n5' 154.9, qC\n6' 122.2, CH 7.17 d (8.7) 4', 2', 5', 1', (1'')\n7' 131.5, HC 8.05 d (8.7) 3', 6', 4', 5' 2'\n8'\n1'' 172.0, qC\n2\" 34.1,   CH 2 2.67 t (7.5) 1\", 3\", 4\"\n3\" 25.1,   CH 2 2.12 m 1\", 2\", 4\", 5\"\n4\" 25.3,   CH 2 2.83 t (7.5) 2\", 3\", 6\"\n5\" 147.3, qC\n6\" 122.7, CH 7.55 s 5''\nI 41.1,   CH 2a) 2.71 s\nb) 2.90\n dd (5.1; 7.8)II, VI, VII\nII\nII 60.7,   CH 4.47 m I, VII, IV (VI)\nIII             NH 6.02\nIV 164.1, qC\nV             NH 6. 2\nVI 62.3,   CH 4.30 m I, VII, IV, (II)\nVII 56.0,   CH 3.15 dt (4.6; 7.4) IX, X\nVIII 26.1,   CH 2 1.64 m VII, VI, IX, X, XI\nIX 28.6,   CH 2 1.43 m VIII, X, XI, VII\nX 28.6,   CH 2 1.62-1.75 m\nXI 36.3,   CH 2 2.18 t (7.5) X, IX, VIII, XII\nXII 173.4, qC\nXIII             NH 6.43 s XII\nXIV 39.8,   CH 2 3.38 quar (5.2) XV, XII\nXV 70.4,   CH 2 3.51 t (5.2) XVI-XIX, XIV\nXVIa \nXVIIa \nXVI\nIIa\nXIXa71.2-70.7, 4 x CH 2 3.55-3.60 m XVI-XIX\nXX 70.1,   CH 2 3.86 t (5.2) XXI, XVI-XIX\nXXI 50.8,   CH 2 4.51 t (5.2) XX, C6\u201c4\nO3\n1\u00b4O\n7\u00b4\n6\u00b4\n5\u00b44\u00b42\u00b4\nO1\u00b4\u00b4\nO2\u00b4\u00b4\n3\u00b4\u00b44\u00b4\u00b4\n5\u00b4\u00b4\nNNN XXIXXO\n6\u00b4\u00b4XVIIO\nXVIIIXIXXVIOXV XIVNHXIIIXIIOVIII\nXIXVIIVI\nII\nIS\nXINHV\nIV\nHNIIIO\n3\u00b4214Table S3. MALDI-TOF-based peptide identification of eEF1 \uf061 and eEF2 in protein fractions after elution from \n5-la\nbelled streptavidin beads. The sequence coverage (SC) and the root mean square at 90% (RMS90), which is \nused to compare distributions without large non-gaussian tails dominating, are indicated.\nband \nno. identified protein pIMW \n[kDa]Meta \nScore PeptidesSC \n[%]RMS90 \n[ppm]\n1TPA: elongation factor 1-alpha (eEF 1 \uf061)\n[Aspergillus \nnidulans FGSC A4]9.9 50.5 55.0 5 15.0 5.87\n2EF2_NEUCR Elongation factor 2 (eEF 2)\n[Aspergillus \nnidulans FGSC A4]6.2 93.8 199.0 19 29.4 10.38\nTable S4. Molecu lar fingerprint (FP) similarity analysis of 1 and 7 by encoding them into Morgan and 2D \nPharmacophore FPs. Tanimoto similarity values higher than 0.5 could be used as cut-off for similarity when \nMorgan FPs are used. Dice coefficients may have a higher cut-off depending on the FPs used to encode the \ngiven molecules. \nSimilarity metric 2D Pharmacophore Morgan\nTanimoto 0.147 0.164\nDice 0.257 0.2835Table S5. Predicted  binding pockets for 1 in A. nidulans eEF2 model  by the Achilles blind docking server. \nRanks for the first seven binding pockets are given along with their predicted free energies of binding (BE). 5 \u00c5 \nresidues around the predicted binding coordinates for 1 in A. nidulans eEF2 are listed. Residue numbering is \nshown in accordance with A. nidulans eEF2 (An ), C. albicans eEF2 (Ca)  and S. cerevisiae eEF2 (Sc) . Amino acid \nresidues differences are highlighted in bold. \n# BE organ. 5 \u00c5 residues from predicted DAO binding location\n1 -8.3An\nCa\nSc466K 484FS 515SDPC 534AG 537LH 541IC 545D 550H 731F 795PQSV\n   K    FS    SDPC    TG    LH    IC    D    H    F    PQLI\n   K    FS    SDPC    TG    LH    IC    D    H    F    PQMV\n2 -7.5An\nCa\nSc171EKED 250Y 262QPE 267GKP VER 275NM\n   TKED    \nY    DKD    GKPLER    NM\n   SKED    F    DTD    GKPLER    NM\n3 -7.5An\nCa\nSc418N 484FSVS 565R 600K 603EE 638GPD 643GA N 672T 681PMRS 799FDHW\n   N    FSVS    R    L    EN    GPD    G PN    T    NCRS    FDHW\n   N    FSVS    R    L    EN    GPD    G PN    T    EMRS    FDHW\n4 -7.1An\nCa\nSc42R 79AKFA 86D 224RQF 228VK 305E 327KFLP 333ADA 336LE\n  K   ASMT\n   D    RQF    NK    E    KFLP    ADA    LE\n  R   SEMS   D    RQF    TR    E    KFLP    ADA    LE\n5 -7.0An\nCa\nSc492R 536E 559DPVV 564Y 727E 752R 776NE 779F 805L 816K 819QI 823E\n   V    E    P\nPVV    Y    E    R    NE    F    M    K    AI    E\n   V    E    PPVV    Y    E    R    NE    F    L    K    EI    A\n6 -7.0An\nCa\nSc165LLE 169QVEK 280D 283YK  286FQ 290TN\n   LLE    QTTK    D    FR    FA    MN\n   LLE    QVSK    D    FR    FT    MN\n7 -7.0An\nCa\nSc226F 229KF  232KKF 251F 253P 276MFI 280DP 284K 303KIE\n   F    KY     KKF    F    P    MFI    DP    R    KLE\n   F    RY     KKF    F    P    MFI    DP    R    KLE6A\nB C D\n \n  \nFigure S1. 1H NMR  spectra of 5 in CD 3OD. A. Full range  1H NMR spectrum of 5 in CD 3OD. B-D. Close-up view of \nportions (5.0-3.0 ppm, 3.0-2.0 ppm, and 1.8-1.0 ppm) of the 1H NMR spectrum of 5.O OH\nH\nOHOH O\nO\nO NNNOOONHOSNH\nHNO7Figure S2. 1H-decoupled 13C NMR spectra of 5 in CD 3OD. O OH\nH\nOHOH O\nO\nO NNNOOONHOSNH\nHNO8A\nB\nO\nO NNOOONHOSNH\nHNO\n1\"2\"\n3\"4\" 5\"6\"IIIIIIIVV\nVIIVIII\nIX\nX\nXIXII\nXIII\nXIV XV\nXVI\nXVII\nXVIIIXIX\nXX\nXXIVI\nO OO OH\nOHH\nH1\n23\n4\n567\n89101112\n1314\n15\n1'\n2'\n3'\n4'\n5'6'7'8'COSY-correlation\nN\nFigure S3. 1H,1H COSY spec trum of 5 in CD 3OD.  A. Full range 1H,1H COSY spectrum of 5. B. COSY key \ncorrelations.9A\nB\nO\nO NNOOONHOSNH\nHNO\n1\"2\"\n3\"4\" 5\"6\"IIIIIIIVV\nVIIVIII\nIX\nX\nXIXII\nXIII\nXIV XV\nXVI\nXVII\nXVIIIXIX\nXX\nXXIVI\nO OO OH\nOHH\nH1\n23\n4\n567\n89101112\n1314\n15\n1'\n2'\n3'\n4'\n5'6'7'8'HMBC-correlation\nN\nFigure S4. 1H,13C HMB C spectrum of 5 in CD 3OD. A. Full range 1H,13C HMBC spectrum of 5. B. HMBC key \ncorrelations.10\nFigure S5. ESI-MS spectrum of 5.11Figure S6. 1H NMR  spectrum of 6 in CD 3OD.O O\nO\nO NNNOOONHOSNH\nHNO12Figure S7. 1H-decoupled 13C NMR spectrum of 6 in CD 3OD.O O\nO\nO NNNOOONHOSNH\nHNO13A\nB\nO\nO NNOOONHOSNH\nHNO\n1\"2\"\n3\"4\" 5\"6\"IIIIIIIVV\nVIIVIII\nIX\nX\nXIXII\nXIII\nXIV XV\nXVI\nXVII\nXVIIIXIX\nXX\nXXIVI\nO O1\n2\n43\n1'\n2'\n3'\n4'\n5'6'7'COSY-correlation\nN\nFigure S8. 1H, 1H COSY spe ctrum of 6 in CD 3OD. A. Full range 1H, 1H COSY spectrum of 6. B. COSY key couplings \nin 6.14A\nB\nO\nO NNOOONHOSNH\nHNO\n1\"2\"\n3\"4\" 5\"6\"IIIIIIIVV\nVIIVIII\nIX\nX\nXIXII\nXIII\nXIV XV\nXVI\nXVII\nXVIIIXIX\nXX\nXXIVI\nO O1 2\n3 4\n1'\n2'\n3'\n4'5'6'7'HMBC-correlation\nN\nFigure S9.  1H,13C HMB C spectrum of 6 in CD 3OD. A. Full range 1H,13C HMBC spectrum. B. HMBC key \ncorrelations.15\nFigure S10.  ESI-MS data of 6.16\nFigure S11. MALDI-TOF-based peptide fingerprinting. Identifie d peptides from A. nidulans eEF2 in protein pull-\ndown fraction with 5-labelled streptavidin beads. Identified peptides from trypsin treated samples were \naligned to A. nidulans eEF2 (highlighted in red). Grey bars indicate the reliance of the identified peptides: The \ndarker the bar the lower is the difference between the measured m/z and the calculated m/z.  17\nFigure S12. Phylo genetic analysis of fungal eEF2 with documented resistance or sensitivity towards 1 (DAO) \nand 2 (arnamial). Multiple amino acid sequence alignments were performed using the MUSCLE Alignment tool \nimplemented in the Geneious 10.2.3 software carried out in default mode with a maximum of 1,000 iterations \nand 1,000 trees to be build. Phylogenetic analyses were performed with Geneious Tree Builder software using \nthe Jukes-Cantor genetic distance model and the neighbour-joining method. The amino acid sequence of the \nhuman eEF2 was used as outgroup to root the tree. The bootstrap method was used as a resampling technique \nto estimate statistics on 1,000 replicates. Bootstrap values (consensus support in %) are given next to the \nbranches in the consensus tree. Red and green spheres indicate resistance and sensitivity, respectively, \ntowards 1 and 2 as reported by Misiek et al.1, Bohnert et al.2, and by this work (Figure 3 A).18\nFigure S13. Optimization of cultivation conditions . A. nidulans tMD03 was cultivated for 48, 72, and 96 h in \nAMM containing 100 mM ethanol and 5, 10, or 25 mM D-glucose. Fluorescence units of cell-free total protein \nextracts were determined and normalised against the fungal biomass.\nFigure S14. Gene expression analyses by qRT-PCR . A. nidulans tMD03 was pre-cultivated for 16 h in presence \nof 10 mM D-glucose and 100 mM ethanol. Compounds 8 (72 \u00b5M) or 2 (22 \u00b5M) were added, and cultures were \ngrown for additional 14 or 36 h prior to expression analysis. Untreated cultures served as control. qRT-PCR \ntargeted the genes for mCherry (mCh), alcohol dehydrogenase (alcA ), eEF2 (eef2 ), eEF1\u03b1 (eef1\u03b1 ), and proteins \nfor the small (40sS2 ) and large (60sL4 ) ribosomal subunits. Expression levels were normalised against two \nhousekeeping genes, i.e., enolase (enoA ) and glycerinaldehyde-3-phosphate dehydrogenase (gpdA ).  \nSignificance of gene expression levels were calculated against the respective untreated control by pairwise \nstudent\u00b4s t-test (n.s., p > 0.05; *, p < 0.05; **, p< 0.01).19\nFigure S15. In vivo  inhibition of protein biosynthesis in A. nidulans tMD03 . The fungus was treated with 2 at 2 \nand 10 \u00b5g mL-1. The untreated control served as internal fluorescence reference standard. The experiment was \ncarried out as described in Figure 4.\nFigure S16. Recovery of A. nidulans in presence of 1 and 2. AMM plates were inoculated with A. nidulans  FGSC \nA4 at a concentration of 1 x 106 conidia mL-1, and 20, 5 or 1 \u00b5g of 1 and 2 were supplied. Plates were incubated \nfor 1, 2, or 3 days at 30 \u00b0C. The size of inhibition zones is time-dependently reduced, indicating a fungistatic \nactivity of 1 and 2. 20Scheme S1. Synthesis route for compound 6 . \nReferences\n1.  Misie\nk, M.; Hoffmeister, D. Mycol. Prog. 2012,  11, 7.\n2.  Bohnert, M.; N\u00fctzmann, H. W.; Schroeckh, V.; Horn, F.; Dahse, H. M.; Brakhage, A. A.; Hoffmeister, D. \nPhytochemistry 2014,  105 , 101.3. Publikationen   50 \n3.2. Publi\nkation 2 \u2013 Melleolides from Honey Mushroom Inhibit  \n5-Lipoxygenase via Cys 159  \nStefanie K\u00f6nig, Erik Romp, Verena Krauth, Michael Ruhl, Maximilian D\u00f6rfer , Stefanie \nLiening, Bettina Hofmann, Ann-Kathrin Hafner, Dieter Steinhilber, Michael Karas, Ulrike \nGarscha, Dirk Hoffmeister, Oliver Werz \nCell Chemical Biology, 2019, Volume 26, 1- 11. \nZusammenfassung  \nDie humane 5-Lipoxigenase (5-LO) wurde in einem Screening als molekulares Wirkziel von \nMelleoliden aus Armillaria mellea  identifiziert. Melleolide wie DAO hemmen die 5-LO und damit \neine Entz\u00fcndungsreaktion aufgrund einer inhibierten Leukotrienbildung. DAO stellt aufgrund \ndes \u03b1- \u03b2-unges\u00e4ttigten Aldehyds in Verbindung mit einem Alkohol einen starken Michael \nAkzeptor dar. Dieser bindet oberfl\u00e4chlich exponierte Cysteine am Eingang des aktiven \nZentrums des Entz\u00fcndungsmediators 5-LO. Die Cysteine 159, 300, 416 und 418 wurden in  \n5-LO gegen Serine ausgetauscht. Durch die verhinderte Bildung des 5-LO/FLAP-Komplexes \nkonnte eine direkte Wechselwirkung, basierend auf einer kovalenten Bindung, zwischen DAO \nund dem Cystein 159 nachgewiesen werden. Cys159 scheint also eine wichtige Funktion in \nder Bildung des 5-LO/FLAP Komplexes an der Membran des Zellkerns und somit f\u00fcr die \nLeukotrienbiosynthese zu besitzen. \nEigenanteil 10%: \nMaximilian D\u00f6rfer: Kultivierung von A. mellea, Extraktion, Isolierung und  \n    Strukturaufkl\u00e4rung von DAO & Derivaten  \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nJena, den \n \n____________________  \nProf. Dr. Dirk Hoffmeister  Article\nMelleolides from Honey Mushroom Inhibit 5-\nLipoxygenase via Cys159\nGraphical Abstract\nHighlights\ndHu\nman 5-lipoxygenase (5-LO) was identi\ufb01ed as a molecular\ntarget of mel\nleolides\ndMelleolides inhibit 5-LO via two or more of the cysteines 159,\n300, 416, and 418\ndMe\nlleolides prevent interaction of 5-LO with its helper protein\nvia Cys159 in 5-LO\ndCy\ns159 in 5-LO determines interaction with its helper protein\nand 5-LO activit\nyAuthors\nStefanie Ko \u00a8nig, Erik Romp,\nVeren\na Krauth, ..., Ulrike Garscha,\nDirk Hoffmeister, Oliver Werz\nCorrespondence\noliver.werz@uni-jena.de\nIn Brief\nKo\u00a8nig et al. revealed human 5-\nlipoxygenase as\na functional target of\nmelleolides from honey mushroom,\nwhere cysteines at the substrate entrance\nof 5-lipoxygenase mediate enzyme\ninhibition. Exploiting melleolides as a tool\nthey identi\ufb01ed Cys159 as a determinant\nfor interaction of 5-lipoxygenase with its\nhelper protein.\nKo\u00a8niget al., 2019, Cell Chemical Biology 26,1\u201311\nJanuary 17,\n2019\u00aa2018 Elsevier Ltd.\nhttps://doi.org/10.1016/j.chembiol.2018.10.010Cell Chemical Biology\nArticle\nMelleolides from Honey Mushroom\nInhibit 5-Lipoxygenase v\nia Cys159\nStefanie Ko \u00a8nig,1Erik Romp,1Verena Krauth,1Michael R \u20acuhl,2Maximilian Do \u00a8rfer,3Stefanie Liening,1Bettina Hofmann,2\nAnn-Kathrin H \u20acafner,2Dieter Steinhilber,2Michael Karas,2Ulrike Garscha,1Dirk Hoffmeister,3and Oliver Werz1,4,*\n1Department of Pharmaceutical/Medicinal Chemistry, Institute of Pharmacy, Friedrich-Schiller-University Jena, 07743 Jena, Germany\n2Institute of Pharmaceutical Chemistry, Goethe University Frankfurt, 60438 Frankfurt, Germany\n3Department of Pharmaceutical Microbiology at the Hans Kno \u00a8ll Institute, Friedrich-Schiller-University Jena, 07745 Jena, Germany\n4Lead Contact\n*Correspondence: oliver.werz@uni-jena.de\nhttps://doi.org/10.1016/j.chembiol.2018.10.010\nSUMMARY\n5-Lipo\nxygenase (5-LO) initiates the biosynthesis\nof pro-in\ufb02ammatory\nleukotrienes from arachidonic\nacid, which requires the nuclear membrane-bound\n5-LO-activating protein (FLAP) for substrate transfer.\nHere, we identi\ufb01ed human 5-LO as a molecular target\nof melleolides from honey mushroom ( Armillaria mel-\nlea). Melleolides inhibit 5-LO via an a,b-unsaturated\naldehyde serving as Michael acceptor for surface\ncysteines at the substrate entrance that are revealed\nas molecular determinants for 5-LO activity. Experi-\nments with 5-LO mutants, where select cysteines\nhad been replaced by serine, indicated that the\ninvestigated melleolides suppress 5-LO product for-\nmation via two distinct modes of action: (1) by direct\ninterference with 5-LO activity involving two or more\nof the cysteines 159, 300, 416, and 418, and (2) by\npreventing 5-LO/FLAP assemblies involving selec-\ntively Cys159 in 5-LO. Interestingly, replacement of\nCys159 by serine prevented 5-LO/FLAP assemblies\nas well, implying Cys159 as determinant for 5-LO/\nFLAP complex formation at the nuclear membrane\nrequired for leukotriene biosynthesis.\nINTRODUCTION\nNatural products are discovered at a rapid rate, and bioactiv-\nities ar\ne extensively screened f or in routine assays. However,\nthe knowledge on the modes of action and molecular targets\nof these bioactive compounds is severely lagging behind. In\nthe arena of mushroom toxins, the mode of action is under-\nstood only for very few compounds, among them the amanitins,\npsilocybin, muscarine, coprine, and ibotenic acid. The melleo-\nlides ( Figure 1 A) are natural products of the basidiomycete\nArmillaria me\nllea (honey mushroom), a globally distributed\nmushroom that also represen ts an important plant pathogen\n(Baumgartner et al., 2011). Bioactivities include antimicrobial\nand antifungal\neffects, as well as cytotoxicity against human\nmonocytes and cancer cells ( Bohnert et al., 2011, 2014b;\nMisiek et al.,\n2009; Momose et al., 2000 ). Intriguingly, these ac-tivities fo\nllow dissimilar structure-activity relationships (SARs)\n(Bohnert et al., 2014a ). With more than 60 published members,\nmelleolid es\nrank among the largest and most diverse classes\nof fungal natural products. Struc turally, they are composed of\nan orsellinic acid moiety esteri\ufb01ed to a protoilludene-type\nsesquiterpene secondary alcohol . Many melleolides feature\nana,b-unsaturated aldehyde moiety that may act as Michael\nacceptor, but molecular targets of the melleolides are thus far\nunknown. We previously showed that Michael acceptor-\ncontaining drugs such as thymoquinone (TQ) ( Maucher et al.,\n2017) or nitro fatty acids ( Awwad et al., 2014) are direct cova-\nlent inhibitors of\nhuman 5-lipoxygenase (5-LO) by targeting\nCys416 and Cys418.\n5-LO is the key enzyme in the biosynthesis of pro-in\ufb02amma-\ntory leukotrienes (LTs) from arachidonic acid (AA) that play\nimportant roles in disorders such as asthma, rheumatoid\narthritis, allergic rhinitis, neurodegenerative and cardiovascular\ndiseases, and cancer ( Radmark et al., 2015 ). LT biosynthesis is\nmainly restricted to leukocytes\nwhere the cytosolic phospholi-\npase A 2(cPLA 2) and 5-LO translocate to the nuclear envelope\nupon cell activation. cPLA 2releases AA from membrane phos-\npholipids ( Leslie, 2015 ), and AA is then transferred by the nuclear\nmembrane-bound 5-LO-activating protein (FLAP)\nto 5-LO,\nwhich assembles a complex with FLAP. 5-LO oxygenates AA\nto yield the intermediate 5(S)-hydroperoxyeicosatetraenoic\nacid (5-HPETE) and then dehydrates 5-HPETE to LTA 4, again\naided by FLAP ( Radmark et al., 2015 ). LTA 4can be enzymatically\nconverted to the chemoattractant LTB 4or to cysteinyl-LTs\n(LTC 4,D4,o rE 4) that contract smooth muscles in the airways\nand microcirculation ( Haeggstrom and Funk, 2011 ). FLAP binds\nAA and is essential\nfor 5-LO activity in intact cells, seemingly by\naccomplishing appropriate substrate access for 5-LO ( Evans\net al., 2008 ). The\n5-LO/FLAP complex assembly at the nuclear\nmembrane requires AA, and\nFLAP inhibitors prevent 5-LO/\nFLAP interactions and 5-LO product formation in an AA-compet-\nitive fashion ( Bair et al., 2012; Gerstmeier et al., 2014, 2016b ).\nRecently, we showed that\nthe cysteines 159, 300, 416, and\n418, located on the 5-LO protein surface close to the AA entry\nsite, are important for co-localization with FLAP ( Hafner\net al., 2015 ).\nThe poor knowledge on\nthe pharmacology behind mushroom\ntoxins, and the fact that honey mushrooms are considered edible\nand collected in many regions prompted us to investigate the\nmode of action of the melleolides. To explore their molecular\nCell Chemical Biology 26, 1\u201311, January 17, 2019 \u00aa2018 Elsevier Ltd. 1Please cite this article in press as: Ko \u00a8nig et al., Melleolide s from Honey Mushroom Inhibit 5-Lipoxygenase via Cys159, Cell Chemical Biology (2018),\nhttps://doi.org/10.1016/j.chembiol.2018.10.010targets in mammalian cells, we investigated four structurally\ndifferent representatives ( Figure 1 A)\nfor interference with human\n5-LO. We identi\ufb01ed 5-LO\nas a molecular target for those melleo-\nlides that possess an a,b-unsaturated aldehyde with thiol-reac-\ntive Michael acceptor functionality. These melleolides mediate\ntheir 5-LO-inhibitory effects via surface cysteines of 5-LO. Our\ndata suggest that melleolides interact with Cys159 at the\nentrance of the catalytic center of 5-LO, which prevents the com-\nplex assembly with FLAP and thus abrogates 5-LO activity. We\nconclude that Cys159 of 5-LO is critical for the assembly of the\n5-LO/FLAP complex, whereas cysteines 300, 416, and 418 do\nnot contribute.\nRESULTS\nMelleolides Inhibit 5-LO Activity\nin Cell-Free and Cell-\nBased Systems\nWe investigated the effects of four structurally related melleo-\nlides isolated from Armillaria mellea (Figure\n1A) on the activity\nof 5-LO in a\ncell-based model using Ca2+-ionophore A23187-\nstimulated human neutrophils, and in a cell-free assay using\npuri\ufb01ed human recombinant 5-LO as enzyme source. The inves-\ntigated compounds included dehydroarmillylorsellinate (DAO)\n(1), arnamial ( 2), armillarin ( 3), and melleolide D ( 4). Concentra-\ntion-response experiments with these melleolides in the cell-\nfree assay revealed 2as most potent derivative with a half\nmaximal inhibitory concentration (IC 50) of 0.3 \u00b1 0.02 mM, followed\nby3(IC50= 2.5 \u00b1 0.4 mM) and 1(IC50= 2.8 \u00b1 0.9 mM,Figure 1 B).\nCompound 4was much less ef\ufb01cient\n(IC50>1 0mM). Of interest,\nin neutrophils, 1was the most ef\ufb01cient derivative against 5-LO\n(IC50= 0.3 \u00b1 0.1 mM, Figure 1 C), with 10-fold higher\npotency versus cell-free assay\nconditions. Melleolides 2(IC50=\n1.0 \u00b1 0.2 mM) and 3(IC50= 5.2 \u00b1 1.4 mM) showed comparable\nef\ufb01ciency as in the cell-free test system. Again, 4caused only\nmoderate inhibition of 5-LO activity in neutrophils (IC 50>\n10mM). Cell viability analysis (trypan blue and light microscopy)\nexclude detrimental effects of 1\u20134during the 10 min pre-incuba-\ntion period of neutrophils (data not shown).DAO (1) Potently Inhibits 5-LO Activity in Intact\nNeutrophils andMonocytes\nToexpl\nore 5-LO inhibition by melleolides, we focused on 1, which\nwas the most\npotent derivative in neutrophils. First, we analyzed\nthe effect of 1against 5-LO in neutrophil homogenates, another\ncell-free test system for assessment of 5-LO activity ( Werz and\nSteinhilber, 2005 ).\nCompared with its high potency in neutrophils,\n1was less active\nagainst 5-LO in corresponding homogenates\n(IC50= 1.1 \u00b1 0.2 mM), similar as for isolated 5-LO ( Figure 2 A). In\ncontrast, the\n5-LO inhibitor zileuton was equally effective for iso-\nlated 5-LO and cellular 5-LO activity (IC 50/C240.8mM,Figure 2 B).\nThis suggested\nthat1may interact with other enzyme(s) or fac-\ntors involved in cellular 5-LO product formation such as cPLA 2\nor FLAP. Analysis of AA release using [3H]AA-labeled neutrophils\nindicated weak suppression of AA liberation by 1(at 1mM), which\nwas much less pronounced as compared with RSC-3388, a\nspeci\ufb01c cPLA 2inhibitor ( Table S1 ). We next supplemented neu-\ntrophils with exo\ngenous AA (20 mM), to overcome potential de\ufb01-\nciencies in endogenous AA supply due to potential cPLA 2or\nFLAP inhibition ( Werz and Steinhilber, 2005 ). The strong potency\nof1in absence of\nexogenous AA (i.e., IC 50= 0.3 mM) was about 7-\nfold decreased upon AA supplementation (IC 50= 2.1 mM,Fig-\nure 2 C), suggestin\ng that 1may interfere with AA-related action(s).\nWe also tested whether 1may interfere with signaling processes\nimportant for 5-LO activation, such as its activation by mitogen-\nactivated protein kinases (MAPKs) ( Radmark et al., 2015 ).\nHowever, up to\n10mM,1failed to suppress the phosphorylation\nof p38 MAPK and extracellular signal-regulated kinase-1/2,\nand thus of cPLA 2in neutrophils ( Figure S1 ). Moreover, 1did\nnot cause strong\ninhibition of other enzymes in LT or eicosanoid\nbiosynthesis such as LTC 4synthase, cyclooxygenase-1/2, or\nmicrosomal prostaglandin E2 synthase-1 ( Table S1 ), indicating\na certain sel\nectivity against 5-LO.\nBesides neutrophils, also monocytes have high capacities to\nbiosynthesize 5-LO products ( Surette et al., 1993 ). Melleolide 1\ninhibited 5-LO activity also\nin human monocytes stimulated\nwith A23187, with comparable ef\ufb01ciency (IC 50= 0.8 mM), as in\nneutrophils ( Figure 2 D). A more detailed analysis showed that 1A\nB CFigure 1. Melleolides Inhibit 5-LO Activity in\nCell-Free and Cell-Based\nSystems\n(A) Chemical structures of melleolides 1\u20134.\n(B) Effect of 1\u20134on 5-LO\nproduct formation in a\ncell-free assay. Puri\ufb01ed human recombinant 5-LO\n(0.5mg/mL) was pre-incubated with compounds or\nvehicle (0.1% DMSO) at 4/C 4C for 10 min. Samples\nwere pre-warmed for 30 s at 37/C 4C and incubated\nwith 2 mM CaCl 2and 20 mM AA for another 10 min.\nThe reaction was terminated and 5-LO products\nwere then analyzed by reverse-phase high-perfor-\nmance liquid chromatography (RP-HPLC).\n(C) Effect of 1\u20134on 5-LO product formation in a\ncell-based system. Neutrophils (5 3106/mL) were\npre-incubated with compounds or 0.1% DMSO\n(vehicle) for 10 min at 37/C 4C prior to stimulation with\n2.5mM A23187 for 10 min at 37/C 4C, and 5-LO\nproduct formation was determined. Data are ex-\npressed as percentage of vehicle control (100%),\nmeans \u00b1 SEM, n = 3.\n2Cell Chemical Biology 26, 1\u201311, January 17, 2019Please cite this article in press as: Ko \u00a8nig et al., Melleolides from Honey Mushroom Inhibit 5-Lipoxygenase via Cys159, Cell Chemical Biology (2018),\nhttps://doi.org/10.1016/j.chembiol.2018.10.010(at 1 mM) decreased all lipid mediators formed by 5-LO (i.e.,\ntr-LTB 4isomers, LTB 4, and 5-hydroxyeicosatetraenoic acid\n[HETE]) to a similar degree, which again was less pronounced\nwhen exogenous AA was supplemented ( Figure 2 E).\nFormation\nof 12- and 15-HETE\nwas less affected by 1, and, in the presence\nof exogenous AA (20 mM), 1lost its inhibitory potency to sup-\npress the biosynthesis of these lipid mediators.\nCharacterization of 5-LO Inhibition by Melleolides and\nInteraction with Cysteine\nWe characterized\n5-LO inhibition by 1in more detail. Washout\nexperiments\nwith isolated 5-LO revealed that 1acts in a partially\nirreversible manner ( Figure 3 A), since the suppressive effect of 1\nagainst 5-LO was hardly\nreversed upon 10-fold dilution. 5-LO\nactivity studies with increasing AA concentrations (3\u201360 mM) in\nthe cell-free assay revealed that the inhibitory potency of 1ismarkedly improved at higher AA concentrations (IC 50=7mMa t\n3mM AA versus IC 50= 0.3 mMa t6 0 mM AA, Figure 3 B, left panel),\neven though the absolute\nactivities of 5-LO strongly differ at the\nvarious AA concentrations ( Figure 3 B, right panel). Note that in\nintact neutrophils, exogenous supplementation\nof 20 mMA A\ngave the opposite effect and decreased the potency of 1to\ninhibit 5-LO product formation, suggesting that the molecular\nmechanisms for suppression of 5-LO activity differ between\nintact cells and cell-free assays.\nCompounds featuring a Michael acceptor, such as TQ or nitro\nfatty acids, were shown to act as direct covalent enzyme inhibi-\ntors that target the catalytically relevant Cys416 and Cys418 in\n5-LO ( Awwad et al., 2014; Maucher et al., 2017 ). It appeared\nreasonable that the a,b-unsaturated\naldehyde in 1,2, and 3\nmay function as Michael acceptors and react with these\ncysteines. Incubation of melleolides with glutathione (GSH) forA B C\nD E\nFigure 2. DAO ( 1) Potently Inhibits 5-LO Activity in Intact Neutrophils and Monocytes\n(A) Puri\ufb01ed human recombinant 5-LO, intact human neutrophils (5 3106/mL), or neutrophil homogenates (corresponding to 5 3106cells/mL) were incubated with\n1or vehicle (0.1% DMSO) for 10 min at 37/C 4C (neutrophils) or 4/C 4C (5-LO, homogenates) prior to addition of 2.5 mM A23187 (neutrophils) or 2 mM CaCl 2and 20 mM\nAA (5-LO, homogenates).\n(B) Neutrophils or puri\ufb01ed human recombinant 5-LO were pre-incubated for 10 min with zileuton or vehicle (0.1% DMSO) prior to addition of 2.5 mM A23187\n(neutrophils) or 2 mM CaCl 2and 20 mM AA (5-LO).\n(C) Neutrophils were pre-incubated for 10 min with 1or vehicle (0.1% DMSO) prior to addition of 2.5 mM A23187 with or without 20 mM AA.\n(D) Effect of 1on 5-LO product formation in neutrophils and monocytes. Cells (5 3106/mL) were pre-treated with 1or vehicle (0.1% DMSO) for 10 min. 5-LO\nproduct formation was started by 2.5 mM A23187.\n(E) Effect of 1(1mM) on eicosanoid biosynthesis in intact monocytes stimulated with 2.5 mM A23187 in the presence or absence of 20 mM AA. All incubations (A\u2013E)\nwere performed for 10 min at 37/C 4C, and then 5-LO product formation was determined by RP-HPLC and eicosanoids in (E) were analyzed by ultra-performance\nliquid chromatography-MS/MS. Data are expressed as percentage of uninhibited control (100%), means \u00b1 SEM, n = 3, +p < 0.05 versus vehicle control,\npaired t test.\nSee also Figure S1 andTable S1 .\nCell Chemical Biology 26, 1\u201311, January 17, 2019 3Please cite this article in press as: Ko \u00a8nig et al., Melleolide s from Honey Mushroom Inhibit 5-Lipoxygenase via Cys159, Cell Chemical Biology (2018),\nhttps://doi.org/10.1016/j.chembiol.2018.10.01060 min at 37/C 4C and subsequent analysis of the reaction mixture\nby tandem mass spectrometry (MS/MS) showed that 1(Figures\n3C\nand 3D) and 2(Figure S2 ) reacted with the thiol group of GSH.The spectra revealed the\nexpected signals for the resulting GSH-\nmelleolide adducts (708.5 Da for 1,Figure 3 C, and 756.7 Da for 2,\nFigure S2 ).\nFigure 3. Characterization of 5-LO Inhibition by Melleolides and Interaction with Cysteine\n(A) Reversibility of 5-LO inhibition by 1. Puri\ufb01ed 5-LO (0.5 mg/mL) was pre-incubated with 1(1 or 10 mM) or vehicle (0.1% DMSO) at 4/C 4C for 10 min, pre-warmed at\n37/C 4C for 30 s, and 2 mM CaCl 2and 20 mM AA were added. \u2018\u2018Wash out\u2019\u2019 samples had been diluted 10-fold with assay buffer prior to addition of 2 mM CaCl 2and\n20mM AA. After 10 min at 37/C 4C, 5-LO products were analyzed by RP-HPLC. Data are expressed as percentage of control (100%), means \u00b1 SEM, n = 3, *p < 0.05\nversus control, paired t test.\n(B) Effect of various AA concentrations on 5-LO inhibition by 1. Puri\ufb01ed 5-LO (0.5 mg/mL) was pre-incubated with 1or vehicle (0.1% DMSO) at 4/C 4C for 10 min.\nSamples were pre-warmed at 37/C 4C for 30 s, and 2 mM CaCl 2and the indicated concentrations of AA were added and then incubated for 10 min at 37/C 4C. Data are\nexpressed as percentage of control (100%, left panel) or as ng/mL 5-LO products formed (right panel) and are given as means \u00b1 SEM, n = 3.\n(C) MS2spectrum of 1(DAO)-modi\ufb01ed glutathione.\n(D) Schematic fragmentation reactions with expected mass shifts.\n(E) Results of speci\ufb01city analysis with standard peptides. X, modi\ufb01cation observed; \u2013, no modi\ufb01cation observed. *Indicates the detection of imine-formation in\nmass spectrum (side reaction), **Indicates the modi\ufb01cation of peptide con\ufb01rmed in MS2and/or MS3.\nSee also Figures S2 andS3.\n4Cell Chemical Biology 26, 1\u201311, January 17, 2019Please cite this article in press as: Ko \u00a8nig et al., Melleolides from Honey Mushroom Inhibit 5-Lipoxygenase via Cys159, Cell Chemical Biology (2018),\nhttps://doi.org/10.1016/j.chembiol.2018.10.010(legend on next page)\nCell Chemical Biology 26, 1\u201311, January 17, 2019 5Please cite this article in press as: Ko \u00a8nig et al., Melleolide s from Honey Mushroom Inhibit 5-Lipoxygenase via Cys159, Cell Chemical Biology (2018),\nhttps://doi.org/10.1016/j.chembiol.2018.10.010We next performed an amino acid residue speci\ufb01city analysis\n(Figure 3 E) to study binding of the melleolides to cysteine, histi-\ndine, serine, or lysine\nresidues. These residues react in a\nMichael-like reaction but can also yield a semi-thioacetal or a\nsemi-aminal. High-resolution MS spectra display the predicted\nmasses of the reaction products that show the modi\ufb01cation of\ncysteine, histidine, and lysine by 1and2. MS/MS spectra dis-\nplayed one main peak, which indicated the loss of chloroorsel-\nlinic acid or orsellenic acid, depending on the used melleolide.\nMS3-spectra then showed the expected peptide fragment ion\nspectra and pointed out the binding side of the reactive sesqui-\nterpene ( Figure S3 ). The reaction of the melleolides with 5-LO\ndisplayed the mass of\nthe modi\ufb01ed peptide of 2containing\nCys159. MS/MS spectra yielded poor fragment ion abundance,\nso the exact modi\ufb01cation site could not be con\ufb01rmed.\nModulation of 5-LO Translocation and 5-LO/FLAP\nInteraction by Melleolides\n5-LO\ntranslocation to the nuclear envelope and interaction with\nFLAP is a\ndeterminant for cellular 5-LO product formation ( Gerst-\nmeier et al\n., 2016a; Mandal et al., 2008 ). The superior potency of 1\nagainst 5-\nLO activity in intact cells versus isolated enzyme led us\nto investigate if melleolides could block 5-LO translocation and/or\ninteraction with FLAP. A convenient model based on HEK293\ncells, stably transfected with 5-LO and FLAP, as well as human\nprimary monocytes, were used. Immuno\ufb02uorescence (IF) micro-\nscopy was performed to visualize the localization of the target pro-\nteins in the cell ( Gerstmeier et al., 2014, 2016a ). In agreement with\nprevious\ndata, 5-LO in resting HEK cells or human monocytes was\nmainly nucleosolic but co-localized with FLAP at the nuclear enve-\nlope upon A23187 stimulation ( Figures 4 A and 4C). However,\nneither 1or2no\nr the Michael acceptor TQ or the FLAP inhibitor\nMK886 blocked A23187-induced 5-LO translocation ( Figures 4 A\nand 4C).\nOf interest, 1and2(3mM, each) as well as TQ (10 mM)\nimpeded A23187-induced 5-LO/FLAP complex assembly in\nHEK cells ( Figure 4 B) and in monocytes ( Figure 4 D) that was moni-\ntored by in\nsituproximity ligation assay (PLA). The FLAP inhibitor\nMK886 (0.3 mM, used as control) blocked 5-LO/FLAP complex for-\nmation ( Figures 4 B and 4D), while the 5-LO inhibitor zileuton failed\nin this re\nspect (not shown), as reported previously ( Gerstmeier\net al., 20\n16b). Taken together, the melleolides 1and2as well as\nTQ impede the assembly of the LT-biosynthetic 5-LO/FLAP com-\nplex at the nuclear membrane, yet without blocking 5-LO translo-\ncation. This effect may be causative for superior inhibition of 5-LO\nproduct formation in intact cells.\nMutation of 5-LO Cysteines Affects Product Formation\nand Susceptibility for Melleolides\nPrevious\nstudies suggested a role of the four surface cysteines\n159, 300, 416, and\n418 in 5-LO for cellular product formation(Hafner et al., 2015 ). Michael acceptors can act at either at\nCys416 or Cys418 causing\ninhibition of 5-LO ( Maucher et al.,\n2017 ). Thus, we studied if melleolides require these critical cys-\nteines ( Figure 5 A) for\ninhibition of 5-LO. HEK cells were co-trans-\nfected with FLAP and\nwith wild-type 5-LO (5-LO_WT) or with\n5-LO mutants in which all four cysteines (5-LO_4C) or single cys-\nteines had been replaced by serine. The mutated 5-LO proteins\nwere expressed in HEK cells to a similar (5-LO_4C) or somewhat\nminor degree (5-LO_C159S, 5-LO_C300S, 5-LO_C416S, and\n5-LO_C418S) versus 5-LO_WT ( Figure 5 B). Along these lines,\nthe enzymatic capacities of\ncorresponding HEK cell homoge-\nnates containing these 5-LO mutants were about 2- to 4-fold\nlower versus 5-LO_WT ( Table 1 ). In HEK cell homogenates, 1\n(Figure 5 C,Table 1 ) and 2(Figure S4 ) blocked 5-LO_WT activity,\nwhereas 5-LO_4C was not\naffected at all. As for 5-LO_WT, the\nenzymatic activities of the mutants 5-LO_C159S, 5-LO_C300S,\n5-LO_C416S, or 5-LO_C418S were also inhibited by 1(Fig-\nure 5 C,Table 1 ) and 2(Figure\nS4). In contrast, zileuton inhibited\n5-LO_WT and all mutated\n5-LOs about equally well ( Figure 5 D).\nNext, we analyzed cellular\n5-LO product formation in intact\nHEK cells. Since previous data showed that 5-LO/FLAP-ex-\npressing HEK cells require exogenous AA for signi\ufb01cant 5-LO\nproduct formation ( Gerstmeier et al., 2014, 2016a ), the cells\nwere stimulated with A23187\nplus 3 mM AA. In contrast to 5-LO\nactivity in homogenates, all mutated 5-LOs formed much less\namounts of products versus 5-LO_WT in intact cells (approxi-\nmately 5- to 10-fold lower), in particular 5-LO_C159S ( Table 1 ).\nOf interest, while product\nformation of 5-LO_WT was ef\ufb01ciently\ninhibited by 1(10mM), in HEK cells expressing 5-LO_4C but\nalso 5-LO_C159S, melleolide 1(or2,Figure S4 ) failed to mark-\nedly inhibit 5-LO product\nformation ( Figure 5 E,Table 1 ). Note\nthat in cells expressing\neither 5-LO_C300S, 5-LO_C416S, or\n5-LO_C418S, treatment with 1(or2,Figure S4 ) caused ef\ufb01cient\nand concentration-dependent inhibition\nof 5-LO product forma-\ntion comparable with cells expressing 5-LO_WT ( Figure 5 E). In\ncontrast, zileuton consistently inhibited\n5-LO activity in HEK cells\nregardless of the 5-LO mutations ( Figure 5 F). Hence, 1and2may\ninhibit 5-LO product formation\nin intact cells via Cys159.\nRole of Cysteines in 5-LO for Translocation and 5-LO/\nFLAP Interaction\nIn agreement with\nprevious data ( Hafner et al., 2015 ), the strik-\ningly reduced capacities of\nthe cysteine-mutated 5-LOs in intact\nHEK cells versus the moderately decreased activity of the 5-LO\nmutants in homogenates implied that cysteine mutations could\naffect 5-LO translocation and/or interaction with FLAP. Analysis\nof 5-LO translocation and co-localization with FLAP by IF\nmicroscopy revealed no impact of the cysteine mutations.\nThat is, the subcellular localization of 5-LO_WT and all 5-LO mu-\ntants in resting HEK cells was comparable, and, upon A23187\nFigure 4. Modulation of 5-LO Translocation and 5-LO/FLAP Interaction by Melleolides\nStably transfected HEK293 cells expressing 5-LO and FLAP (A and B) or human monocytes (C and D) were pre-incubated with compounds or vehicle (0.1%\nDMSO) for 10\nmin at 37/C 4C, and subsequently incubated with 2.5 mM A23187 for 10 min. Images show single staining for FLAP (green), 5-LO (red), and overlay of 5-\nLO and FLAP (bottom lane). Results are representative for 100 individual cells of three independent experiments. (B and D) Proximity ligation assay (PLA) for\nassessing cellular in situ 5-LO/FLAP complex assembly. Stably transfected HEK293 cells expressing 5-LO and FLAP (B) or human monocytes (D) were pre-\nincubated with compounds or vehicle (0.1% DMSO) for 10 min at 37/C 4C, and subsequently incubated with 2.5 mM A23187 for 10 min. DAPI (blue) was used to stain\nthe nucleus and PLA signals (magenta dots) visualize 5-LO/FLAP interactions. Results are representative for 100 individual cells analyzed in three independent\nexperiments.\n6Cell Chemical Biology 26, 1\u201311, January 17, 2019Please cite this article in press as: Ko \u00a8nig et al., Melleolides from Honey Mushroom Inhibit 5-Lipoxygenase via Cys159, Cell Chemical Biology (2018),\nhttps://doi.org/10.1016/j.chembiol.2018.10.010stimulation, they all translocated to FLAP at the nuclear envelope\n(Figure 6 A). Of interest, Cys159 seems to be instrumental for the\n5-LO/FLAP interaction which was\nvisualized by in situ PLA ( Fig-\nure6B).Thus, in\nHEK cells expressing 5-LO_WT, 5-LO_C300S,\n5-LO_C416S, or 5-LO_C418S, stimulation\nwith A23187 led to\n5-LO/FLAP complex assembly. However, in HEK cells express-\ning 5-LO_4C or 5-LO_C159S, challenge with A23187 failed inthis respect, implying a critical role of Cys159 in 5-LO/FLAP\ninteraction.\nDISCUSSION\nHere, we identi\ufb01ed human 5-LO as a molecular target of melleo-\nlides from honey mushroom.\nExploiting 1and 2as the most\nFigure 5. Mutation of 5-LO Cysteines Affects Product Formation and the Susceptibility for Melleolides\n(A) Computational model of human 5-LO highlighting cysteine residues 159, 300, 416, and 418. The active site iron is highlighted in red.\n(B) Western blot analysi\ns of 5-LO protein expression in stably transfected HEK293 cells expressing FLAP and various 5-LO proteins (5-LO_WT and the mutants\n5-LO_4C, 5-LO_C159S, 5-LO_C300S, 5-LO_C416S, and 5-LO_C418S). Results are representative for three independent experiments. Densitometric protein\nanalysis: correlation of 5-LO density to b-actin density, means \u00b1 SEM, n = 3.\n(C and D) Inhibition of 5-LO product formation in homogenates of HEK cells expressing FLAP and 5-LO (WT or mutants) by 1at the indicated concentrations (C)\nand by 3 mM zileuton (D). HEK cells were sonicated on ice and pre-incubated with compounds or vehicle (0.1% DMSO) at 4/C 4C for 10 min. Samples were pre-\nwarmed for 30 s at 37/C 4C and incubated with 2 mM CaCl 2and 20 mM AA for another 10 min.\n(E and F) Inhibition of 5-LO product formation in intact HEK cells expressing FLAP and 5-LO (WT or mutants) by 1at the indicated concentrations (E) and by 3 mM\nzileuton (F). HEK cells (1 3106/mL) were pre-incubated with 1, zileuton, or vehicle (0.1% DMSO) for 10 min at 37/C 4C and then stimulated with 2.5 mM A23187 and\n3mM AA for 10 min. Data are expressed as percentage of vehicle control (100%), means \u00b1 SEM, n = 4.\nSee also Figure S4 .\nCell Chemical Biology 26, 1\u201311, January 17, 2019 7Please cite this article in press as: Ko \u00a8nig et al., Melleolide s from Honey Mushroom Inhibit 5-Lipoxygenase via Cys159, Cell Chemical Biology (2018),\nhttps://doi.org/10.1016/j.chembiol.2018.10.010potent melleolide representatives revealed Cys159 in 5-LO as a\ncrucial moiety for functional\ninteraction of 5-LO with FLAP in LT\nbiosynthesis. Our data suggest that melleolides suppress 5-LO\nproduct formation by two distinct modes of action: (1) by direct\ninterference with the 5-LO enzyme activity involving two or\nmore of the cysteines 159, 300, 416, and 418, and (2) by a\nmore ef\ufb01cient mechanism that selectively involves Cys159\nand prevents cellular 5-LO/FLAP complex assembly without\naffecting 5-LO translocation. Thus, our results shed light on the\ncatalytic and regulatory role of cysteines at the substrate\nentrance of the 5-LO active site for the cellular capacity to bio-\nsynthesize LTs.\nMelleolides were shown to exhibit antimicrobial activity and\ncytotoxic properties for cancer cells and primary human mono-\ncytes ( Bohnert et al., 2011, 2014b ),\nbut interference with LT\nbiosynthesis is thus far\nunexplored. With 5-LO, we identi\ufb01ed a\nmolecular target for these bioactive natural products. The ef\ufb01-\ncient 5-LO-inhibitory melleolides possess a reactive aldehyde\ngroup at position 1 and a D2,4(i.e.,1and2)o rD2,3(i.e.,3) double\nbond in the sesquiterpene moiety. Our SAR analysis indicates\nthat the Michael acceptor functionality impacts 5-LO inhibitory\nactivity, but also minor structural arrangements in the sesquiter-\npene moiety ( a,bdouble bond at D2,4versus D2,3position, and\nthe 4-OH moiety) and in the orsellinic acid residue (50-OH methyl-\nation, 60-chlorine). Strong potencies of 5-LO inhibitors often\ncorrelate with high lipophilicity ( Werz, 2002 ), which may explain\nthe superior effect of 2with\n50-methoxy and 60-chlorine residues\nover 1in the cell-free assay.\nUnexpectedly, the SARs for 5-LO inhibition by melleolides in\nintact neutrophils differ and reveal 1as the most potent com-\npound with a 10-fold lower IC 50value compared with interfer-\nence with 5-LO in cell-free assays. Such superior potency in\nintact cells was not observed for the 5-LO inhibitor zileuton\n(this study and others [ Carter et al., 1991 ]) and implies that addi-\ntional factors that govern\ncellular 5-LO activity might be affected\nby melleolides. In fact, cellular regulation of 5-LO is complex, and\nseveral points of attack are conceivable that eventually cause or\npotentiate suppression of 5-LO product formation including\ninterference with (1) AA release, (2) AA transfer via FLAP, (3)\n5-LO translocation, and (4) upstream 5-LO signaling pathwayssuch as MAPK and Ca2+, and other 5-LO-activating processes\n(Radmark et al., 2015; Werz and Steinhilber, 2005 ). Our data\nshow that melleolides, in\naddition to directly inhibiting 5-LO ac-\ntivity, prevent the 5-LO/FLAP complex assembly and, thus,\ncould interfere with the AA transfer from FLAP to 5-LO. This\nmay explain why excess of AA (20 mM) in intact cells diminishes\nthe 5-LO-inhibitory potency of melleolides, although inhibition\nof 5-LO activity in cell-free assays is favored by high AA\nconcentrations.\nMost direct 5-LO inhibitors comprise lipophilic redox-active\nand/or iron-chelating compounds as well as AA mimetics that\nreversibly block AA conversion at the active or allosteric sites\nof 5-LO ( Werz, 2002; Werz and Steinhilber, 2005 ). Based on\nthe chemical structures of\nmelleolides, fatty acid-like features\nare not readily apparent, and iron-chelating or redox properties\nhave not been reported. Of interest, structurally different com-\npounds containing SH-reactive groups such as the Michael ac-\nceptors TQ ( Maucher et al., 2017 ), nitro fatty acids ( Awwad\net al., 2014 ), unsubstituted\naminophenols ( Kretschmer et al.,\n2017 ), or the maleimide-featured inhibitor U73122 ( Feisst et al.,\n2005; Hornig et al.,\n2012 ) were shown to form covalent adducts\nwith the surface cysteines\n159, 416, and/or 418 and thereby\npotently and irreversibly inhibit 5-LO activity. The 5-LO structure\nexposes nine cysteine residues on the surface ( Gilbert et al.,\n2011 ). We previously identi\ufb01ed four cysteines (cysteines 159,\n300, 416, and 418)\nlocated on the 5-LO surface in the region\naround the substrate entrance of the catalytic center that\nmediate dimerization of 5-LO ( Hafner et al., 2011 ) and are impor-\ntant for the co-localization\nof 5-LO with FLAP at the nuclear\nmembrane ( Hafner et al., 2015 ). In our present study, melleolides\nfailed to inhibit the\nactivity of the 5-LO_4C mutant in cell-free and\ncell-based assays, suggesting that one or more of these cyste-\nines are necessary to confer the 5-LO suppressive effect. In\ncontrast, zileuton, which chelates the active site iron in 5-LO\n(Carter et al., 1991 ), suppressed the activity of this mutant, as ex-\npected. Note that 5-LO\nsingle mutants, with only one of the cys-\nteines 159, 300, 416, or 418 being replaced by serine, were still\neffectively inhibited by melleolides in cell-free assays, implying\nthat at least two of these cysteines are involved. This contrasts\nthe suppressive effect of melleolides on 5-LO activity in intactTable 1. Formation of 5-LO Products of Wild-Type and Mutated 5-LOs in HEK Cells and Corresponding Homogenates; Effects of\nCompound 1\nEnzyme5-LO\nProduct Formation\nHEK\nHomogenates (ng/106Cells) Intact HEK Cells (ng/106Cells)\nw/o + Compound 1(% Inhibition) w/o + Compound 1(% Inhibition)\n5-LO_WT 919.4 \u00b1 40.0 243.0 \u00b1 80.0 (72.6%) 346.8 \u00b1 97.2 101.9 \u00b1 23.3 (77.7%)\n5-LO_4C 484.3 \u00b1 58.8 477.7 \u00b1 74.0 (0.4%) 48.1 \u00b1 7.1 42.1 \u00b1 6.3 (12.4%)\n5-LO_C159S 456.9 \u00b1 177.5 76.5 \u00b1 11.9 (72.6%) 31.2 \u00b1 12.4 24.6 \u00b1 6.5 (9.8%)\n5-LO_C300S 374.5 \u00b1 29.7 71.6 \u00b1 12.2 (81.0%) 71.5 \u00b1 8.9 11.8 \u00b1 4.5 (87.6%)\n5-LO_C416S 223.1 \u00b1 18.3 28.3 \u00b1 12.0 (88.1%) 48.9 \u00b1 9.5 5.0 \u00b1 0.8 (89.6%)\n5-LO_C418S 465.3 \u00b1 22.8 124.9 \u00b1 5.2 (73.2%) 66.6 \u00b1 23.1 23.0 \u00b1 9.5 (66.7%)\nFor analysis of 5-LO product formation in intact cells, HEK cells (1 3106/mL) stably expressing FLAP and 5-LO enzymes (wild-type or mutants) were\npre-incubated with 10 mMo f 1or vehicle (0.1% DMSO), and then stimulated with 2.5 mM A23187 and 3 mM AA for 10 min at 37/C 4C. For analysis of 5-LO\nproduct formation in homogenates, the HEK cells (1 3106/mL) were sonicated, the resulting homogenates were pre-incubated with 10 mMo f 1or\nvehicle (0.1% DMSO) and then incubated with 20 mM AA for 10 min at 37/C 4C. Data are expressed as ng 5-LO products formed per 106cells;\nmeans \u00b1 SEM, n = 4. w/o, without.\n8Cell Chemical Biology 26, 1\u201311, January 17, 2019Please cite this article in press as: Ko \u00a8nig et al., Melleolides from Honey Mushroom Inhibit 5-Lipoxygenase via Cys159, Cell Chemical Biology (2018),\nhttps://doi.org/10.1016/j.chembiol.2018.10.010cells, where Cys159 emerged as a crucial residue required to\nmediate inhibition of 5-LO\nproduct formation. Thus, our results\nsuggest that melleolides act via Cys159 to prevent the 5-LO/\nFLAP complex assembly while cysteines 300, 416, and 418 do\nnot contribute.\nFLAP, a nuclear membrane protein without any known enzy-\nmatic activity, is essential for 5-LO product formation in intact\ncells ( Miller et al., 1990 )\nby enabling AA substrate transfer to\n5-LO for conversion to\nLTA 4(Ferguson et al., 2007 ). Accordingly,\nFLAP inhibitors ef\ufb01ciently inhibit\ncellular LT biosynthesis by pre-\nventing 5-LO/FLAP assemblies ( Garscha et al., 2016; Gerstmeier\net al., 2016b ) but\nthey fail to inhibit 5-LO activity in cell-free as-\nsays where FLAP is\ndispensable for 5-LO to convert AA ( Evans\net al., 2008 ). Along\nthese lines, mutation of cysteines 159, 300,\n416, or 418, which\nwere postulated to be important for 5-LO/\nFLAP co-localization ( Hafner et al., 2015 ), hardly affected 5-LO\nactivity in cell-free homogenates,\nbut strikingly in intact cells.\nMoreover, 5-LO_C159S or 5-LO_4C failed to form complex as-\nsemblies with FLAP, in contrast to 5-LOs possessing Cys159.\nInterestingly, 1and2(but not zileuton) required Cys159 to inhibit\n5-LO product formation in intact cells. However, when this\ncysteine was replaced by serine, these mutants were not sus-\nceptible to the tested melleolides. Therefore, Cys159 is of major\nimportance for 5-LO to interact with FLAP and as such mediates\nsuppression of cellular 5-LO product formation by melleolides.\n5-LO translocation to the nuclear envelope is mediated by\nelevated intracellular Ca2+that binds to the C2-like domain of\nFigure 6. Role of Cysteines in 5-LO for\nTranslocation and 5-LO/\nFLAP Interaction\n(A) Immuno\ufb02uorescence microscopy analysis of\n5-LO translocation and\nco-localization with FLAP.\nImages show overlay of 5-LO (red) and FLAP\n(green).\n(B) PLA for analysis of cellular in situ 5-LO/FLAP\ncomplex assembly. DAPI (blue) was used to stain\nthe nucleus and in situ PLA signals (magenta dots)\nvisualize 5-LO/FLAP complexes. Scale bars, 25 mm\n(insets) and 100 mm (overview). For both (A) and (B),\nstably transfected HEK cells expressing FLAP and\n5-LO (WT or mutants) were incubated with 2.5 mM\nA23187 or vehicle (0.1% DMSO) for 10 min at 37/C 4C.\nResults are representative for 100 individual cells of\nthree independent experiments.\n5-LO ( Kulkarni et al., 2002 ), and is essen-\ntialfor product biosynthesis\n(Gerstmeier\net al., 2016b; Mandal\net al., 2008; Rad-\nmark et al., 2015 ). The prenylated acyl-\nphloroglucinol hyperforin binds to\nthe\n5-LO C2-like domain and blocks 5-LO\ntranslocation and activity ( Feisst et al.,\n2009 ), while FLAP inhibitors primarily pre-\nvent 5-LO/FLAP interaction without\nde\ufb01-\nnite blockade of 5-LO movement ( Gar-\nscha et al., 2016;\nGerstmeier et al.,\n2016b ). In analogy to MK886, 1and2as\nwell as TQ failed\nto block 5-LO transloca-\ntion but they clearly inhibited the 5-LO/\nFLAP interaction.\nTaken together, we identi\ufb01ed human 5-LO as a molecular\ntarget of melleolides from the honey mushroom. We propose\nthat melleolides containing an a,b-unsaturated aldehyde func-\ntion as Michael acceptors that interfere with critical surface cys-\nteines of 5-LO. While two or more of these cysteines mediate the\ndirect inhibitory effects of melleolides on the enzymatic level,\nCys159 confers suppression of cellular 5-LO product formation\nby melleolides via preventing the 5-LO/FLAP complex assembly.\nFinally, our data highlight the importance of Cys159 for 5-LO to\ninteract with FLAP, a prerequisite for the biosynthesis of LTs in\nthe cellular context.\nSIGNIFICANCE\nOnly for very few mushroom toxins is the pharmacological\nmode of action understood\nand the molecular targets\nknown. Melleolides are a family of sesquiterpene aryl esters\nof the globally distributed plant pathogenic and edible honey\nmushroom ( Armillaria mellea ). This family of natural prod-\nucts comprises >60 published members and represents\none of the largest family of fungal small bioactive molecules.\nWe discovered human 5-lipoxygenase (5-LO), the key\nenzyme in leukotriene biosynthesis, as a molecular target\nfor those melleolides that possess an a,b-unsaturated alde-\nhyde with thiol-reactive Michael acceptor functionality.\nSince leukotrienes are potent bioactive mediators with\npivotal functions in in\ufb02ammation and in the immune\nCell Chemical Biology 26, 1\u201311, January 17, 2019 9Please cite this article in press as: Ko \u00a8nig et al., Melleolide s from Honey Mushroom Inhibit 5-Lipoxygenase via Cys159, Cell Chemical Biology (2018),\nhttps://doi.org/10.1016/j.chembiol.2018.10.010response, their formation needs to be tightly controlled, for\nexample, by temporal assembly\nof the biosynthetic protein\ncomplex of 5-LO with its helper protein FLAP. We provide ev-\nidence that melleolides mediate 5-LO inhibition via critical\nsurface cysteines of the enzyme by two distinct modes of\naction: (1) by direct interference with the 5-LO catalytic ac-\ntivity involving two or more of the cysteines 159, 300, 416,\nand 418, and (2) by a more ef\ufb01cient cellular mechanism\ninvolving selectively Cys159, which prevents assembly of\nthe 5-LO/FLAP complex in leukotriene biosynthesis. In\nconclusion, identi\ufb01cation of 5-LO as a target for melleolides\nrepresents a basis for further investigations that will help\nevaluate the bioactions of this mushroom and its ingredients\nin view of the use for culinary purposes. By exploiting\nthese melleolides as chemical tools we shed light on the\ncatalytic and regulatory role of cysteines of 5-LO at the\nsubstrate entrance of the active site for the cellular capacity\nto generate bioactive mediators. Therefore, our study also\nunravels Cys159 in 5-LO as a crucial residue for accomplish-\ning the functional interaction of 5-LO with FLAP in leuko-\ntriene biosynthesis, which offers a potential site for novel\nsmall-molecule inhibitors to intervene with 5-LO-related\ndisorders.\nSTAR+METHODS\nDetailed methods are provided in the online version of this paper\nandinclude the following:\ndKEY\nRESOURCES TABLE\ndCONTACT\nFOR REAGENT AND RESOURCE SHARING\ndEXPERIMENTAL MODEL AND SUBJECT DETAILS\nBHuman Cells\ndMETHODS DETAILS\nBExpression and\nPuri\ufb01cation of Human Recombinant\n5-LO\nBDetermination of 5-LO Product Formation in Intact\nCells and Homogenates\nBDetermination of Release of [3H]-Labeled Arachi-\ndonic Acid\nBLTC 4Synthase Activity Assay\nBDetermination of Isolated COX-1 and -2 Activity\nBDetermination of PGE 2Synthase Activity in a Cell-\nFree Assay\nBSDS PAGE and Western Blot\nBGSH Incubation\nBStandard Peptide Incubation\nBMALDI-MS Measurement and Data Analysis\nBAnalysis of Subcellular Localization of 5-LO by Immu-\nno\ufb02uorescence Microscopy\nBIn Situ Analysis of 5-LO/FLAP Interaction by Proximity\nLigation Assay\ndQUANTIFICATION AND STATISTICAL ANALYSIS\nSUPPLEMENTAL INFORMATION\nSupplemental Information includes four \ufb01gures and one table and can be\nfound with this article\nonline at https://doi.org/10.1016/j.chembiol.2018.\n10.010 .ACKNOWLEDGMENTS\nWe thank Sven George for expert technical assistance and Dr. Michael Ho \u00a8rnig\nformu\ntation of 5-LO plasmids. The study was supported by Else Kro \u00a8ner-Frese-\nnius-Stiftung (Else Kro \u00a8ner-Graduiertenkolleg), LOEWE TMP and Fraunhofer-\nProjektgruppe f \u20acur Translationale Medizin und Pharmakologie (TMP), Deutsche\nForschungsgemeinschaft (DFG; SFB 1039). Work in the groups of O.W. and\nD.H. is supported by the Collaborative Research Center ChemBioSys\n(SFB1127) of the DFG and by the DFG-funded excellence graduate school\nJena School for Microbial Communication (JSMC).\nAUTHOR CONTRIBUTIONS\nS.K., B.H., D.S., M.K., U.G., D.H., and O.W. designed the research, gave\nadvice, and planed the\nstudy. S.K., E.R., V.K., M.R., S.L., A.-K.H., M.D., and\nU.G., performed the experiments and analyzed the data. S.K. and O.W. wrote\nthe manuscript.\nDECLARATION OF INTERESTS\nThe authors declare no competing interests.\nReceived: May 28, 2018\nRevised:\nJuly 25, 2018\nAccepted: October 5, 2018\nPublished: November 8, 2018\nREFERENCES\nAlbert, D., Zundorf, I., Dingermann, T., Muller, W.E., Steinhilber, D., and Werz,\nO.(2002). Hyperforin\nis a dual inhibitor of cyclooxygenase-1 and 5-lipoxyge-\nnase. Biochem. Pharmacol. 64, 1767\u20131775 .\nAwwad, K., Steinbrink, S.D., Fromel, T., Lill, N., Isaak, J., Hafner, A.K., Roos,\nJ.,Hofmann, B., Hei\nde, H., Geisslinger, G., et al. (2014). Electrophilic fatty\nacid species inhibit 5-lipoxygenase and attenuate sepsis-induced pulmonary\nin\ufb02ammation. Antioxid. Redox Signal. 20, 2667\u20132680 .\nBair, A.M., Turman, M.V., Vaine, C.A., Panettieri, R.A., Jr., and Soberman, R.J.\n(2012). The nuclear\nmembrane leukotriene synthetic complex is a signal inte-\ngrator and transducer. Mol. Biol. Cell 23, 4456\u20134464 .\nBaumgartner, K., Coetzee, M.P., and Hoffmeister, D. (2011). Secrets of the\nsubterranean pathosystem of Armilla\nria. Mol. Plant Pathol. 12, 515\u2013534 .\nBohnert, M., Miethbauer, S., Dahse, H.M., Ziemen, J., Nett, M., and\nHoffmeister, D. (2011)\n. In vitro cytotoxicity of melleolide antibiotics: structural\nand mechanistic aspects. Bioorg. Med. Chem. Lett. 21, 2003\u20132006 .\nBohnert, M., Nutzmann, H.W., Schroeckh, V., Horn, F., Dahse, H.M.,\nBrakhage , A.A., and\nHoffmeister, D. (2014a). Cytotoxic and antifungal activities\nof melleolide antibiotics follow dissimilar structure-activity relationships.\nPhytochemistry 105, 101\u2013108 .\nBohnert, M., Scherer, O., Wiechmann, K., Konig, S., Dahse, H.M., Hoffmeister,\nD., and Werz, O.\n(2014b). Melleolides induce rapid cell death in human primary\nmonocytes and cancer cells. Bioorg. Med. Chem. 22, 3856\u20133861 .\nCarter, G.W., Young, P.R., Albert, D.H., Bouska, J., Dyer, R., Bell, R.L.,\nSummers, J.B., and\nBrooks, D.W. (1991). 5-Lipoxygenase inhibitory activity\nof zileuton. J. Pharmacol. Exp. Ther. 256, 929\u2013937 .\nEvans, J.F., Ferguson, A.D., Mosley, R.T., and Hutchinson, J.H. (2008). What\u2019s\nall the FLAP\nabout?: 5-lipoxygenase-activating protein inhibitors for in\ufb02amma-\ntory diseases. Trends Pharmacol. Sci. 29, 72\u201378 .\nFeisst, C., Albert, D., Steinhilber,D.,and Werz,O. (2005). The aminosteroid phos-\npholipase\nC antagonist U-73122 (1-[6-[[17-beta-3-methoxyestra-1,3,5(10)-trien-\n17-yl]amino]hexyl]-1H-pyrrole-2,5- dione) potently inhibits human 5-lipoxyge-\nnase in vivo and in vitro. Mol. Pharmacol. 67, 1751\u20131757 .\nFeisst, C., Pergola, C., Rakonjac, M., Rossi, A., Koeberle, A., Dodt, G.,\nHoffmann, M., Ho ernig,\nC., Fischer, L., Steinhilber, D., et al. (2009).\nHyperforin is a novel type of 5-lipoxygenase inhibitor with high ef\ufb01cacy in vivo.\nCell Mol. Life Sci. 66, 2759\u20132771 .\n10Cell Chemical Biology 26, 1\u201311, January 17, 2019Please cite this article in press as: Ko \u00a8nig et al., Melleolides from Honey Mushroom Inhibit 5-Lipoxygenase via Cys159, Cell Chemical Biology (2018),\nhttps://doi.org/10.1016/j.chembiol.2018.10.010Ferguson, A.D., McKeever, B.M., Xu, S., Wisniewski, D., Miller, D.K., Yamin,\nT.T., Spencer, R.H., Chu,\nL., Ujjainwalla, F., Cunningham, B.R., et al. (2007).\nCrystal structure of inhibitor-bound human 5-lipoxygenase-activating protein.\nScience 317, 510\u2013512 .\nFischer, L., Poeckel, D., Buerkert, E., Steinhilber, D., and Werz, O. (2005).\nInhibitors of actin polymerisatio\nn stimulate arachidonic acid release and 5-lip-\noxygenase activation by upregulation of Ca2+ mobilisation in polymorphonu-\nclear leukocytes involving Src family kinases. Biochim. Biophys. Acta 1736 ,\n109\u2013119 .\nFischer, L., Szellas, D., Radmark, O., Steinhilber, D., and Werz, O. (2003).\nPhosphoryla tion- and stimulus-\ndependent inhibition of cellular 5-lipoxygenase\nactivity by nonredox-type inhibitors. FASEB J. 17, 949\u2013951 .\nGarscha, U., Voelker, S., Pace, S., Gerstmeier, J., Emini, B., Liening, S., Rossi,\nA.,Weinigel, C.,\nRummler, S., Schubert, U.S., et al. (2016). BRP-187: a potent\ninhibitor of leukotriene biosynthesis that acts through impeding the dynamic\n5-lipoxygenase/5-lipoxygenase-activating protein (FLAP) complex assembly.\nBiochem. Pharmacol. 119, 17\u201326 .\nGerstmeier, J., Newcomer, M.E., Dennhardt, S., Romp, E., Fischer, J., Werz,\nO.,and Garscha,\nU. (2016a). 5-Lipoxygenase-activating protein rescues activ-\nity of 5-lipoxygenase mutations that delay nuclear membrane association and\ndisrupt product formation. FASEB J. 30, 1892\u20131900 .\nGerstmeier, J., Weinigel, C., Barz, D., Werz, O., and Garscha, U. (2014). An\nexperimenta l cell-based model\nfor studying the cell biology and molecular\npharmacology of 5-lipoxygenase-activating protein in leukotriene biosyn-\nthesis. Biochim. Biophys. Acta 1840 , 2961\u20132969 .\nGerstmeier, J., Weinigel, C., Rummler, S., Radmark, O., Werz, O., and\nGarscha, U. (2016b). Time-res\nolved in situ assembly of the leukotriene-syn-\nthetic 5-lipoxygenase/5-lipoxygenase-activating protein complex in blood leu-\nkocytes. FASEB J. 30, 276\u2013285 .\nGilbert, N.C., Bartlett, S.G., Waight, M.T., Neau, D.B., Boeglin, W.E., Brash,\nA.R., and Newcomer, M.E.\n(2011). The structure of human 5-lipoxygenase.\nScience 331, 217\u2013219 .\nHaeggstrom, J.Z., and Funk, C.D. (2011). Lipoxygenase and leukotriene path-\nways: biochemistry, biology,\nand roles in disease. Chem. Rev. 111,\n5866\u20135898 .\nHafner, A.K., Cernescu, M., Hofmann, B., Ermisch, M., Hornig, M., Metzner, J.,\nSchneider, G., Brutschy,\nB., and Steinhilber, D. (2011). Dimerization of human\n5-lipoxygenase. Biol. Chem. 392, 1097\u20131111 .\nHafner, A.K., Gerstmeier, J., Hornig, M., George, S., Ball, A.K., Schroder, M.,\nGarscha, U., Werz, O.,\nand Steinhilber, D. (2015). Characterization of the inter-\naction of human 5-lipoxygenase with its activating protein FLAP. Biochim.\nBiophys. Acta 1851 , 1465\u20131472 .\nHornig, M., Markoutsa, S., Hafner, A.K., George, S., Wisniewska, J.M., Rodl,\nC.B., Hofmann, B., Maie\nr, T., Karas, M., Werz, O., et al. (2012). Inhibition of\n5-lipoxygenase by U73122 is due to covalent binding to cysteine 416.\nBiochim. Biophys. Acta 1821 , 279\u2013286.\nKoeberle, A., Northoff, H., and Werz, O. (2009). Curcumin blocks prostaglandin\nE2biosynthesis through\ndirect inhibition of the microsomal prostaglandin E2\nsynthase-1. Mol. Cancer Ther. 8, 2348\u20132355 .\nKoeberle, A., Siemoneit, U., Buhring, U., Northoff, H., Laufer, S., Albrecht, W.,\nand Werz, O. (2\n008). Licofelone suppresses prostaglandin E2 formation by\ninterference with the inducible microsomal prostaglandin E2 synthase-1.\nJ. Pharmacol. Exp. Ther. 326, 975\u2013982 .\nKretschmer, S.B., Woltersdorf, S., Vogt, D., Lillich, F.F., Ruhl, M., Karas, M.,\nMaucher,\nI.V., Roos, J., Hafner, A.K., Kaiser, A., et al. (2017). Characterization\nof the molecular mechanism of 5-lipoxygenase inhibition by 2-aminothiazoles.\nBiochem. Pharmacol. 123, 52\u201362 .\nKulkarni, S., Das, S., Funk, C.D., Murray, D., and Cho, W. (2002). Molecular\nbasis of the speci\ufb01c\nsubcellular localization of the C2-like domain of 5-lipoxy-\ngenase. J. Biol. Chem. 277, 13167\u201313174.Leslie, C.C. (2015). Cytosolic phospholipase A(2): physiological function and\nrolein disease .\nJ. Lipid Res. 56, 1386\u20131402 .\nLiening, S., Scriba, G.K., Rummler, S., Weinigel, C., Kleinschmidt, T.K.,\nHaeggstrom, J.Z., Werz, O.,\nand Garscha, U. (2016). Development of smart\ncell-free and cell-based assay systems for investigation of leukotriene C4 syn-\nthase activity and evaluation of inhibitors. Biochim. Biophys. Acta 1861 ,\n1605\u20131613 .\nMandal, A.K., Jones, P.B., Bair, A.M., Christmas, P., Miller, D., Yamin, T.T.,\nWisniews ki, D., Menke,\nJ., Evans, J.F., Hyman, B.T., et al. (2008). The nuclear\nmembrane organization of leukotriene synthesis. Proc. Natl. Acad. Sci. U S A\n105, 20434\u201320439 .\nMaucher, I.V., Ruhl, M., Kretschmer, S.B., Hofmann, B., Kuhn, B., Fettel, J.,\nVogel, A., Flugel, K.T.,\nManolikakes, G., Hellmuth, N., et al. (2017). Michael\nacceptor containing drugs are a novel class of 5-lipoxygenase inhibitor target-\ning the surface cysteines C416 and C418. Biochem. Pharmacol. 125, 55\u201374 .\nMiller, D.K., Gillard, J.W., Vickers, P.J., Sadowski, S., Leveille, C., Mancini,\nJ.A., Charleson, P., Dixon,\nR.A., Ford-Hutchinson, A.W., Fortin, R., et al.\n(1990). Identi\ufb01cation and isolation of a membrane protein necessary for leuko-\ntriene production. Nature 343, 278\u2013281.\nMisiek, M., Williams, J., Schmich, K., Huttel, W., Merfort, I., Salomon, C.E.,\nAldrich, C.C., and Hoffmeis\nter, D. (2009). Structure and cytotoxicity of arnamial\nand related fungal sesquiterpene aryl esters. J. Nat. Prod. 72, 1888\u20131891 .\nMomose, I., Sekizawa, R., Hosokawa, N., Iinuma, H., Matsui, S., Nakamura,\nH.,Naganawa, H.,\nHamada, M., and Takeuchi, T. (2000). Melleolides K, L\nand M, new melleolides from Armillariella mellea . J. Antibiot. (Tokyo) 53,\n137\u2013143 .\nPace, S., Rossi, A., Krauth, V., Dehm, F., Troisi, F., Bilancia, R., Weinigel, C.,\nRummler, S., Werz, O.,\nand Sautebin, L. (2017). Sex differences in prosta-\nglandin biosynthesis in neutrophils during acute in\ufb02ammation. Sci. Rep.\n7, 3759 .\nPergola, C., Gerstmeier, J., Monch, B., Caliskan, B., Luderer, S., Weinigel, C.,\nBarz, D., Maczewsky, J.,\nPace, S., Rossi, A., et al. (2014). The novel benzimid-\nazole derivative BRP-7 inhibits leukotriene biosynthesis in vitro and in vivo by\ntargeting 5-lipoxygenase-activating protein (FLAP). Br. J. Pharmacol. 171,\n3051\u20133064 .\nRadmark, O., Werz, O., Steinhilber, D., and Samuelsson, B. (2015).\n5-Lipoxyg enase, a key\nenzyme for leukotriene biosynthesis in health and dis-\nease. Biochim. Biophys. Acta 1851 , 331\u2013339 .\nScherer, O., Steinmetz, H., Kaether, C., Weinigel, C., Barz, D., Kleinert, H.,\nMenche, D., Muller,\nR., Pergola, C., and Werz, O. (2014). Targeting\nV-ATPase in primary human monocytes by archazolid potently represses the\nclassical secretion of cytokines due to accumulation at the endoplasmic retic-\nulum. Biochem. Pharmacol. 91, 490\u2013500 .\nSoderberg, O., Gullberg, M., Jarvius, M., Ridderstrale, K., Leuchowius, K.J.,\nJarvius, J., Wester, K.,\nHydbring, P., Bahram, F., Larsson, L.G., et al. (2006).\nDirect observation of individual endogenous protein complexes in situ by prox-\nimity ligation. Nat. Methods 3, 995\u20131000 .\nSteinhilber, D., Herrmann, T., and Roth, H.J. (1989). Separation of lipoxins and\nleukotrienes from human\ngranulocytes by high-performance liquid chromatog-\nraphy with a Radial-Pak cartridge after extraction with an octadecyl reversed-\nphase column. J. Chromatogr. 493, 361\u2013366.\nSurette, M.E., Palmantier, R., Gosselin, J., and Borgeat, P. (1993).\nLipopolys accharides prime\nwhole human blood and isolated neutrophils for\nthe increased synthesis of 5-lipoxygenase products by enhancing arachidonic\nacid availability: involvement of the CD14 antigen. J. Exp. Med. 178,\n1347\u20131355 .\nWerz, O. (2002). 5-Lipoxygenase: cellular biology and molecular pharma-\ncology. Curr. Drug Target\ns In\ufb02amm. Allergy 1, 23\u201344 .\nWerz, O., and Steinhilber, D. (2005). Development of 5-lipoxygenase inhibi-\ntors \u2013 lesson s\nfrom cellular enzyme regulation. Biochem. Pharmacol. 70,\n327\u2013333 .\nCell Chemical Biology 26, 1\u201311, January 17, 2019 11Please cite this article in press as: Ko \u00a8nig et al., Melleolide s from Honey Mushroom Inhibit 5-Lipoxygenase via Cys159, Cell Chemical Biology (2018),\nhttps://doi.org/10.1016/j.chembiol.2018.10.010STAR+ METHODS\nKEY RESOURCES TABLE\nREAGENT or RESOURCE SOURCE IDENTIFIER\nAntibodies\np-ERK1/2 (Thr202/Tyr204) Cell Signaling\nTechnology 9106S; RRID: AB_331768\nERK1/2 Cell Signaling Technology 9102S; RRID: AB_330744\np-cPLA 2(Ser505) Cell Signaling Technology 2831S; RRID: AB_2164445\np-p38 (Thr180/Tyr182) Cell Signaling Technology 9211S; RRID: AB_331641\nb-actin Cell Signaling Technology 3700S; RRID: AB_2242334\nGAPDH Santa Cruz Sc-47724; RRID: AB_627678\nIRDye 800CW Goat anti-Mouse IgG (H+L) LI-COR [P/N 925-32210]; RRID: AB_2687825\nIRDye 680LT Goat anti-Rabbit IgG (H+L) LI-COR [P/N 925-68020]; RRID: AB_2687826\nFLAP Abcam ab85227; RRID: AB_10673941\nAlexa Fluor 488 goat anti-rabbit IgG (H+L) Invitrogen A11034; RRID: AB_2576217\nAlexa Fluor 555 goat anti-mouse IgG (H+L) Invitrogen A21424; RRID: AB_141780\nChemicals, Peptides, and Recombinant Proteins\nDMSO VWR 1029500500\nbovine serum albumin AppliChem A1391.0500\npenicillin/streptomycin GE Healthcare Life Sciences A2213\nRPMI-1640 GE Healthcare Life Sciences R8758-6\nfetal calf serum Sigma F7524\nHistopaque /C210-1077 Sigma 10771-500ML\nThymoquinone Sigma 03416-100MG\nCelecoxib Sigma PZ0008\nN-Formyl-Met-Leu-Phe (fMLP) Sigma F3506-10MG\nDuolink /C210insitu PLA probe anti-mouse minus Sigma DUO92004-100RXN\nDuolink /C210insitu PLA probe anti-rabbit plus Sigma DUO92002-100RXN\nDuolink /C210insitu detection reagents far red Sigma DUO92013\nDuolink /C210insitu PLA wash buffers \ufb02uorescence Sigma DUO82049-4L\nRotiszint /C210eco plus Carl Roth 0016.4\novine COX-1 Cayman Chemicals 60100\nhuman recombinant COX-2 Cayman Chemicals 60122\nLTA 4methyl ester Cayman Chemicals 20010.25 mg\nLTC 4methyl ester d 5 Cayman Chemicals 9001287-50\nMK886 Cayman Chemicals 10133-5\narachidonic acid Cayman Chemicals 90010\nZileuton Sequoia Research Products SRP01100z\nCritical Commercial Assays\nDC protein assay kit Biorad 5000111\nExperimental Models: Cell Lines\nHEK293 ATCC CRL-153\nHEK293_5-LO Hafner et al., 2015 N/A\nHEK293\n_5-LO_C159S Hornig et al.,\n2012 N/A\nHEK293_5-LO_C300S Hornig et al.,\n2012 N/A\nHEK293_5-LO_C416S Hornig et al.,\n2012 N/A\nHEK293 _5-LO_C418S Hornig etal.,\n2012 N/A\nHEK293_5-LO_C159S_C300S_C416S_C41 8S Hafner\net al., 2015 N/A\nA549 ATCC CCL-185\n(Continue d\non next page )\ne1Cell Chemical Biology 26, 1\u201311.e1\u2013e4 , January 17, 2019Please cite this article in press as: Ko \u00a8nig et al., Melleolides from Honey Mushroom Inhibit 5-Lipoxygenase via Cys159, Cell Chemical Biology (2018),\nhttps://doi.org/10.1016/j.chembiol.2018.10.010CONTACT FOR REAGENT AND RESOURCE SHARING\nFurther information and requests for resources and reagents should be directed to and will be ful\ufb01lled by the Lead Contact, Oliver\nWerz ( oliver.werz@uni-jena.de )\nEXPERIMENTAL MODEL AND\nSUBJECT DETAILS\nHuman Cells\nNeutrophils and monocytes\nwere isolated from peripheral human blood of adult healthy male and female volunteers (18-65 years) as\ndescribed ( Pace et al.,\n2017; Scherer et al., 2014 ) and with consent obtained from the Institute of Transfusion Medicine, University\nHospital Jena. Individual blood\nsamples provided and used for leukocyte isolation were blinded and thus, the exact age and the sex\nof the donor was unknown. The protocols for experiments with human neutrophils and monocytes were approved by the ethical com-\nmission of the Friedrich-Schiller-University Jena (approval no. 4025-02/14). All methods were performed in accordance with the rele-\nvant guidelines and regulations. Leukocyte concentrates were prepared by centrifugation (4000 3g, 20 min, 20/C 4C) and erythrocytes\nwere removed by dextran sedimentation, followed by centrifugation on lymphocyte separation medium (Histopaque/C210-1077, Sigma-\nAldrich) to obtain peripheral blood mononuclear cells (PBMC) and neutrophils. Resulting neutrophils were \ufb01nally resuspended in PBS\npH 7.4 containing 1 mg/mL glucose and 1 mM CaCl 2(PGC buffer). PBMC were seeded in RPMI 1640 (Sigma-Aldrich) containing 10%\n(v/v) heat inactivated fetal calf serum (FCS), 100 U/mL penicillin, and 100 mg/mL streptomycin in cell culture \ufb02asks (Greiner Bio-one,\nFrickenhausen, Germany) for 1.5 h at 37/C 4C and 5% CO 2. Adherent monocytes were washed twice with PBS and were resuspended in\nPGC buffer. HEK (human embryonic kidney, female fetus)293 cells stably transfected with FLAP and 5-LO or 5-LO mutants ( Hornig\net al., 2012; Hafner\net al., 2015 ) were cultured in monolayers in DMEM High Glucose (4.5 g/L) medium supplemented with heat-in-\nactivated FCS (10%, v/v),\n100 U/mL penicillin, and 100 mg/mL streptomycin at 37/C 4C in a 5% CO 2incubator.\nMETHODS DETAILS\nExpression and Puri\ufb01cation of\nHuman Recombinant 5-LO\nEscherichia coli (BL21) cells were transformed with plasmid pT3-5-LO, and human recombinant 5-LO protein was expressed over-\nnight at 30/C 4C as previously described ( Fischer et al., 2003 ). Cells were lysed in 50 mM triethanolamine/HCl pH 8.0, 5 mM EDTA, 1 mM\nphenylmethanesulphonyl \ufb02uoride (PMSF), soybean\ntrypsin inhibitor (STI, 60 mg/mL), and lysozyme (1 mg/mL), homogenized by son-\nication (3 320 s), and centrifuged at 40,000 3g for 20 min at 4/C 4C. For puri\ufb01cation of 5-LO, ATP af\ufb01nity chromatography was used and\nthe 40,000 3g supernatant (S40) was applied to an ATP agarose column (Sigma-Aldrich). Aliquots of semi-puri\ufb01ed 5-LO were diluted\nwith ice-cold PBS containing 1 mM EDTA. Samples were pre-incubated with the test compounds or vehicle (0.1% DMSO). After\n10 min at 4/C 4C, samples were stimulated with 2 mM CaCl 2plus the indicated concentrations of AA to start 5-LO product formation.\nThe reaction was stopped after 10 min by addition of one volume of ice-cold methanol, and the formed metabolites were analyzed by\nRP-HPLC as described ( Pergola et al., 2014; Steinhilber et al., 1989 ). 5-LO products include the all-trans isomers of LTB 4as well as\n5-HPETE and its corresponding alcohol 5-HETE.\nDetermination of 5-LO Product Formation in Intact Cells and Homogenates\nFor activity assays with intact cells, 5 3106freshly isolated neutrophils or monocytes, or 1 3106HEK293 cells stably producing the\nindicated recombinant proteins, were resuspended in 1 mL PGC buffer. After pre-incubation with compounds 1-4(10 min, 37/C 4C),\n5-LO product formation was started by addition of 2.5 mM A23187 with or without 20 mM AA (neutrophils, monocytes) or 3 mMA A\n(HEK cells). After 10 min at 37/C 4C, the reaction was stopped with 1 mL of ice-cold methanol. Formed 5-LO metabolites were extractedContinued\nREAGENT or RESOURCE SOURCE IDENTIFIER\nExperimental Models: Organisms/Strains\nEscherichia\ncoliBL21 (DE3) New England Biolabs C2525l\nSoftware and Algorithms\nGraphPad InStat 3 GraphPad Software Inc https://www.graphpad.com/scienti\ufb01c-software/\ninstat/\nOdyssey 3.0 software LI-COR https://www.licor.com/bio/products/software/\nimage_studio/index.html\nXcalibur Qual\nBrowser Software 2.0.7 Thermo Fisher Scienti\ufb01c http://www.thermo\ufb01sher.com/order/catalog/\nproduct/OPTON-30487\nmMass version 5.5.0 open\nsource mass spectometry http://www.mmass.org/download/\nAxioVision Se64 Rel. 4.9 Carl Zeiss https://www.zeiss.de/mikroskopie/downloads/\naxiovision-downloads.html\nCell Chemical Biology 26, 1\u201311.e1\u2013e4, January 17, 2019 e2Please cite this article in press as: Ko \u00a8nig et al., Melleolide s from Honey Mushroom Inhibit 5-Lipoxygenase via Cys159, Cell Chemical Biology (2018),\nhttps://doi.org/10.1016/j.chembiol.2018.10.010and analyzed by RP-HPLC using a C18 RP Radial PAK column (Waters, Eschborn, Germany) ( Pergola et al., 2014; Steinhilber et al.,\n1989 ) or optionally by UPLC-MS/MS as described ( Pace et al., 2017 ).\nTo determine 5-LO product\nformation in homogenates, neutrophils (5 3106) or HEK293 cells (1 3106) were resuspended in 1 mL\nPBS containing 1 mM EDTA. Cells were lysed on ice by sonication (3 320 s) and resulting cell homogenates were pre-incubated with\ncompounds or vehicle (0.1% DMSO) for 10 min on ice. 5-LO product formation was started by addition of 2 mM CaCl 2and 20 mMA A\n(neutrophils) or 10 mM AA (HEK cells). After 10 min at 37/C 4C, reaction was stopped by 1 mL ice-cold methanol. 5-LO product formation\nwas analyzed as described above for intact cells.\nDetermination of Release of [3H]-Labeled Arachidonic Acid\nRelease of [3H]-labeled AA from human neutrophils was analyzed as described ( Fischer et al., 2005 ). In brief, freshly isolated\nneutrophils were immediately resuspended\nat 107cells/mL RPMI 1640 medium containing 5 nM [3H]AA (corresponding to\n0.5mCi/mL, speci\ufb01c activity 200 Ci/mmol) and incubated for 120 min at 37/C 4Ci n5 %C O 2atmosphere. Cells were then washed twice\nwith PBS containing 1 mg/mL glucose and 2 mg/mL fatty acid-free bovine albumin, to remove unincorporated [3H]AA. Labelled neu-\ntrophils (2 3107) were resuspended in 1 mL PGC containing 2 mg/mL fatty acid-free bovine albumin and pre-incubated with 0.1%\nDMSO or test compounds (15 min, 37/C 4C) and then stimulated with 2.5 mM A23187 for 10 min. The samples were then placed on ice,\ncentrifuged and aliquots (300 mL) of the supernatants were assayed for radioactivity by scintillation counting (Micro Beta Trilux, Perkin\nElmer, Waltham, MA, USA).\nLTC 4Synthase Activity Assay\nPreparation of HEK293 cells stably expressing LTC 4synthase and generation of microsomes were performed as described ( Liening\net al., 2016 ). Microsomes\nwere pre-incubated with compounds or vehicle (0.1% DMSO) for 10 min at 4/C 4C prior stimulation with 1mM\nLTA 4methyl ester (Cayman, Ann Harbor, MI) for 10 min. The reaction was stopped by 1 vol ice-cold methanol and acidi\ufb01ed PBS, and\nthe internal standard LTC 4methyl ester- d5was added prior to solid phase extraction. LTC 4methyl ester formation was analyzed by\nUPLC-MS/MS as described previously ( Liening et al., 2016 ).\nDetermination of Isolated COX-1 and -2 Activity\nPuri\ufb01ed COX-1 (ovine, 50 units) or COX-2 (human recombinant, 20 units) were pre-incubated with compounds or vehicle (0.1%\nDMSO) for 5 min\nat 4/C 4C in 1 mL reaction buffer containing 100 mM Tris buffer pH 8, 5 mM GSH, 5 mM hemoglobin, and 100 mM\nEDTA prior 1 min at 37/C 4C to prewarm samples. COX product formation was started by adding AA (COX-1: 5 mM, COX-2: 2 mM) which\nresulted in generation of 12-HHT (12( S)-hydroxy-5- cis-8,10- trans-heptadecatrienoic acid) non-enzymatically formed from COX-\nderived PGH 2. 12-HHT was measured by RP-HPLC as previously reported ( Albert et al., 2002 ).\nDetermination of PGE 2Synthase Activity in a Cell-Free Assay\nPreparation of A549 cells, induction of mPGES-1 by IL-1 b, generation of microsomes, and analysis of mPGES-1 activity was per-\nformed exactly as described previously ( Koeberle et al., 2008, 2009 ).\nSDS PAGE and Western Blot\nNeutrophils (1 3107/100 mL ice-cold PGC buffer) were pre-incubated for 10 min at 37/C 4C with test compounds at 37/C 4C, stimulated\nwith 1 mMN-formyl-methionyl-leucyl-phenylalanine (fMLP) for 1.5 min at 37/C 4C. The reaction was stopped by addition of 100 mL ice-\ncold 23SDS loading buffer (20 mM Tris-HCl pH 8, 2 mM EDTA, 5% (m/v) SDS, 10% (v/v) b-mercaptoethanol, 10 mg/mL leupeptin,\n60mg/mL STI, 1 mM PMSF, 40 mL glycerol and 0.1% bromophenol blue (1:1, v/v). Samples were boiled for 5 min at 96/C 4C, sonicated\n(3310 sec, 4/C 4C) and proteins were separated and analyzed by SDS\u2013PAGE and Western Blotting.\nTo control stable expression of transfected enzymes, HEK cells (1 3106/100 mL) were washed and lysed with Triton X-100 lysis\nbuffer (20 mM Tris-HCl pH 7.4, 150 mM NaCl, 2 mM EDTA, 1% (v/v) Triton X-100, 0.5% (v/v) NP-40, 10 mg/mL leupeptin, 60 mg/\nmL STI, 1 mM PMSF) for 15 min on ice with occasional vortexing. Lysates were centrifuged (21,000 3g, 10 min, 4/C 4C) and the super-\nnatant was mixed with 4 3Laemmli buffer (50 mM Tris-HCl pH 6.8, 12.5 mM EDTA, 2% (m/v) SDS, 10% (v/v) glycerol, 1% (v/v) b-mer-\ncaptoethanol, 0.02% (m/v) bromophenol blue) and samples were boiled for 5 min at 96/C 4C.\nCorrect protein loading on the gels and transfer of proteins to nitrocellulose membrane (Amersham PROTRAN /C210supported 0.45\nNC, GE Healthcare, Freiburg, Germany) were con\ufb01rmed by Ponceau staining. Antibodies recognizing phosphorylated ERK1/2\n(Thr202/Tyr204), ERK1/2, p-cPLA 2(Ser505), p-p38 (Thr180/Tyr182) or b-actin were from Cell Signaling Technology (Boston, MA)\nand used at 1:1000 dilution. The antibody against GAPDH (1:1000) was purchased from Santa Cruz (Dallas, TX) and the rabbit\nFLAP (1:1000) antibody was obtained from Abcam (Cambridge, UK). The rabbit 5-LO antiserum (1551, AK7, 1:8 dilution) was kindly\nprovided by Dr. Olof Ra \u02dadmark, Karolinska Institutet, Stockholm, Sweden. Infrared-labeled secondary antibody IRDye 800CW goat\nanti-mouse was from LI-COR Biosciences (Lincoln, NE). For detection, the Odyssey Infrared Imaging System (LI-COR Bioscience,\nLincoln, NE) and for analysis the Odyssey application software (version 3.0.25) were used.\nGSH Incubation\nGlutathione (GSH) adduct formation tests were carried out directly on the MALDI-target in a total volume of 2 mL. 1 mLof 2 mM GSH in\nPBS pH 7.4 and 1 mLo f2 0 mM compound or vehicle in PBS pH 7.4 were mixed on the target to obtain a \ufb01nal concentration of 1 mM\ne3Cell Chemical Biology 26, 1\u201311.e1\u2013e4 , January 17, 2019Please cite this article in press as: Ko \u00a8nig et al., Melleolides from Honey Mushroom Inhibit 5-Lipoxygenase via Cys159, Cell Chemical Biology (2018),\nhttps://doi.org/10.1016/j.chembiol.2018.10.010GSH and 10 mM compound. The reaction mixture was kept humid for 30 min at 37/C 4C using a SunDigest digestion chamber\n(SunChrom, Friedrichsdorf, Germany). The reaction was stopped after 30 min of incubation with 1 mL CHCA-solution (3 mg/mL\nCHCA ( a-cyano-4-hydroxy-cinnamic acid) in 70/30/0.1 acetonitrile/water/tri\ufb02uoroacetic acid (TFA)). After matrix crystallization,\nwe used chilled 5%-formic acid to remove salt contaminations from the matrix crystals and recrystallized the sample with\nacetonitrile/water (80/20, v/v) mixture containing 0.1% TFA to obtain a homogeneous crystallization.\nStandard Peptide Incubation\nBinding assays using the standard peptides AAAACAAAAR, AAAAHAAAAR, AAAAKAAAAR, AAAASAAAAR (JPT Peptide technol-\nogy, Berlin, Germany) were\nalso directly carried out on the MALDI-target. Peptides were diluted in PBS pH 7.4 to a concentration\nof 20 mM and mixed separately with each compound at a concentration of 20 mM in a total volume of 2 mL to obtain a \ufb01nal concen-\ntration of 10 mM peptide and 10 mM compound. Incubation was performed using the SunDigest system for 1 h at 37/C 4C. The reaction\nwas stopped using the same matrix solution as described above. Washing and recrystallization of the formed spots were performed\nas previously described ( Kretschmer et al., 2017 ).\nMALDI-MS\nMeasurement and Data Analysis\nMALDI-MS measurements were carried out using a MALDI-Duo ion source coupled to an Orbitrap LTQ XL mass spectrometer\n(Thermo Fisher Scienti\ufb01c, Bremen,\nGermany). MS measurements were carried out on an Orbitrap mass analyzer. For GSH adducts,\nthe mass was recorded from m/z 200.00 to 800.00 and for standard peptide assay, the mass range was between m/z 800.00 and\n2000.00. 50 subspectra were accumulated for data analysis. Mass resolution was set to 30,000 (FWHM at m/z: 400), laser energy\nwas adjusted to optimize MS spectra quality. MS/MS spectra of reaction products and peptides were recorded using the ion trap\nmass analyzer. 100 subspectra were accumulated for data analysis. Normalized collision energy was set to 50. Isolation of the partic-\nular reaction product was performed using an isolation width of 1 Da. MS spectra were analyzed using the Qual Browser software\nversion 2.0.7 (Thermo Fisher Scienti\ufb01c). This software was also used to compare the theoretical masses. Theoretical masses of pep-\ntides, reaction products, and MS/MS ion masses were calculated using mMass version 5.5.0.\nAnalysis of Subcellular Localization of 5-LO by Immuno\ufb02uorescence Microscopy\nFor analysis of 5-LO and FLAP subcellular localization in monocytes, PBMC were seeded in RPMI medium containing 2 mM L- glutam ine,\n100 U/ml penicillin, and 100 mg/ml streptomycin onto glass coverslips in a 12-well plate and cultured for 1.5 h. The 5-LO/FLAP subcellular\nlocalization was also analyzed using HEK293 cells stably transfected with 5-LO enzymes and FLAP. Cells (0.45 3106/mL) were seeded\non poly-D-lysine-coated coverslips and cultured at 37/C 4C, 5% CO 2until 60% con\ufb02uence. Cells were washed with PGC buffer and pre-\nincubated with test compounds or vehicle (0.1% DMSO) 10 min at 37/C 4C in PGC buffer prior to activation. Cells were then stimulated for\n10 min with 2.5 mM A23187 and stopped by \ufb01xation with 4% paraformaldehyde solution. Ice-cold acetone (5 min, 4/C 4C) was used for\npermeabilization prior to blocking with non-immune goat serum. Samples were incubated with mouse monoclonal anti-5-LO antibody\n(1:300; made in-house, Goethe University Frankfurt, Germany) ( Gerstmeier et al., 2014; Pergola et al., 2014 ) and rabbit polyclonal anti-\nFLAP anti\nbody (1:500; Abcam, Cambridge, UK) at 4/C 4C overnight. 5-LO and FLAP were stained with the \ufb02uorophore-labeled secondary\nantibodies; Alexa Fluor 488 goat anti-rabbit (1:1000) and Alexa Fluor 555 goat anti-mouse (1:1000, Invitrogen, Darmstadt, Germany).\nNuclear DNA was stained with DAPI (Invitrogen). Samples were analyzed with a Zeiss Axiovert 200 M microscope, and a Plan Neo\ufb02uar\n3100/1.30 Oil (DIC III) objective (Zeiss, Jena, Germany). A Zeiss AxioCam MR camera was used for image acquisition.\nIn Situ Analysis of 5-LO/FLAP Interaction by Proximity Ligation Assay\nTo analyze the in situ inte raction of 5-LO with FLAP in monocytes and HEK293 cells, an in situ proximity ligation assay (PLA) was per-\nformed, according to the manufacturers\u2019 protocol ( Soderberg et al., 2006 ) and as described ( Gerstmeier et al., 2016b ). Samples were\ntreated,\n\ufb01xed and incubated with primary antibody as described for IF microscopy above. Cells were then incubated with species spe-\nci\ufb01c secondary antibodies conjugated with oligonucleotides (PLA probe anti-mouse MINUS and anti-rabbit PLUS) for 1 h at 37/C 4C. By\naddition of two other circleforming DNA oligonucleotides and a ligase (30 min at 37/C 4C) the antibody-bound oligonucleotides form a\nDNA circle when the target proteins are less than 40 nm distant from each other. The newly generated DNA circle was ampli\ufb01ed by rolling\ncircle ampli\ufb01cation and visualized by hybridization with \ufb02uorescently labeled oligonucleotides. Nuclear DNA was stained with DAPI. The\nPLA interaction signal appears as a \ufb02uorescent spot and was analyzed using the above described microscope and equipment.\nQUANTIFICATION AND STATISTICAL ANALYSIS\nResults are presented as means \u00b1 standard error of the mean (SEM) of nindependent observations, where nrepresents the number\nof performed experiments at different days or with different donors. Statistical analysis of the data was performed by one-way\nANOVA using GraphPad InStat (Graphpad Software Inc., San Diego, CA) followed by a Bonferroni post-hoc test for multiple or stu-\ndent t-test for single comparisons, respectively. P-values < 0.05 were considered as signi\ufb01cant.\nCell Chemical Biology 26, 1\u201311.e1\u2013e4, January 17, 2019 e4Please cite this article in press as: Ko \u00a8nig et al., Melleolide s from Honey Mushroom Inhibit 5-Lipoxygenase via Cys159, Cell Chemical Biology (2018),\nhttps://doi.org/10.1016/j.chembiol.2018.10.010Cell Chemical Biology, Volume 26\nSupplemental Information\nMelleolides from Honey\nMushroom\nInhibit 5-Lipoxygenase via Cys159\nStefanie K\u00f6nig, Erik Romp, Verena Krauth, Michael R\u00fchl, Maximilian D\u00f6rfer, Stefanie\nLiening, Bettina Hofmann, Ann-Kathrin H\u00e4fner, Dieter Steinhilber, Michael Karas, Ulrike\nGarscha, Dirk Hoffmeister, and Oliver Werz1\u00a0\n\u00a0Supporting Information \nMelleolides fr om hone y mushroom i nhibit 5\n-lipoxygenase via Cys1 59 \nStefanie K\u00f6nig, Erik Romp, Veren a Krauth, Michael R\u00fchl, Maximil ian D\u00f6rfer, Stefanie Liening, Bettina \nHofmann, Ann-Kathrin H\u00e4fner, Dieter Steinhilber, Michael Karas, Ulrike Garscha, Dirk Hoffmeister, and Oliver \nWerz \n \nContent :  \nSupplemental Table 1 \nSupplemental Figures 1 - 4 \n \n \n \n  2\u00a0\n\u00a0Supplemen tal Table 1 \nassa\ny / enzyme cmpd. 1 \n(% remaining activity) control inhibitor \n(% remaining activity) \n[3H]AA release (neutrophils) 75.2 \u00b1  3.1 48.8 \u00b1 2.6 ( RSC-3388, 10 \u00b5M) \nLTC 4 synthase 83.7 \u00b1 14.5  3. 5 \u00b1 0.7 (MK886, 10 \u00b5M)  \nCOX-1 89.7 \u00b1 5.7  26.2 \u00b1 7.2 (indo methacin, 10 \u00b5M)  \nCOX-2 114.3 \u00b1 8.2  59.1 \u00b1 0.8 (celecoxib, 5 \u00b5M) \n25.4 \u00b1 1.7 (indo methacin, 10 \u00b5M)  \nmPGES-1 79.8 \u00b1 2.9  18.1 \u00b1 3.2 (MK886, 10 \u00b5M)  \n \nTable S1 . Ef\nfects of 1 on various enzymes involved in eicosanoid biosynth esis, related to Figure 2. \nMelleolide 1 (1 \u00b5M) or control inhibitors (as indicated) were added to the respective enzymes or isolated \nneutrophils 10 min prior starting the reaction. Data are expres sed as percentage of control (vehicle, 100%), mean \n\u00b1 SEM, n = 3. \n  3\u00a0\n\u00a0Supplemental Figure 1 \n \nFig. S\n1. Effects of 1 on the phosphorylation of p38 MAPK, ERK-1 /2 and cPLA 2 in neutrophils, related to \nFigure 2. Neutroph\nils were pre-incubated with 1, reference inhibitor U0126 (3 \u00b5M), or vehicle (0.1% DMSO) \nfor 10 min at 37 \u00b0C prior stimulation with 1 \u00b5M N-formyl-methionyl-leucyl-phenylalanine (fMLP) for 1.5 min. \nThe amounts of phospho-ERK-1/2 and ERK1/-2 (for normalization), phospho-p38 MAPK, phospho-cPLA 2 and \nGAPDH \n(for normalization) were analyzed by Western blot. Data, obtained by densitometry (bar charts, \nmean + S.E.M.; n  = 3), are expressed as percentage of fMLP-stimulated control. \n \n  \n4\u00a0\n\u00a0Supplemental Figure 2 \n \nFig. S2. \nMS\u00b2-spectra of modified cmpd. 2-modified GSH indicate covalent binding of cmpd. 2 to GSH, \nrelated to Figure 3.  \n \n  \n5\u00a0\n\u00a0Supplemental Figure 3 \n \nFig. S\n3. MS\u00b2-spectra covalent binding of cmpd. 1 and cmpd. 2 to syntheti c peptides, related to Figure 3. \n(A) Modification of standard peptides by compd. 1. Upper panel shows MS\u00b2 spectra of modified \nAAAACAAAAR (left row), AAAAHAAAAR (middle row) and AAAAKAAAAR ( right row). Lower panel \nshows MS\u00b3 spectra of the main fragments m/z = 1096.67, 1130.67 and 1121.67. (B) Modification of standard \npeptides by cmpd. 2 . Upper panel shows MS\u00b2 spectra of modified AAAACAAAAR (left row), AAAAHAAAAR \n(middle row) and AAAAKAAAAR (right row). Lower panel shows MS\u00b3 spectra of the main fragments m/z = \n1096.67, 1130.67 and 1121.67.  \n  \n6\u00a0\n\u00a0Supplemen tal Figure 4 \nA         B \n \n \nFig. \nS4. Inhibition of 5-LO by cmpd. 2, related to Figure 5. (A) Intact HEK cells. (B) HEK homogenates. \nHEK cells (106/ml) expressing 5-LO_FLAP, 4C_FLAP, C159S_FLAP, C300S_FLAP, C41 6S_FLAP or \nC418S_FLAP mutant were pretreated with compd. 2 or 0.1% DMSO (vehicle) for 10 min at 37 \u00b0C. Cells were \nstimulated with 2.5 \u00b5M A23187 and 3 \u00b5M AA for 10 min at 37 \u00b0C. Data are expressed as percentage of control \n(100%), mean \u00b1 SEM, n = 4, * p<0.0 5, ** p< 0.01, *** p< 0.001 versus vehicle control. 0.1 1 10 0.3 30255075100125150 5-LO_wt\n5-LO_4C\n5-LO_C159S\n5-LO_C300S\n5-LO_C416S\n5-LO_C418S\ncmpd. 2 [\u00b5M]5-LO product formation\n(% of control)\n0.1 1 10 0.3 30255075100125150 5-LO_wt\n5-LO_4C\n5-LO_C159S\n5-LO_C300S\n5-LO_C416S\n5-LO_C418S\ncmpd. 2 [\u00b5M]5-LO product formation\n(% of control)3. Publikationen   73 \n3.3. \nPublikation 3 \u2013 Diversity and bioactivity of Armillaria sesquiterpene \naryl ester natural product \nMaximilian D\u00f6rfer, Markus Gressler, Dirk Hoffmeister \nMycological Progress, 2019, Volume 18, 1027-1037. \nZusammenfassung \nDie Melleolide aus Basidiomyceten der Gattung Armillaria sind niedermolekulare Naturstoffe. \nBiosynthetisch aus einem trizyklischen Sesquiterpen-Protoilludenalkohol verestert mit einem \nTetraketid (Orsellins\u00e4ure und Derivate) bestehend, stellen die Melleolide mit mehr als 70 \nbekannten Verbindungen ein Lehrbuchbeispiel f\u00fcr diversit\u00e4tsorientierte Biosynthese dar. \nDieser \u00dcbersichtsartikel fasst die strukturelle Vielfalt der Melleolide zusammen und beschreibt, \nsoweit bekannt, die enzymatische Grundlage zur Biosynthese der Verbindungen. Des \nWeiteren wurden aktuelle Kenntnisse \u00fcber die antimikrobielle, phytotoxische und cytotoxische \nAktivit\u00e4t der Melleolide mit Fokus auf deren molekulare Zielstrukturen sowie deren \nunterschiedliche Beziehungen zwischen Struktur und Aktivit\u00e4t und letztlich deren \nWirkmechanismen herausgearbeitet. \nEigenanteil 40%: \nMaximilian D\u00f6rfer:  Literaturrecherche, Gestaltung von Abbildungen, Verfassen des  \n    Manuskripts \n \n \n \n \n \n \n \n \n \n \n \n \nJena, den \n \n____________________  \nProf. Dr. Dirk Hoffmeister ORIGINAL ARTICLE\nDiversity and bioactivity of Armill aria sesquiterpene aryl ester\nnatural products\nMaximilian D\u00f6rfer1&Markus Gressler1&Dirk Hoffmeister1\nReceived: 11 June 2019 / Accepted: 25 July 2019\n#Germ\nan Mycological Society and Springer-Verlag GmbH Germany, part of Springer Nature 2019\nAbstract\nSpecies of the basidiomycete genus Armillaria produce bioactive small molecule natural products, referred to as melleolides.\nWith more than 70 described members, this class of natural products is a prime example for diversity-oriented biosynthesis.\nChemically, they represent hybrid molecules, composed of a tricyclic, chiral sesquiterpene protoilludene alcohol, esterified with\nthe tetraketide orsellinic acid or its derivatives. In this review article, we summarize the melleolide \u2019s structural diversity and\npresent \u2014to the extent elucidated \u2014the enzymatic basis how their backbone structures are biosynthesized and modified. We also\nhighlight the current knowledge on their antimicrobial, phytotoxic, and cytotoxic bioactivities, along with a view on the\nmolecular targets of the melleolides, their unparalleled structure-activity relationships, and their modes of action.\nKeywords Armillaria mellea .Biosynthesis .Natural product .Melleolide .Orsellinic acid .Protoilludene .Sesquiterpene\nIntroduction\nProbably the most intriguing phenomenon of fungal biology is\norganismal and morphological diversity. On the molecular\nand chemical level, this biological diversity is mirrored by\nthe plethora of small yet structurally complex, highly func-\ntionalized, and often chiral bioactive natural products that fun-\ngi produce. This secondary metabolism has evolved, often in a\nspecies- or genus-specific way, towards structural diversity,\nwhile the primary metabolism is rather uniform to secure fun-\ndamental cellular functions. In the field of basidiomycete sec-\nondary metabolism, excellent reviews summarize various as-\npects of this metabolic wealth (Gill and Steglich 1987 ; Gill\n2003 ;Z j a w i o n y 2004 ;Z h o ua n dL i u 2010 ; Jiang et al. 2011 ;\nSandargo et\nal.2019 ). The so-called screening hypothesis\nprovides the theoretical\nframework to explain chemicaldiversity in an evolutionary context. Strong bioactivity is a\nrare property of a molecule. Consequently, those organisms\nthat have evolved the capacity to produce a maximum number\nof metabolites at a minimal cost are more likely to produce\none or various compounds that confer useful properties on the\nproducer and, hence, the respective biosynthesis is favored by\nselection (Firn and Jones 2003 ; Firn and Jones 2009 ).\nThis contribution\nfocuses on the melleolides, a unique\nclass of basidiomycete metabolites. They are produced by\nspecies of the genus Armillaria (Physalacriaceae,\nAgaricales) in the traditional wide sense (Fig. 1). This ge-\nnusunderwent\nchanges, as the non-annulate species were\nsegregated to represent the closely related genus\nDesarmillaria (D.ectypa ,D.tabescens ;K o c he ta l .\n2017). Also, the circumscription of species changed, based\non morphological,\nbiological, and phylogenetic species\nconcepts. For example, what was traditionally considered\nArmillaria mellea in North America was confirmed to\ninclude ten Armillaria species (Brazee et al. 2012 ). These\nfungi a\nre best known as notorious hardwood or conifer\npathogens as they cause butt and root rot in both managed\nand unmanaged forests (Baumgartner et al. 2011). Beyond\nthe economic b\nurden for forestry, Armillaria species also\ndamage agriculturally important crops, such as peach or\ncoffee trees, and grapes. Yet, as white-rot fungi,\nArmillaria species help disintegrate lignocellulose and thus\nserve a positive ecological role as they maintain the carbonThis article is part of the \u201cTopic c ollection on Basidiomycote Mycology\nin honor of Franz Oberwinkler who passed away in March 2018. \u201d\nResponsible editor: Marc Stadler\n*Dirk Hoffmeister\ndirk.hoffmeister@hki-jena.de\n1Department Pharmaceutical Microbiology at the\nHans-Kn\u00f6ll-Institute, Friedrich-Schiller-Universit\u00e4t, Winzerlaer\nStrasse 2, 07745 Jena, GermanyMycological Progress (2019) 18:1027\u2013 1037\nhttp\ns://doi.org/10.1007/s11557-019-01508-z\nflux. Here, we present an overview of the diversity of the\nmelleolides, i.e.,\nthe natural products that define the genus\nArmillaria with regard to secondary metabolism. As prob-\nably the most diverse family of basidiomycete small mol-\necules, they represent a textbook example of diversity-\noriented biosynthesis. Chemical structures are shown in\nFigs. 2,3,4,a n d5 . We also highlight \u2014to the extent\nknown \u2014the enzymes that create this diversity. An intro-\nduction to the bioactivities and pharmacological modes of\naction concludes this article.Structural diversity of the melleolides\nFrom antibacterially active chloroform extracts of A. mellea cul-\ntures, Oduro et al. ( 1976) identified four compounds and partial-\nlycharac\nterized one of them by spectroscopic methods. Notably,\nthey discovered a signature UV/vis spectrum and observed nu-\nclear magnetic resonance (NMR) signals that are compatible\nwith those later found for the m elleolides. Subsequently,\nDonnelly et al. ( 1982 ,1984 ; Donnelly and Coveney 1987 )\nsucceede\nd in isolation and structural elucidation of armillyl\norsellinate (Fig. 4b; for references and che mical properties o f\nall melleolides, please refer to Table 1) as the first member of\nthe melleolides.\nThe same authors also showed that armillyl\norsellinate inhibited Bacillus subtilis andStaphylococcus\naureus .E v e rs i n c eArmillaria natural products have been stud-\nied intensively, and even though only produced by one fungal\ngenus, the melleolides have emerged as one of the largest classes\nof fungal natural products with as yet 71 described and charac-\nterized naturally occurring structural congeners, including one\nunnatural, yet biocatalytica lly synthesized compound, 6 \u2032-\nbromomelleolide F (Wick et al. 2016,F i g .5f ). Melleolides rep-\nresent molecular\nhybrids as two structural elements of dissimilar\nbiosynthetic origin are merged into one final scaffold: the first\nelement is the C 15tricyclic protoillude ne framework. It origi-\nnates from geranyldiphosphate, the universal precursor to the\nsesquiterpenes. In some melleolides (e.g., 15-hydroxy-5\u2032 -\nOOH\nOHO\nOR3R1\nR2\nOOH\nOHO\nO\nR2HO\nR1OH\nR3\nR4\nOO\nH\nOHO\nOR7R1\nR6R2\nR5OOH\nOHO\nOR3H\nO\nR2R1\nOHR1R2R3\n4\n-dehydro-\ndihydromelleolideHHH\nmelleolideFOHHH\n6'-chloromelleolideFOH ClH\nA52aOH Cl CH3\nA52bOHHCH3R1R2R3\nmelledonolOHHH\nmelleolideBHHCH3\nmelleolideCOHHCH3\nmelleolideDOH Cl CH3\nmelleolideEHHH\nmelleolideIHCl CH3\nmelleolideMHClH\nR1R2\n13-hydroxy-\ndihydro-\nmelleolideHH\n10-dehydroxy-\nmelleolideDCl CH3\n6'-chloro-13-\ndihydro-\nmelleolideClHR1R2R3R4R5R6R7\n14-hydroxy-\ndihydro-\nmelleolideOHHCH3CH2OHHHH\n4-dehydro-\n14-hydroxy-\ndihydro-\nmelleolideHHCH3CH2OHHHH\n13,14-\ndihydroxy-\nA52aOH OH CH3CH2OHHCl CH3\nmelleolideGOHHCH2OHCH3OHHCH3123\n4\n5\n67\n8910111213\n1415\n1'\n2'\n3'\n4'\n5'6'7'8'\nFig. 2 Chemical structures of melleolides featuring primary alcohol at C-\n1 and\na\u03942,3skeleton. The numbering of carbon atoms does not follow\nIUPAC rules but reflects numbering in all previous literature. Thestructural element typical for the respective sub-category is highlighted\nin red. Exact molecular weights and literature references for all com-\npounds in Figs. 2through 5are given in Table 1\nFig. 1 Carpophores of Armill aria mellea in a Central European\ndeciduous forest (photograph taken in September 2018)1028 Mycol Progress (2019) 18:1027 \u20131037methoxymelledonal, Fig. 3) this tricyclic sesquiterpene core fea-\ntures as m\nany as six consecutive stereocenters. The second moi-\nety is orsellinic acid, i.e., a planar phenolic acid derivative of\npolyketidic origin. Armillaria uniquely combines these two moi-\neties by esterification. Intriguing ly, the individual structural ele-\nments are common natural product classes: orsellinic acid or its\nderivatives are known from lichen and countless bacterial and\nfungal sources (Yamazaki et al. 1965;S h e n 2003;S c h r o e c k h\netal.2009;\nBraesel et al. 2017 ). Likewise, protoilludenederivatives\nhave been isolated from numerous basidiomycetes,\namong them the tsugicolines A \u2013Ef r o m Laurilia tsugicola and\nthe prototypical \u03946-protoilludene and \u03947-protoilludene-6-ol,\nwhich were first discovered in Fomitopsis insularis (Abraham\n2001). The terms (proto)illudene or illudol root in the species\nname Omphalotus illudens (=Cl\nitocybe illudens ), after which\nthese compounds were named (McMorris et al. 1967).\nThe first\nlayer of structural diversity among the melleolides\nresults from esterification of these two moieties. In the vastOO\nOHO\nOR3R1\nR2\nOO\nOHO\nOH\n5-hyd\nroxyarmillarivinHOR1\nR2\nOO\nOHO\nOR4HO\nR3OHO\nH\nOO\nOHO\nOR3HO\nR2R1\nOHOO\nO\nHO\nOR3R1\nR2OHR1R2R3\nar\nmillarivinHHH\nmelleolideOHHH\n4-methoxymelleolideOCH3H H\narmillarinOHHCH3\nmelleolideKOH ClH\narmillaridinOH ClCH3\nA51aOCH3HCH3\n4-methoxy-\narmillaridinOCH3ClCH3R1R2R3\narmillaritinOHHH\narmillaripinHHCH3\narmillarilinOHHCH3\n13-hydroxy-4-\nmethoxymelleolideOCH3HH\n13-hydroxy-\nmelleolideKOH ClH\narmillarininOH Cl CH3\nR1R2R3R4\nmelledonalDCH3CH2OHClH\nmelledonalECH3CH2OHHCH3\n15-hydroxy-\n5'-methoxy-\nmelledonalCH2OHCH3HCH3R1R2R3\n10-hydroxy-\nmelleolideHHH\nmelledonalOHHH\n5\u00b4-methoxy-\nmelledonalOHHCH3\nmelledonalBOH ClH\nmelledonalCOH Cl CH3\nmelleolideHHHCH3\nmelleolideJHCl CH3\nmelleolideLHClH\nFig. 3 Chemical structures of melleolides with an aldehyde at C-1 and a \u03942,3skeleton\nOOH\nOHO\nOR3R2OH\nR1\nOOH\nO HO\nOHOH\njudeolOHOOH\nOHO\nOH\na rmi\nllaricacidO\nHOR1R2R3\narmil\nlylorsellinateHHH\narmillyleverninateHHCH3\narnamiolHCl CH3\nA45OHHCH3ab\nFig. 4 Chemical structures of melleolides. aArmi ll aric acid that carries a carboxylic acid at C-1. bMelleolides with primary alcohol at C-1 and a \u03942,4\nterpene moietyMycol Progress (2019) 18:1027 \u20131037 102 9majority of cases, ester formation involves the secondary alcohol\nat the 5-OH\nof the protoilludene. Seven melleolides show ester-\nification via the 1-OH group. However, the true structural diver-\nsity stems from a near-permuta tional organization of how the\nscaffold is modified (Figs. 2,3,4,a n d5 ). Modifications that\noccur inv\nariably are terpene hydroxylations at C-1 to introduce\nprimary alcohol, at C-5 for secondary alcohol, and mutually\nexclusive hydroxylation at C-3 or C-4 with nearly all melleolides.\nOther modifications may or may not be introduced and include:\ni) Stereoselective hydroxylations at C-10, C-13, e.g., in\nmelledonol (Donnelly et al. 1985b ), and at C-14 or\nC-15, e.\ng., in melledonal D and melleolide G, respec-\ntively (Arnone et al. 1988c )\nii) Oxidat\nion of the primary alcohol at C-1 to an aldehyde\nor carboxy group, e.g., found for melleolide (Midland\net al. 1982 ), or armillaric acid (Obuchi et al. 1990 )\niii) Regio\nselective orsellinic acid chlorination at C-6 \u2032,e . g . ,\narmillaridin (Yang et al. 1984 ) or melleolide D (Arnone\net al. 1986 )iv\n)Methyl\nether formation at O-5 \u2032of the aromatic moiety,\ne.g., with armillaridin (Yang et al. 1984 ), or melleolide\nD (Arnon\ne et al. 1986 ) to convert orsellinic acid into\nevernini\nc acid and/or at the oxygen atom O-4 (if pres-\nent) in the terpene, e.g., with 4-methoxymelleolide\n(Donnelly et al. 1985a )\nv) Adouble bond\nshift to isomerize the \u03942,4to a\u03942,3\nskeleton, e.g., in melleolide (Midland et al. 1982 ).\nIn the two\n-dimensional structural representation,\nthis isomerization appears a minor modification\nbut has major consequences for the three-\ndimensional spatial configuration (Fig. 6) which al-\nsoimpacts\nbioactivity.\nvi) Reductive removal of the terpene double bond, e.g.,\nfound for armillane (Donnelly and Hutchinson\n1990 )\nvii)Introduction of\na second, conjugated double bond,\nprobably by water elimination, to create a\ncyclohexadiene ring system, e.g., the one of\narmillaricin (Yang et al. 1989a ).\nOOH\nOHO\nOHH\nO\nBr\n6'-bromomelleolideFO\nOHO\nOR2R1OHO\nOO\nR3\nHOO\nHOR1R2\nHO\nOO\nHOO\nHOC\nl\nmell\neolideROHOHOO\nOHO\nOCH3ROOH\nOHO\nOR3R2R1OH\nHO\nOO\nOHO\nOR2R1OH\nHR1R2\nde\nhyd\nro-\narmillyl\norsellinateHH\narnamialCl CH3\n6'-\ndechloro-\narnamialHCH3R1R2R3\narmillaneHHH\nmelleolideQHClH\n6'-chloro-\n10-hydroxy-\n5'-methoxy-\narmillaneOH Cl CH3\n6'-chloro-5'-\nmethoxy-\narmillaneHCl CH3R\narmillaribin H\narmillaricinCl\nR1R2R3\n5,10-dihydroxy-1-\norsellinate-\ndihydromelleolideH H H\narmellideAOHHCH3\narmellideBOH ClCH3\nmelleolideNHClH\n13-deoxyarmellideAHHCH3\n13-deoxyarmellideBHClCH3R1R2\narmillasinHH\n5'-methoxy-\narmillasinHCH3\narmillatinCO-(CH2)14-CH3Hb c\nda\nef\nFig. 5 Chemical structures of melleolides. aRepre sentatives featuring an\naldehyde at C-1 and a \u03942,4skeleton. bArmillane and congeners whose\ntricyclic terpene ring system does not possess a double bond. c\nMelleolides whose tricyclic terpene ring systems possess two doublebonds (\u03942,4,\u03943,13).dMelleolides whose ester bond involves C-1. e\nMelleolides lacking C-1. fStructure of the non-natural 6\u2032 -\nbromomelleolide F which was produced biocatalytically1030 Mycol Progress (2019) 18:1027 \u20131037Table 1 Overview on published melleolides. Compounds are grouped according to Figs. 2,3,4,a n d 5\nFi\ng. Compound Exact m ass\n(m/z)Sum\nformulaSpecies of the first\nisolationReference\n2 4-Dehydro-dihydromelleolide 388.2249 C 23H32O5 Desarmillaria\ntabescensDonnelly et al. ( 1997 )\nMelleol\nide F 402.2042 C 23H30O6 Armillaria mellea Arnone et al. ( 1988c )a\n4-Dehydro-14-hydroxy-dihydromelleolide 402.2042 C 23H30O6 D. tabescens Donnelly et al. ( 1997 )\nA52b 416.21\n99 C 24H32O6 A. cepistipes Sonnenbichler et al. ( 1997 )\nMelleol\nide E 418.1992 C 23H30O7 A. mellea Arnone et al. ( 1988c )b\n14-Hydroxy-dihydromelleolide 418.1992 C 23H30O7 D. tabescens Donnelly et al. ( 1997 )\n13-Hydr\noxydihydro-melleolide 418.1992 C 23H30O7 A. mellea Donnelly et al. ( 1990 )\nMelleol\nide B 432.2148 C 24H32O7 A. mellea Arnone et al. ( 1986 )\nMelledo\nnol 434.1941 C 23H30O8 A. mellea Donnelly et al. ( 1985b )\n6\u2032-Chlor\nomelleolide F 436.1652 C 23H29ClO 6A. mellea Bohnert et al. (2014)\nMelleolide C 448.2097 C 24H32O8 A. mellea Arnone et al. ( 1986 )\nMelleol\nide G 448.2097 C 24H32O8 A. mellea Arnone et al. ( 1988c )\nA52a 450.18\n09 C 24H31ClO 6A. cepistipes Sonnenbichler et al. ( 1997 )\nMelleol\nide M 452.1602 C 23H29ClO 7A. mellea Momose et al. ( 2000 )\n6\u2032-Chlor\no-13-hydroxy-dihydromelleolide 452.1602 C 23H29ClO 7A. mellea Bohnert et al. ( 2011)\n10-Dehy\ndroxymelleolide D 466.1758 C 24H31ClO 7Armillaria sp. Kobori et al. ( 2015 )\nMelleol\nide I 466.1758 C 24H31ClO 7A. novae-zelandiae Arnone et al. ( 1988a )\nMelleol\nide D 482.1707 C 24H31ClO 8A. mellea Arnone et al. ( 1986 )\n13,14-D\nihydroxy-A52a 482.1707 C 24H31ClO 8A. mellea Bohnert et al. ( 2011)\n3 Armil\nlarivin 384.1937 C 23H28O5 A. mellea Yang et al. ( 1991a )\n5-Hy\ndroxyarmillarivin 400.1886 C 23H28O6 A. mellea Li et al. ( 2016 )\nMelleol\nide = melleolide A 400.1886 C 23H28O6 A. mellea Midland et al. ( 1982 )\n4-Methy\noxymelleolide 414.2042 C 24H30O6 A. mellea Donnelly et al. ( 1985a )\nArmilla\nrin 414.2042 C 24H30O6 A. mellea Yang et al. ( 1984 )\nArmilla\nripin 414.2042 C 24H30O6 A. mellea Yang et al. ( 1990a )\nA51a 416.21\n99 C 24H32O6 A. ostoyae Peipp and Sonnenbichler ( 1992 )\nArmilla\nritin 416.1835 C 23H28O7 A. mellea Yang et al. ( 1991a )\n10\u03b1-Hydroxy\nmelleolide 416.1835 C 23H28O7 A. mellea Donnelly et al. ( 1990 )\nArmilla\nrilin 430.1991 C 24H30O7 A. mellea Yang et al. ( 1990b )\n13-H\nydroxy-4-methoxy- melleolide 430.1991 C 24H30O7 D. tabescens Donnelly et al. ( 1997 )\nMelleol\nide H 430.1991 C 24H30O7 A. mellea Arnone et al. ( 1988c )c\nMelledonal = melledonal A 432.1784 C 23H28O8 A. mellea Donnelly et al. ( 1985b )\nMelleol\nide K 434.1496 C 23H27ClO 6A. mellea Momose et al. ( 2000 )\n5\u2032-Methy\noxymelledonal 446.1940 C 24H30O8 A. mellea Donnelly et al. ( 1987 )\nArmilla\nridin 448.1653 C 24H29ClO 6A. mellea Yang et al. ( 1984 )\nMell\nedonal E 448.1733 C 23H28O9 A. elegans Arnone et al. ( 1988c )\n13-H\nydroxymelleolide K 450.1445 C 23H27ClO 7Armillaria sp. Kobori et al. ( 2015 )\n6\u2032-Chlor\no-10\u03b1-hydroxy melleolide = melleolide L 450.1445 C 23H27ClO 7A. mellea; A.\nnovae-zelandiaeMomose et al. ( 2000 ); Cremin\net al.\n(2000 )\n15-Hydr\noxy-5 \u2032-methoxymelledonal 462.1890 C 24H30O9 A. mellea Donnelly et al. ( 1987 )\n4-Me\nthoxyarmillaridin 463.1887 C 25H32ClO 6A. mellea Donnelly and Hutchinson ( 1990 )\nArmilla\nrinin 464.1601 C 24H29ClO 7A. mellea Yang et al. ( 1989a )\nMelleol\nide J 464.1601 C 24H29ClO 7A. mellea Arnone et al. ( 1988c )d\nMelledonal B 466.1394 C 23H27ClO 8A. mellea Arnone et al. ( 1988b )Mycol Progress (2019) 18:1027 \u20131037 103 1Further, in rare or singular cases, the following modifica-\ntions we\nre observed:\nviii) Additional hydroxylation of the aromatic ring whose\nexact position has not been described (judeol,\nDonnelly et al. 1985a )\nix) Asecond hydro\nxylation of C-5 in the case of 5-\nhydroxyarmillarivin (Li et al. 2016 )x) Palmity\nl ester formation via O-4 (armillatin, Yang et al.\n1991b )\nxi) Armillasi\nn, 5\u2032-methoxyarmillasin, and armillatin lack the\ncarbon atom 1 of the protoilludene core (Yang et al.\n1991b ;L ie ta l . 2016).\nThe term\nmelleolides is used as an umbrella term to sum-\nmarize all Armillaria sesquiterpene aryl esters. However, theTable 1 (continued)\nFig. Co\nmpound Exact mass\n(m/z)Sum\nformulaSpecies of the first\nisolationReference\nMelledonal C 480.1550 C 24H29ClO 8A. mellea Arnone et al. ( 1988b )\nMell\nedonal D 496.1500 C 24H29ClO 9A. elegans Arnone et al. ( 1988c )\n4A Armill\naric acid 416.1835 C 23H28O7 A. mellea Obuchi et al. ( 1990 )\n4B Armill\nyl orsellinate 402.2042 C 23H30O6 A. mellea Donnelly et al. ( 1982 )\nArmillyl\neverninate 416.2199 C 24H32O6 A. mellea Donnelly et al. ( 1986 )\nJudeole418.1992 C 23H30O7 A. mellea Donnelly et al. ( 1985a )\nA45 432\n.2148 C 24H32O7 A. ostoyae Peipp and Sonnenbichler ( 1992 )\nArnamio\nl 450.1809 C 24H31ClO 6A. mellea Donnelly et al. ( 1986 )\n5A Dehydr\noarmillyl orsellinate 400.1886 C 23H28O6 A. mellea Bohnert et al. ( 2011)f\n6\u2032-Dechloroarnamial 414.2042 C 24H30O6 A. mellea Bohnert et al. ( 2014a )\nArnamia\nl 448.1653 C 24H29ClO 6A. mellea Misiek et al. ( 2009 )\n5B Armill\nane 420.2148 C 23H32O7 A. mellea Donnelly and Hutchinson ( 1990 )g\nMelleolide Q 454.1758 C 23H31ClO 7A. mellea Chen et al. ( 2015 )\n6\u2032-Chlor\no-5\u2032-methoxy-armillane 468.1912 C 24H33ClO 7A. mellea Bohnert et al. ( 2011)\n6\u2032-Chlor\no-10-hydroxy-5 \u2032-methoxyarmillane 484.1864 C 24H33ClO 8A. mellea Bohnert et al. ( 2014a )\n5C Armill\naribin 396.1937 C 24H28O5 A. mellea Yang and Cong ( 1988 )\nArmilla\nricin 430.1547 C 24H27ClO 5A. mellea Yang et al. ( 1989a )\n5D 5 \u03b2-10\u03b1-Di\nhydroxy-1-orsellinate-dihydromelleolide 418.1992 C 23H30O7 D. tabescens Donnelly et al. ( 1997 )\n13-Deox\nyarmellide A 432.2148 C 24H32O7 A. mellea Bohnert et al. ( 2014a )\nArmelli\nde A 448.2097 C 24H32O8 A. novae-zelandiae Arnone et al. ( 1988a )\nMelleol\nide N 452.1602 C 23H29ClO 7A. mellea Chen et al. ( 2015 )\n13-Deox\nyarmellide B 466.1758 C 24H31ClO 7A. mellea Bohnert et al. ( 2014a )\nMelleol\nide R 468.1912 C 24H33ClO 7A. mellea Chen et al. ( 2015 )\nArmelli\nde B 482.1707 C 24H31ClO 8A. novae-zelandiae Arnone et al. ( 1988a )\n5E Armill\nasin 372.1937 C 22H28O5 A. mellea Yang et al. ( 1991b )\n5\u2032-Metho\nxyarmillasinh386.2093 C 23H30O5 A. mellea Li et al. ( 2016 )\nArmilla\ntin 610.4233 C 38H58O6 A. mellea Yang et al. ( 1991b )\n5F 6 \u2032-Brom\nomelleolide F 480.1148 C 23H29BrO 6biosynthetic in vitro\nreactionWick et al. ( 2016 )\naAlso described as dihydromelleolide by Cremin et al. ( 1995 ) and as 4-dehydrodihydromelleolide by Donnelly et al. ( 1997 )\nbAlso described as 10 \u03b1-hydroxydihydromelleolide by Donnelly et al. ( 1997 )\ncAlso described as armillarigin by Yang et al. ( 1989b ) and as 10 \u03b1-hydrox yarmillarin by Donnelly et al. ( 1990 )\ndAlso described as armillarikin by Yang et al. ( 1989b )\neStructure not fully solved: positions of phenolic hydroxyl groups not assigned\nfDescribed by Donnelly et al. ( 1982 ) as a synthetic oxidation product of armillyl orsellinate\ngAlso described as armillarizin by Yang et al. ( 1993 )\nhIn Li et al. ( 2016 ), stereocenters are shown inversed, compared with armillasin1032 Mycol Progress (2019) 18:1027 \u20131037presence/absence of a double bond and its position is reflected\nin the n\nomenclature as well. In the strict sense, the term\nmelleolide, introduced by Midland et al. ( 1982 )f o ras i n g l e\ncompound\n, refers to compounds whose backbones feature a\n\u03942,3scaffold whereas terpenes with a \u03942,4double bond are\nreferred to as armillyl orsellinates (Donnelly et al. 1982 )a n d\nthose wi\nth a fully saturated terpene as armillanes (Donnelly\nand Hutchinson 1990 ). However, a consequent nomenclature\ndoes not\nexist. In this article, the structures of all described\nmelleolides are presented primarily by presence/absence and\nposition of the terpene double bond, using the degree of oxi-\ndation of C-1 (alcohol, aldehyde, acid) as a secondary addi-\ntional criterion (Figs. 2,3,4,a n d 5, Table 1). Likewise, the\nnumb ering of\ncarbon atoms in our review does not follow\nIUPAC nomenclature but is shown according to essentially\nall previous literature on Armillaria terpenes.\nMelleolide biosynthesis\nUsually, melleolides are present in the mycelium as a complex\nmixture, although not all Armillaria species have been tested\nyet for melleolide biosynthesis. All ten North American spe-\ncies are confirmed producers (Misiek and Hoffmeister 2012 ),\naswell\nas European and Asian isolates of A. mellea (Donnelly\net al. 1984 ; Yang et al. 1984 ,1989a ; Momose et al. 2000 ;\nChen et al\n.2015 ),A. gallica (Engel s et al. 2011 ),A.cepistipes ,\nA. ostoyae ,E u\nr o p e a na n dN o r t hA m e r i c a ni s o l a t e so f\nA. tabescens (=Desarmillaria tabescens,C r e m i ne ta l .\n1995 ;D o n n e l l ye ta l . 1997 ), and a New Zealand strain of A.\nnovae-ze\nlandiae (Cremin et al. 2000 ). Virtually all melleolideshave been isolated from\nartificially cultivated mycelium,\nwhile carpophores contain only very low metabolite titers\n(Wang et al. 1996 ). Research into the molecular basis of the\nbiosyn th\nesis of melleolides began with [1,2-13C]acetate incor-\nporation experiments to prove the polyketide origin of the\norsellinic acid moiety via 2D INADEQUATE nuclear mag-\nnetic resonance (NMR) spectroscopy (Misiek et al. 2009 ). The\nresults\ndemonstrated that A. mellea uses intact acetate units for\nbiosynthesis, which in turn suggested a non-reducing polyke-\ntide synthase catalyzing ors ellinic acid biosynthesis.\nAnalogously to illudol, whose sesquiterpenoid origin has been\nestablished (McMorris et al. 1967 ), 6-protoilludene was likely\ntorepres\nent a terpene as well. A major achievement was the\nidentification of Pro1, the protoilludene synthase of A. gallica ,\na 40 kDa enzyme whose sequence includes the canonical and\ncharacteristic terpene cyclase motifs DExxD and\nNDxxSxxxE. Heterologous reconstitution of its enzymatic ac-\ntivity in vitro was proven by cyclization of\nfarnesyldiphosphate, i.e., the universal precursor of all sesqui-\nterpenes, into the exclusive product 6-protoilludene (Engels\net al. 2011 ). This result demonstrated that \u03942,4-configured\nmelleolides biosynthetically precede the \u03942,3configuration.\nThe second major melleolide biosynthesis enzyme discovered\nwas the polyketide synthase (PKS) ArmB which was among\nthe first characterized PKSs of basidiomycete origin. The en-\nzyme was heterologously produced in E. coli , and orsellinic\nacid synthase activity was shown in vitro. ArmB is a non-\nreducing, seven-domain iterative type I PKS and has 2209\naa and a molecular mass of 237 kDa. Importantly, ArmB\nwas shown to provide a second biosynthetic function, as its\nterminal thioesterase domain catalyzes transesterification to\nconnect the carboxylic acid functionality of orsellinic acid\nwith the protoilludene via its C-5 hydroxyl to generate the\nactual melleolide backbone (Lackner et al. 2013 ). This reac-\ntion was\nshown in vitro, using orsellinic acid that was made in\nsitu by ArmB and 1,4,5,10,13-pentahydroxy- \u03942,3-\nprotoilludene. In its presence, this reaction yielded a product\nthat was identical to melledonol (Fig. 2).\nSo-called tailoring en\nzymes decorate a natural product\nbackbone structure, which leads to an incredible diversity of\nrelated compounds in the case of the melleolide family. Nearly\n30 melleolides are known to show regioselective\nmonochlorination at C-6 \u2032of the aromatic moiety. Five\nflavin-dependent halogenases (ArmH1 \u2013ArmH5) that are phy-\nlogenetically distantly related (ArmH1 \u2013H3 versus ArmH4\nversus ArmH5) were heterologously produced in E. coli.\nThe enzymes showed the typical length of flavin-dependent\nnatural product halogenases (504 \u2013533 aa and 55.3 \u201358.1 kDa).\nAll of these enzymes feature the fingerprint double tryptophan\nsignature motif GW(A/V)W(F/L)I. In the three-dimensional\nhalogenase structure, this motif is located inside a tunnel\nthrough which hypochloric acid, i.e., the chlorinating agent,\nis routed from the flavin toward the halogen acceptor\nFig. 6 Three-dimensional representation of dehydroarmillyl orsellinate\n(\u03942,4skeleton, panel a)a n do fm e l l e o l i d e( \u03942,3terpene skeleton, panel b)Mycol Progress (2019) 18:1027 \u20131037 103 3substrate. All five Armillaria halogenases were active and\nconverted\nmelleolide F into its 6 \u2032-chloro analogue (Wick\net al. 2016 ). This remarkable result indicates that melleolide\nhalogen\nation is secured five-fold, which is an unprecedented\ndegree of biosynthetic redundancy. ArmH4 was used to\nbiocatalytically produce the non-natural 6 \u2032-bromomelleolide\nF( F i g . 5f). Genomic sequencing of A. mell ea(Collins et al.\n2013 ) revealed a biosynthetic locus in which a total of 16\nmelleolide biosynthesis genes are\nclustered, some of them\nwith hypothetical character or encoding proteins of unknown\nfunction for melleolide biosynthesis (Fig. 7). While ArmB and\nPro1ar\ne located within this gene cluster, they surprisingly do\nnot encode any of the halogenases. Curiously, ArmH1 and\nArmH2 are encoded in the vicinity of a quinone synthetase \u2013\nlike gene ( ArmA ) which, however, does not serve any apparent\nrole in melleolide biosynthesis (Misiek et al. 2011 ). Further,\ngenes fo\nr five P 450-dependent monooxygenases were found in\nA. mellea , which are incompatible with the total number of\neight positions at which oxygen atoms must or may be intro-\nduced. This may imply that other hydroxylases, encoded out-\nside the melleolide gene cluster, contribute to the biosynthesis,\nor that some of the monooxygenases target two positions.\nBased on elegant experimental design and using transgenic\nyeast, one P 450monooxygenase of A. gallica (Cyp-Arm3)\nwas functionally characterized and identified as protoilludene\n8\u03b1-hydroxylase (Engels 2013 ).\nThe mell\neolides have also attracted the interest of organic\nchemists. A synthetic route for armillaridin has been devel-\noped in which the protoilludene moiety is synthesized in a\ncomplex route and esterified to 6-chloroeveninic acid as a\npenultimate step to yield armillaridin (Fig. 3) after a final\ndeprotec\ntion step (Hovey et al. 2017 ).\nMelleoli\nde bioactivities and mode of action\nResearch into the bioactivity of Armillaria metabolites began\nabout 70 years ago, when Oppermann ( 1951 )o b s e r v e di n h i b -\nitory ef\nfects on other microorganisms. Since then, numerous\npublications reported growth-inhibiting or microbicidal activ-\nities of Armillaria extracts and for individual melleolides.\nTheir structural diversity allowed for insights into the\nrelevance of particular structural elements for biologicalactivity. A systematic survey for biological activities of\nmelleolides has not been carried out yet. This is due to\nvarious reasons. Firstly, an immense number of different\nbacterial and fungal species and strains has been used to\nassay for melleolide bioacti vites; some species were not\neven identified. Secondly, except Bohnert et al. ( 2014a ,b)\nand Li et\nal. (2016 ), prior work did not include complete sets\nof struct\nurally highly similar melleolides, which would have\nallowed to systematically observe structure-activity relation-\nships. Thirdly, the assay design varies massively between in-\ndividual reports. Hence, a direct comparison of these data is\ncomplicated. Here, we do not consider data generated with\nnon-identified test strains and activity data of Armillaria crude\nextracts. However, two distinct and non-congruent structure-\nactivity relationships were found for their cytotoxic and anti-\nfungal effects, respectively (Bohnert et al. 2014a ).\nActivity\nagainst bacteria At least 29 melleolides have been\nisolated and tested for antibacterial activity. With the excep-\ntion of melleolides B \u2013D and their derivatives, which are re-\nported to be active on Escherichia coli (Arnone et al. 1986 ;\nSonnenb\nichler et al. 1997 ), melleolides are exceptionally ac-\ntive against\nGram-positive strains including coccoid\n(Micrococcus, Streptococcus, Staphylococcus ), rod-shaped\n(Bacillus, Corynebacterium ), or filamentous bacteria (actino-\nmycetes), but not against Gram-negative ones ( Pseudomonas,\nEscherichia, Proteus, Salmonella, Serratia, Shigella,\nXanthomonas ) (Donnelly et al. 1982 ;A r n o n ee ta l . 1988b ).\nOnly five\nof eleven melleolides with a C-3 hydroxylation\ninhibit bacterial growth, while 18 out of 26 C-4-\nhydroxylated congeners are active, indicating that the position\nof this hydroxyl group and/or the double bond position impact\nantibacterial activity. All ten tested melleolides featuring a C-\n13 hydroxylation (melleolide B derivatives) inhibit Gram-\npositive bacteria. Additional methylation at 5\u00b4-OH on the\norsellinic backbone is associated with the expansion of the\nactivity spectrum to Gram-negative bacteria. In addition, 12\nout of 14 melleolides with C-10-hydroxylation inhibit Gram-\nnegative strains. In summary, the most active compounds\n(melledonal A \u2013C, melleolides B and C, and metabolites\nA28a and A49a) all meet these criteria and feature at least a\n4,10,13-trihydroxylated terpene scaffold (Arnone et al. 1986 ,\n1988b; Sonnenbichler et al. 1997;C r e m i ne ta l . 2000).\nFig. 7 Schematic representation of the genetic locus for melleolide\nbiosynthesis i\nnArmillaria mellea . Arrows represent genes in the\ntranscriptional direction. For clarity, introns are not shown. Some genes\nare hypothetical. Genes encode the following verified or putative\nenzymes: ArmB, orsellinic acid synthase (Lackner et al. 2013 ); 468,\nNAD(P)-binding dehyd\nrogenase; 469, short-chain dehydrogenase/reductase; 470, NAD-dependent epimerase/dehydratase; 471 and 472,\nhypothetical protein; 473, O-methyltransferase; 474, aryl-alcohol dehy-\ndrogenase; 475, NAD(P)-binding dehydrogenase; 476, cytochrome P 450\nmonooxygenase; Pro1, protoilludene synthase (Engels et al. 2011); 478,\nshort-chain dehydroge nase/red\nuctase; 479 \u2013482, cytochrome P 450\nmonooxygenase1034 Mycol Progress (2019) 18:1027 \u20131037However, the mode of action of antibacterial activity has not\nbeen invest\nigated yet but may involve the \u03b1,\u03b2-unsaturated\ncarbonyl as a Michael acceptor.\nFungi In contrast to antibacterial activity, the position of the\nprotoilludene double bond is critical for the inhibition of fun-\ngi.\u03942,4-unsaturated melleolides are highly active against fil-\namentous ascomycetes and basidiomycetes, but not against\nzygomycetes (Peipp and Sonnenbichler 1992 ;M o m o s ee ta l .\n2000 ; Misiek and Hoffmeister 2012;D \u00f6 r f e re ta l . 2019 ),\nwhereas \u03942,3-unsaturated melleolides are not active against\nfilamentous ascomycetes (Misiek and Hoffmeister 2012 ;\nBohnert et al. 2014a ). The\nlatter melleolides, but not their\nreduced\n1-OH analogs, are growth inhibitors for basidiomy-\ncetes such as Heterobasidion annosum andGloeophyllum\nabietinum (Peipp and Sonnenbichler 1992 ). Esterification of\nthe sesq\nuiterpene backbone via 1-OH (rather than 5-OH) re-\nduces activity (Bohnert et al. 2014a ). Neither methylation on\n5\u00b4-OH no\nr chlorination on C-6 \u2032on the orsellinate residue alters\nantifungal activity (Sonnenbichler et al. 1997 ;C r e m i ne ta l .\n2000 ;M o m o s ee ta l . 2000 ) .T h em o d eo fa c t i o no na n t i f u n g a l\nactivity has recently\nbeen el ucidated: dehydroarmillyl\norsellinate (DAO) and arnamial (Fig. 5a) inhibit fungal trans-\nlation by\nbinding to the fungal elongation factor 2 (eEF2) in\nAspergillus and probably Candida strains (D\u00f6rfer et al. 2019 ).\nHowever, dermatoph\nytes (Trichoderma ) and some yeasts\n(Saccharomyces ) are resistant to DAO, most likely conferred\nby mutations in the putative DAO binding site of eEF2\n(D\u00f6rfer et al. 2019 ).\nPlants With regard to\nsaturation, state of oxidation, or the\ndegree of hydroxylation of the terpenoid moiety, no clear\nstructure-action-relationship emerges for the phytotoxic activ-\nity, suggesting that the mode of action differs from those\nagainst microorganisms (Peipp and Sonnenbichler 1992 ;\nKobori et\nal.2015 ). In contrast, alterations at the orsellinic\nacid mo\niety significantly impact phytotoxicity: a methyl ester\non the 5\u00b4-OH increases phytotoxicity against Picea abies calli\nand lettuce seedlings (Peipp and Sonnenbichler 1992 ; Kobori\netal.2015 ).\nMa\nmmali\nan cells Pharmacologically, the most relevant feature\nof melleolides is their ability to induce apoptosis in adherent\nor human cancer cell lines. There is a clear correlation that\naldehyde melleolides such as DAO and armillaridin are more\npotent (MIC 1.7 \u201315.4\u03bcM) than their reduced counterparts\n(13-hydroxy-dihydromelleolide and melleolide B) (MIC >\n100\u03bcM). Unlike with the antifungal activity, here, the double\nbond position does not impact cytotoxicity. This has been\ndemonstrated for the pairs of armillarin versus 6 \u2032-\ndechloroarnamial and armillaridin versus arnamial, which\neach differ only in the \u03942,3- versus \u03942,4-unsaturation. All\ncompounds are equally cytotoxic, e.g., against K-562 humanleukemia cells with GI 50values between 2.3 and 9.9 \u03bcM\n(Bohnert et al. 2014a ). DAO and arnamial were subjected to\nan in-depth investigat\nion of their mode of action (Bohnert\net al. 2014b ): in monocytes and HeLa cells, DAO caused a\nrapid on\nset on cell death within 5 h mainly due to rapid cell\nlysis after forming organelle-free membrane blebs within the\nfirst 15 \u201360 min of contact. Necrosis and apoptotic pathways\nwere induced, and reduced viability of mitochondria was ev-\nident. This is in agreement with mechanistic studies on the\ntoxicity of melleolide, a \u03942,3-unsaturated aldehyde metabo-\nlite, which causes apoptosis, condensation of chromatin, and\nfragmentation of the cell \u2019s nucleus (Li et al. 2016).\nMelleoli\nde-treated HepG2 cells are arrested at the G2/M phase\nby reducing the activity of Ki67, a nuclear cell proliferation\nmarker. Recent studies on human leukocytes showed that\nDAO and arnamial inhibit 5-lipoxygenase (5-LO) at 1 \u03bcM,\ni.e., the key enzyme in the biosynthesis of pro-inflammatory\nleukotrienes from arachidonic acid (K\u00f6nig et al. 2019 ). The\nmelleoli\nde aldehyde at C-1 serves as a selective Michael ac-\nceptor to covalently bind to Cys-159 of 5-LO. This reduces its\nenzymatic activity and, consequently, decreased all lipid me-\ndiators formed by 5-LO (K\u00f6nig et al. 2019 ). This offers the\npotenti\nal of melleolides as low molecular weight inhibitors of\n5-LO-related disorders such as asthma, rheumatoid arthritis,\nallergic rhinitis, or neurodegenerative and cardiovascular\ndiseases.\nConcluding remarks\nNumerous questions around the melleolides, their biosynthe-\nsis, and their activities and mode of actions are yet to be\nanswered. In the area of biosynthesis, the as yet unresolved\nsequential and combinatorial hydroxylation and the underly-\ning enzymes deserve attention. From the pharmacological per-\nspective, further work is warranted to explore the intriguing\nphenomenon of rapid eukaryotic cell death upon exposure to\nmelleolides. Perhaps the most complex problem remaining to\nbe solved is the ecological reason that drove on the evolution\nof this unparalleled biosynthesis. Future work needs to show\nwhy Armillaria relied on a permutationally varied backbone\nstructure to elaborate a breathtakingly diverse repertoire of\nbioactive natural products.\nFunding information Studies on melleolide biosynthesis and mode of\naction in D.H. \u2019s laboratory were supported by the Excellence Graduate\nSchool JSMC (Jena School for Microbial Communication) and by the\nCollaborative Research Center ChemBioSys (Deutsche\nForschungsgemeinschaft, grant SFB1127).\nCompliance with ethical standards\nConflict of interest The authors declare that they have no conflict of\ninterest.Mycol Progress (2019) 18:1027 \u20131037 103 5References\nAbraha\nm WR (2001) Bioactive sesquiterpenes produced by fungi: are\nthey useful for humans as well? Curr Med Chem 8:583 \u2013606\nArnone A, Cardillo R, Nasini G (1986) Structures of melleolides B-D,\nthree antibacterial sesquiterpenoids from Armillaria mellea .\nPhytochemistry 25:471 \u2013474\nArnone A, Cardillo R, Nasini G (1988a) Isolation and structure elucida-\ntion of melleolides I and J and armellides A and B, novel\nsesquiterpenoid aryl esters from Armillaria novae-zelandiae . Gazz\nChim Ital 118:523 \u2013527\nArnone A, Cardillo R, Nasini G (1988b) Secondary mould metabolites\npart 19: structure elucidation a nd absolute configuration of\nmelledonals B and C, novel antibacterial sesquiterpenoids from\nArmillaria mellea . X-ray molecular structure of Melledonal C. J\nChem Soc Perkin Trans 1 I:503 \u2013510\nArnone A, Nasini G, Di Modugno V , Cardillo R (1988c) Isolation and\nstructure elucidation of melledonals D and E and melleolides E-H,\nnovel sesquiterpenoid aryl esters from Clitocybe elegans and\nArmillaria mellea . Gazz Chim Ital 118:517 \u2013521\nBaumgartner K, Coetzee MP, Hoffmeister D (2011) Secrets of the sub-\nterranean pathosystem of Armillaria . Mol Plant Pathol 12:515 \u2013534\nBohnert M, Miethbauer S, Dahse HM, Ziemen J, Nett M, Hoffmeister D\n(2011) In vitro cytotoxicity of melleolide antibiotics: structural and\nmechanistic aspects. Bioorg Med Chem Lett 21:2003 \u20132006\nBohnert M, N\u00fctzmann HW, Schroeckh V , Horn F, Dahse HM, Brakhage\nAA, Hoffmeister D (2014a) Cytotoxic and antifungal activities of\nmelleolide antibiotics follow dissimilar structure \u2013activity relation-\nships. Phytochemistry 105:101 \u2013108\nBohnert M, Scherer O, Wiechmann K, K\u00f6nig S, Dahse HM, Hoffmeister\nD, Werz O (2014b) Melleolides induce rapid cell death in human\nprimary monocytes and cancer cells. Bioorg Med Chem 22:3856 \u2013\n3861\nBraesel J, Fricke J, Schwenk D, Hoffmeister D (2017) Biochemical and\ngenetic basis of orsellinic acid biosynthesis and prenylation in a\nstereaceous basidiomycete. Fungal Genet Biol 98:12 \u201319\nBrazee NJ, Ortiz-Santana B, Banik MT, Lindner DL (2012) Armillaria\naltimontana , a new species from the western interior of North\nAmerica. Mycologia 104:1200\u2013 1205\nChen CC, Kuo YH, Cheng JJ, Sung PJ, Ni CL, Chen CC, Shen CC\n(2015) Three new sesquiterpene aryl esters from the mycelium of\nArmillaria mellea . Molecules 20:9994 \u201310003\nCollins C, Keane TM, Turner DJ, O \u2019Keeffe G, Fitzpatrick DA, Doyle S\n(2013) Genomic and proteomic dissection of the ubiquitous plant\npathogen, Armillaria mellea : toward a new infection model system.\nJ Proteome Res 12:2552 \u20132570\nCremin P, Donnelly DMX, Wolfender JL, Hostettmann K (1995) Liquid\nchromatography \u2013thermospray mass spectrometric analysis of ses-\nquiterpenes of Armillaria (Eumycota: Basidiomycotina) species. J\nChromatogr A 710:273 \u2013285\nCremin P, Guiry PJ, Wolfender JL, Hostettmann K, Donnelly DMX\n(2000) A liquid chromatography\u2013 thermospray ionisation \u2013mass\nspectrometry guided isolation of a new sesquiterpene aryl ester from\nArmillaria novae-zelandiae . J Chem Soc Perkin Trans 1:2325 \u20132329\nDonnelly DMX, Sanada S, O \u2019Reilly J, Polonsky J, Prang\u00e9 T, Pascard CJ\n(1982) Isolation and structure (X-ray analysis) of the orsellinate of\narmillol, a new antibacterial metabolite from Armillaria mellea .J\nChem Soc Chem Comm 135 \u2013137\nDonnelly DMX, Polonsky J, Prang\u00e9 T, Snatzke, G, Wagner U (1984) The\nabsolute configuration of the orsellinate of armillol; application of\nthe coupled oscillator theory. J Chem Soc Chem Comm 222 \u2013223\nDonnelly DMX, Abe F, Coveney D, Fukuda N, O \u2019Reilly J, Polonsky J,\nPrang\u00e9 T (1985a) Antibacterial sesquiterpene aryl esters from\nArmillaria mellea . J Nat Prod 48:10 \u201316Donnelly DMX, Coveney DJ, Polonsky J (1985b) Melledonal and\nmelledonol, sesquiterpene esters from Armillaria mellea .\nTetrahedron Lett 26:5343 \u20135344\nDonnelly DMX, Coveney DJ, Fukuda N, Polonsky J (1986) New sesqui-\nterpene aryl esters from Armillaria mellea . J Nat Prod 49:111 \u2013116\nDonnelly DMX, Coveney DJ (1987) Antibacterial sesquiterpene aryl\nesters from Armillaria mellea. In: Hostettmann K, Lea PJ (eds)\nBiologically active natural products. Clarendon Press, Oxford, pp\n19\u201332\nDonnelly DMX, Quigley PF, Coveney DJ, Polonsky J (1987) Two new\nsesquiterpene esters from Armillaria mellea . Phytochemistry 26:\n3075 \u20133077\nDonnelly DMX, Hutchinson RM (1990) Armillane, a saturated sesqui-\nterpene ester from Armillaria mellea . Phytochemistry 29:179 \u2013182\nDonnelly DMX, Hutchinson RM, Coveney DJ, Yonemitsu M (1990)\nSesquiterpene aryl esters from Armillaria mellea . Phytochemistry\n29:2569 \u20132572\nDonnelly DMX, Konishi T, Dunne O, Cremin P (1997) Sesquiterpene\naryl esters from Armillaria tabescens . Phytochemistry 44:1473 \u2013\n1478\nD\u00f6rfer M, Heine D, K\u00f6nig S, Gore S, Werz O, Hertweck C, Gressler M,\nHoffmeister D (2019) Melleolides impact fungal translation via\nElongation Factor 2. Org Biomol Chem 17:4906 \u20134916\nEngels B, Heinig U, Grothe T, Stadler M, Jennewein S (2011) Cloning\nand characterization of an Armillaria gallica cDNA encoding\nprotoilludene synthase, which catalyzes the first committed step in\nthe synthesis of antimicrobial melleolides. J Biol Chem 286:6871 \u2013\n6878\nEngels B (2013) Untersuchungen zur Biosynthese sesquiterpenoider\nNaturstoffe, der Melleolide. In Armillaria gallica . Dissertation,\nRWTH Aachen\nFirn RD, Jones GC (2003) Natural products \u2013a simple model to explain\nchemical diversity. Nat Prod Rep 20:382 \u2013391\nFirn RD, Jones GC (2009) A Darwinian view of metabolism: molecular\nproperties determine fitness. J Exp Bot 60:719 \u2013726\nGillM, Steglich W (1987) Pigments of fungi (Macromycetes). Prog\nChem Org Nat Prod 51:1 \u2013317\nGill M (2003) Pigments of fungi (Macromycetes). Nat Prod Rep 20:615 \u2013\n639\nHovey MT, Cohen DT, Walden DM, Cheong PH, Scheidt KA (2017) A\ncarbene catalysis strategy for the synthesis of protoilludane natural\nproducts. Angew Chem Int Ed 56:9864 \u20139867\nJiang MY, Feng T, Liu JK (2011) N-containing compounds of\nmacromycetes. Nat Prod Rep 28:783 \u2013808\nKobori H, Sekiya A, Suzuki T, Choi JH, Hirai H, Kawagishi H (2015)\nBioactive sesquiterpene aryl esters from the culture broth of\nArmillaria sp. J Nat Prod 78:163 \u2013167\nKoch RA, Wilson AW, S\u00e9n\u00e9 O, Henkel TW, Aime MC (2017) Resolved\nphylogeny and biogeography of the root pathogen Armillaria and its\ngasteroid relative, Guyanagaster. BMC Evol Biol 17:33\nK\u00f6nig S, Romp E, Krauth V , R\u00fchl M, D\u00f6rfer M, Liening S, Hofmann B,\nH\u00e4fner AK, Steinhilber D, Karas M, Garscha U, Hoffmeister D,\nWerz O (2019) Melleolides from honey mushroom inhibit 5-\nlipoxygenase via Cys159. Cell Chem Biol 26:60 \u201370\nLackner G, Bohnert M, Wick J, Hoffmeister D (2013) Assembly of\nmelleolide antibiotics involves a polyketide synthase with cross-\ncoupling activity. Chem Biol 20:1101 \u20131106\nLi Z, Wang Y , Jiang B, Li W, Zheng L, Yang X, Bao Y , Sun L, Huang Y ,\nLi Y (2016) Structure, cytotoxic activity and mechanism of\nprotoilludane sesquiterpene aryl esters from the mycelium of\nArmillaria mellea . J Ethnopharmacol 184:119 \u2013127\nMcMorris TC, Nair MSR, Anchel M (1967) The structure of illudol, a\nsesquiterpenoid triol from Clitocybe illudens . J Am Chem Soc 89:\n4562 \u201345631036 Mycol Progress (2019) 18:1027 \u20131037Midland SL, Izac RR, Wing RM, Zaki AL, Munnecke DE, Sims JJ\n(1982) Melleolide, a\nnew antibiotic from Armillaria mellea .\nTetrahedron Lett 23:2515 \u20132518\nMisiek M, Williams J, Schmich K, H\u00fcttel W, Merfort I, Salomon CE,\nAldrich CC, Hoffmeister D (2009) Structure and cytotoxicity of\narnamial and related fungal sesquiterpene aryl esters. J Nat Prod\n72:1888 \u20131891\nMisiek M, Braesel J, Hoffmeister D (2011) Characterization of the ArmA\nadenylation domain implies a more diverse secondary metabolism in\nthe genus Armillaria . Fungal Biol 115:775 \u2013781\nMisiek M, Hoffmeister D (2012) Sesquiterpene aryl ester natural products\nin North American Armillaria species. Mycol Prog 11:7 \u201315\nMomose I, Sekizawa R, Hosokawa N, Iinuma H, Matsui S, Nakamura H,\nNaganawa H, Hamada M, Takeuchi T (2000) Melleolides K, L and\nM, new melleolides from Armillariella mellea . J Antibiot 53:137 \u2013\n143\nObuchi T, Kondoh H, Watanabe N, Tamai M, Omura S, Yang JS, Liang\nXT (1990) Armillaric acid, a new antibiotic produced by Armillaria\nmellea .P l a n t aM e d5 6 : 1 9 8 \u2013201\nOduro KA, Munnecke DE, Sims JJ, Keen NT (1976) Isolation of antibi-\notics produced in culture by Armillaria mellea . Trans Br Mycol Soc\n66:195 \u2013199\nOppermann A (1951) Das antibi otische Verhalten einiger\nholzzersetzender Basidiomyceten zueinander und zu Bakterien.\nArch Mikrobiol 16:364 \u2013409\nPeipp H, Sonnenbichler J (1992) Secondary fungal metabolites and their\nbiological activities, II. Occurrence of antibiotic compounds in cul-\ntures of Armillaria ostoyae growing in the presence of an antago-\nnistic fungus or host plant cells. Biol Chem Hoppe Seyler 373:675 \u2013\n683\nSandargo B, Chepkirui C, Cheng T, Chaverra-Munoz L, Thongbai B,\nStadler M, H\u00fcttel S (2019) Biological and chemical diversity go\nhand in hand: Basidiomycota as source of new pharmaceuticals\nand agrochemicals. Biotechnol Adv. https://doi.org/10.1016/j.\nbiotecha\ndv.2019.01.011\nSchroeckh V , Scherlach K, N\u00fctzmann HW, Shelest E, Schmidt-Heck W,\nSch\u00fcman\nn J, Martin K, Hertweck C, Brakhage AA (2009) Intimate\nbacterial-fungal inter action triggers biosynt hesis of archetypal\npolyketides in Aspergillus nidulans . Proc Natl Acad Sci U S A\n106:14558 \u201314563\nShen B (2003) Polyketide biosynthesis beyond the type I, II and III\npolyketide synthase paradigms. Curr Opin Chem Biol 7:285 \u2013295\nSonnenbichler J, Guillaumin JJ, Peipp H, Schwarz D (1997) Secondary\nmetabolites from dual cultures of genetically different Armillaria\nisolates. Eur J Forest Path 27:241 \u2013249\nWang C, Guo S, Chen X, Ca W, Xu J, Xiao P (1996) Studies on the\ncontents of armillarin and melleolide at different stages ofdevelopment of Armillaria mellea . Zhongguo Zhong Yao Za Zhi\n21:274 \u2013276\nWick J, Heine D, Lackner G, Misiek M, Tauber J, Jagusch H, Hertweck\nC, Hoffmeister D (2016) A fivefold parallelized biosynthetic process\nsecures chlorination of Armillaria mellea (honey mushroom) toxins.\nAppl Environ Microbiol 82:1196 \u20131204\nYamazaki M, Matsuo M, Shibata S (1965) Biosynthesis of lichen\ndepsides, lecanoric acid and atranorin. Chem Pharm Bull 13:\n1015 \u20131017\nYang JS, Chen Y , Feng X, Yu D, Liang X (1984) Chemical constituents of\nArmillaria mellea mycelium I. Isolation and characterization of\narmillarin and armillaridin. Planta Med 50:288 \u2013290\nYang JS, Cong PZ (1988) Mass spectrometric studies on the sesquiter-\npenol aromatic esters from mycelium of Armillaria mellea .A c t a\nChim Sin 46:1093 \u20131100\nYang JS, Chen YW, Zeng XZ, Yu DQ, He CH, Zheng QT, Yang J, Liang\nXT (1989a) Isolation and structure elucidation of armillaricin. Planta\nMed 55:564 \u2013565\nYang JS, Su YL, Wang YL, Feng XZ, Yu DQ, Cong PZ, Tamai M,\nObuchi T, Kondoh H, Liang XT (1989b) Isolation and structures\nof two new sesquiterpenoid aromatic esters: armillarigin and\narmillarikin. Planta Med 55:479 \u2013481\nYang JS, Su YL, Wang YL, Feng XZ, Yu DQ, Liang XT, He CH, Zheng\nQT, Yang JJ, Yang J (1990a) Chemical constituents of Armillaria\nmellea mycelium VI. Isolation and structure of armillaripin. Acta\nPharm Sin 25:353 \u2013356\nYang JS, Su YL, Wang YL, Feng XZ, Yu DQ, Liang XT (1990b) Studies\non the chemical constituents of Armillaria mellea mycelium V.\nIsolation and characterization of armillarin and armillarinin. Acta\nPharm Sin 24:24 \u201328\nYang JS, Su YL, Wang YL, Feng XZ, Yu DQ, Liang XT (1991a)\nChemical constituents of Armillaria mellea mycelium VII.\nIsolation and characterization of chemical constituents of the ace-\ntone extract. Acta Pharm Sin 26:117 \u2013122\nYang JS, Su YL, Wang YL, Feng XZ, Yu DQ, Liang XT (1991b) Two\nnovel protoilludane norsesquiterp enoid esters, armillasin and\narmillatin from Armillaria mellea . Planta Med 57:478 \u2013480\nYang JS, Su YL, Yu DQ, Liang XT (1993) Carbon-13 nuclear magnetic\nresonance spectra of some protoilludane sesquiterpenoid aromatic\nesters from Armillaria mellea . J Chin Pharm Sci 2:11 \u201317\nZhou ZY , Liu JK (2010) Pigments of fungi (macromycetes). Nat Prod\nRep 27:1531 \u20131570\nZjawiony JK (2004) Biologically active compounds from\nAphyllophorales (polypore) fungi. J Nat Prod 67:300 \u2013310\nPublisher \u2019sn o t e Springer Nature remains neutral with regard to\njurisdictional claims in published maps and institutional affiliations.Mycol Progress (2019) 18:1027 \u20131037 103 74. Unver\u00f6ffentlichte Ergebnisse   85 \n4. Unver\u00f6ffentli\nchte Ergebnisse \n \n4.1. Rapid cell death induction by the honey mushroom mycotoxin \ndehydroarmillyl-orsellinate through covalent reaction with membrane \nphosphatidylethanolamines  \nStefanie K\u00f6nig, Konstantin L\u00f6ser, Helmut Pein, Konstantin Neukirch, Anna Czapka, \nStephanie Hoeppener, Maxim ilian D\u00f6rfer , Dirk Hoffmeister, Andreas Koeberle, Oliver Werz \nManuskript in Erstellung, geplante Publikation: erstes Quartal 2020 in Cell Chemical Biology \nZusammenfassung \nDas Melleolid DAO aus Armillaria mellea  induziert in humanen Krebszellen und prim\u00e4ren \nhumanen Monozyten einen raschen Zelltod innerhalb von 15 Minuten. Durch die kovalente \nBindung von DAO an Phosphatidylethanolamin (PE) in der Zellmembran kommt es zu einem \ndrastischen Verlust der Plasmamembranpermeabilit\u00e4t und somit der zellul\u00e4ren Viabilit\u00e4t in \nVerbindung mit einer PARP-Spaltung.  \nDas \u03b1 -\u03b2 unges\u00e4ttigte Aldehyd des DAO-Molek\u00fcls fungiert als Michael-Akzeptor und reagiert \n\u00fcber eine 1,4-Addition kovalent mit reinem Ethanolamin (EA) und mit PE, jedoch nicht mit \nanderen Phospholipiden, welche Serin- oder Cholin-Kopfgruppen besitzen. Die DAO-PE \nProduktbildung geht zeitlich mit der Membransch\u00e4digung einher. Die exogene Zugabe von EA \nverhindert einen DAO-induzierten Zelltod. Fraktionierungsuntersuchungen zeigten, dass die \nDAO -PE-Produktakkumulation mit einer Abnahme des PE in der Membran einhergeht. \nEigenanteil 10% \nMaximilian D\u00f6rfer: Isolation von DAO aus A. mellea  \n \n \n \n \n \n \n \n \nJena, den \n \n____________________  \nProf. Dr. Dirk Hoffmeister 1 \n Rapid cell death induction by the honey mushroom mycotoxin dehydroarmillylorsellinate \nthr\nough covalent reaction with membrane phosphatidylethanolamines   \nStefanie K\u00f6nig1*, Konstantin L\u00f6ser1*, Helmut Pein1*, Konstantin Neukirch1, Anna Czapka1, \nSte\nphanie Hoeppener2,3, Maximilian D\u00f6rfer4, Dirk Hoffmeister4, Andreas Koeberle1, and \nOli\nver Werz1,3\u00a7 \n1 De\npartment of Pharmaceutical/Medicinal Chemistry, Institute of Pharmacy, Friedrich Schiller \nUnive\nrsity Jena, Philosophenweg 14, D-07743 Jena, Germany. \n2 Laboratory of Organic and Macromolecular Chemistry (IOMC), Friedrich Schiller \nUnive\nrsity Jena, Humboldtstr. 10, D-07743 Jena, Germany \n3Jena Center of Soft Matter (JCSM), Friedrich Schiller University Jena, Philosophenweg 7, D-\n07743 Jena\n, Germany \n4 Department of Pharmaceutical Microbiology at the Hans Knoell Institute, Friedrich Schiller \nUnive\nrsity Jena, Winzerlaer Stra\u00dfe 2, D-07745 Jena, Germany \n* contributed equally \n\u00a7 corresponding author : P rof. Dr. Oliver Werz, Chair of Pharmaceutical/ Medicinal \nChemistry, Institute of Pharmacy, Friedrich Schiller University Jena, Philosophenweg 14, D-\n07743 Jena, Germany; Phone: +49-03641-949801; Fax: +49-03641-949802;  \ne-mail: oliver.werz@uni-jena.de. \nAbbreviations \nATP \u2013 adenosine triphosphate, DAO -  dehydroarmillylorsellinate, EA \u2013 ethanolamine, ER \u2013 \nendoplasmic reticulum, LDH \u2013 lactate dehydrogenase, PL \u2013 phospholipid, PE \u2013 \nphosphatidylethanolamine, ROS \u2013 reactive oxygen species, Stsp \u2013 staurosporine.  2 \n Summary \nMel\nleolides form a group of fungal mycotoxins of the basidiomycete genius Armillaria mellea  \nthat induce rapid cell death in various mammalian cells with yet unknown mode of action. Here, \nwe show that the melleolide dehydroarmillylorsellinate (DAO) covalently binds to \nphosphatidylethanolamine (PE) contained in cell membranes, accompanied by rapid loss of \nplasma membrane integrity and cellular viability. DAO caused a remarkable rapid onset of cell \ndeath of human cancer cells and primary human monocytes (i.e. within 15 min), which was \ntemporally accompanied by PARP cleavage and loss of membrane integrity. DAO possesses a \nreactive \u03b1,\u03b2-unsaturated aldehyde group as Michael acceptor and covalently reacted via 1,4-\naddition with ethanolamine (EA) and with PE but not with other phospholipids containing \nserine or choline head groups. DAO-PE adduct formation coincided with membrane damage, \nand excess of exogenous EA prevented DAO-induced cell death. Moreover, DAO caused \nleakage of artificial PE-composed liposomes in a cell-free system. Subcellular fractionation \nstudies indicate that DAO-PE adducts accumulate in cellular membranes along with decreased \nPE contents. Conclusively, DAO causes cell death by membrane damage seemingly due to \ncovalent modification of PE with detrimental consequences for cell integrity and viability.  \n  3 \n Introduction \nThe \nhoney mushroom Armillaria mellea produces antimicrobial and cytotoxic natural products \nbelonging to the large group of melleolides with more than 60 elucidated members [1-5]. These \nsecondary metabolites combine sesquiterpene arylesters with orsellinic acid residues and \nexhibit mainly secondary alcohols. Up to now only a few targets and mode of actions are \ninvestigated for these mushroom toxins [6, 7]. Several melleolides show antitumor and \ncytotoxic effects in various human cells [1, 3, 8-10]. For example, armillarikin induces ROS-\nmediated and caspase-dependent apoptosis by downregulation of the mitochondrial \ntransmembrane potential in leukemia cells [9, 11], and armillaridin induces autophagy-\nassociated apoptosis in human leukemia cells and negatively influences the mitochondrial \ntransmembrane potential [8, 12, 13]. Furthermore, decreased DNA synthesis was observed in \ndifferent human cancer cell lines for some melleolides [1]. \nCell death can be classified in three major subgroups \u2013 apoptosis, autophagic cell death and \nnecrosis [14-16]. Typical characteristics for apoptosis are caspase activation, mitochondrial \nouter membrane permeabilization, cell rounding, nuclear condensation, and cell fragmentation \nto apoptotic bodies [17]. Autophagy is also a programmed physiological process in organism \nrequired to recycle macromolecules, cytoplasmic material, and cell organelles [18] but also for \nATP production [19] via a lysosomal degradation pathway. In contrast, necrosis is an \nuncontrolled process and is constituted by signaling- and damage-induced lesions like \nmitochondrial dysfunction, ATP depletion, increased reactive oxygen species (ROS) formation \nor early plasma membrane ruptures [20, 21]. \nMembrane phospholipids (PL) constitute of a phosphate-bound head group (sn-3 position) and \na glycerol residue connected with two ester-linked fatty acid chains (sn-1/sn-2 position). PL are \nclassified by the functional head group, encompassing PE, phosphatidylcholine (PC), \nphosphatidylserine (PS), phosphatidylinositol (PI), phosphatidylglycerol (PG), phosphatidic 4 \n acid (PA), sphingomyelins (SP), and cardiolipins (CL). Typical cellular membranes consists of \n45-55%  P\nC, 15-25% PE, 10-15% PI, and 5-10% PS, where PE and PS are mainly found in the \ninner membrane leaflet [22]. During the early stage of apoptosis, PE and PS are exposed to the \nouter leaflet of the plasma membrane [23]. PE is participating in a wide range of cellular \nprocesses like the formation of hexagonal phases within the membrane because of its cone \nshape [24], protein arrangement inside the membrane [25], enhancing membrane fusion [24, \n26], oxidative phosphorylation [27], mitochondrial stability [28] and autophagy [29, 30] and \nplays a substantial role in lipid synthesis as precursor of other lipids [31].  \nHere we show that the melleolide dehydroarmillylorsellinate (DAO, Fig. 1A ) interferes with \nPE in cellular membranes by covalent binding to the EA head group. DAO possesses an \u03b1,\u03b2-\nunsaturated aldehyde that functions as Michael acceptor to react with nucleophilic residues such \nas thiol moieties of cysteine residue in 5-lipoxygenase (5-LO) [7]. Previous data showed that \nin contrast to other cytotoxic cell death-inducing agents, DAO causes remarkably rapid cell \ndeath with equal effectiveness in primary human monocytes and various cancer cell lines [3]. \nOur data suggest that covalent binding of DAO to membranous PE is the cause for the rapid \nperturbation of membrane integrity and consequent induction of cell death with characteristics \nof apoptosis and necrosis. \n \n  5 \n Results \nDAO\n causes rapid cell death in human cells with unique characteristics \nAs reported before [3], the effectiveness of DAO and of the pan kinase inhibitor staurosporine \n(Stsp) for induction of cell death (assessed by MTT assay) in HeLa cells and primary monocytes \nwas strikingly different. Thus, while Stsp-induced cell death is mainly mediated by apoptosis \n[32], DAO might confer its cytotoxicity primarily via necrotic features [3]. Moreover, DAO \nwas about equipotent in monocytes and HeLa cells (EC 50 = 1.6 and 2.3 \u00b5M, respectively), while \nSts\np was much more (40-fold) effective in HeLa cells (EC 50 = 0.01 \u00b5M) as compared to \nmonocyt\nes (EC 50 = 0.4 \u00b5M). The onset in cell death induction by DAO was remarkably rapid. \nThus, \nexposure to DAO for only 15 min caused significant loss of viability of monocytes which \nwas hardly different from 1 hr or 24 hrs treatment ( Fig. 1B ). In contrast, for Stsp, exposure for \nmore than 5 hrs was needed to cause cytotoxicity in monocytes (not shown, see [3]). Release \nof lactate dehydrogenase (LDH) from cells to the external space reflects the loss of plasma \nmembrane integrity. In agreement with the loss of cell viability assessed by MTT assay, LDH \nrelease from monocytes and HeLa cells was rapidly induced by DAO with almost maximal \neffects after about 30 min of exposure (Fig. 1C ).  \nWe next studied the effects of DAO and Stsp on cell morphology using light microscopy and \ntransmission electron microscopy (TEM). DAO (even at low concentrations such as 0.1 \u00b5M) \ncaused morphological signs of cells death within 3 hrs, reflected by wrinkling and shriveling of \nthe plasma membrane (PM, Fig. 1D ), which is actually a typical feature of necrosis. In contrast, \nStsp caused classical signs of apoptosis in HeLa cells such as cellular fragmentation and \nformation of apoptotic bodies, along with shrinkage of the cells ( Fig. 1D ). Analysis by TEM \nrevealed typical morphological features of monocytes with bean-shaped nucleus as well as \nintact organelles and plasma membrane ( Fig. 1E ). Upon Stsp-treatment (3 hrs), the nucleus lost \nits bean shape and rendered to a round structure with seemingly intact nuclear membrane and 6 \n also intact mitochondria. In contrast, 3 hrs treatment of monocytes with DAO caused defects of \nthe \nnuclear membrane and in particular, mitochondria appeared to be lost ( Fig. 1E ). Together, \nDAO induces a remarkable rapid onset of cell death of primary cells and cancer cells \naccompanied by apparent membrane damages, which are characteristics that differ from those \nof classical apoptotic cell death inducers like Stsp. \n \nContribution of apoptotic pathways in mediating cell death by DAO \nIn order to explore the contribution of apoptotic pathways in mediating cell death by DAO, we \nanalyzed hallmarks of apoptosis and stress signaling on a molecular level in monocytes. In fact, \nthe rapid cell death induction by DAO (5 \u00b5M) within 15 min coincided with cleavage of PARP \nto a 89 kDa fragment as marker for apoptosis in monocytes; in contrast Stsp failed to induce \nPARP cleavage during short term treatment (within 1 hr, Fig. 2A ) but instead required at least \n5 hrs ( Supplemental Fig. 1). The intrinsic pathway of apoptosis is initialized by a loss of \nmitochondrial membrane potential ( \uf044\uf059m) and the release of cytochrome c from mitochondria \n[33]. \nWe found that in contrast to vehicle-treated monocytes exposure to 10 \u00b5M DAO for 3 hrs \ncaused substantial release of cytochrome c into the cytosol, while in parallel the cytochrome c \nlevels in organelles was minute ( Fig. 2B ). Also Stsp (3 \u00b5M) induced cytochrome c release from \nmitochondria within 3 hrs, albeit much less pronounced as compared to DAO. \nProtein kinase signaling critically regulates the initiation of apoptosis, where the survival kinase \nAkt counteracts apoptosis [34] while p38 MAPK rather promotes it [35]. Exposure of \nmonocytes to DAO (5 \u00b5M) and Stsp (3 \u00b5M) suppressed phosphorylation and thus activation of \nAkt. In contrast, both compounds elevated phosphorylation/activation of p38 MAPK ( Fig. 2C ). \nAgain, the effects of DAO were more rapidly apparent (15 min) as compared to Stsp (30-60 \nmin, Fig. 2C ). The activation of p38 MAPK was independent on endoplasmic reticulum (ER) 7 \n stress and on the activation of the unfolded protein response (UPR), reflected by the failure of \nDAO\n to induce the UPR genes immunoglobulin heavy chain-binding protein (BiP), C/EBP \n[CCAAT/enhancer-binding protein]-homologous protein (CHOP), and activating transcription \nfactor 4 (ATF4), at the protein level assessed by Western blot ( Fig. 2D ). Finally, we employed \nthe pan-caspase inhibitor QVD to block apoptotic signaling. QVD (10 \u00b5M) inhibited DAO-\ninduced PARP cleavage in monocytes (Fig. 2E ). In contrast, QVD failed to reverse cell death \ninduction by DAO after 3 and 48 hrs, but also loss of cell viability in response to Stsp was not \ncompletely reversed by QVD ( Fig. 2F), in line with the reported necroptosis induction in \nmonocytic U937 cells [36]. Conclusively, DAO-induced cell death is accompanied by apoptotic \nfeatures which are seemingly not operative but rather necrotic pathways are responsible.  \n \nDAO interacts with the ethanolamine residue of phosphatidylethanolamine  \nThe \u03b1,\u03b2-unsaturated aldehyde of DAO functions as Michael acceptor to react with nucleophilic \nresidues such as thiol moieties of cysteine residue in 5-lipoxygenase [7]. It appeared reasonable \nthat the rapid induction of cell death by DAO and the associated detrimental membrane \nalterations could be due to reaction of the \u03b1,\u03b2-unsaturated aldehyde of DAO with amine \nmoieties of ethanolamine (EA) or serine (Ser) head group of membrane PE and PS thereby \nperturbing membrane integrity . We incubated different types of phospholipids (i.e., PE, PC, PS) \nwit\nh DAO followed by cleavage of the PL between the phosphate and the EA, Ser or choline \nmoiety, respectively, using exogenously added phospholipase (PL)D and UPLC-MS/MS \nanalysis of potentially formed adducts of DAO with the head group moieties. As shown in Fig. \n3A, two major signals at 442.4 and 485.3 m/z appeared upon incubation of DAO with PE and \nsubsequent PLD cleavage which may represent adducts of DAO with one or two EA molecules. \nThese DAO-EA adducts are reaction products, where (i) the primary amine of one EA molecule \nforms an \u03b1,\u03b2-unsaturated Schiff base with the aldehyde group of DAO (resulting in 442.4 m/z) 8 \n and/or (ii) the primary amine moieties of two EA molecules react in 1,4-addition to yield imine \nstr\nuctures (485.3 m/z) ( Fig. 3A ). Note that only a weak signal was detectable for DAO itself \n(399.4 m/z), suggesting that DAO efficiently reacted with PE to form the two adducts. In \ncontrast, when DAO was incubated in parallel with PS or PC, the signal for DAO remained \npronounced, whereas peaks with 442.4 or 485.3 m/z were not detectable ( Fig. 3B ), suggesting \nthat DAO does not react with PS or PC.  \nWe then studied if DAO-PE adducts might be formed also from intact monocytes and HeLa \ncells upon exposure to DAO for 3 hrs, by analysis of DAO-EA after treatment of cell lysates \nwith exogenous PLD. Incubation of these cells with DAO caused concentration-dependent \nincreases in DAO-EA adducts, starting at 0.1 \u00b5M DAO (Fig. 3C ). The cellular amount of PE \nwas maintained/decreased ( Fig. XY ). Next, we explored if DAO-PE interactions temporally \ncorrelate with detrimental effects on membrane integrity and thus with cell death induction. \nTreatment of monocytes or HeLa cells with 5 \u00b5M DAO resulted in rapid formation of DAO-\nPE adducts already after 15 min, reaching a plateau after about 1 hr to 3 hrs ( Fig. 3D ), which \nresembles the kinetics for the loss of membrane integrity (Fig. 1C) and decrease in cell viability \n(Fig. 1B ). Note that for both the loss of membrane integrity and DAE-PE adduct formation, \nDAO displays more pronounced effects in monocytes versus HeLa cells ( Fig. 3D and Fig. 1C). \nTaken together, DAO-EA adduct formation proceeds in parallel to membrane damage, \nsuggesting that the interaction of DAO with PE in the plasma membrane might be eventually \ncausative for cell death induction. In fact, incubation of DAO (10 \u00b5M) or Stsp (3 \u00b5M) with 50 \nmM EA for 2 hrs prior to addition to monocytes or HeLa cells abrogated the cytotoxic effect of \nDAO but not of Stsp ( Fig. 3E ), assessed by MTT assay. Note that preincubation of DAO with \ncholine failed in this respect and L-serine could only marginally restore cell viability ( Fig. 3F). \nAgain, Stsp-induced loss of monocyte viability was not affected by preceeding reaction with \nEA, serine or choline ( Fig. 3F) . Together, DAO binds to EA in PL and exogenous EA prevents 9 \n DAO-induced cell death suggesting that DAO acts by covalent modification of PE in cellular \nmem\nbranes. \n \nSubcellular locales of DAO-PE interactions and consequences for PE contents \nIn order to explore the interaction between DAO and PE in the cellular context and to locate \nthe subcellular PE binding sites of DAO, we performed subcellular fractionation of HeLa cells \nto obtain fractions enriched in nuclei, mitochondria, cytosol, and membranes. HeLa cells were \npreincubated with or without DAO for 15 or 180 min and cells were subjected to hypotonic \nlysis by passing them through a 25 G needle and subsequent differential centrifugation. Western \nblot for respective markers proteins confirmed correct cell fractionation and enrichment of \nrelated organelles ( Supplemental Fig. 2). In cells treated with vehicle for 15 min, the cellular \nPE content was about equally distributed between fractions where nuclei, mitochondria, or \nmembranes are enriched, while no PE was detectable in the cytosol ( Fig. 4A ). DAO did not \nsignificantly alter the subcellular distribution of PE (Fig. 4A). After 180 min, nuclear PE \nincreased at the expense of membranous PE, and about 5% of the total PE was cytosolic. DAO \nfurther promoted this redistribution and increased nuclear PE at the expense of membranous PE \n(Fig. 4A ). Importantly, when we analyzed the subcellular fractions for DAO-PE adducts \n(measured as DAO-EA after treatment of the fractions with PLD to cleave PE), we found that \nmost of the DAO-PE (44% after 15 min and 62% after 180 min) was formed in the membrane \nfraction, with about equal or somewhat elevated contents in the mitochondrial as compared to \nthe nuclear fraction ( Fig. 4B ).  \nNext, we analyzed whether DAO affects specific PE species in the subcellular fractions of HeLa \ncells after 3 hrs incubation using a targeted phospholipidomics approach (UPLC-MS/MS). In \ngeneral, PE(18:0/18:1) and PE(18:1/18:1) were the most abundant species in the nuclear, \nmitochondrial and membrane fraction (Fig. 4C ). However, the contents of PE species were not 10 \n markedly affected by DAO in comparison to the vehicle, the amounts of PE(18:0/18:1) and \nPE(\n18:1/18:1) were slightly increased in the nuclear fraction upon exposure to DAO after 3 hrs \n(Fig. 4C ). Interestingly, after 15 min, PE(18:0/18:1) was the most common PE species in the \nmembrane fraction closely followed by PE(18:1/18:1) ( Fig. 4D ) and after 3 hrs, these two PE \nspecies behaved exactly the other way ( Fig. 4C ). If we compared PE levels after 15 min DAO \nexposure with PE levels after 3 hrs DAO treatment in correlation to the total PE amount, a \npotent reduction of PE levels in the membrane fraction, especially PE(18:0/18:1) and \nPE(18:1/18:1) was obvious. Similar effects were observed also for less abundant PE species, \nsuch as PE(18:0/20:4), PE(16:0/18:1) or PE(16:1/18:1) ( Fig. 4F). Together, DAO covalently \nreacts with the major PE species, preferably with those in membranes, which as a consequence \nleads to a subcellular rearrangement of single PE species within cell organelles.  \nIn order to confirm that DAO reacts with PE in membranes and thus abrogates membrane \nintegrity, we studied if DAO could cause leakage of artificial PE-composed liposomes in a cell-\nfree system [37]. DAO caused release of the fluorescent dye 8-hydroxypyrene-1,3,6-trisulfonic \nacid trisodium salt (HPTS) from liposomes composed PE but not of PC indicating that it induces \nliposome leakage ( Fig. 4G and Supplemental Fig. 3). Moreover, incubation of monocytes with \nDAO induced rapid (within 15 min) acidification of vesicles, starting at 1 \u00b5M DAO being \ncomparable to the effect of the protonophore carbonyl cyanide m-chlorophenyl hydrazine \n(CCCP), as demonstrated by fluorescence microscopy using Lysotracker\u00ae as pH-sensitive dye \nfor lysosomal staining (Fig. 4H ).  \n  11 \n Discussion \nMel\nleolides belong to one of the largest globally distributed mycotoxin group of mushrooms. \nOnly for a few of these mycotoxins the modes of action and targets are explored like for \nmuscarine, coprine, psilocybin, and ibotenic acid. Since the last century, researchers have \nfollowed up with the bioactions of secondary metabolites of the basidiomycete species \nArmillaria mellea in plants and human cells [38-41]. Here, we reveal a mode of action \nunderlying the cytotoxic properties of the melleolide DAO in human cells. We showed before \n[3] that DAO induces remarkably rapid cell death in human cancer cell lines and in primary \nimmune cells, but the mode of action remained obscure. Here, we provide evidence that DAO \ncovalently binds to PE in cellular membranes. Our data suggest, that DAO covalently reacts \nwith the EA head group of PE thereby perturbing plasma membrane structure and integrity, \neventually leading to rapid cell death.   \nBesides DAO, several other melleolides display cytotoxic properties [1, 2, 4, 8, 9], but the rapid \nonset of cell death by DAO is unique. Interestingly, in contrast to other well-known cell death-\ninducing agents such as Stsp or pretubulysin that are more effective in cancer cells versus \nnormal untransformed cells, DAO is equally potent in primary monocytes and cancer cell lines, \nand loss of cell viability due to DAO is apparent within few minutes as compared to Stsp that \nneeded at least 5 hrs to cause cell death [3]. As described before, DAO displayed apoptotic as \nwell as necrotic features of cell death measured by flow cytometry with an Annexin V/7-amino-\nactinomycin staining, and marked apoptosis induction was only obvious after 5 hrs [3]. Here, \nwe find that DAO causes cleavage of the classical apoptosis marker PARP in human monocytes \nto a 89 kDa fragment within 15 min. Furthermore, the increase of phosphorylation of the stress-\nregulated p38 MAPK and the simultaneous decrease of the phosphorylation of the survival \nfactor Akt due to DAO may contribute to cell death induction. Cells treated with Stsp \ndemonstrated classical apoptotic characteristics like apoptotic bodies and fragmentation of 12 \n nuclei [15, 17], DAO-treated cells were crumpled and shrunk along with membrane rupture, \npar\nticular of mitochondrial membranes. These properties are typical characteristics of necrosis \n[20, 21] suggesting that both apoptotic and necrotic features of DAO-induced cell death.  \nRecently, the plant toxin ophiobolin A from the Bipolaris  genus [42] was shown to react with \nPE and/or EA [43], accompanied by strong cytotoxic properties in various cancer cells [44-46]. \nOf interest also ophiobolin A possesses an \u03b1,\u03b2-unsaturated aldehyde moiety that covalently \nreacts with the EA moiety in one PE molecule yielding the formation of a pyrrole [43], while \nDAO forms first an imine (as for ophiobolin A) with PE but then couples via 1,4 addition to a \nsecond PE molecule. Our data suggest that via covalent binding to the amine moiety of EA \nresidues DAO interacts with the head group of PE without forming adducts with PC, and \nseemingly also not with PS, although serine possesses a primary amine function like EA. In \nfact, substantial excess of exogenously added L-serine partially reverted the cytotoxic effects \nof DAO (Fig. 3G), while choline failed in this respect.  \nWe suggest that DAO-PE adduct formation causes perturbances of cellular membranes \nresulting in loss of membrane integrity. Thus, formation of DAO-EA adducts from cells treated \nwith DAO temporally correlated to LDH release as marker for impaired plasma membrane \nintegrity, processes that occurred within 15 min upon cell exposure to DAO, and DAO caused \ndisappearance of mitochondria as visualized by TEM. PE is a cone-shaped lipid and responsible \nfor the formation of hexagonal membrane phases [24]. If DAO covalently binds to the EA \nmoiety in PE, the arranged membrane structure might become perturbed and prone to ruptures \nwith consequent LDH release. In fact, the cytotoxic effects of DAO were abrogated by \nsupplementation of exogenous EA and serine, but not of choline, that may capture the reactive \naldehyde moiety of DAO, and DAO cause leakage of liposomes composed of PE but not of \nliposomes made from PC. Therefore, we hypothesize that the interaction of DAO with \nmembranous PE is the major cause for the rapid cell death induction. 13 \n In normal untransformed cells, PE is arranged in the inner leaflet of the plasma membrane and \nthe \nmitochondrial membrane [22] but during cell death PE and also PS are translocated to the \nouter plasma membrane [23]. Upon treatment of HeLa cells with DAO, adducts with PE were \nmost abundant in the membrane fraction, supporting the hypothesis that DAO acts on \nmembranous PE. Moreover, treatment of HeLa cells with DAO caused primarily a \nrearrangement of various PE species (particularly PE (18:0/18:1) and PE (18:1/18:1)) in the \nplasma membrane fraction leading to the presumption that DAO might affect various metabolic \nprocesses.  \nPE is necessary for autophagosomal membranes and autophagy which is essential to gain ATP \nby recycling cytoplasmic compounds [19]. During apoptosis, cells increase the autophagic \nresponse to support cell functions and to eliminate toxic molecules. These effects were \nintensified by reduced caspase-8 levels [47, 48]. Cells become hyperactive and lysosomal \nresorption of DAO is enhanced. Simultaneously, DAO interacts with PE in the inner leaflet of \nlysosomes followed by a lysosomal membrane rupture and as consequence the pH declines, as \nshown in monocytes by using the pH-sensitive dye Lysotracker\u00ae, eventually inducing necrosis. \nTaken together, DAO causes apoptosis and necrosis by manipulating several cellular \nmechanisms initialized by perturbing membrane integrity.  \nIn conclusion, we identified membrane PE as molecular target for the melleolide DAO that via \nthe \u03b1,\u03b2-unsaturated aldehyde moiety covalently reacts with the EA headgroup of PE. These \nDAO-PE interactions translate into perturbation of cellular membrane structure with \nconsequent loss of integrity which eventually causes the remarkably rapid onset of cell death in \nvarious cell types. \n \n  14 \n Materials and Methods \nMate\nrials \nDAO was isolated as described before [3]. Antibodies against Lamin B1, Lamp1, and syntaxin \n6, abcam (Cambridge, United Kingdom); DPX, abcr GmbH (Karlsruhe, Deutschland); bovine \nserum albumin (BSA), EDTA, and Tris, AppliChem (Darmstadt, Germany); DOPC, and \nDOPE, Avanti Polar Lipids (Alabaster, AL); L-glutamine, BioChem GmbH (Karlsruhe, \nGermany); AA, Cayman Chemical (Biomol, Hamburg, Germany); Antibodies against cleaved \nPARP (Asp214), phospho-p38 MAPK (Thr180/Tyr182), phospho-Akt (Ser473), ATF-4, \nCHOP, BiP, calnexin, COX IV, and \u03b2-actin were from Cell Signaling Technology (Boston, \nMA); phosphoplipase D from Streptomyces chromofuscus , ENZO life sciences (L\u00f6rrach, \nGermany); cytochrome c, Epitomics Inc. (Burlingame, CA); acetonitrile, Dulbecco's modified \nEagle's high glucose medium with glutamine, penicillin/streptomycin-solution, sepharose and \ntrypsin-EDTA, GE Healthcare Life Science (Freiburg, Germany); goat anti-rabbit IgG Alexa \nFluor 488 antibody, and goat anti-mouse IgG Alexa Fluor 555 antibody, Invitrogen (Darmstadt, \nGermany); DMSO, Merck (Darmstadt, Germany); ATP, Roche (Mannheim, Germany); SDS, \nRoth GmbH (Karlsruhe, Germany); GAPDH, and \u03b2-tubulin, Santa Cruz Biotechnology \n(Heidelberg, Germany); Dulbecco\u00b4s Buffer Substance (PBS), staurosporine, and HPLC \nsolvents, VWR (Darmstadt, Germany); dextrane, fetal calf serum (FCS), 3-(4,5-\ndimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), RPMI 1640 Medium, \nphenylmethanesulfonyl fluoride, soybean trypsin inhibitor, lysozyme, leupeptin, HPTS, \nethanolamine, choline, L-serine, triton X-100, chicken egg PE, chicken egg PC, QVD, \nLysoTracker\u00ae as well as other chemicals were from Sigma-Aldrich (Taufkirchen, Germany).  \nCells \nMonocytes were isolated from peripheral human blood of adult (18-65 years) healthy volunteers \nwith written informed consent, obtained from the Institute of Transfusion Medicine, University \nHospital Jena, as described [49]. The experimental protocol was approved by the ethical 15 \n committee of the University Hospital Jena. All methods were performed in accordance with the \nrel\nevant guidelines and regulations. Leukocyte concentrates were prepared by centrifugation \n(4000\u00d7g, 20 min, 20 \u00b0C) and erythrocytes were removed by dextran sedimentation followed by \ncentrifugation on lymphocyte separation medium (Histopaque\u00ae-1077, Sigma, Taufkirchen, \nGermany) to obtain peripheral mononuclear blood cells (PBMCs). PBMCs were seeded in \nRPMI 1640 (Sigma Aldrich, Taufkirchen, Germany) containing 10% (v/v) heat inactivated fetal \ncalf serum (FCS), 100 U/mL penicillin, and 100 \u00b5g/mL streptomycin in cell culture flasks \n(Greiner Bio-one, Frickenhausen, Germany) for 1.5 h at 37 \u00b0C and 5% CO 2. Adherent \nmonocyt\nes were washed twice with PBS and were resuspended in PBS containing 1 mg/ml \nglucose. HeLa cells were cultured in monolayers in DMEM High Glucose (4.5 g/L) medium \nsupplemented with heat-inactivated fetal calf serum (FCS, 10%, v v), 100 U/mL penicillin, and \n100 \u00b5g/mL streptomycin at 37 \u00b0C in a 5% CO 2 incubator. \nAnal\nysis of cell viability by MTT assay \nMonocytes (2 \u00d7 106/mL in RPMI 1640 containing 5% heat inactivated FCS, 100 U/mL \npeni\ncillin and 100 \u00b5g/mL streptomycin) or 0.1 \u00d7 106/mL HeLa cells in DMEM High Glucose \nsuppl\nemented with 5% FCS, 100 U/mL penicillin and 100 \u00b5g/mL streptomycin were seeded in \na 96-well plate. Monocytes were allowed to adhere for 1.5 h at 37 \u00b0C, 5% CO 2. Cell were \nincub\nated at 37 \u00b0C and 5% CO 2 with vehicle (0.5% DMSO) or compounds (i.e. DAO or Stsp) \nfor \nindicated time points. In some experiments, EA, choline, L-serine or QVD were added 15 \nmin prior to DAO or Stsp. After the times indicated, cells were incubated with thiazolyl blue \ntetrazolium bromide (MTT, 5 mg/mL PBS) until blue staining of the vehicle-containing control \ncells. Formazan formation was stopped by 100 \u00b5L SDS lysis buffer (10%, w/v in 20 mM HCl) \nand the well plate was shake overnight. Finally, absorbance was measured at 570 nm with a \nMultiskan\u2122 microplate spectrophotometer (Thermo Scientific, Ulm, Germany). The pan \nprotein kinase inhibitor staurosporine (1 \u00b5M) was used as cytotoxic control inhibitor. 16 \n LDH release assay \nFor \nanalysis of extracellular LDH as marker for loss of plasma membrane integrity, we used \nthe CytoTox96\u00ae Non-Radioactive Cytotoxicity assay kit (Promega, Madison, WI, USA). \nFreshly prepared monocytes (0.5 \u00d7 106/mL RPMI 1640 containing 5% heat inactivated FCS, \n100 U/\nmL penicillin and 100 \u00b5g/mL streptomycin) or 0.1 \u00d7 106/mL HeLa cells in DMEM High \nGluc\nose supplemented with 5% FCS, 100 U/mL penicillin and 100 \u00b5g/mL streptomycin were \nseeded in a 96-well plate. Monocytes were allowed to adhere for 1.5 h at 37 \u00b0C, 5% CO 2 prior \ntre\natment with vehicle (0.5% DMSO), triton X-100 (lysis control) or 5 \u00b5M DAO for indicated \ntime points. After incubation, the manufactures instructions were followed and the LDH release \nwas\n measured by recording the absorbance at 490 nm with a Multiskan\u2122 microplate \nspectrophotometer (Thermo Scientific, Ulm, Germany). \nMicroscopic morphology analysis \nHeLa cells (0.25 \u00d7 106/mL DMEM High Glucose supplemented with 5% FCS, 100 U/mL \npeni\ncillin and 100 \u00b5g/mL streptomycin) were incubated for 3 hrs with vehicle (0.1% DMSO, \nv/v), DAO or Stsp. Then, cells were placed on ice, washed with PBS, and analyzed by light \nmicroscopy using an AxioCam MR3 camera (Zeiss, Jena, Germany). Images were acquired, \ncut, linearly adjusted in the overall brightness and contrast, and exported to TIF by the \nAxioVision 4.8 software. The microscope incubator (Axio Observer Z1 inverted microscope, \nLCI Plan-Neofluar 63x/1.3 Imm Corr DIC M27 objective, Carl Zeiss, Jena, Germany) was kept \nat 37 \u00b0C and 5% CO 2. \nLysotracker\u00ae analysis  \nFor \nacidification analysis of monocytes by fluorescence microscopy, freshly isolated \nmonocytes (2.5 \u00d7 105/mL RPMI 1640 containing 5% heat inactivated FCS, 100 U/mL penicillin \nand 100 \n\u00b5g/mL streptomycin) were seated in Glass Bottom Microwell Dishes (MatTek \nCorporation, MA). After 1.5 hr adhesion time at 37 \u00b0C and 5% CO 2, cells were treated for 1 hr 17 \n with vehicle (0.1% (v/v) DMSO), 10 \u00b5M CCCP or 0.1 \u00b5M, 1 \u00b5M, 10 \u00b5M DAO at 37 \u00b0C and \n5% C\nO2 followed by washing with pre-warmed PBS. Cells were resuspended in PBS containing \n1 mM\n CaCl 2, 1 mM MgCl 2 and 0.1% glucose. For the staining, 50 nM LysoTracker\u00ae Red-\nDND\n-99 (Sigma, Taufkirchen, Germany) was added to the cells and after 5 min, red \nfluorescence of the accumulated probe in acidic cell organelles was imaged using an Axio \nObserver Z1 microscope (Carl Zeiss, Jena, Germany). \nFor analysis by a fluorescence microplate reader (NOVOstar\u00ae, BMG Labtechnologies, \nOffenburg, Germany), freshly isolated monocytes (1.5 \u00d7 106/mL RPMI 1640 containing 5% \nheat\n inactivated FCS, 100 U/mL penicillin and 100 \u00b5g/mL streptomycin) were seated into a \nblack 96-well plate with glass bottom. Monocytes were allowed to adhere for 1.5 hr at 37 \u00b0C, \n5% CO 2 prior treatment with vehicle (0.1% (v/v) DMSO), 10 \u00b5M CCCP as control, and DAO \nas \nindicated concentrations for 1 hr. After washing and resuspension in PBS (0.1% glucose, 1 \nmM CaCl 2, 1 mM MgCl 2), cells were stained with 50 nM LysoTracker\u00ae and 0.5% (v/v) \nHoec\nhst for 5 min at 37 \u00b0C, 5% CO 2. After washing, fluorescence was excited at 577 nm \n(Lys\noTracker\u00ae) and 350 nm (Hoechst staining) and the emission was recorded at 590 nm \n(LysoTracker\u00ae) and 480 nm (Hoechst staining). Acidification was calculated from ratio of \nfluorescence intensities of LysoTracker\u00ae in relation to the fluorescence of Hoechst staining.  \nTEM \nMonocytes, resuspended in RPMI 1640 containing 5% heat-inactivated FCS, 5 ml L-glutamine, 100 \nU/mL\n penicillin and 100 \u00b5g/mL streptomycin, were incubated with DAO, Stsp or vehicle for 3 hrs at 37 \n\u00b0C and 5% CO 2. Cells were washed in PBS pH 7.4, centrifuged (800\u00d7g, 5 min, 20 \u00b0C) and resuspended in \n2.5\n% glutaraldehyde (v/v, in water) for fixation. After 20 min at RT, cells were washed by centrifugation \n(5000 rpm, 5 min, 4 \u00b0C) and resuspended in PBS. For the embedding process, cells were washed 3 times \nwith PBS pH 7.4 for 5 min. After each washing step, the sample was centrifuged at 2000 rpm for 2 min. \nPost-fixation was performed by osmium tetroxide (1% OsO 4 in PBS pH 7.4) for 1 hr. Samples were \nwash\ned again with PBS pH 7.4 and the monocytes were gradually dehydrated by a series of increasing 18 \n ethanol:water mixtures (50%, 70%, 90% and 100% ethanol, 10 min for each step and centrifugation at \n2000 rpm for 2 min). Resin infiltration was performed in 2 steps (Embed812: EtOH 2:1 with 18 \u00b5L per \nmL resin DMP-30 (for 1 hr at RT), Science Services). Samples were centrifuged at 2000 rpm for 8 min. \nThe second infiltration step was performed in undiluted Embed812 resin (overnight at RT). After an \nadditional centrifugation step the resin was exchanged and infiltrated for 2 hrs. Samples were \nsubsequently transferred to BEEM capsules (Plano), centrifuged once (2000 rpm, 8 min) and cured at \n60\u00b0 C for 24 hrs. The embedded samples were sectioned in 80 to 100 nm thick slices utilizing an \nultramicrotome (PowerTome PC, RMC Products) equipped with a diamond knife (Diatome). The slices \nwere placed on a carbon coated TEM grid (Quantifoil) and imaged with a 200 kV FEI Tecnai G\u00b220 (FEI \nCompany).  \nDetection of DAO-PE adducts in vitro \nFor \nanalysis of DAO-PE adduct formation, 5.2 \u00b5L solution of DAO (5 mM) and 2 \u00b5L \ntransphosphorylated chicken egg PE (13 mM, Sigma Aldrich, Taufkirchen, Germany) were \nadded to 44.8 \u00b5L reaction buffer containing 1 M triethylammonium acetate, CHCl 3 and MeOH \n(1:1:\n3, v/v/v). Vehicle and chicken egg PC (13 mM, instead of PE) were used as controls. After \n3 hrs incubation at 37 \u00b0C, samples were diluted with MeOH to 500 \u00b5L, internal standard was \nadded and 50 \u00b5L were dried under a nitrogen stream. The pellet was resuspended with 25 \u00b5L \nMeOH and diluted to 250 \u00b5L with PBS, following incubation with 275 U phospholipase D from \nStreptomyces chromofuscus  (ENZO life sciences, L\u00f6rrach, Germany) for 16 hrs at 37 \u00b0C. DAO \nadducts were extracted with 1 mL CHCl 3/MeOH (2:1, v/v). The lower organic phase was dried \nby a\n nitrogen stream and the pellet was resuspended with 1 mL MeOH before measuring by \nUPLC-MS/MS. \nIsolation of cellular DAO-PE adducts \nMonocytes (5 \u00d7 106 cells/mL) in RPMI 1640 containing 5% FCS, 100 U/mL penicillin and 100 \n\u00b5g/m\nL streptomycin or HeLa cells (0.25 \u00d7 106 cells/mL) in DMEM High Glucose supplemented \nwit\nh 5% FCS, 100 U/mL penicillin and 100 \u00b5g/mL streptomycin were incubated with vehicle 19 \n (0.1% DMSO, v/v) or DAO for the indicated time points at 37 \u00b0C and 5% CO 2. Cells were \npla\nced on ice and washed twice with ice-cold PBS. The cell pellet was resuspended with ice-\ncold 200 \u00b5L CHCl 3/MeOH (2:1, v/v) supplemented with 50 mM pentyl-pyridoxamine. The cell \nsusp\nension was allowed to homogenize for 20 min at RT followed by addition of internal \nstandard and extraction with 40 \u00b5L 0.9% NaCl solution. The suspension was vortexed for 30 \nsec and centrifuged (4000 rpm, 5 min, 4 \u00b0C). The lower phase was dried under a stream of \nnitrogen and the pellet was resuspended with 50 \u00b5L MeOH by sonication. An aliquot of the \nsolution (50 \u00b5L) was diluted with 200 \u00b5L PBS and sonicated for 2 min in an ultrasonic bath, \nfollowed by incubation of extracted phospholipids with 875 U phospholipase D from S. \nchromofuscus for 16 hrs at 37 \u00b0C. The solution was extracted with 1 mL ice-cold CHCl 3/MeOH \nmixt\nure (2:1, v/v). The lower organic phase was dried, and the pellet was resuspended with 0.5 \nmL CHCl 3/MeOH mixture (2:1, v/v) followed by addition of 125 \u00b5L 0.9% NaCl solution and \nanothe\nr extraction. The dried lower phase was resuspended with 100 \u00b5L MeOH and DAO-EA \nadducts were measured by UPLC-MS/MS. \nReversed phase liquid chromatography and mass spectrometry \nChromatography was carried out on an Acquity UPLC BEH C8 column (1.7 \u03bcm, 1 \u00d7 100 mm) \nusing an AcquityTM Ultra Performance liquid chromatography system from Waters (Milford, \nMA, \nUSA). DAO, PL\u2019s, and DAO-PE conjugates were separated at 0.75 ml/min and 45\u00b0C using \na gradient of 30% mobile phase A (acetonitrile/water, 10/90, 10 mM ammoniumacetate)/70% \nmobile phase B (acetonitrile/water, 95/5, 10 mM ammonium acetate) to 20% mobile phase \nA/80% mobile phase B within 5 min and to 100% mobile phase B within 2 min followed by \nisocratic elution for another 2 min. The chromatography system, controlled by Acquity UPLC \nSoftware 1.40 (Waters), was coupled to a QTRAP 5500 Mass Spectrometer (Sciex, Darmstadt, \nGermany) equipped with an electrospray ionization source.   \nFor identification of DAO, the precursor-to-product ion transitions in multiple reaction \nmonitoring were m/z 399.2 \u2192 104.9 (collision energy: -50 eV; collision cell exit potential: -13 20 \n V), and 399.2 \u2192 148.9 (collision energy: -24 eV; collision cell exit potential: -16 V). \nQuant\nification of DAO was based on the transition 399.2 \u2192 148.9 using an external calibration \ncurve, quantification of phospholipids and PL-conjugates was based on the internal standard \nDMPC (collision energy: -38 eV; collision cell exit potential: -12 V). Analytes with varying \ncollision energies (CE) and collision cell exit potentials are listed below in table 1. The ion \nspray voltage was set to -4000 V, the heated capillary temperature to 650\u00b0C, the curtain gas \npressure to 30 psi, the declustering potential to -50 V, collisionally activated dissociation (CAD) \nto medium, nebulizer gas (GS1) to 50, heater gas (GS2) to 60, and the entrance potential -10 V. \nAnalyst software 1.6 (Sciex, Darmstadt, Germany) was used for the processing of analytical \ndata. \nanalyt precursor-to-product \nion transition (m/z) Collision energy \n(CE) Collision cell exit \npotential (CXP) \nDAO 1xEA T1 442.4 \uf0e0  149.0 -20 \uf0e0  50 -17 \uf0e0  64 \nDAO 1xEA T2 442.4 \uf0e0  105.0 -56 \uf0e0  36 -7 \uf0e0  2 \nDAO 2xEA T1 484.8 \uf0e0  149.0 -41 \uf0e0  46 -52 \nDAO 2xEA T2 484.4 \uf0e0  105.0 -66 \uf0e0  44 -52 \uf0e0  90 \nDAO-PE(16:0/18:1) 1098.7 \uf0e0  948.5 -52 \uf0e0  35 -42 \uf0e0  7 \nDAO-PE(16:0/18:11) 1098.7 \uf0e0  281.2 -76 \uf0e0  80 -42 \uf0e0  7 \nDAO-PE(18:1/18:1) 1126.8 \uf0e0  976.6 -49 \uf0e0  20 -12 \nDAO-PE(18:0/20:4) 1148.7 \uf0e0  998.5 -49 \uf0e0  51 -12 \nDAO-PE(18:0/20:41) 1148.7 \uf0e0  283.4 -79 \uf0e0  33 - 12 \nd8-AA 311.3 \uf0e0  267.1 -16 -18 \nd4-LTB4 339.3 \uf0e0  197.2 -22 -13 \nd4-PGE2 355.3 \uf0e0  193.2 -38 -18 \n 21 \n Liposomal leakage assay \nSolut\nions containing either 5 \u00b5mol dioleoyl-PC (DOPC) or 2.5 \u00b5mol dioleoyl-PE (DOPE) plus \n2.5 \u00b5mol DOPC (Avanti Polar Lipids, Inc.) were prepared in CHCl 3. The solvent was removed \nusing \na nitrogen stream and subsequent evaporation under vacuum. Lipid films were rehydrated \nby vortexing in a water bath (30 \u00b0C) with 1 mL of a solution of 35 mM 8-hydroxypyrene-1,3,6-\ntrisulfonic acid trisodium salt (HPTS, fluorophore) and 50 mM 1,1'-[1,4-\nphenylenebis(methylene)]-bis pyridinium dibromide (DPX, colissional quencher) in 20 mM \nHEPES, 150 mM NaCl, and 1 mM EDTA forming essentially heterogenous multilamellar \nvesicles (MLV). Then, large unilamellar vesicles (LUV) were formed by six freeze-thaw cycles. \nLiposome suspensions were extruded 20 times through 100 nm polycarbonate filters \n(LiposoFast-Basic, Avestin Inc.) to generate LUVs with HPTS/DPX encapsulated [50]. LUVs \nwere separated from free HPTS/DPX by size exclusion chromatography using a Sepharose \ncolumn and 20 mM HEPES, 150 mM NaCl, 1 mM EDTA as buffer.  \nA 100 \u00b5L sample of HPTS/DPX-containing liposomes diluted (1:20) in 20 mM HEPES, 150 \nmM NaCl, 1 mM EDTA was dispensed in 96-well-plates. Then, 10 \u00b5M DAO was added and \nthe fluorescence of HPTS was monitored each 14 s on a NOVOstar (BMG LABTECH GmbH) \nusing excitation at 450 nm and emission at 520 nm over 15 min and at RT. A negative control \nusing DMSO was used as the 0% leakage reference, and 0.2% Triton X-100 was used as \npositive control yielding 100% leakage. For each time point, the fluorescence data were \nnormalized to these two reference samples. \nCytochrome c release \nCells were seeded in RPMI 1640 containing 5% FCS, 100 U/mL penicillin and 100 \u00b5g/mL \nstreptomycin (4 \uf0b4 106/ml) and incubated with the test compounds or vehicle (DMSO). After 3 \nhrs, \ncells were washed once in PBS and 107 cells were resuspended in 200 \u00b5l PBS. For \nper\nmeabilization of the plasma membrane, 20.3 \u00b5M digitonin was added and immediately 22 \n vortexed (10 sec), incubated for another 30 seconds at room temperature and centrifuged at \n20,000g a t\n 4\u00b0C for 1 min. The supernatant (cytosolic fraction) and pellet (non-cytosolic \nfraction) were transferred to a new tube, respectively, and mixed 1:1 (vol/vol) with 5% \ntrichloroacetic acid. Precipitation of cytosolic proteins was performed at 4\u00b0C overnight. \nProteins were pelleted by centrifugation at 20,000g at 4\u00b0C for 30 min and resuspended in 25 \u00b5l \nPBS. Aliquots of 5 \u00b5l were used for determination of protein concentration using Roti-\nNanoquant (Roth, Karlsruhe, Germany). Equal amounts of protein were mixed 1:1 (vol/vol) \nwith 2 \uf0b4 SDS/PAGE sample loading buffer and analyzed for cytochrome c by SDS-PAGE and \nWestern Blot using an anti-cytochrome c-antibody (Epitomics Inc., Burlingam, CA). \nSubcellular fractionation  \nHeLa cells (0.25 \u00d7 106 cells/mL, in DMEM High Glucose supplemented with 5% FCS, 100 \nU/m\nL penicillin and 100 \u00b5g/mL streptomycin) were pre-incubated with vehicle (0.1% DMSO, \nv/v) or DAO (5 \u00b5M) for the indicated time points at 37 \u00b0C and 5% CO 2. Cells were placed on \nice\n and the cell pellet was washed with 500 \u00b5L PBS followed by 5 min centrifugation (4600 \nrpm) at 4 \u00b0C. The cell pellet was resuspended with hypotonic lysis buffer pH 7.4 (10 mM \nHEPES, 2 mM MgCl 2, 0.1 mM EDTA, 0.1 mM EGTA, 10 mM KCl, 1 mM DTT) and cells \nwer\ne passed through a 25 G needle (sterican 0.5 \u00d7 40 mm, Gr 17/42, B. Braun Melsungen AG) \n10 times using a 10 mL syringe. The cell suspension was kept on ice for 20 min before adding \nkinase inhibitor cocktail. To get nuclei, the cell suspension was centrifuged for 10 min at 550 g \nand 4 \u00b0C. Supernatant was used for continuing subcellular fractionation and pellet was again \nwashed with hypotonic lysis buffer, centrifuged (550 g, 10 min, 4 \u00b0C) and frozen at -20 \u00b0C. The \nsupernatant was centrifuged at 10,000 g and 4 \u00b0C for 10 min. The resulting mitochondrial pellet \nwas again washed as described for the nuclear pellet and subsequently frozen at -20 \u00b0C. The \nsupernatant was used to obtain the cytosolic and microsomal fraction by ultracentrifugation at \n100,000 g and 4 \u00b0C for 1 h. The cytosolic fraction corresponds to the supernatant and was 23 \n evaporated until dryness with Eppendorf\u00ae concentrator at 30 \u00b0C. The pellet corresponds to the \nmic\nrosomal fraction and was frozen at -20 \u00b0C.  \nFor preparation of Western Blot samples, pellets were resuspended in 100 \u00b5L Western Blot \nlysis buffer and homogenized by sonification on ice. On the other hand, pellets were used for \nmass spectroscopy analysis. Lipids were extracted as described before by Bligh and Dyer \nmethod [51] and cellular DAO-PE adducts were analyzed as specified above. \nSDS PAGE and Western Blot \nSubcellular fractions (see above) or isolated monocytes were resuspended in 100 \u00b5L ice-cold 2 \n\u00d7 SDS loading buffer (20 mM Tris-HCl pH 8, 2 mM EDTA, 5% (m/v) SDS, 10% (v/v) \u03b2-\nmercaptoethanol, 10 \u00b5g/mL leupeptin, 60 \u00b5g/mL soybean trypsin (STI), 1 mM PMSF, 40 \u00b5L \nglycerol and 0.1% bromophenol blue (1:1, v/v). Samples were heated for 5 min at 96 \u00b0C and \nproteins were separated by SDS-PAGE on a 10% acrylamide gel. Correct protein loading on \nthe gels and transfer of proteins to the nitrocellulose membrane (Amersham PROTRAN\u00ae \nsupported 0.45 NC, GE Healthcare, Freiburg; Germany) was confirmed by Ponceau staining. \nAntibody recognizing cleaved PARP (Asp214), phospho-p38 MAPK (Thr180/Tyr182), \nphosho-Akt (Ser473), ATF-4, CHOP, BiP, calnexin, syntaxin 6, COX IV and \u03b2-actin were from \nCell Signaling Technology (Boston, MA) and used at 1:1000 dilution. Antibodies against \nGAPDH and \u03b2-tubulin were purchased from SantaCruz (Dallas, TX) and also used at 1:1000 \ndilution. Antibodies against Lamin B1 (1:200), syntaxin 6 (1:1000) and Lamp1 (1:1000) were \npurchased from abcam (Cambridge, United Kingdom). Infrared labeled secondary antibody \nIRDye 800CW goat anti-mouse was from LI-COR Biosciences (Lincoln, NE). For detection, \nthe Odyssey Infrared Imaging System (LI-COR Bioscience, Lincoln, NE) and for analysis the \nOdyssey application software (version 3.0.25) were used. \n \n 24 \n Statistics \nRes\nults are presented as means \u00b1 standard error of the mean (SEM) of n independent \nobservations, where n represents the number of performed experiments at different days or with \ndifferent donors. Statistical analysis of the data was performed by one-way ANOVA using \nGraphPad InStat (Graphpad Software Inc., San Diego, CA) followed by a Bonferroni post-hoc \ntest for multiple or student t-test for single comparisons, respectively. P-values < 0.05 were \nconsidered as significant. \n \nAcknowledgments \nThis work was supported by the Collaborative Research Centers ChemBioSys (SFB1127) and \nPolytarget (SFB1278) of the Deutsche Forschungsgemeinschaft (DFG) and by the DFG-funded \nexcellence graduate school Jena School for Microbial Communication (JSMC).  \n \nDeclaration of Interests \nThe authors declare no competing interests. \nLegends for the figures \nFigure 1: DAO causes rapid cell death in human cells with unique characteristics.  \n(A) Chemical structure of DAO. (B) Monocytes were incubated with DAO at indicated \nconcentrations for 15 min, 60 min, and 24 hrs. Cell viability was analyzed by MTT assay. \nMeans \u00b1 SEM, n =3. (C) Monocytes or HeLa cells were incubated with DAO (5 \u00b5M) for the \nindicated time points. Plasma membrane integrity was analyzed by LDH assay. Means \u00b1 SEM, \nn =3. *p < 0.05, **p < 0.01, ***p < 0.001 vs vehicle control; ANOVA plus Bonferroni post \nhoc test. (D) Morphological analysis of HeLa cells by light microscopy. Cells were treated with \nthe compounds at indicated concentrations for 3 hrs and were then analyzed by light \nmicroscopy. Pictures shown are representatives out of three independent experiments. (E) TEM \nanalysis of monocytes. Freshly isolated human monocytes were pretreated with 10 \u00b5M DAO, \n3 \u00b5M Stsp or vehicle (0.1% DMSO) for 3 hrs. Cells were prepared for TEM analysis which \nwas performed as described in the Method section. Arrows indicate the presence of \nmitochondria.  25 \n Figure 2: Contribution of apoptotic pathways in mediating cell death by DAO.  \n(A) M\nonocytes were treated with DAO (5 \u00b5M) or staurosporine (Stsp, 3 \u00b5M) for the indicated \ntime points. Then, PARP cleavage to an 89 kDa fragment was assessed by Western Blotting \n(left panel) and densitometric analysis (right panel) was performed in correlation to GAPDH. \nMeans \u00b1 SEM, n = 3. (B) Cytochrome C release from human monocytes. Intact monocytes \nwere pretreated with 10 \u00b5M DAO, 3 \u00b5M Stsp or vehicle (0.1% DMSO) for 3 hrs. Then, cells \nwere fractionated by mild detergent lysis and the cytosolic and the non-cytosolic fractions were \nanalyzed by Western blot for cytochrome (Cyt) c. \u03b2-Actin and calnexin were used as marker \nproteins for respective fractions. (C) Monocytes were incubated with 5 \u00b5M DAO, 3 \u00b5M Stsp \nor vehicle. Total cell lysates were prepared after the indicated times and analyzed for phospho-\np38 MAPK and phospho-Akt by Western blot (left panel). Densitometric analysis (right panel) \nwas performed in correlation to \u03b2-actin. Means \u00b1 SEM, n = 3. (D) Protein expression of BiP, \nATF-4 and CHOP in monocytes. Cells were incubated with DAO (5 \u00b5M) or vehicle (0.1% \nDMSO) for the indicated time points and then analyzed by Western blot (left panel). \nDensitometric analysis (right panel) was performed in correlation to \u03b2-actin. Means \u00b1 SEM, n \n= 3. (E) Monocytes were pre-incubated with the pan-caspase inhibitor QVD (10 \u00b5M) 30 min \nprior incubation with 5 \u00b5M DAO, 3 \u00b5M Stsp or vehicle for 3 hrs. Protein levels were analyzed \nby Western Blot (lower panel) and densitometric analysis (upper panel) were performed in \ncorrelation to GAPDH. (F) Monocytes were pre-incubated with the pan-caspase inhibitor QVD \n(10 \u00b5M) 30 min prior incubation with 10 \u00b5M DAO, 3 \u00b5M Stsp or vehicle for 3 hrs (left panel) \nor 48 hrs (right panel). Then, cell viability was assessed by MTT assay. Means \u00b1 SEM, n = 3. \n*p < 0.05, **p < 0.01, ***p < 0.001 vs vehicle control; ANOVA plus Bonferroni post hoc test.  \nFigure S1: Effect of staurosporine on PARP cleavage after 5 hrs incubation.  \nMonocytes were treated with DAO (5 \u00b5M) or staurosporine (Stsp, 3 \u00b5M) for 5 hrs. Then, PARP \ncleavage to a 89 kDa fragment was assessed by Western Blotting (left panel) and densitometric \nanalysis (right panel) was performed in correlation to GAPDH. Means \u00b1 SEM, n = 3. p < 0.05, \n**p < 0.01, ***p < 0.001 vs vehicle control; students t-test. \nFigure 3: DAO interacts with the ethanolamine (EA) residue of \nphosphatidylethanolamine.  \n(A, B) DAO (0.5 mM) was incubated with chicken egg PE (13 mM in CHCl 3), chicken PC (13 \nmM \nin CHCl 3) and bovine brain PS in reaction buffer for 3 hrs at 37 \u00b0C. Then, phospholipids \nwer\ne cleaved by exogenously added phospholipase D for 16 hrs at 37 \u00b0C (insert panel A). DAO-\nEA, -choline or \u2013serine adducts were analyzed by UPLC-MS/MS. (C) Monocytes and HeLa \ncells were incubated with DAO at the indicated concentrations for 3 hrs. DAO-PE adducts were \nextracted with CHCl 3/MeOH (3:1) and cleaved by phospholipase D treatment for analysis of \nDAO\n-EA adducts by UPLC-MS/MS. Means \u00b1 SEM, n = 3. (D) Monocytes and HeLa cells were \nincubated with 5 \u00b5M DAO for the indicated periods. DAO-PE adducts were extracted and \nanalyzed by UPLC-MS/MS. Means \u00b1 SEM, n = 3. (E) DAO (5 \u00b5M), Stsp (1 \u00b5M) or vehicle \n(0.1% DMSO) were incubated with 50 mM EA for 2 hrs at 37 \u00b0C and subsequently extracted \nusing MeOH/CHCl 3 (1:2, vol:vol)  as described in the Method section. Extracts containing EA-\nadduct\ns or unreacted DAO or Stsp were resolved in ethanol (vehicle) and added to monocytes \n(left panel) or HeLa cells (right panel) for 3 hrs, and cell viability was assessed by MTT assay. 26 \n (F) DAO (10 \u00b5M), Stsp (3 \u00b5M) or vehicle (0.1% DMSO) were incubated with EA, choline \n(Chol\n) or L-serine (L-Ser) (50 mM, each) for 2 hrs at 37 \u00b0C and subsequently extracted as \ndescribed above. Extracts containing adducts or unreacted agents (in ethanol as vehicle) were \nadded to monocytes for 3 hrs (left panel) or 48 hrs (right panel), and cell viability was assessed \nby MTT assay. Data are means \u00b1 S.E, n = 3. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < \n0.0001 vs vehicle control; ANOVA plus Bonferroni post hoc test.  \nFigure S2: Markers subcellular fractionation.  \nHeLa cells were incubated with DAO (5 \u00b5M) or vehicle (0.1% DMSO) 15 min. Subcellular \nfractions were generated by hypotonic cell lysis and differential centrifugation. Respective \nfractions were analyzed by Western blot for specific fraction proteins. Western blots are \nrepresentative for three independent experiments.  \nFigure 4: Subcellular locales of DAO-PE interactions and consequences for PE contents \nand membrane stability.  \nHeLa cells were incubated with DAO (5 \u00b5M) or vehicle (0.1% DMSO) for the indicated time \npoints. Subcellular fractions were generated by hypotonic cell lysis and differential \ncentrifugation. (A) Subcellular distribution of PE in HeLa cells after 15 min (left panel) and 3 \nhrs (right panel). (B) Subcellular distribution of DAO-PE adducts. The DAO-PE adducts \nformed within 15 min (left panel) or after 3 hrs (right panel) were extracted with CHCl 3/MeOH \n(3:1)\n, cleaved by phospholipase D from PE, and then analyzed with UPLC-MS/MS. (C, D, E) \nHeLa cells were pre-incubated with 5 \u00b5M DAO for 3 hrs (C) or 15 min only (D). PE species \nwere extracted by the Bligh and Dyer method and were analyzed by UPLC-MS/MS. (E) \nCorrelation of PE species obtained after 15 min and after 3 hrs to total PE. (F) Correlation of \nPE species obtained after 15 min and after 3 hrs to vehicle control, shown as heat map. Data \nare given as mean + S.E, n = 3. *p < 0.05, **p < 0.01, ***p < 0.001 vs vehicle control; ANOVA \nplus Bonferroni post hoc test. (G) Liposomal leakage test. Liposomes (LUVs) composed of \nDOPC or DOPC/DOPE (1:1) containing HPTS/DPX were incubated with DAO (10 \u00b5M) and \nthe fluorescence was measured. Liposomal leakage is expressed as % of the positive control \nincubated with Triton X-100 (=100%). (H) Monocytes were incubated with DAO at the \nindicated concentrations or vehicle (0.1% DMSO) for 15 min or 60 min, acidic vesicles (red) \nwere stained with the Lysotracker probe for 5 min. Fluorescence microscopy pictures (left \npanel) are representative of four independent experiments. Acidification of vesicles (right \npanel) was assessed by fluorescence measured by NOVOstar\u00ae. Acidification is expressed in \ncorrelation to Hoechst staining of each cell per sample with vehicle = 100%. Data are given as \nmean + S.E, n = 3. *p < 0.05, **p < 0.01, ***p < 0.001 vs vehicle control; ANOVA plus \nBonferroni post hoc test.  \nFigure S3: Liposomal leakage test.  \nLiposomes (LUVs) composed of DOPC or DOPC/DOPE (1:1) containing HPTS/DPX were \nincubated with vehicle (DMSO, negative control) or DAO (10 \u00b5M) and the fluorescence was \nmeasured. Results are representative for n=3 independent experiments. \n 27 \n References \n1. Bohnert, M., et al., In vitro cytotoxicity of melleolide antibiotics: structural and mechanistic \nasp\nects. Bioorg Med Chem Lett, 2011. 21(7): p. 2003-6. \n2. Bohnert, M., et al., Cytotoxic and antifungal activities of melleolide antibiotics follow \ndissimilar structure-activity relationships. Phytochemistry, 2014. 105: p. 101-8. \n3. Bohnert, M., et al., Melleolides induce rapid cell death in human primary monocytes and \ncancer cells. Bioorg Med Chem, 2014. 22 (15): p. 3856-61. \n4. Misiek, M., et al., Structure and cytotoxicity of arnamial and related fungal sesquiterpene aryl \nesters. J Nat Prod, 2009. 72 (10): p. 1888-91. \n5. Momose, I., et al., Melleolides K, L and M, new melleolides from Armillariella mellea. J \nAntibiot (Tokyo), 2000. 53 (2): p. 137-43. \n6. Dorfer, M., et al., Melleolides impact fungal translation via elongation factor 2. Org Biomol \nChem, 2019.17(19):4906-16 \n7. Konig, S., et al., Melleolides from Honey Mushroom Inhibit 5-Lipoxygenase via Cys159. Cell \nChem Biol, 2019. 26 (1): p. 60-70 e4. \n8. Chang, W.H., et al., Armillaridin induces autophagy-associated cell death in human chronic \nmyelogenous leukemia K562 cells. Tumour Biol, 2016. 37(10): p. 14291-14300. \n9. Chen, Y.J., C.C. Chen, and H.L. Huang, Induction of apoptosis by Armillaria mellea \nconstituent armillarikin in human hepatocellular carcinoma. Onco Targets Ther, 2016. 9 : p. \n4773-83. \n10. Yin, X., T. Feng, and J.-K. Liu, Structures and cytotoxicities of three new sesquiterpenes from \ncultures of Armillaria sp. Nat Prod and Bioprospect, 2012. 2(6): p. 245-248. \n11. Chen, C.C., et al., Three New Sesquiterpene Aryl Esters from the Mycelium of Armillaria \nmellea. Molecules, 2015. 20(6): p. 9994-10003. \n12. Chi, C.W., C.C. Chen, and Y.J. Chen, Therapeutic and radiosensitizing effects of armillaridin \non human esophageal cancer cells. Evid Based Complement Alternat Med, 2013. 2013: p. \n459271. \n13. Liu, T.P., et al., Armillaridin, a Honey Medicinal Mushroom, Armillaria mellea (Higher \nBasidiomycetes) Component, Inhibits Differentiation and Activation of Human Macrophages. \nInt J Med Mushrooms, 2015. 17(2): p. 161-8. \n14. Clarke, P.G., Developmental cell death: morphological diversity and multiple mechanisms. \nAnat Embryol (Berl), 1990. 181(3): p. 195-213. \n15. Galluzzi, L., et al., Cell death modalities: classification and pathophysiological implications.  \nCell Death Differ, 2007. 14 (7): p. 1237-43. \n16. Kroemer, G. and M. Jaattela, Lysosomes and autophagy in cell death control. Nat Rev Cancer, \n2005. 5(11): p. 886-97. \n17. Taylor, R.C., S.P. Cullen, and S.J. Martin, Apoptosis: controlled demolition at the cellular \nlevel. Nat Rev Mol Cell Biol, 2008. 9(3): p. 231-41. \n18. Mizushima, N., Autophagy: process and function. Genes Dev, 2007. 21 (22): p. 2861-73. \n19. Levine, B. and G. Kroemer, Autophagy in the pathogenesis of disease. Cell, 2008. 132(1): p. \n27-42. \n20. Festjens, N., T. Vanden Berghe, and P. Vandenabeele, Necrosis, a well-orchestrated form of \ncell demise: signalling cascades, important mediators and concomitant immune response. \nBiochim Biophys Acta, 2006. 1757 (9-10): p. 1371-87. \n21. Golstein, P. and G. Kroemer, Cell death by necrosis: towards a molecular definition. Trends \nBiochem Sci, 2007. 32 (1): p. 37-43. \n22. Vance, J.E., Phospholipid synthesis and transport in mammalian cells.  Traffic, 2015. 16(1): p. \n1-18. \n23. Emoto, K., et al., Exposure of phosphatidylethanolamine on the surface of apoptotic cells. Exp \nCell Res, 1997. 232 (2): p. 430-4. \n24. Dowhan, W. and M. Bogdanov, Lipid-dependent membrane protein topogenesis. Annu Rev \nBiochem, 2009. 78 : p. 515-40. 28 \n 25. van den Brink-van der Laan, E., J.A. Killian, and B. de Kruijff, Nonbilayer lipids affect \nperipheral and integral membrane proteins via changes in the lateral pressure profile. \nBiochim Biophys Acta, 2004. 1666 (1-2): p. 275-88. \n26. Verkleij, A.J., et al., Non-bilayer structures in membrane fusion. Ciba Found Symp, 1984. \n103: p. 45-59. \n27. Bottinger, L., et al., Phosphatidylethanolamine and cardiolipin differentially affect the \nstability of mitochondrial respiratory chain supercomplexes. J Mol Biol, 2012. 423(5): p. 677-\n86. \n28. Birner, R., et al., Roles of phosphatidylethanolamine and of its several biosynthetic pathways \nin Saccharomyces cerevisiae. Mol Biol Cell, 2001. 12 (4): p. 997-1007. \n29. Ichimura, Y., et al., A ubiquitin-like system mediates protein lipidation. Nature, 2000. \n408(6811): p. 488-92. \n30. Rockenfeller, P., et al., Phosphatidylethanolamine positively regulates autophagy and \nlongevity. Cell Death Differ, 2015. 22 (3): p. 499-508. \n31. Menon, A.K. and V.L. Stevens, Phosphatidylethanolamine is the donor of the ethanolamine \nresidue linking a glycosylphosphatidylinositol anchor to protein. J Biol Chem, 1992. 267(22): \np. 15277-80. \n32. Falcieri, E., et al., The protein kinase inhibitor staurosporine induces morphological changes \ntypical of apoptosis in MOLT-4 cells without concomitant DNA fragmentation. Biochem \nBiophys Res Commun, 1993. 193(1): p. 19-25. \n33. Green, D.R. and G. Kroemer, The pathophysiology of mitochondrial cell death. Science, 2004. \n305(5684): p. 626-9. \n34. Hemmings, B.A., Akt signaling: linking membrane events to life and death decisions. Science, \n1997. 275 (5300): p. 628-30. \n35. Watanabe, T., et al., Apoptosis Signal-regulating Kinase 1 (ASK1)-p38 Pathway-dependent \nCytoplasmic Translocation of the Orphan Nuclear Receptor NR4A2 Is Required for Oxidative \nStress-induced Necrosis. J Biol Chem, 2015. 290(17): p. 10791-803. \n36. Dunai, Z.A., et al., Staurosporine induces necroptotic cell death under caspase-compromised \nconditions in U937 cells. PLoS One, 2012. 7(7): p. e41945. \n37. Mebarek, N., et al., Polymeric micelles based on poly(methacrylic acid) block-containing \ncopolymers with different membrane destabilizing properties for cellular drug delivery. Int J \nPharm, 2013. 454 (2): p. 611-20. \n38. Campbell, W.G., The chemistry of the white rots of wood: The effect on wood substance of \nArmillaria mellea (Vahl.) Fr., Polyporus hispidus (Bull.) Fr., and Stereum hirsutum Fr. \nBiochem J, 1931. 25(6): p. 2023-7. \n39. Richard, C., [Antibiotic activity of Armillaria mellea]. Can J Microbiol, 1971. 17 (11): p. 1395-\n9. \n40. Donnelly, D.M., et al., Antibacterial sesquiterpene aryl esters from Armillaria mellea. J Nat \nProd, 1985. 48 (1): p. 10-6. \n41. Obuchi, T., et al., Armillaric acid, a new antibiotic produced by Armillaria mellea. Planta \nMed, 1990. 56 (2): p. 198-201. \n42. Evidente, A., et al., Herbicidal potential of ophiobolins produced by Drechslera gigantea. J \nAgric Food Chem, 2006. 54(5): p. 1779-83. \n43. Chidley, C., et al., The anticancer natural product ophiobolin A induces cytotoxicity by \ncovalent modification of phosphatidylethanolamine. Elife, 2016. 5 . \n44. Morrison, R., et al., Ophiobolin A, a sesterpenoid fungal phytotoxin, displays different \nmechanisms of cell death in mammalian cells depending upon the cancer cell origin. \nInternational Journal of Oncology, 2017. 50(3): p. 773-786. \n45. Bury, M., et al., Ophiobolin A induces paraptosis-like cell death in human glioblastoma cells \nby decreasing BKCa channel activity. Cell Death Dis, 2013. 4 : p. e561. \n46. Rodolfo, C., et al., Ophiobolin A Induces Autophagy and Activates the Mitochondrial Pathway \nof Apoptosis in Human Melanoma Cells. PLoS One, 2016. 11(12): p. e0167672. \n47. Bell, B.D., et al., FADD and caspase-8 control the outcome of autophagic signaling in \nproliferating T cells. Proc Natl Acad Sci U S A, 2008. 105(43): p. 16677-82. \n48. Yu, L., et al., Regulation of an ATG7-beclin 1 program of autophagic cell death by caspase-8. \nScience, 2004. 304 (5676): p. 1500-2. 29 \n 49. Garscha, U., et al., BRP-187: A potent inhibitor of leukotriene biosynthesis that acts through \nimpeding the dynamic 5-lipoxygenase/5-lipoxygenase-activating protein (FLAP) complex \nassembly. Biochem Pharmacol, 2016. 119 : p. 17-26. \n50. MacDonald, R.C., et al., Small-volume extrusion apparatus for preparation of large, \nunilamellar vesicles. Biochim Biophys Acta, 1991. 1061(2): p. 297-303. \n51. Koeberle, A., et al., Role of lysophosphatidic acid acyltransferase 3 for the supply of highly \npolyunsaturated fatty acids in TM4 Sertoli cells. FASEB J, 2010. 24(12): p. 4929-38. \n \n 4. Unver\u00f6ffentlichte Ergebnisse   115 \n \n  \n4. Unver\u00f6ffentlichte Ergebnisse   116 \n \n  \n4. Unver\u00f6ffentlichte Ergebnisse   117 \n \n  \n4. Unver\u00f6ffentlichte Ergebnisse   118 \n \n \n4. Unver\u00f6ffentlichte Ergebnisse   119 \n \n  \n5. Diskussion   120 \n5. Diskus\nsion \n5.1. Vom Naturstoff zum Arzneimittel am Beispiel des Melleolids DAO \nDie Verwendung eines Naturstoffs als Arzneimittel erfordert intensive Vorarbeit. Nach einem \nmehrj\u00e4hrigen Prozess, welcher sich von der Untersuchung physikochemischer Eigenschaften \n\u00fcber Tierversuche bis hin zu klinischen Studien am Menschen erstreckt, kann der Naturstoff, \nformuliert in eine entsprechende Arzneiform, auf den Markt kommen. Doch vor all diesen \nUntersuchungen steht zun\u00e4chst ein intensives Screening, in dem untersucht wird, wof\u00fcr oder \nwogegen das neue Molek\u00fcl \u00fcberhaupt wirken kann. Sowohl Wirkziele f\u00fcr eine erw\u00fcnschte \nHauptwirkung, aber auch f\u00fcr m\u00f6gliche Nebenwirkungen m\u00fcssen bekannt sein. Wie findet man \ndas molekulare Wirkziel eines neuen Naturstoffs? \n5.1.1. Die Entdeckung des molekularen Wirkziels \nIn dieser Arbeit musste zun\u00e4chst die Entscheidung f\u00fcr eine geeignete Methode getroffen \nwerden. Mit der eingangs favorisierten Methode der Drug Affinity Response Target Stability \n(DARTS) wurden bereits Wirkmechanismen des Immunsuppressivums Rapamycin oder des \nCOX-2 Inhibitors Celecoxib aufgekl\u00e4rt (Lomenick et al., 2011b) . Auch EF1\u03b1, das Wirkziel des \nZytostatikums Didemnin wurde \u00fcber DARTS gefunden (Lomenick et al., 2009) . Die Methode \nbasiert auf der Bindung kleiner Molek\u00fcle (SM - small molecule) an Zielproteine, welche \ndadurch unempfindlicher f\u00fcr eine nachfolgende Proteasebehandlung werden und somit \nidentifiziert werden k\u00f6nnen. Der Vorteil dieser Methode ist, dass SM unmodifiziert angewendet \nwerden k\u00f6nnen. Jedoch sind gro\u00dfe Proteinmengen zur Wirkzielidentifizierung notwendig \n(Lomenick et al., 2009; Lomenick et al., 2011b) . Nur so k\u00f6nnten von SMs selbst mit niedriger \nAffinit\u00e4t gebundene Proteine \u00fcber eine Natriumdodecylsulfat-Polyacrylamid-\nGelelektrophorese ( SDS-PAGE) angereichert und analysiert werden (Lomenick et al., 2011a). \nEin ungef\u00e4hrer Anhaltspunkt, z. B. in welcher Zellfraktion ein Wirkziel vermutet wird, erh\u00f6ht die \nErfolgsaussichten. Da dieser Anhaltspunkt genauso wenig gegeben war, wie ausreichend \nTestsubstanz DAO, musste eine andere Methode gew\u00e4hlt werden. \nBei der Methode des aktivit\u00e4tsbasierten Protein-Profilings  (ABPP) lassen sich Kulturen \nsowohl in vivo  als auch in vitro  untersuchen. Das urspr\u00fcngliche radioaktive Labeling von \nProteinen (McFedries et al., 2013; Ostrowski und Barnard, 1961) ist in heutigen ABPP-\nUntersuchung en dreiteiligen Sonden, bestehend aus einem SM, einem \u201einerten\u201c Spacer und \neinem Marker wie Fluoreszenz- oder Biotinmarker, gewichen. Die Sondenbestandteile werden \nnach dem Proteinlabeling \u00fcber bioorthogonale Reaktionen, heute mit der klassischen \n\u201eKlickchemie\u201c, zusammengef\u00fcgt  (B\u00f6ttcher et al., 2010; Speers et al., 2003). F\u00fcr einen in vivo  \nAnsatz fehlten hier Kenntnisse \u00fcber die Membrang\u00e4ngigkeit von Sondenbestandteilen im \nModellorganismus A. nidulans.  5. Diskussion   121 \nDiese \nArbeit behandelt deshalb einen klassischen, affinit\u00e4tsbasierten in vitro Ansatz \nnachfolgend auch als Pulldown-Assay  oder Targetfishing bezeichnet. Hierf\u00fcr musste das SM \nDAO zun\u00e4chst chemisch-synthetisch mit einem Spacer und Biotinmarker verbunden werden, \num im Anschluss Proteine aus einem Zelllysat von A. nidulans \u00fcber eine Streptavidin-\nFestphase aufreinigen zu k\u00f6nnen. Die Schwachstelle des in vitro  Ansatzes ist, dass bei der \nGewinnung eines Zelllysates Zellorganellen und \u2013kompartimente gesch\u00e4digt werden, was die \nEnzymaktivit\u00e4t beeinflussen kann (Bogyo et al., 2004). Um unspezifische Wirkziel-\nWechselwirkungen mit DAO auszuschlie\u00dfen wurde eine Kontrollsonde entwickelt. Die \nSynthese der Sonden wird nachfolgend diskutiert. \n5.1.2. Synthese einer Sonde f\u00fcr eine affinit\u00e4tsgesteuerte Proteinaufreinigung \nDie Leitstrukturen verschiedener Naturstoffe sind komplex, oft wenig erforscht und durch \n\u201eLehrbuchchemie\u201c selten zug\u00e4nglich. Drei Hauptmerkmale unterscheiden Naturstoffe von \neiner de novo  synthetisierten Substanz oft ma\u00dfgeblich: Die Struktur ist meist komplex und sehr \ndivers. Es gibt mehr sp3-hybridisierte, ges\u00e4ttigte Kohlenstoffe als sp2-hybridisierte. Naturstoffe \nhaben meist mehrere Chiralit\u00e4tszentren und eine komplexe Stereochemie (Guo, 2017).  \nA. mellea produziert ein komplexes Gemisch sehr \u00e4hnlicher Molek\u00fcle, die bis zu sechs, \nteilweise benachbarte Stereozentren enthalten k\u00f6nnen (Vgl. Abbildung 6). Diese \u00c4hnlichkeiten \nmachen eine saubere Isolation einzelner Melleolide sehr schwierig. Um die sauber \naufgereinigten Melleolide nicht zu verschwenden, wurde von Synthesen mit ungeeigneten \nModellsubstanzen wie Salicyls\u00e4urephenylester oder Salicylaldehyd auf Reaktionen im \nMikroma\u00dfstab mit Kleinstmengen ausgewichen.   \nDurch eine Carbonat-katalysierte Ethersynthese nach Williamson mit Propargylbromid gelang \nam Salicylaldehyd die Einf\u00fchrung einer C-Dreifachbindung (Banday et al., 2010; Lingam et al., \n2008) , welche auf DAO nicht \u00fcbertragbar war. Es konnte aber gezeigt werden, dass die \nHydroxylgruppe der Reaktion am Modell zug\u00e4nglicher ist, als ein Aldehyd (Purushothaman et \nal., 2013). Die Verwendung des reaktiveren Propargyliodids (Abbildung 8), welches \u00fcber eine \nFinkelstein-Reaktion (Finkelstein, 1910) oder unter Verwendung von Propargylalkohol \nhergestellt wurde (Jammi et al., 2013), brachte keinen Umsatz. Ethersynthesen waren an der \nC5\u2018-Hydroxygruppe nicht m\u00f6glich, ohne dass DAO-Molek\u00fcl zu zerst\u00f6ren. Reaktionsprodukte \naus DAO hatten h\u00e4ufig dieselbe Molek\u00fclmasse wie das zu erwartende Produkt. NMR-\nAnalysen ergaben, dass aufgrund von Umlagerungen nicht die gew\u00fcnschte Struktur entstand. 5. Diskussion   122 \n \nAbbildung 8. Reaktionsschema zur Sondensynthese. Versuch der Einf\u00fchrung einer  \nC-Dreifachbindung \u00fcber Propargyliodid oder -bromid (1), \u00fcber Propargyls\u00e4ure (2) und final \u00fcber Pentin- \nund Hexins\u00e4ure. Erfolgreiche Syntheseroute in rot mit Cu(I)- katalysierter \u201eKlick -Reaktion\u201c zum Biotin -\ngekoppelten Endprodukt. \nIn einem neuen Ansatz wurde die Einf\u00fchrung einer C-Dreifachbindung in das DAO-Molek\u00fcl \n\u00fcber\n eine Steglich-Veresterung dennoch erreicht. Die Bindung einer Carbons\u00e4ure an die freie, \nsterisch ungehinderte C5\u2018 -OH Gruppe \u00fcber Propargyls\u00e4ure (Propiols\u00e4ure , Abbildung 8), f\u00fchrte \nnicht zum Ziel (Coles et al., 2018; Jolit et al., 2017). Mit demselben Reaktionsprinzip, aber \nl\u00e4ngerkettiger und daher weniger reaktive r Pentin- und Hexins\u00e4ure, konnte das in Publikation 1 \ngezeigte Zwischenprodukt gebildet werden. Die hierbei verwendeten Kupplungsreagenzien \nwie die Carbodiimide Dicyclohexylcarbodiimid (DCC) oder 1-Ethyl-3- (3-dimethylamino-\npropyl)carbodiimid (EDC) aber auch Phosphoniumsalze wie Benzotriazol-1-yl-\noxytripyrrolidino-phosphonium-hexafluorophosphat (PyBOP) sind klassische Edukte zur \nKn\u00fcpfung von Peptidbindungen in der Proteinsynthese, welche vor allem bei l\u00e4ngeren \nPeptidketten zum Einsatz kommen (Al-Warhi et al., 2012). Anwendung finden sie aber auch \nf\u00fcr die Bildung von Estern oder S\u00e4ure-Anhydriden aus Carbons\u00e4uren. Die Verwendung eines \nAcylierungskatalysators wie 4-(Dimethylamino)-pyridin (DMAP) erm\u00f6glicht vor allem bei \nEsterbindungen h\u00f6here Ausbeuten mit weniger Nebenprodukten (Neises und Steglich, 1978) .  \nDurch die erfolgreiche Funktionalisierung des DAOs war es m\u00f6glich, \u00fcber eine dipolare \nHuisgen-1,4- Cycloaddition (\u201e Klick-Reaktion \u201c) unter Kupfer (I)-Katalyse einen Biotin- PEG 3-Azid \nLinker einzuf\u00fchren (Rostovtsev et al., 2002). Nach Optimierung der Reaktionsbedingungen, \ninsbesondere der Auswahl eines geeigneten L\u00f6sungsmittels, sowie der optimalen \n5. Diskussion   123 \nKonzent\nration von Reduktionsmittel (Ascorbat) und Katalysator, konnten die laut Lehrbuch \nquantitativen Ausbeuten (hier 92 %) erreicht werden (Wu et al., 2004). \nAnalog wurde eine Sonde zur Verwendung als Negativkontrolle, basierend auf Butylparaben, \nsynthetisiert . Die Sonde erf\u00fcllte im Nachgang ihre Funktion: da die Pulldown-Assays \nunterschiedliche Proteinbanden zeigten, waren die Sonden stabil. Der Spacer hatte ein \noptimales Verh\u00e4ltnis von Hydrophilie/Hydrophobie, um die Aktivit\u00e4t der SMs nicht zu st\u00f6ren. \nDie Komplexit\u00e4t der Synthesestrategien zeigt, dass Naturstoffchemie selten nach \nLehrbuchmethoden funktioniert und eine Analyse von Wirkzielen oder Struktur-Wirkungs-\nBeziehungen bereits an dieser Stelle scheitern kann, da s\u00e4mtliche Folgeversuche auf dem \nGelingen einer solchen Synthese aufbauen. \n5.2. Melleolide im Vergleich  zu anderen Antibiotika  \n5.2.1\n. Melleolide im Vergleich zu anderen Zytostatika \nWie bereits gezeigt wurde, sind einige Melleolide in der Lage, humane Zelllinien in ihrer \nEntwicklung zu inhibieren und das bis hin zum Zelltod. Um das Potenzial von DAO einordnen \nzu k\u00f6nnen, wurden eingangs die Wirkmechanismen etablierter Zytostatikagruppen erl\u00e4utert. \nWirkmechanismen: In dieser Arbeit wurde festgestellt, dass Melleolide \u00fcber eine kovalente \nBindung von Cysteinen im aktiven Zentrum von 5-LO, vor allem von C159, die Bildung von \nArachidons\u00e4ure und somit von Entz\u00fcndungsmediatoren wie Leukotrienen inhibieren. Der in \nVorarbeiten beobachtete, rasche Zelltod ist \u00fcber diesen Mechanismus aber nicht erkl\u00e4rbar. \nEine Inhibition der Proteinbiosynthese wird ausgeschlossen, da in Experimenten parallel zur \nErmittlung der antifungalen Wirkmechanismen keine entsprechenden Wirkziele in humanen \nZellen nachgewiesen werden konnten.  \nBei einigen 2-Aminothiazolen wurde eine \u00e4hnliche Wirkung beobachtet. Diese binden neben \nC159 auch C418 der 5-LO und inhibieren diese ebenfalls (Kretschmer et al., 2017). Das in den \nUSA als antiinflammatorisches Arzneimittel zugelassene Zileuton hemmt die 5-LO \u00fcber einen \ng\u00e4nzlich unterschiedlichen Mechanismus: Wie die sich noch in klinischen Studien befindenden \nSubstanzen Atreleuton oder Setileuton reduziert Zileuton das im aktiven Zentrum der 5-LOX \nbefindliche Fe3+-nicht-H\u00e4m Eisen zu Fe2+ und inaktiviert so das Enzym (Sinha et al., 2019). \nEs zeigte sich , dass DAO \u00fcber das \u03942,4-unges\u00e4ttigte Aldehyd kovalent an \nPhosphatidylethanolamin (PE) bindet und dieses in ein Imin \u00fcberf\u00fchrt (Vgl. 4. Unver\u00f6ffentlichte \nErgebnisse). Diese Reaktion f\u00fchrt \u00fcber die Bildung cytotoxischer Zwischenprodukte zur \nDestabilisierung der doppellagigen Phospholipid-Zellmembran und somit zum Zelltod durch \nZelllyse. Bekannt ist ein \u00e4hnlicher Mechanismus bereits bei Ophiobolin A , einem Phytotoxin \naus Pilzen der Gattung Bipolaris  (Chidley et al., 2016). Auch bei Polygodial, einem Naturstoff \naus Warburgia spp ., ist eine Zerst\u00f6rung der Membranintegrit\u00e4t, basierend auf einem 5. Diskussion   124 \nunges\u00e4tti\ngten Aldehyd bekannt (Kubo et al., 2001; Taniguchi et al., 1988). Der \nWirkmechanismus ist hier allerdings sehr divers, so ist neben einer antimikrobiellen (Anke und \nSterner, 1991) und antifungalen Aktivit\u00e4t (Lee et al., 1999) auch eine antientz\u00fcndliche sowie \nantiallergische (da Cunha et al., 2001) , Schmerzempfindlichkeit senkende (Mendes et al., \n2000)  und Gef\u00e4\u00df relaxierende Wirkung bekannt (Andr\u00e9 et al., 1999). Die unspezifische \nWirksamkeit der genannten Molek\u00fcle bedeutet auch f\u00fcr DAO eine hohe Reaktivit\u00e4t des \n\u03942,4- unges\u00e4ttigten Aldehyds. \nNebenwirkungen : Den meisten Zytostatika ist gemein, dass sie sich in ihrer Wirkung gegen \nproliferierende Zellen richten. Da sich Krebszellen unkontrolliert und sehr schnell teilen \n(Lambert, 1913) , ist die Wirkung gegen sie prinzipiell st\u00e4rker. Gesunde und entartete Zellen \nunterliegen grunds\u00e4tzlich denselben Mechanismen wie Zellzyklus, Stoffwechsel etc. \nZytostatika k\u00f6nnen aufgrund dessen nicht ausschlie\u00dflich gegen malignes Gewebe wirken, \nworaus sich viele Nebenwirkungen ergeben.   \nDer menschliche K\u00f6rper reagiert auf eine Zytostatikabehandlung oftmals zuerst mit \ngrippe\u00e4hnlichen Symptomen wie Fieber mit Schwitzen oder Fr\u00f6steln, sowie allergischen \nReaktionen, \u00dcbelkeit und Erbrechen, was auf eine erste Immunantwort des K\u00f6rpers hinweist . \nDa Zytostatika auch gesunde, sich schnell teilende Zellen bek\u00e4mpft en (Epithelzellen, \nBindegewebszellen), sind sp\u00e4tere Nebenwirkungen einer Behandlung unter anderem \nKnochenmarksdepression, Schleimhautatrophie, Haarausfall, oder Reproduktionsprobleme \n(Ovulation, Spermatogenese) bedingt durch die Proliferationshemmung der Zellen (Carelle et \nal., 2002; Coates et al., 1983).  \nAu\u00dferdem bringen viele Zytostatika eine Organtoxizit\u00e4t mit sich. Am h\u00e4ufigsten betroffen sind \ndie Nieren, aber auch Blase, Herz, Lunge, Haut, Leber und Nervensystem k\u00f6nnen durch \nbestimmte Wirkstoffe gesch\u00e4digt werden (Malyszko et al., 2017; Siddik, 1986).  \nDa DAO in Reinsubstanz bisher weder an Menschen noch Tieren in vivo getestet wurde, kann \nhier nur spekuliert werden, in welchem Rahmen die Nebenwirkungen ausfallen w\u00fcrden. Fest \nsteht, dass hinsichtlich der Destabilisierung der Zellmembranintegrit\u00e4t ein Einsatz zu \ntherapeutischen Zwecken nicht m\u00f6glich w\u00e4re, da die zu erwartenden Effekte nicht speziell auf \nTumorzellen einzugrenzen w\u00e4ren. DAO w\u00e4re zu toxisch. Zellsch\u00e4digungen w\u00e4ren in jedem \nOrgan m\u00f6glich, in welches der Wirkstoff gelangen kann. Reduziert auf die Interaktion des \nMichael-Akzeptors mit Cysteinen der 5- LO ist das Nebenwirkungspotenzial ebenfalls sehr \ngro\u00df, weshalb es auch daf\u00fcr keine Studiendaten gibt (Hofmann et al., 2012; Maucher et al., \n2017) . In Zahlen ausgedr\u00fcckt zeigte DAO bzw. Arnamial IC50-Werte von 8,0 \u00b5M/15,4 \u00b5M \ngegen MCF7- und 16,9 \u00b5M/3,96 \u00b5M gegen Jurkat- Zelllinien (Bohnert et al., 2011) . Zum \nVergleich: bei Paclitaxel ist eine IC50 von ca. 0,7 \u00b5M gegen Jurkat Zellen bekannt (Myrick et \nal., 1999), was dem 24- bzw. 5,6-fachen von DAO und Arnamial entspricht. Die gebr\u00e4uchliche \nKonzentration von Vinblastin in der Tumortherapie liegt bei ca. 0,12 \u00b5M (Ammon, 2014), die 5. Diskussion   125 \nIC50 folgl\nich darunter.  \nLi et al. testeten 2016 verschiedene Melleolide gegen HepG2-Zellen. Alle Melleolide mit einem \nAldehyd an C1 und einer \u03b2 -Doppelbindung zeigten gleicherma\u00dfen Aktivit\u00e4t gegen Krebszellen \nund normale L02-Leberzellen (Li et al., 2016). Dies ist ebenfalls ein Argument gegen den \nEinsatz von Melleoliden als Zytostatikum. \nResistenzmechanismen : Zahlreiche Reviews geben einen guten \u00dcberblick \u00fcber die \nResistenzmechanismen von Zytostatika auf zellul\u00e4rer Ebene (Dietel, 1991, 2007; Giaccone \nund Pinedo, 1996; Mansoori et al., 2017; Pan et al., 2016; Vendrik et al., 1992). Eine Resistenz \nkann sich basierend auf der Zellkinetik ergeben. Bei soliden, nicht aktiv proliferierenden \nTumoren haben die meisten Zellen eine schlechte Ansprechrate auf zellzyklusspezifische \nChemotherapeutika (Chauffert et al., 1998). Pharmakokinetische Hindernisse stellen \nK\u00f6rperbarrieren wie die Blut- Hirn-Schranke dar, welche von Arzneimitteln nicht passiert \nwerden k\u00f6 nnen  (Wilhelm et al., 2013). Auch \u00c4nderungen im Metabolismus von Wirkstoffen \nbeispielsweise bei der Aktivierung von Prodrugs k\u00f6nnen Ursache einer pl\u00f6tzlichen Resistenz \nsein (Dumontet et al., 1999). Tumore k\u00f6nnen \u00fcber den Verlust des Wirkziels oder die \n\u00dcberexpression anti-apoptotischer Proteine (p53, p21, bcl- 2) resistent werden (Torgovnick et \nal., 2018) . \u00dcber den Verlust eines Carriers und eine dadurch bedingte verringerte Aufnahme \neines Pharmakophors wie beispielsweise bei Methotrexat (Mosow, 1998) kann ebenso eine \nResistenz erzeugt werden, wie durch einen verst\u00e4rkten Efflux, beispielsweise von Vinca-\nAlkaloiden durch p-Glycoprotein (Sharom, 2007). Eine verst\u00e4rkte Reparatur \nzytostatikabedingter DNA -Sch\u00e4den und die Amplifikation von Zielgenen stellen weitere \nResistenzm\u00f6glichkeiten dar (Mansoori et al., 2017). \nWie bei Chidley et al. beschrieben, f\u00fchrt bei Ophiobolin A die Abwesenheit von PE zu einer \nResistenz der Zellen (Chidley et al., 2016). Wenn DAO dasselbe Wirkziel ansteuert, ist diese \nResistenzentwicklung auch hier relevant. Aufgrund der hohen Reaktivit\u00e4t des Michael-\nSystems (Liebler, 2008; Wondrousch et al., 2010) sind aber auch weitere noch unbekannte \nWirkungen zu erwarten, wogegen eine Resistenzausbildung schlecht vorherzugsagen ist. \nUngekl\u00e4rt ist, ob bez\u00fcglich der inhibierenden Wirkung auf 5- LO die vermehrte Freisetzung von \nGlutathion zu einer Inaktivierung des Michael-Systems f\u00fchren k\u00f6nnte (Schw\u00f6bel et al., 2010) . \nDes Weiteren ist noch unbekannt, welche weiteren Effekte der Ausl\u00f6sung einer Apoptose-\nreaktion in humanen Zellen zugrunde liegen, sodass weitere Resistenzentwicklungen aktuell \nnicht beurteilt werden k\u00f6nnen. \n \n \n 5. Diskussion   126 \n5.2.\n2. Melleolide im Vergleich zu anderen Antimykotika \nWie eingangs vermutet produzieren  Armillaria spp. eine Vielzahl strukturell sehr \u00e4hnlicher \nMelleolide zum Zwecke der Verteidigung gegen, oder zur chemischen Kommunikation mit \nanderen bodenbesiedelnden Konkurrenten um Lebensraum und N\u00e4hrstoffe.   \nDie Suche nach antifungalen Wirkstoffen ist auch heute noch von gro\u00dfer Bedeutung. Aufgrund \nder aktuellen Resistenzlage vieler pflanzen- und humanpathogener Pilze gegen Antimykotika, \nwerden neue Leitstrukturen dringend ben\u00f6tigt (Gauwerky et al., 2009). Die potentesten \nPathogene sind Vertreter der Arten Cryptococcus, Candida  und Aspergillus.  Diese stellen vor \nallem f\u00fcr immunsupprimierte Patient en eine lebensbedrohliche Gefahr dar (Brown et al., \n2012) . \nWirkmechanismen: Heute steht nur eine \u00fcberschaubare Menge an Wirkstoffklassen zur \nBehandlung von Pilzinfektionen zur Verf\u00fcgung. Deren Wirkmechanismen wurden eingangs \nbereits erl\u00e4utert.  \nMit DAO als Stellvertreter f\u00fcr \u03942,4-unges\u00e4ttigte Melleolide mit einem Aldehyd an C1 wurde eine \nneue Leitstruktur eines antifungalen Stoffes identifiziert. Auch das molekulare Wirkziel dieser \nStrukturen stellt im Vergleich zu heute pharmazeutisch genutzten Wirkstoffen eine Neuheit \ndar. Wie eingangs erw\u00e4hnt, wurde der eukaryotische Elongationsfaktor 2 (eEF2)  als pilzliches \nWirkziel von Sordarin bereits entdeckt. Allerding ergab sich u. a. aufgrund der kurzen \nPlasmahalbwertszeit bis heute keine Anwendung als Arzneimittel (Odds, 2001) . Auch \nnachfolgende Untersuchungen zu potenteren Derivaten blieben erfolglos (S\u00f8e et al., 2007). \nDer Vergleich des EF2 aus A. nidulans zeigt zum humanen eEF2 in der Aminos\u00e4uresequenz \neine \u00dcbereinstimmung von 67 %, unter Ber\u00fccksichtigung \u00e4hnlich polarer Aminos\u00e4uren sogar \n81 %. Diese Unterschiede k\u00f6nnten f\u00fcr eine pharmazeutische Anwendung antimykotischer \nSubstanzen von Bedeutung sein und zuk\u00fcnftig bei DAO zum Tragen kommen.  \nIm Unterschied zu Sordarin scheint DAO den in silico -Vorhersagen zufolge eine v\u00f6llig andere \nBindestelle am eEF2 zu bevorzugen. In die modellierte Sordarin-Bindetasche von A. nidulans \nkonnte Sordarin gut eingef\u00fcgt werden, f\u00fcr DAO ergaben sich hier aber keine relevanten \nBindungsm\u00f6glichkeiten. Eine entsprechende Konformations\u00e4nderung des eEF2, wie sie durch \nSordarin hervorgerufen wird (J\u00f8rgensen et al., 2003), konnte durch DAO nicht dargestellt \nwerden . Bisher ungekl\u00e4rt ist der molekulare Mechanismus, \u00fcber welche Wechselwirkung(en) \n\u03942,4-unges\u00e4ttigte Melleolide an eEF2 binden. F\u00fcr eine irreversible Bindung mit dem Wirkziel \nfehlt es an zug\u00e4nglichen reaktiven Strukturen wie Schwefelatomen aus Cystein-Resten, so wie \nf\u00fcr 5-LO gezeigt. Interessant ist auch, dass die Bindung von DAO im eEF2 von A. nidulans zu \neinem gr\u00f6\u00dferen Teil auf der Interaktion des Orsellins\u00e4ureteils mit den zwei Aminos\u00e4uren Prolin \nP262 und Thyrosin Y249 beruht . Das f\u00fcr die Wirksamkeit wichtigere Pharmakophor , interagiert \nmit der Glutamins\u00e4ure E171. Wie bereits in einer Vorarbeit festgestellt, wird die molekulare 5. Diskussion   127 \nStruk\ntur des Melleolids durch die Lage der Doppelbindung beeinflusst (Bohnert et al., 2014a) . \nEine \u03942,4-Doppelbindung scheint also den aromatischen Anteil in die Bindetasche zu dirigieren.  \nNebenwirkungen : Aus der Tatsache, das sich humane und pilzliche Zellen als heterotrophe \nOrganismen in Katabolismus und Anabolismus stark \u00e4hneln, resultier en eine Vielzahl an \nNebenwirkungen (Musiol und Kowalczyk, 2012). Seit der Entdeckung der Azole 1944 wird die \nWirkstoffklasse fortw\u00e4hrend entwickelt, um sowohl Resistenzen zu umgehen, als auch das \nNebenwirkungsprofil zu verbessern (Allen et al., 2015) \u2013 zumindest hinsichtlich der \nResistenzaussichten ohne gro\u00dfe Erfolge.   \nDie strukturelle \u00c4hnlichkeit pilzlichen Ergosterols und humanen Cholesterols sorgt auch f\u00fcr \nProbleme . Die Hemmung der pilzlichen Monooxygenasen geht mit einer Inhibition human er \nCYP-Enzyme einher, welche vor allem bei Co-Medikationen zu starken Muskel- und \nNierensch\u00e4den f\u00fchrt (Dybro et al., 2016) . Polyene verursachen aufgrund einer nicht \nausreichenden Selektivit\u00e4t Nebenwirkungen wie Blutbild-, Nieren- oder Lebersch\u00e4den und \ngef\u00e4hrliche Wechselwirkungen mit anderen Arzneimitteln. (Kotler-Brajtburg et al., 1974; \nLaniado-Laborin und Cabrales-Vargas, 2009)  \nViele der Nebenwirkungen lassen sich durch eine gezielte Weiterentwicklung der Wirkstoffe, \nz. B. hin zu selektiveren Molek\u00fclen umgehen (Mast et al., 2013). Auch durch die geeignete \nAuswahl der Formulierung des Arzneimittels l\u00e4sst sich die Toxizit\u00e4t verringern (Aversa et al., \n2017) . \nBisher gab es mit Melleoliden noch keine in vivo -Tests an Lebewesen. Somit k\u00f6nnen m\u00f6gliche \nNebenwirkungen noch nicht vorausgesagt werden. Da sich die Anwendung von A. mellea  in \nder TCM auf die Fruchtk\u00f6rper beschr\u00e4nkt, sind auch hier keine verwertbaren Aussagen zu \ntreffen. Es existieren lediglich Einzelfallberichte \u00fcber Unvertr\u00e4glichkeiten zu den als Speisepilz \nverwendeten Fruchtk\u00f6rpern. Ob diese Reaktionen auf Melleolide zur\u00fcckgef\u00fchrt werden \nk\u00f6nnen, ist fraglich, da der Pilz nicht grunds\u00e4tzlich als giftig beschrieben wird (An et al., 2017). \nPrinzipiell ist eine sch\u00e4digende Wechselwirkung von \u03942,4-unges\u00e4ttigten Melleoliden mit \nCyste in-haltigen Proteinen aber denkbar, da der vorhandene Micha el-Akzeptor sehr reaktiv \ngegen proteingebundene Schwefelatome wie in Cystein-Proteasen wirkt (Kitahata et al., 2017; \nK\u00f6nig et al., 2018; Maucher et al., 2017). \nBei den meisten getesteten Hefen zeigten sich gegen Arnamial in vivo  MICs im Bereich von \n40-200 \u00b5g/ml. F\u00fcr Azole wie Itraconazol, Polyene wie Amphotericin B oder Echinocandine wie \nCaspofungin sind deutlich geringere Literaturwerte von 0,03-8 \u00b5g/ml, 0.125-4 \u00b5g/ml oder 0,03-\n2 \u00b5g/ml zu finden (Cordeiro et al., 2013). Melleolide m\u00fcssten f\u00fcr einen therapeutischen Effekt \nim Vergleich zu klassischen Antimykotika in viel h\u00f6heren Mengen eingesetzt werden. Hierbei \nspielen jedoch auch die Aufnahme und Verteilung im K\u00f6rper eine Rolle. Eine bessere \nAufnahme und Verteilung als bei herk\u00f6mmlichen Wirkstoffen w\u00e4ren vorteilhaft f\u00fcr 5. Diskussion   128 \ntherap\neutische Zwecke. Im wirksamen Bereich sind aber schon zytotoxische Effekte zu \nerwarten (Bohnert et al., 2011; Bohnert et al., 2014b). \nResistenzmechanismen : Die wenigen Angriffspunkte der Antimykotika erm\u00f6glichen es den \nOrganismen in k\u00fcrzester Zeit, Resistenzmechanismen auszubilden (Cowen, 2008) . Ein \nm\u00f6glicher Mechanismus ist hierbei die vermehrte Produktion des zellul\u00e4ren Wirkziels. \nC. albicans  kann beispielsweise bei Azol-Exposition das Gen ERG11 \u00fcberexprimieren, \nwelches f\u00fcr die Bildung des Enzyms CYP51A verantwortlich ist (Perea et al., 2001). Auch \nMutationen an ERG11 sind bekannt, welche zu einer Unempfindlichkeit gegen\u00fcber Fluconazol \nf\u00fchren (Feng et al., 2010).  \nBekannt ist aber auch die Modifikation der Aufnahme pilzlicher Toxine. ATP-abh\u00e4ngige ABC-\nTransportproteine kommen vielfach in Candida  spp. oder Aspergillus spp. vor (Cowen et al., \n2015)  und sind h\u00e4ufig f\u00fcr eine Azolresistenz durch einen effektiven Efflux und daraus \nresultierende verringerte Toxin-Anreicherung verantwortlich (Coste et al., 2009). Durch eine \nMutation im Fcy1 Gen zur Expression der Cytosin-Deaminase sorgt C. glabrata  daf\u00fcr, dass \nProdrugs wie Flucytosin nicht in ihre aktive, wirksame Form umgewandelt werden (Edlind und \nKatiyar, 2010). \u00dcber die genannten Wege wird jeweils die effektive Wirkstoffkonzentration \nverringert (Sanglard, 2016) . Im Falle der Zellwandbiosynthese ist auch eine Abweichung der \nErgosterolproduktion \u00fcber andere Biosyntheseenzyme, einem sogenannten metabolischen \nBypass denkbar (Cowen et al., 2015; Sanglard, 2003, 2016; Sanglard et al., 1998) .  \nEine erworbene Resistenz konnte aufgrund der beschr\u00e4nkten Anwendungsm\u00f6glichkeiten f\u00fcr \nMelleolide noch nicht beobachtet werden. Jedoch stellt sich die Frage, warum Armillaria  \nOrganismen aus seinen Habitaten verdr\u00e4ngt, w\u00e4hrend z. B. Ascomyceten wie Trichoderma \nkeine Reaktion auf \u03942,4-unges\u00e4ttigte Melleolide zeigen. Der EF2 von T. harzianum  zeigt im \nVergleich zu A. nidulans  eine genetische \u00dcbereinstimmung von 80 %. An der im Model \nvorhergesagten Stelle im Protein (Vgl. Publikation 1), besitzt T. harzianum  wie die resistenten \nHefen C. glabrata  und S. cerevisiae  ein Serin anstelle eines Threonins (170S statt 170T) bzw. \nGlutamins\u00e4ure (170E) bei A. nidulans. Diese Abweichungen sind aber keiner spontan \nerworbenen Resistenz zuzuordnen, da der Prozess der Proteintranslation zu stark konserviert \nist, also \u00fcber evolution\u00e4r gesehen gro\u00dfe Zeitspannen nicht oder nur minimal ver\u00e4ndert worden \n(Justice et al., 1998).   \nDa beobachtet wurde, dass sich A. nidulans nach Toxin-Exposition wieder erholt, ist eine \n\u00dcberexpression von eEF2 vorstellbar. In einem Experiment sollte die Menge an Arnamial nach \nExposition mit A. nidulans  ermittelt werden. Es zeigte sich, dass innerhalb weniger Stunde n \nkein Arnamial mehr vorhanden war (Daten nicht gezeigt). A. nidulans scheint also auch \nMechanismen zur Detoxifizierung der Melleolide zu besitzen. \n 5. Diskussion   129 \n5.3. \nZuk\u00fcnftige Anwendungen von Melleoliden \nMelleolide als potenzielle Arzneimittel : Mit der Entdeckung konkreter Wirkziele der \nMelleolide und der damit verbundenen antifungalen und cytotoxischen Wirkung, wird die \nVerwendung dieser Naturstoffe als Arzneimittel zunehmend interessanter. Basierend auf der \naktuellen Resistenzlage humanpathogener Pilze und der wachsenden Anzahl an Krebs \nerkrankender Menschen sind neue Arzneimittel auf diesen Gebieten sehr gefragt und \nnotwendig (Cowen et al., 2015; Xu et al., 2019). \nDie Nutzung von Melleoliden mit \u03942,4-unges\u00e4ttigten Aldehyden als Antimykotikum ist \nbesonders interessant, da die Blockade des Wirkziels eEF2 einen v\u00f6llig neuen Ansatz in der \nantifungalen Therapie darstellt, welcher bisher von keiner auf dem Markt befindlichen \nSubstanz adressiert wird (D\u00f6rfer et al., 2019). In der Behandlung entz\u00fcndlicher Erkrankungen \nliefern Melleolide durch die Hemmung der 5-LO neben Zileuton eine neue Substanzgruppe mit \neinem neuen inhibitorischen Mechanismus an der 5- LO (Rossi et al., 2010). Da Entz\u00fcndungen \nletztlich auch Verursacher maligner Tumore sein k\u00f6nnen, bieten die genannten Melleolide mit \nihrer zytotoxischen Wirkung durch die Bindung an PE und die damit verbundene Reduktion \nder Zellmembranintegrit\u00e4t (siehe 4.1.) gleich zwei therapierelevante Wirkmechanismen im \nmenschlichen Organismus. \nDoch reicht es nicht, ein neues Wirkziel zu entdecken, um gleich ein Arzneimittel geschaffen \nzu haben. Arzneimittel m\u00fcssen wichtige Anforderungen erf\u00fcllen, um \u00fcberhaupt einen \npharmazeutischen Nutzen erbringen zu k\u00f6nnen:  \nDie verwendete Substanz muss (im K\u00f6rper) den Ort erreichen, an dem sie wirken soll. Zur \nVerteilung der Melleolide in vivo gibt es bisher keine Studien. Experimente an M\u00e4usen wurden \nnur mit Rohextrakten durchgef\u00fchrt (Zhang et al., 2019). Eine Verteilung von DAO oder \nArnamial wurde bisher nicht ermittelt. Auch Metabolismus und Biotransformation spielen bei \nder Distribution eine wichtige Rolle. Der Wirkstoff darf vor Erreichen des Zielortes nicht ab- , \numgebaut oder ausgeschieden werden. Im konkreten Fall bietet vor allem der unges\u00e4ttigte \nAldehyd im Molek\u00fcl in C1 Position im Protoilluden-Teil des Molek\u00fcls eine gute Angriffsstelle \nf\u00fcr reduktive Angriffe. Die vorhandenen Hydroxylgruppen k\u00f6nnen f\u00fcr Wasseranlagerungen \noder Wasserstoffbr\u00fcckenbindungen zur Verf\u00fcgung stehen und somit die Molek\u00fclbewegung \nin vivo beeinflussen. \nDem Erreichen des zellul\u00e4ren Wirkziels stehen zahlreiche Barrieren wie die Zellmembranen \noder die pilzliche Zellwand entgegen. Aktuell existieren keine Kenntnisse \u00fcber die Verteilung \nvon Melleoliden in pilzlichen Zellen zur Inhibition des EF2 oder der Verteilung in humanen \nZellen f\u00fcr antiinflammatorische oder antitumorale Wirkungen .  5. Diskussion   130 \nIst ei\nne Wirkung eingetreten, muss der Wirkstoff nach einer gewissen Zeit auch wieder \nabgebaut werden k\u00f6nnen. Ein Um - oder Abbau ist jetzt also erw\u00fcnscht. Meist ist eine \nbiotransformatorische Umwandlung vor allem von lipophilen Arzneistoff en die Voraussetzung \nf\u00fcr eine renale oder bili\u00e4re Ausscheidung . Gelingt dies nicht, kommt es zu einer Anreicherung \nder Arzneimolek\u00fcle haupts\u00e4chlich in Fettgeweben , was zu einer Anreicherung und Vergiftung \nf\u00fchren kann (Mutschler, 2013) . Auch irreversible Molek\u00fclinteraktionen zwischen \nPharmakophor und Wirkziel k\u00f6nnen zu bleibenden Sch\u00e4den f\u00fcr den Organismus f\u00fchren.\n  \n\u00dcber diese Prozesse gibt es am Beispiel der Melleolide ebenso wenig Daten, wie \u00fcber die \nVertr\u00e4glichkeit. Ein Arzneimittel sollte nur wenige und ungef\u00e4hrliche Nebenwirkungen \nverursachen. Wechselwirkungen mit Nahrungsmitteln oder anderen Medikamenten sind \nunerw\u00fcnscht. Wie bereits erw\u00e4hnt ist bei den \u03942,4-unges\u00e4ttigten Aldehyden von einer erh\u00f6hten \nReaktivit\u00e4t auszugehen. Sollten Substanzen wie DAO oder Arnamial \u00fcberhaupt unver\u00e4ndert \nein Wirkziel erreichen ist fraglich, ob nicht aufgrund des Michael-Systems zahlreiche \nunerw\u00fcnschte Reaktionen mit umliegenden Proteinen und Zellorganellen stattfinden, welche \nNebenwirkungen mit sich ziehen k\u00f6nnen. In puncto  Sicherheit erfordert eine pharmazeutische \nAnwendung am Menschen also weitere intensive Forschung.  \nFinal sei noch erw\u00e4hnt, dass eine gro\u00dftechnische Herstellung der Naturstoffe notwendig ist, \num eine Arzneimittelproduktion realisieren zu k\u00f6nnen. Die Ausbeute der Melleolide m\u00fcsste \nselektiv optimiert werden k\u00f6nnen, um eine Totalsynthese zu umgehen. Bisher war nur eine \nSteigerung der Melleolid-Gesamtmenge m\u00f6glich. Eine Isolierung sauberer Derivate wird \ndadurch aber nicht erleichtert. Der Gencluster zur Melleolid-Biosynthese ist mittlerweile \nbekannt, aber noch nicht vollst\u00e4ndig charakterisiert. Proteine wie die Protoilluden-Synthase \nPro1 und die Orsellins\u00e4ure-Synthase ArmB k\u00f6nnen heterolog produziert werden (Engels et al., \n2011; Lackner et al., 2013). Wichtige modifizierende Enzyme, wie Halogenasen, liegen jedoch \nau\u00dferhalb des Genclusters oder sind, wie einige Methyltransferasen, ebenfalls nicht \ncharakterisiert (Wick et al., 2016). Erst eine vollst\u00e4ndige Charakterisierung erm\u00f6glicht eine \nbiotechnologische Produktion. Hier schlie\u00dft sich die Frage nach einem geeigneten Wirt an. \nDen Ergebnissen zufolge w\u00e4ren Melleolid-resistente Aspergillen oder Hefen denkbar. 5. Diskussion   131 \n \nAbbildung 9. Weitere bioaktive Sesquiterpene aus Protoilluden. Links Illuden S und Illuden M aus \nOmphalotus olearius, rechts das daraus semisynthetisch erzeugte Irofulven.  \nEin weiteres antibiotisch wirksames Sesquiterpen pilzlicher Herkunft hat es in der Entwicklung \nzum Ar\nzneimittel in klinische Studien der Phase 2 geschafft. Ausgehend von den 1950 \nentdeckten Illudinen S und M aus Omphalotus olearius  wurden weniger toxische Derivate \nentwickelt. Erfolgreich getestet werden konnte das Alkylans Irofulven. Die Substanz wurde an \nPatienten mit kleinzelligem Krebs (Dowell et al., 2001), Melanomen in Stadium IV (Pierson et \nal., 2002), Lungenkrebs (Sherman et al., 2004) sowie Prostata-, Brust-, Leberzell- oder \nDarmzellkarzinomen getestet (Baekelandt, 2002). F\u00fcr einige wenige Krebs-Arten wie \nOvarialkarzinome wurde Irofulven in Kombination mit anderen Zytostatika eine positive \nWirkung zugeschrieben (Dings et al., 2008). Viele der vorausgenannten Karzinome sprachen \ngegen die Wirkung des Irofulvens nicht an. Ein therapeutischer Nutzen ergab sich deshalb und \naufgrund der Toxizit\u00e4t der Substanz nicht. Es gibt jedoch Hoffnung auf die Entdeckung weiterer \nsemisynthetischer Derivate mit einer h\u00f6heren Tumorselektivit\u00e4t und geringerer Toxizit\u00e4t (Puyo \net al., 2014).  \nDie Bestimmung einer neu entdeckten, bioaktiven Substanz muss jedoch nicht zwangsl\u00e4ufig \nin der Formulierung als Arzneimittel liegen. So k\u00f6nnten Melleolide zuk\u00fcnftig auch eine andere \nAnwendung finden. \nMelleolide als molekulare Sonde zur Erforschung neuer SAR:  Die Wirkung einiger \nMelleolide als Inhibitor von pilzlichem eEF2 oder von humanen 5-LO abh\u00e4ngigen Prozessen \nwurde in dieser Arbeit bereits ausf\u00fchrlich erl\u00e4utert. So kann die Zukunft der Melleolide, vor \nallem aufgrund ihrer hohen Diversit\u00e4t und Selektivit\u00e4t auch in der Verwendung als molekulare \nSonde zur Erforschung neuer SAR liegen . Ebenso k\u00f6nnten die durch Melleolide beeinflussten \nProzesse aus anderen Blickwinkeln neu beobachtet und bewertet werden. Es ist anzunehmen, \ndass die Diversit\u00e4t der Melleolide mit der Verwendung als Sonde auch zur Entdeckung weiterer \nWirkziele f\u00fchrt. \n6. Ausblick   132 \n6. Ausbli\nck \nUm Melleolide in der Zukunft als Arzneimittel verwenden zu k\u00f6nnen, sind eine Vielzahl weiterer \nUntersuchungen, besonders hinsichtlich der Arzneimittelverteilung, der Rezeptoraffinit\u00e4t und \ndes Nebenwirkungsprofils notwendig. Um einzelne Derivate zu sicheren Arzneimitteln zu \nmachen, m\u00fcssten s\u00e4mtliche Wirkziele, auch die weniger selektiven, aufgekl\u00e4rt und evaluiert \nwerden. Daf\u00fcr m\u00fcssten die SAR noch weiter erforscht werden, z. B. durch die Synthese und \nVerwendung neuer Sonden. Kurz: es besteht Bedarf an selektiven und dennoch hoch aktiven \nPharmakophoren. Vorstellbar w\u00e4ren hier vor allem antifungale Melleolide zur topischen \nAnwendung. So k\u00f6nnte man die Wirkung gegen Pilzzellen forcieren und umgeht einen Gro\u00dfteil \nder systemischen Nebenwirkungen an gesunden, humanen Zellen.  \nEine weitere vorstellbare Verwendung von \u03942,4-unges\u00e4ttigten Melleoliden liegt in der \nForschung. Da EF2 als Wirkziel identifiziert wurde, ist nun ein wirkzielorientiertes Screening \nnach effektiveren Hemmstoffen der ribosomalen Translation m\u00f6glich. So k\u00f6nnten st\u00e4rker \nantifungale, aber gleichzeitig weniger cytotoxische Substanzen mit demselben Wirkziel \ngefunden werden. \nDie Bedeutung der Melleolide f\u00fcr Pilze der Gattung Armillaria  ist bisher v\u00f6llig ungekl\u00e4rt. Mit \nheutigen Mitteln k\u00f6nnen Effekte auf Zellen in vivo/in vitro  nur nachgewiesen werden, wenn \nman messbare Mengen an Wirkstoffen im Experiment verwendet. F\u00fcr die gr\u00f6\u00dften Organismen \nder Welt k\u00f6nnten Melleolide jedoch schon in Kleinstmengen eine \u00f6kologische Bedeutung \nhaben. Die stark diversit\u00e4tsorientierte Biosynthese der Sekund\u00e4rstoffe k\u00f6nnte Quorum-\nSensing-Funktionen erf\u00fcllen oder je nach Zusammensetzung des resultierenden Melleolid-\nCocktails spezifische Reaktionen in anderen Organismen hervorrufen. Die chemische \nKommunikation mit oder Inhibition von umgebenden Lebewesen bzw. Nahrungsmittel-\nkonkurrenten in den Habitaten der Armillarien  wird zuk\u00fcnftig Forschungsthema bleiben.  7. Zusammenfassung   133 \n7. Zusammenfass\nung \nMelleolide, Sekund\u00e4rstoffe aus Vertretern der Basidiomyceten-Gattung Armillaria,  besitzen \neine hohe Bioaktivit\u00e4t . Die zugrundeliegenden Mechanismen der phytotoxischen, antifungalen , \nantibakteriellen und cytotoxischen Aktivit\u00e4t wurden bisher nie untersucht. Diese Arbeit setzt \nsich deshalb mit Struktur-Aktivit\u00e4ts-Beziehungen und Wirkmechanismen ausgew\u00e4hlter \nMelleolid-Antibiotika auseinander. \nDas Wirkziel f\u00fcr eine antifungale Wirkung wurde mittels einer chemisch synthetisierten Sonde \nbasierend auf Dehydroarmillylorsellinat (DAO) im Modellorganismus A. nidulans  identifiziert . \nProteine, die an das Biotin-gekoppelte Melleolid banden, konnten an einer Streptavidin-Matrix \naffinit\u00e4tschromatographisch aufgereinigt werden. \u00dcber MALDI-Massenspektrometrie und \nWestern-Blotting wurde der pilzliche, eukaryotische Elongationsfaktor 2 (EF2) als Wirkziel von \nDAO f\u00fcr eine antifungale Wirkung gefunden und \u00fcber Inhibitionsexperimente mit \nverschiedenen Hefen mit dem bereits bekannten EF2-Inhibitor Sordarin als Referenzsubstanz \nbest\u00e4tigt. Der Wirkmechanismus von DAO konnte auf weitere Melleolide mit \u03942,4-\nunges\u00e4ttigtem Aldehyd in Position C1 \u00fcbertragen werden. Die Annahme unterschiedlicher \nBindungsstellen im pilzlich en EF2-Protein konnte in silico an einem Modellprotein des EF2 von \nA. nidulans  nachgestellt, und so eine putative DAO-Bindestelle identifiziert werden.  \nDAO interagiert in humanen Zellen mit 5-Lipoxygenase, einem Enzym der \nEntz\u00fcndungskaskade. Durch eine Michael Addition basierend auf dem \u03942,4-unges\u00e4ttigten \nAldehyd bindet DAO selektiv und irreversibel an das Cystein 159 (C159) am Eingang des \nkatalytischen Zentrums der 5- LO, wodurch die Interaktion von 5- LO mit dem Helferprotein \nFLAP unterbunden und final die Leukotrien-Biosynthese reduziert wird.   \nDie beobachtete rasche Zytotoxizit\u00e4t humaner Krebszellen und Monozyten beruht auf einem \nweiteren Mechanismus. Die kovalente Bindung von DAO an die Kopfgruppe von Phosphatidyl-\nethanolamin (PE) verursacht einen induzierten Zelltod. Es wurde herausgefunden, dass DAO \nbevorzugt mit dem PE aus Plasmamembran/Lysosomen-Fraktion en interagiert, was \u00fcber die \nVerringerung des PE-Gehalt es zur Reduktion der Zellmembranpermeabilit\u00e4t und letztlich zu \nnekrotischen und apoptotischen Effekten f\u00fchrte. \nIn dieser Arbeit konnten also drei v\u00f6llig unterschiedliche Wirkmechanismen von DAO bzw. \n\u03942,4-unges\u00e4ttigten Melleoliden identifiziert werden, welche erste Erkenntnisse zum \npharmazeutischen Einsatz der Melleolide liefern. 8. Summary   134 \n8. Summary \nThe ba\nsidiomycete genus Armillaria  is known to produce highly bioactive secondary \nmetabolites, known as melleolides . Studies showed phytotoxic, antifungal, antibacterial and \ncytotoxic activity but no pharmacological reasons for these effects. This work reveals structure-\nactivity-relationships and the mode of action of selected melleolides. \nThe target for the antifungal effect in the model organism A. nidulans was found using a \ndehydroarmillylorsellinate (DAO)-based chemically synthesized molecular probe. Proteins \nbinding to the biotin-coupled DAO were enriched by affinity chromatography using a \nstreptavidin matrix. T he fungal eukaryotic elongation factor 2 (EF2) was detected as a target \nby MALDI and Western Blotting . This finding was confirmed in growth experiments on different \nyeast strain in comparison with the previously known EF2-inhibitor sordarin. This mode of \naction was confirmed for other melleolides possessing an \u03942,4-unsaturated aldehyde in C1 \nposition, like arnamial. In our experiments, DAO and sordarin showed diffe rent effects on the \nyeast strains used. By in silico  protein modeling based on an A. nidulans EF2 protein model \ntwo differing binding pockets for these substances were found .   \nThe cytotoxic effect of DAO in human cell lines could not be explained by EF2-inhibition. \nInstead we could identify 5-lipoxygenase (5- LO), as a target. The \u03942,4-unsaturated aldehyde \nselectively and irreversibly bound to the enzyme\u2019 s cystein 159 (C159) located at the entrance \nof 5-LO catalytic center, performing a Michael-addition. The interaction of DAO with C159 \nprevents 5- LO to bind FLAP, resulting in a reduced leukotriene biosynthesis.   \nThis anti-inflammatory interaction is no declaration for the quick cell death we observed in \nformer experiments on human cancer cell lines and monocytes. The induced cell death is the \nreason of DAO covalently binding to the head groups of phosphatidylethanolamines (PE). W e \nfound that DAO preferably binds PE from fractions of the plasma membrane and lysosomes \nleading to a diminished PE content. The DAO-PE interaction finally led to a reduction of the \ncell permeability resulting in necrotic and apoptotic effects in the cell. \nIn this work, three completely different mechanisms of action of DAO and related \u03942,4-\nunsaturated melleolides were identified, providing first important hints for possible future \npharmaceutical applications of the melleolides. 9. Literaturverzeichnis   135 \n9. Literaturverzeic\nhnis \nAbraham, W.R. (2001). Bioactive sesquiterpenes produced by fungi: are they useful for humans as well? \nCurr Med Chem 6 (8), 583- 606. \nAl-Warhi, T.I., Al-Hazimi, H.M.A., and El-Faham, A. (2012). Recent development in peptide coupling \nreagents. Journal of Saudi Chemical Society 2 (16), 97-116. \nAlam, P., and Sharaf-Eldin, M.A. (2016). Limited production of plant derived anticancer drugs vinblastine \nand vincristine. Planta Medica 05 (82), PC4. \nAlberts, A.W., Chen, J., Kuron, G., Hunt, V., Huff, J., Hoffman, C., Rothrock, J., Lopez, M., Joshua, H., \nHarris, E. , et al.  (1980). Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-\ncoenzyme A reductase and a cholesterol-lowering agent. Proceedings of the National Academy of \nSciences of the United States of America 7 (77), 3957-3961. \nAllen, D., Wilson, D., Drew, R., and Perfect, J. (2015). Azole antifungals: 35 years of invasive fungal \ninfection management. Expert Review of Anti-infective Therapy 6 (13), 787-798. \nAmmon, H.P.T. (2014). Hunnius Pharmazeutisches W\u00f6rterbuch, Vol 9 (Berlin: De Gruyter). \nAn, S., Lu, W., Zhang, Y., Yuan, Q., and Wang, D. (2017). Pharmacological basis for use of Armillaria \nmellea polysaccharides in Alzheimer's disease: antiapoptosis and antioxidation. Oxid Med Cell \nLongevity 4184562/4184561-4184562/4184511. \nAnderson, J.B., Bruhn, J.N., Kasimer, D., Wang, H., Rodrigue, N., and Smith, M.L. (2018). Clonal \nevolution and genome stability in a 2,500-year-old fungal individual. Proceedings of the Royal Society \nB: Biological Sciences 1893 (285), 20182233. \nAndr\u00e9, E., Malheiros, \u00c2., Cechinel-Filho, V., Yunes, R.A., and Calixto, J.B. (1999). Mechanisms \nunderlying the relaxation caused by the sesquiterpene polygodial in vessels from rabbit and guinea-pig. \nEuropean Journal of Pharmacology 1 (386), 47-53. \nAndroulla, N.M., and Lefkothea, C.P. (2018). CAR T-cell therapy: A new era in cancer immunotherapy. \nCurrent Pharmaceutical Biotechnology 1 (19), 5-18. \nAnke, H., and Sterner, O. (1991). Comparison of the antimicrobial and cytotoxic activities of twenty \nunsaturated sesquiterpene dialdehydes from plants and mushrooms. Planta Med 04 (57), 344- 346. \nArnone, A., Cardillo, R., Di Modugno, V., and Nasini, G. (1989). Secondary mould metabolites. Part 29. \nIsolation and structure elucidation of candicansol, 3- epi-illudol and 1-O-acetyl-3- epi-illudol, novel \nsesquiterpenoids from Clitocybe candicans , and absolute configuration of 3-epi-illudol. Journal of the \nChemical Society, Perkin Transactions 1 (11), 1995-2000. \nArnone, A., Nasini, G., Di Modugno, V., and Cardillo, R. (1988). Isolation and structure elucidation of \nmelledonals D and E and Melleolides E-H, Novel Sesquiterpenoid Aryl Esters from clitocybe elegans \nand armillaria mellea. Gazzetta chimica Italiana 118 (7), 517 -521. \nAversa, F., Busca, A., Candoni, A., Cesaro, S., Girmenia, C., Luppi, M., Nosari, A.M., Pagano, L., \nRomani, L., Rossi, G. , et al.  (2017). Liposomal amphotericin B (AmBisome\u00ae) at beginning of its third \ndecade of clinical use. Journal of Chemotherapy 3 (29), 131 -143. \nBaekelandt, M. (2002). Irofulven (MGI Pharma). Current opinion in investigational drugs (London, \nEngland : 2000) 10 (3), 1517-1526. \nBalandrin, M., Klocke, J., Wurtele, E., and Bollinger, W. (1985). Natural plant chemicals: sources of \nindustrial and medicinal materials. Science 4704 (228), 1154-1160. \nBanday, A.H., Shameem, S.A., Gupta, B.D., and Kumar, H.M.S. (2010). D-ring substituted 1,2,3-triazolyl \n20-keto pregnenanes as potential anticancer agents: Synthesis and biological evaluation. Steroids 12 \n(75), 801-804. \nBartsch, V. (2004). Das Taxol Buch, 2. erweiterte Auflage edn (Stuttgart: Georg Thieme Verlag). \nBaumgartner, K., Coetzee, M.P.A., and Hoffmeister, D. (2011). Secrets of the subterranean \npathosystem of Armillaria . Molecular Plant Pathology 6 (12), 515-534. \nBoddy, L., Hynes, J., Bebber, D.P., and Fricker, M.D. (2009). Saprotrophic cord systems: dispersal \nmechanisms in space and time. Mycoscience 1 (50), 9. 9. Literaturverzeichnis   136 \nBogyo, \nM., Baruch, A., Jeffery, D.A., Greenbaum, D., Borodovsky, A., Ovaa, H., and Kessler, B. (2004). \nApplications for chemical probes of proteolytic activity. Current Protocols in Protein Science 21 (21), 17. \nBohnert, M., Miethbauer, S., Dahse, H.M., Ziemen, J., Nett, M., and Hoffmeister, D. (2011). In vitro \ncytotoxicity of melleolide antibiotics: structural and mechanistic aspects. Bioorg Med Chem Lett 7 (21), \n2003-2006. \nBohnert, M., N\u00fctzmann, H.-W., Schroeckh, V., Horn, F., Dahse, H.-M., Brakhage, A.A., and Hoffmeister, \nD. (2014a). Cytotoxic and antifungal activities of melleolide antibiotics follow dissimilar structure \u2013activity \nrelationships. Phytochemistry 1 (105), 101-108. \nBohnert, M., Scherer, O., Wiechmann, K., K\u00f6nig, S., Dahse, H.M., Hoffmeister, D., and Werz, O. \n(2014b). Melleolides induce rapid cell death in human primary monocytes and cancer cells. Bioorg Med \nChem 15 (22), 3856-3861. \nB\u00f6ttcher, T., Pitscheider, M., and Sieber, S.A. (2010). Naturstoffe und ihre biologischen Angriffsziele: \nproteomische und metabolomische Markierungsstrategien. Angewandte Chemie 15 (122), 2740-2759. \nBrown, G.D., Denning, D.W., Gow, N.A.R., Levitz, S.M., Netea, M.G., and White, T.C. (2012). Hidden \nkillers: Human fungal infections. Science Translational Medicine 165 (4), 165-177. \nCabral, M.E., Delgado, O.D., Sampietro, D.A., C.A., C., Figueroa, L.I.C., and Farina, J.I. (2010). \nAntifungal Activity and the Potential Correlation with Statin-Producing Ability: An Optimized Screening \nApplied to Filamentous Fungi from Las Yungas Subtropical Rainforest. Research Journal of \nMicrobiology 9 (5), 833-848. \nCacho, R.A., Jiang, W., Chooi, Y.-H., Walsh, C.T., and Tang, Y. (2012). Identification and \nCharacterization of the Echinocandin B Biosynthetic Gene Cluster from Emericella rugulosa NRRL \n11440. Journal of the American Chemical Society 40 (134), 16781-16790. \nCaputi, L., Franke, J., Farrow, S.C., Chung, K., Payne, R.M.E., Nguyen, T.-D., Dang, T.-T.T., Soares \nTeto Carqueijeiro, I., Koudounas, K., Dug\u00e9 de Bernonville, T. , et al.  (2018). Missing enzymes in the \nbiosynthesis of the anticancer drug vinblastine in Madagascar periwinkle. Science 6394 (360), 1235-\n1239. \nCarelle, N., Piotto, E., Bellanger, A., Germanaud, J., Thuillier, A., and Khayat, D. (2002). Changing \npatient perceptions of the side effects of cancer chemotherapy. Cancer 1 (95), 155- 163. \nChang, W.-H., Huang, H.-L., Huang, W.-P., Chen, C.-C., and Chen, Y.-J. (2016). Armillaridin induces \nautophagy-associated cell death in human chronic myelogenous leukemia K562 cells. Tumor Biology \n10 (37), 14291-14300. \nChauffert, B., Dimanche-Boitrel, M.T., Garrido, C., Ivarsson, M., Martin, M., Martin, F., and Solary, E. \n(1998). New insights into the kinetic resistance to anticancer agents. Cytotechnology 1-3 (27), 225-235. \nChen, C.-C., Cheng, J.J., and Shen, C.-C. (2011). Protoilludane norsesquiterpenoid esters and uses \nthereof. USA, US 2011/0262561 A1 \nChen, C.-C., Kuo, Y.-H., Cheng, J.-J., Sung, P.-J., Ni, C.-L., Chen, C.-C., and Shen, C.-C. (2015). Three \nnew sesquiterpene aryl esters from the mycelium of Armillaria mellea. Molecules 6 (20), 9994-10003. \nChen, Y.-J., Chen, C.-C., and Huang, H.-L. (2016). Induction of apoptosis by Armillaria mellea  \nconstituent armillarikin in human hepatocellular carcinoma. OncoTargets and therapy 1 (9), 4773-4783. \nChidley, C., Trauger, S.A., Birsoy, K., and O'Shea, E.K. (2016). The anticancer natural product \nophiobolin A induces cytotoxicity by covalent modification of phosphatidylethanolamine. eLife 1 (5), \n14601. \nChristianson, D.W. (2017). Structural and chemical biology of terpenoid cyclases. Chemical Reviews 17 \n(117), 11570-11648. \nClive, D.L.J., Murthy, K.S.K., Wee, A.G.H., Prasad, J.S., Da Silva, G.V.J., Majewski, M., Anderson, P.C., \nEvans, C.F., and Haugen, R.D. (1990). Total synthesis of both (+)-compactin and (+)-mevinolin. A \ngeneral strategy based on the use of a special titanium reagent for dicarbonyl coupling. Journal of the \nAmerican Chemical Society 8 (112), 3018-3028. \nCoates, A., Abraham, S., Kaye, S.B., Sowerbutts, T., Frewin, C., Fox, R.M., and Tattersall, M.H.N. \n(1983). On the receiving end \u2014patient perception of the side-effects of cancer chemotherapy. European \nJournal of Cancer and Clinical Oncology 2 (19), 203-208. 9. Literaturverzeichnis   137 \nColes, N.T., M\nahon, M.F., and Webster, R.L. (2018). 1,1-Diphosphines and divinylphosphines via base \ncatalyzed hydrophosphination. Chemical Communications 74 (54), 10443-10446. \nCollins, C., Hurley, R., Almutlaqah, N., O\u2019Keeffe, G., Keane, M.T., Fitzpatrick, A.D., and Owens, A.R. \n(2017). Proteomic characterization of Armillaria mellea  reveals oxidative stress response mechanisms \nand altered secondary metabolism profiles. Microorganisms 3 (5), 60-75. \nCordeiro, R.A., Teixeira, C.E.C., Brilhante, R.S.N., Castelo-Branco, D.S.C.M., Paiva, M.A.N., Giffoni \nLeite, J.J., Lima, D.T., Monteiro, A.J., Sidrim, J.J.C., and Rocha, M.F.G. (2013). Minimum inhibitory \nconcentrations of amphotericin B, azoles and caspofungin against Candida  species are reduced by \nfarnesol. Medical Mycology 1 (51), 53-59. \nCoste, A., Ferrari, S., and Sanglard, D. (2009). Antifungal drug resistance mechanisms in fungal \npathogens from the perspective of transcriptional gene regulation. Federation of European \nMicrobiological Society - Yeast Research 7 (9), 1029-1050. \nCowen, L.E. (2008). The evolution of fungal drug resistance: modulating the trajectory from genotype to \nphenotype. Nature Reviews Microbiology 3 (6), 187. \nCowen, L.E., Sanglard, D., Howard, S.J., Rogers, P.D., and Perlin, D.S. (2015). Mechanisms of \nantifungal drug resistance. Cold Spring Harbor Perspectives in Medicine 7 (5), a019752. \nCox, R.J. (2007). Polyketides, proteins and genes in fungi: programmed nano-machines begin to reveal \ntheir secrets. Organic and Biomolecular Chemistry 13 (5), 2010-2026. \nCrawford, J.M., Korman, T.P., Labonte, J.W., Vagstad, A.L., Hill, E.A., Kamari-Bidkorpeh, O., Tsai, S.C., \nand Townsend, C.A. (2009). Structural basis for biosynthetic programming of fungal aromatic polyketide \ncyclization. Nature 7267 (461), 1139-1143. \nda Cunha, F.M., Fr\u00f6de, T.S., Mendes, G.L., Malheiros, A., Filho, V.C., Yunes, R.A., and Calixto, J.B. \n(2001). Additional evidence for the anti-inflammatory and anti-allergic properties of the sesquiterpene \npolygodial. Life Sciences 2 (70), 159-169. \nDenis, J.N., Greene, A.E., Guenard, D., Gueritte-Voegelein, F., Mangatal, L., and Potier, P. (1988). \nHighly efficient, practical approach to natural taxol. Journal of the American Chemical Society 17 (110), \n5917-5919. \nDenning, D.W. (1997). Echinocandins and pneumocandins-a new antifungal class with a novel mode of \naction. Journal of Antimicrobial Chemotherapy 5 (40), 611-614. \nDietel, M. (1991). What's new in cytostatic drug resistance and pathology. Pathology - Research and \nPractice 7 (187), 892-905. \nDietel, M. (2007). Predictive pathology of cytostatic drug resistance and new anti-cancer targets. Recent \nResults in Cancer Research 1 (176), 25-32. \nDings, R.P.M., Van Laar, E.S., Webber, J., Zhang, Y., Griffin, R.J., Waters, S.J., MacDonald, J.R., and \nMayo, K.H. (2008). Ovarian tumor growth regression using a combination of vascular targeting agents \nanginex or topomimetic 0118 and the chemotherapeutic irofulven. Cancer letters 2 (265), 270- 280. \nDom \u0131\u0301nguez, J.M., G\u00f3mez-Lorenzo, M.G., and Mart \u0131\u0301n, J.J. (1999). Sordarin inhibits fungal protein \nsynthesis by blocking translocation differently to fusidic acid. Journal of Biological Chemistry 32 (274), \n22423-22427. \nDom\u00ednguez, J.M., and Mart\u00edn, J.J. (1998). Identification of elongation factor 2 as the essential protein \ntargeted by sordarins in  Candida albicans . Antimicrobial agents and chemotherapy 9 (42), 2279-2283. \nD\u00f6rfer, M., Heine, D., K\u00f6nig, S., Gore, S., Werz, O., Hertweck, C., Gressler, M., and Hoffmeister, D. \n(2019). Melleolides impact fungal translation via elongation factor 2. Organic & Biomolecular Chemistry \n19 (17), 4906-4916. \nDowell, J.E., Johnson, D.H., Rogers, J.S., Shyr, Y., McCullough, N., Krozely, P., and DeVore, R.F. \n(2001). A Phase II trial of 6-Hydroxymethylacylfulvene (MGI-114, Irofulven) in Patients with Advanced \nNon-Small Cell Cancer Previously Treated with Chemotherapy. Investigational New Drugs 1 (19), 85-\n88. \nDumontet, C., Fabianowska-Majewska, K., Mantincic, D., Callet Bauchu, E., Tigaud, I., Gandhi, V., \nLepoivre, M., Peters, G.J., Rolland, M.O., Wyczechowska, D. , et al.  (1999). Common resistance \nmechanisms to deoxynucleoside analogues in variants of the human erythroleukaemic line K562. British \nJournal of Haematology 1 (106), 78-85. 9. Literaturverzeichnis   138 \nDybro, A.\nM., Damkier, P., Rasmussen, T.B., and Hellfritzsch, M. (2016). Statin-associated \nrhabdomyolysis triggered by drug-drug interaction with itraconazole. British Medical Journal case \nreports 1 (2016) , 1-3. \nEdlind, T.D., and Katiyar, S.K. (2010). Mutational analysis of flucytosine resistance in Candida glabrata . \nAntimicrobial agents and chemotherapy 11 (54), 4733- 4738.  \nEngels, B., Heinig, U., Grothe, T., Stadler, M., and Jennewein, S. (2011). Cloning and characterization \nof an Armillaria gallica  cDNA encoding protoilludene synthase, which catalyzes the first committed step \nin the synthesis of antimicrobial melleolides. J Biol Chem 9 (286), 6871-6878. \nFeng, L.J., Wan, Z., Wang, X.H., Li, R.Y., and Liu, W. (2010). Relationship between antifungal resistance \nof fluconazole resistant Candida albicans  and mutations in ERG11 gene. Chin Med J (Engl) 5 (123), \n544-548. \nFerguson, B.A., Dreisbach, T.A., Parks, C.G., Filip, G.M., and Schmitt, C.L. (2003). Coarse-scale \npopulation structure of pathogenic Armillaria species in a mixed-conifer forest in the Blue Mountains of \nnortheast Oregon. Canadian Journal of Forest Research 4 (33), 612-623. \nFinkelstein, H. (1910). Darstellung organischer Jodide aus den entsprechenden Bromiden und \nChloriden. Berichte der deutschen chemischen Gesellschaft 2 (43), 1528-1532. \nFirn, R.D., and Jones, C.G. (2003). Natural products-a simple model to explain chemical diversity. \nNatural Product Reports 4 (20), 382-391. \nFirn, R.D., and Jones, C.G. (2009). A Darwinian view of metabolism: molecular properties determine \nfitness. Journal of Experimental Botany 3 (60), 719-726. \nGauwerky, K., Borelli, C., and Korting, H.C. (2009). Targeting virulence: A new paradigm for antifungals. \nDrug Discovery Today 3 (14), 214 -222. \nGeissel, B., Loiko, V., Klugherz, I., Zhu, Z., Wagener, N., Kurzai, O., van den Hondel, C., and Wagener, \nJ. (2018). Azole-induced cell wall carbohydrate patches kill Aspergillus fumigatus . Nature \nCommunications 1 (9), 3098. \nGeorgopapadakou, N.H. (2001). Update on antifungals targeted to the cell wall: focus on \u03b2 -1,3-glucan \nsynthase inhibitors. Expert Opinion on Investigational Drugs 2 (10), 269- 280. \nGershenzon, J., and Dudareva, N. (2007). The function of terpene natural products in the natural world. \nNature chemical biology (3), 408.  \nGiaccone, G., and Pinedo, H.M. (1996). Drug Resistance. The Oncologist 1 (1), 82-87. \nGressler, M., Hortschansky, P., Geib, E., and Brock, M. (2015). A new high-performance heterologous \nfungal expression system based on regulatory elements from the Aspergillus terreus  terrein gene \ncluster. Frontiers in Microbiology (6), 184. \nGuo, Z. (2017). The modification of natural products for medical use. Acta Pharmaceutica Sinica B 2 \n(7), 119 -136. \nHamedi, J., Khodagholi, F., and Hassani-Nasab, A. (2005). Increased erythromycin production by \nalginate as a medium ingredient or immobilization support in cultures of Saccharopolyspora erythraea . \nBiotechnology Letters 9 (27), 661 -664. \nHamilton-Miller, J.M.T. (1974). Fungal sterols and the mode of action of the polyene antibiotics. \nAdvances in Applied Microbiology 1 (17), 109-134. \nHanson, J.R. (2008). The chemistry of fungi (Cambridge: Royal Society of Chemistry Publishing). \nHauser, D., and Sigg, H.P. (1971). Isolierung und Abbau von Sordarin. 1. Mitteilung \u00fcber Sordarin. \nHelvetica Chimica Acta 4 (54), 1178-1190. \nHawksworth, D.L. (2001). The magnitude of fungal diversity: the 1.5 million species estimate revisited. \nMycological Research 12 (105), 1422-1432. \nHeathcock, C.H., Hadley, C.R., Rosen, T., Theisen, P.D., and Hecker, S.J. (1987). Total synthesis and \nbiological evaluation of structural analogues of compactin and dihydromevinolin. Journal of Medicinal \nChemistry 10 (30), 1858-1873. \nHeijden, R.v.d., Jacobs, D.I., Snoeijer, W., Hallard, D., and Verpoorte, R. (2004). The Catharanthus  \nalkaloids: pharmacognosy and biotechnology. Curr Med Chem 5 (11), 607-628. 9. Literaturverzeichnis   139 \nHeo, J.C., \nWoo, S.U., Son, M., Park, J.Y., Choi, W.S., Chang, K.T., Kim, S.U., Yoon, E.K., Kim, Y.H., \nShin, H.M. , et al.  (2007). Anti-tumor activity of Gastrodia elata  Blume is closely associated with a GTP-\nRas-dependent pathway. Oncol Rep 4 (18), 849-853. \nHerath, H.M.T.B., Jacob, M., Wilson, A.D., Abbas, H.K., and Nanayakkara, N.P.D. (2013). New \nsecondary metabolites from bioactive extracts of the fungus Armillaria tabescens . Natural product \nresearch 17 (27), 1562-1568. \nHerreros, E., Martinez, C.M., Almela, M.J., Marriott, M.S., De Las Heras, F.G., and Gargallo-Viola, D. \n(1998). Sordarins: In vitro activities of new antifungal derivatives against pathogenic yeasts, \nPneumocystis carinii , and Filamentous Fungi. Antimicrobial agents and chemotherapy 11 (42), 2863-\n2869. \nHertweck, C. (2009). The biosynthetic logic of polyketide diversity. Angewandte Chemie International \nEdition 26 (48), 4688-4716. \nHertweck, C., Luzhetskyy, A., Rebets, Y., and Bechthold, A. (2007). Type II polyketide synthases: \ngaining a deeper insight into enzymatic teamwork. Natural Product Reports 1 (24), 162-190. \nHintikka, V. (1973). A note on the polarity of Armillariella mellea . Karstenia 13 (1), 32-39. \nHirama, M., and Iwashita, M. (1983). Total synthesis of (+)-monacolin K (mevinolin). Tetrahedron Letters \n17 (24), 1811-1812. \nHofmann, B., R\u00f6dl, C.B., Kahnt, A.S., Maier, T.J., Michel, A.A., Hoffmann, M., Rau, O., Awwad, K., \nPellowska, M., Wurglics, M. , et al.  (2012). Molecular pharmacological profile of a novel thiazolinone-\nbased direct and selective 5-lipoxygenase inhibitor. British Journal of Pharmacology 7 (165), 2304-2313. \nHolton, R.A., Somoza, C., Kim, H.-B., Liang, F., Biediger, R.J., Boatman, P.D., Shindo, M., Smith, C.C., \nKim, S., Nadizadeh, H. , et al.  (1994). The total synthesis of paclitaxel starting with camphor. In Taxane \nAnticancer Agents (Washington D. C.: American Chemical Society), pp. 288-301. \nHolz, R.W. (1974). The effects of the polyene antibiotics nystatin and amphotericin B on thin lipid \nmembranes. Ann N Y Acad Sci 0 (235), 469- 479. \nHood, I.A. (1991). Armillaria  in planted hosts. In Armillaria  root Disease, C.G. Shaw, and G.A. Kile, eds. \n(Washington D. C.: United States Department of Agriculture), pp. 122-154. \nHovey, M.T., Cohen, D.T., Walden, D.M., Cheong, P.H., and Scheidt, K.A. (2017). A carbene catalysis \nstrategy for the synthesis of protoilludane natural products. Angewandte Chemie International Edition \n33 (56), 9864-9867. \nH\u00fcttel, W. (2017). Structural diversity in echinocandin biosynthesis: the impact of oxidation steps and \napproaches toward an evolutionary explanation. Zeitschrift f\u00fcr Naturforschung 1-2 (72), 1-20. \nH\u00fcttel, W., Youssar, L., Gr\u00fcning, B.A., G\u00fcnther, S., and Hugentobler, K.G. (2016). Echinocandin B \nbiosynthesis: a biosynthetic cluster from Aspergillus nidulans  NRRL 8112 and reassembly of the \nsubclusters Ecd and Hty from Aspergillus pachycristatus  NRRL 11440 reveals a single coherent gene \ncluster. BMC genomics 17 (0), 570 -570. \nJammi, S., Mouysset, D., Siri, D., Bertrand, M.P., and Feray, L. (2013). Theoretical support for the \ninvolvement of a radical pathway in the formation of allenylzincs from propargyl iodides and dialkylzincs: \ninfluence of zinc coordination. Journal of Organic Chemistry 4 (78), 1589-1603. \nJolit, A., Dickinson, C.F., Kitamura, K., Walleser, P.M., Yap, G.P.A., and Tius, M.A. (2017). Catalytic \nenantioselective nazarov cyclization. European Journal of Organic Chemistry 40 (2017) , 6067-6076. \nJustice, M.C., Hsu, M.-J., Tse, B., Ku, T., Balkovec, J., Schmatz, D., and Nielsen, J. (1998). Elongation \nfactor 2 as a novel target for selective inhibition of fungal protein synthesis. Journal of Biological \nChemistry 6 (273), 3148-3151. \nKitahata, S., Yakushiji, F., and Ichikawa, S. (2017). Impact of the structures of macrocyclic Michael \nacceptors on covalent proteasome inhibition. Chemical science 10 (8), 6959-6963. \nK\u00f6nig, S., Romp, E., Krauth, V., Ruhl, M., D\u00f6rfer, M., Liening, S., Hofmann, B., Hafner, A.-K., Steinhilber, \nD., Karas, M., et al.  (2018). Melleolides from honey mushroom inhibit 5-Lipoxygenase via Cys159. Cell \nchemical biology 26 (1), 60-70. \nKorhonen, K. (1978). Infertility and clonal size in the Armillariella mellea  complex. Karstenia 2 (18), 31-\n42. 9. Literaturverzeichnis   140 \nKorhonen\n, K., and Hintikka, V. (1974). Cytological evidence for somatic diploidization in dikaryotic cells \nof Armillariella mellea . Archives of Microbiology 1 (95), 187. \nKotler-Brajtburg, J., Price, H.D., Medoff, G., Schlessinger, D., and Kobayashi, G.S. (1974). Molecular \nbasis for the selective toxicity of amphotericin B for yeast and filipin for animal cells. Antimicrobial agents \nand chemotherapy 4 (5), 377-382. \nKotlobay, A.A., Sarkisyan, K.S., Mokrushina, Y.A., Marcet-Houben, M., Serebrovskaya, E.O., Markina, \nN.M., Gonzalez Somermeyer, L., Gorokhovatsky, A.Y., Vvedensky, A., Purtov, K.V. , et al. (2018). \nGenetically encodable bioluminescent system from fungi. Proceedings of the National Academy of \nSciences 50 (115), 12728. \nKretschmer, S.B.M., Woltersdorf, S., Vogt, D., Lillich, F.F., R\u00fchl, M., Karas, M., Maucher, I.V., Roos, J., \nH\u00e4fner, A.-K., Kaiser, A. , et al.  (2017). Characterization of the molecular mechanism of 5-lipoxygenase \ninhibition by 2-aminothiazoles. Biochemical Pharmacology (123), 52-62. \nKubo, I., Fujita, K.i., and Lee, S.H. (2001). Antifungal mechanism of polygodial. Journal of Agricultural \nand Food Chemistry 3 (49), 1607-1611. \nKudo, F., Matsuura, Y., Hayashi, T., Fukushima, M., and Eguchi, T. (2016). Genome mining of the \nsordarin biosynthetic gene cluster from Sordaria araneosa  Cain ATCC 36386: characterization of \ncycloaraneosene synthase and GDP-6-deoxyaltrose transferase. J Antibiot (Tokyo) 1 (69), 541. \nKuehne, M.E., Matson, P.A., and Bornmann, W.G. (1991). Enantioselective syntheses of vinblastine, \nleurosidine, vincovaline and 20'-epi-vincovaline. The Journal of Organic Chemistry 2 (56), 513-528. \nLackner, G., Bohnert, M., Wick, J., and Hoffmeister, D. (2013). Assembly of melleolide antibiotics \ninvolves a polyketide synthase with cross-coupling activity. Chemistry and Biology 9 (20), 1101-1106. \nLackner, G., Misiek, M., Braesel, J., and Hoffmeister, D. (2012). Genome mining reveals the evolutionary \norigin and biosynthetic potential of basidiomycete polyketide synthases. Fungal Genetics and Biology \n12 (49), 996-1003. \nLambert, R.A. (1913). Comparative studies upon cancer cells and normal cells: II. The Character of \ngrowth in vitro with special reference to cell division. The Journal of experimental medicine 5 (17), 499-\n510. \nLamour, A., Termorshuizen, A.J., Volker, D., and Jeger, M.J. (2007). Network formation by rhizomorphs \nof Armillaria lutea  in natural soil: their description and ecological significance. FEMS Microbiology \nEcology 2 (62), 222-232. \nLaniado-Laborin, R., and Cabrales-Vargas, M.N. (2009). Amphotericin B: side effects and toxicity. Rev \nIberoam Micol 4 (26), 223- 227. \nLee, S.H., Lee, J.R., Lunde, C.S., and Kubo, I. (1999). In vitro  antifungal susceptibilities of Candida \nalbicans  and other fungal pathogens to polygodial, a sesquiterpene dialdehyde. Planta Medica 03 (65), \n204-208. \nLi, Z., Wang, Y., Jiang, B., Li, W., Zheng, L., Yang, X., Bao, Y., Sun, L., Huang, Y., and Li, Y. (2016). \nStructure, cytotoxic activity and mechanism of protoilludane sesquiterpene aryl esters from the mycelium \nof Armillaria mellea . Journal of Ethnopharmacology 1 (184), 119-127. \nLiang, H. (2008). Sordarin, an antifungal agent with a unique mode of action. Beilstein journal of organic \nchemistry 31 (4), 1-14. \nLiebler, D.C. (2008). Protein damage by reactive electrophiles: targets and consequences. Chemical \nresearch in toxicology 1 (21), 117 -128. \nLingam, V.S.P.R., Vinodkumar, R., Mukkanti, K., Thomas, A., and Gopalan, B. (2008). A simple \napproach to highly functionalized benzo[b]furans from phenols and aryl iodides via aryl propargyl ethers. \nTetrahedron Letters 27 (49), 4260-4264. \nLiu, R., Luo, F., Liu, X., Wang, L., Yang, J., Deng, Y., Huang, E., Qian, J., Lu, Z., Jiang, X. , et al.  (2016). \nBiological response modifier in cancer immunotherapy. In Progress in Cancer Immunotherapy, S. \nZhang, ed. (Dordrecht: Springer Netherlands), pp. 69-138. \nLomenick, B., Hao, R., Jonai, N., Chin, R.M., Aghajan, M., Warburton, S., Wang, J., Wu, R.P., Gomez, \nF., Loo, J.A. , et al.  (2009). Target identification using drug affinity responsive target stability (DARTS). \nProceedings of the National Academy of Sciences 51 (106), 21984-21989. 9. Literaturverzeichnis   141 \nLomenic\nk, B., Jung, G., Wohlschlegel, J.A., and Huang, J. (2011a). Target identification using drug \naffinity responsive target stability (DARTS). Current protocols in chemical biology 4 (3), 163-180. \nLomenick, B., Olsen, R.W., and Huang, J. (2011b). Identification of direct protein targets of small \nmolecules. ACS Chemical Biology 1 (6), 34-46. \nMalyszko, J., Kozlowska, K., Kozlowski, L., and Malyszko, J. (2017). Nephrotoxicity of anticancer \ntreatment. Nephrology Dialysis Transplantation 6 (32), 924-936. \nMansoori, B., Mohammadi, A., Davudian, S., Shirjang, S., and Baradaran, B. (2017). The different \nmechanisms of cancer drug resistance: a brief review. Advanced Pharmeutical Bulletin 3 (7), 339-348. \nMarahiel, M.A. (2016). A structural model for multimodular NRPS assembly lines. Natural Product \nReports 2 (33), 136-140. \nMarahiel, M.A., Stachelhaus, T., and Mootz, H.D. (1997). Modular peptide synthetases involved in \nnonribosomal peptide synthesis. Chemical Reviews 7 (97), 2651-2674. \nMartin, S.M., and Bushell, M.E. (1996). Effect of hyphal micromorphology on bioreactor performance of \nantibiotic-producing  Saccharopolyspora erythraea  cultures. Microbiology 7 (142), 1783-1788. \nMast, N., Zheng, W., Stout, C.D., and Pikuleva, I.A. (2013). Antifungal azoles: structural insights into \nundesired tight binding to cholesterol-metabolizing CYP46A1. Molecular Pharmacology 1 (84), 86-94. \nMaucher, I.V., R\u00fchl, M., Kretschmer, S.B.M., Hofmann, B., K\u00fchn, B., Fettel, J., Vogel, A., Fl\u00fcgel, K.T., \nManolikakes, G., Hellmuth, N. , et al.  (2017). Michael acceptor containing drugs are a novel class of 5-\nlipoxygenase inhibitor targeting the surface cysteines C416 and C418. Biochemical Pharmacology 1 \n(125), 55-74. \nMcFedries, A., Schwaid, A., and Saghatelian, A. (2013). Methods for the elucidation of protein-small \nmolecule interactions. Chemistry and Biology 5 (20), 667-673. \nMendes, G.L., Santos, A.R.S., Malheiros, A., Filho, V.C., Yunes, R.A., and Calixto, J.B. (2000). \nAssessment of mechanisms involved in antinociception caused by sesquiterpene polygodial. Journal of \nPharmacology and Experimental Therapeutics 1 (292), 164.  \nMeyers, M.A. (2007). Veni, Vidi, Vinca : The healing power of periwinkle. In Happy accidents-Serendipity \nin modern medical breakthroughs, M.A. Meyers, ed. (New York: Arcade Publishing), pp. 131-134. \nMisiek, M., and Hoffmeister, D. (2012). Sesquiterpene aryl ester natural products in North American \nArmillaria  species. Mycological Progress 1 (11), 7-15. \nMisiek, M., Williams, J., Schmich, K., H\u00fcttel, W., Merfort, I., Salomon, C.E., Aldrich, C.C., and \nHoffmeister, D. (2009). Structure and cytotoxicity of arnamial and related fungal sesquiterpene aryl \nesters. Journal of Natural Products 10 (72), 1888-1891. \nMogil\u2019naya, O.A., Ronzhin, N.O., Medvedeva, S.E., and Bondar\u2019, V.S. (2015). Total peroxidase and \ncatalase activity of luminous basidiomycetes Armillaria borealis  and Neonothopanus nambi  in \ncomparison with the level of light emission. Applied Biochemistry and Microbiology 4 (51), 419-424. \nMosow, J.A. (1998). Methotrexate transport and resistance. Leukemia and Lymphoma 3-4 (30), 215-\n224. \nMusiol, R., and Kowalczyk, W. (2012). Azole antimycotics - A highway to new drugs or a dead end? \nCurr Med Chem 9 (19), 1378-1388. \nMutschler, E. (2013). Mutschler Arzneimittelwirkungen : Lehrbuch der Pharmakologie, der klinischen \nPharmakologie und Toxikologie, 10., vollst\u00e4ndig \u00fcberarbeitete und erweiterte Auflage edn (Stuttgart: \nWVG, Wissenschaftliche Verlagsgesellschaft). \nMyrick, D., Blackinton, D., Klostergaard, J., Kouttab, N., Maizel, A., Wanebo, H., and Mehta, S. (1999). \nPaclitaxel-induced apoptosis in Jurkat, a leukemic T cell line, is enhanced by ceramide. Leukemia \nResearch 6 (23), 569-578. \nNeises, B., and Steglich, W. (1978). Einfaches Verfahren zur Veresterung von Carbons\u00e4uren. \nAngewandte Chemie 7 (90), 556 -557. \nNicolaou, K.C., and Guy, R.K. (1994). The total synthesis of paclitaxel by assembly of the ring system. \nIn Taxane anticancer agents (Washington D. C.: American Chemical Society), pp. 302-312. \nOdds, F.C. (2001). Sordarin antifungal agents. Expert Opinion on Therapeutic Patents 2 (11), 283-294. 9. Literaturverzeichnis   142 \nOduro, \nK.A., Munnecke, D.E., Sims, J.J., and Keen, N.T. (1976). Isolation of antibiotics produced in \nculture by A mellea. Trans Brit Mycol Soc 2 (66), 195- 199. \nOhr, H.D., and Munnecke, D.E. (1974). Effects of methyl bromide on antibiotic production by Armillaria \nmellea . Transactions of the British Mycological Society 1 (62), 65-73. \nOhr, H.D., Munnecke, D.E., and Bricker, J.L. (1973). The interaction of Armillaria mellea  and \nTrichoderma spp . as modified by methyl bromide. Phytopathlogy 8 (63), 965-973. \nOppolzer, W., and Nakao, A. (1986). Synthesis of (\u00b1)-6-protoilludene and (\u00b1)-3- EPI-6-protoilludene by \nintramolecular magnesium- ene- and ketene/alkene addition reactions. Tetrahedron Letters 45 (27), \n5471-5474. \nOstrowski, K., and Barnard, E.A. (1961). Application of isotopically-labelled specific inhibitors as a \nmethod in enzyme cytochemistry. Experimental Cell Research 2 (25), 465-468. \nPan, S.-T., Li, Z.-L., He, Z.-X., Qiu, J.-X., and Zhou, S.-F. (2016). Molecular mechanisms for tumour \nresistance to chemotherapy. Clinical and Experimental Pharmacology and Physiology 8 (43), 723-737. \nParrot, D., Peresse, T., Hitti, E., Carrie, D., Grube, M., and Tomasi, S. (2015). Qualitative and spatial \nmetabolite profiling of lichens by a LC \u2013MS approach combined with optimised extraction. Phytochemical \nAnalysis 1 (26), 23-33. \nPeipp, H., and Sonnenbichler, J. (1992). Secondary fungal metabolites and their biological activities, II. \nOccurrence of antibiotic compounds in cultures of Armillaria ostoyae growing in the presence of an \nantagonistic fungus or host plant cells. Biol Chem Hoppe Seyler 8 (373), 675-683. \nPerea, S., L\u00f3pez-Ribot, J.L., Kirkpatrick, W.R., McAtee, R.K., Santill\u00e1n, R.A., Mart \u0131\u0301nez, M., Calabrese, \nD., Sanglard, D., and Patterson, T.F. (2001). Prevalence of molecular mechanisms of resistance to \nazole antifungal agents in Candida albicans  strains displaying high-level fluconazole resistance isolated \nfrom human immunodeficiency virus-infected patients. Antimicrobial agents and chemotherapy 10 (45), \n2676- 2684. \nP\u00e9rez-S\u00e1nchez, A., Uribe-Carvajal, S., Cabrera-Orefice, A., and Barrios-Gonz\u00e1lez, J. (2017). Key role \nof alternative oxidase in lovastatin solid-state fermentation. Applied Microbiology and Biotechnology 19 \n(101), 7347-7356. \nPetercord, R., Leonhard, S., Muck, M., Lemme, H., Lobinger, G., Immler, T., and Konnert, M. (2009). \nKlima\u00e4nderung und Forstsch\u00e4dlinge. LWF aktuell 1 (72), 4-7. \nPeters, G.J. (2014). Novel developments in the use of antimetabolites. Nucleosides, Nucleotides and \nNucleic Acids 4-6 (33), 358- 374. \nPetranyi, G., Ryder, N., and Stutz, A. (1984). Allylamine derivatives: new class of synthetic antifungal \nagents inhibiting fungal squalene epoxidase. Science 4654 (224), 1239-1241. \nPierson, A.S., Gibbs, P., Richards, J., Russ, P., Eckhardt, S.G., and Gonzalez, R. (2002). A Phase II \nStudy of Irofulven (MGI 114) in Patients with Stage IV Melanoma. Investigational New Drugs 3 (20), \n357-362. \nPurtov, K.V., Petushkov, V.N., Baranov, M.S., Mineev, K.S., Rodionova, N.S., Kaskova, Z.M., Tsarkova, \nA.S., Petunin, A.I., Bondar, V.S., Rodicheva, E.K. , et al.  (2015). The chemical basis of fungal \nbioluminescence. Angewandte Chemie International Edition 28 (54), 8124-8128. \nPurtov, K.V., Petushkov, V.N., Rodionova, N.S., and Gitelson, J.I. (2017). Why does the bioluminescent \nfungus Armillaria mellea  have luminous mycelium but nonluminous fruiting body? Biochemistry, \nBiophysics, and Molecular Biology 1 (474), 217-219. \nPurushothaman, S., Prasanna, R., and Raghunathan, R. (2013). Regioselective synthesis of \nspiropyrrolidine/spiropyrrolizidine/spirothiazolidine-grafted macrocycles through 1,3-dipolar \ncycloaddition methodology. Tetrahedron 46 (69), 9742- 9750.  \nPuyo, S., Montaudon, D., and Pourquier, P. (2014). From old alkylating agents to new minor groove \nbinders. Critical Reviews in Oncology/Hematology 1 (89), 43-61. \nRaabe, R. (1962). Host list of the root rot fungus,  Armillaria mellea . Hilgardia 2 (33), 25 - 88. \nRathinasamy, K., Jindal, B., Asthana, J., Singh, P., Balaji, P.V., and Panda, D. (2010). Griseofulvin \nstabilizes microtubule dynamics, activates p53 and inhibits the proliferation of MCF-7 cells \nsynergistically with vinblastine. BMC Cancer 1 (10), 213. 9. Literaturverzeichnis   143 \nRay, L., \nand Moore, B.S. (2016). Recent advances in the biosynthesis of unusual polyketide synthase \nsubstrates. Natural Product Reports 2 (33), 150-161. \nRibera, J., Panzarasa, G., Stobbe, A., Osypova, A., Rupper, P., Klose, D., and Schwarze, F.W.M.R. \n(2019). Scalable biosynthesis of melanin by the basidiomycete Armillaria cepistipes . Journal of \nAgricultural and Food Chemistry 1 (67), 132- 139. \nRiemsma, R., Forbes, C.A., Kessels, A., Lykopoulos, K., Amonkar, M.M., Rea, D.W., and Kleijnen, J. \n(2010). Systematic review of aromatase inhibitors in the first-line treatment for hormone sensitive \nadvanced or metastatic breast cancer. Breast Cancer Research and Treatment 1 (123), 9-24. \nRossi, A., Pergola, C., Koeberle, A., Hoffmann, M., Dehm, F., Bramanti, P., Cuzzocrea, S., Werz, O., \nand Sautebin, L. (2010). The 5-lipoxygenase inhibitor, zileuton, suppresses prostaglandin biosynthesis \nby inhibition of arachidonic acid release in macrophages. British Journal of Pharmacology 3 (161), 555-\n570. \nRostovtsev, V.V., Green, L.G., Fokin, V.V., and Sharpless, K.B. (2002). A stepwise huisgen \ncycloaddition process: copper(I)-catalyzed regioselective \"ligation\" of azides and terminal alkynes. \nAngewandte Chemie International Edition 14 (41), 2596-2599. \nSanglard, D. (2003). Resistance and tolerance mechanisms to antifungal drugs in fungal pathogens. \nMycologist 2 (17), 74-78. \nSanglard, D. (2016). Emerging threats in antifungal-resistant fungal pathogens. Frontiers in Medicine \n11 (3), 1-10. \nSanglard, D., Ischer, F., Calabrese, D., Micheli, M.d., and Bille, J. (1998). Multiple resistance \nmechanisms to azole antifungals in yeast clinical isolates. Drug Resistance Updates 4 (1), 255-265. \nSch\u00e4fer, B. (2010). Statine. Cholesterolsenker. Chemie in unserer Zeit 5 (44), 344- 364. \nSchiff, P.B., Fant, J., and Horwitz, S.B. (1979). Promotion of microtubule assembly in vitro  by taxol. \nNature 5698 (277), 665-667. \nSchmidt-Dannert, C. (2015). Biosynthesis of terpenoid natural products in fungi. In Biotechnology of \nIsoprenoids, J. Schrader, and J. Bohlmann, eds. (Cham: Springer International Publishing), pp. 19- 61. \nSchmitt, C.L., and Tatum, M.L. (2008). The Malheur National Forest - Location of the world\u2019s largest \nliving organism [The Humongous Fungus] U.S.D.o. Agriculture. 1-8 \nSchnabel, G., Rollins, A.P., and Henderson, G.W. (2011). Field evaluation of Trichoderma spp.  for \ncontrol of Armillaria root rot of peach. Plant Health Progress 1 (12), 3. \nSchroeckh, V., Scherlach, K., N\u00fctzmann, H.-W., Shelest, E., Schmidt-Heck, W., Schuemann, J., Martin, \nK., Hertweck, C., and Brakhage, A.A. (2009). Intimate bacterial \u2013fungal interaction triggers biosynthesis \nof archetypal polyketides in Aspergillus nidulans . Proceedings of the National Academy of Sciences 34 \n(106), 14558-14563. \nSchw\u00f6bel, J.A.H., Wondrousch, D., Koleva, Y.K., Madden, J.C., Cronin, M.T.D., and Sch\u00fc\u00fcrmann, G. \n(2010). Prediction of Michael-type acceptor reactivity toward glutathione. Chemical research in \ntoxicology 10 (23), 1576-1585. \nSharom, F.J. (2007). ABC multidrug transporters: structure, function and role in chemoresistance. \nPharmacogenomics 1 (9), 105-127. \nShaw, C.G., and Kile, G.A. (1991). Armillaria  root disease (Washington, D.C.: Forest Service, U.S. Dept. \nof Agriculture). \nSherman, C.A., Herndon, J.E., Watson, D.M., and Green, M.R. (2004). A phase II trial of 6-\nhydroxymethylacylfulvene (MGI-114, irofulven) in patients with relapsed or refractory non-small cell lung \ncancer. Lung Cancer 3 (45), 387 -392. \nSiddik, Z.H. (1986). Minimising the organ toxic effects of chemotherapy. European Journal of Cancer \nand Clinical Oncology 8 (22), 905 -907. \nSinha, S., Doble, M., and Manju, S.L. (2019). 5-Lipoxygenase as a drug target: A review on trends in \ninhibitors structural design, SAR and mechanism based approach. Bioorganic and Medicinal Chemistry \n17 (27), 3745-3759. \nSmith, E.F. (1894). Field notes, 189 2. The Journal of Mycology 4 (7), 373- 377. 9. Literaturverzeichnis   144 \nS\u00f8e, R., \nMosley, R.T., Justice, M., Nielsen-Kahn, J., Shastry, M., Merrill, A.R., and Andersen, G.R. \n(2007). Sordarin derivatives induce a novel conformation of the yeast ribosome translocation factor \neEF2. Journal of Biological Chemistry 1 (282), 657-666. \nSpeers, A.E., Adam, G.C., and Cravatt, B.F. (2003). Activity-based protein profiling in vivo  using a \ncopper(I)-catalyzed azide-alkyne [3 + 2] cycloaddition. Journal of the American Chemical Society 16 \n(125), 4686-4687. \nStaunton, J., and Weissman, K.J. (2001). Polyketide biosynthesis: a millennium review. Natural Product \nReports 4 (18), 380-416. \nSturtevant, J. (2002). Translation elongation-3-like factors: are they rational antifungal targets? Expert \nOpinion on Therapeutic Targets 5 (6), 545-553. \nSucher, A.J., Chahine, E.B., and Balcer, H.E. (2009). Echinocandins: the newest class of antifungals. \nAnn Pharmacother 10 (43), 1647-1657. \nTaniguchi, M., Yano, Y., Tada, E., Ikenishi, K., Oi, S., Haraguchi, H., Hashimoto, K., and Kubo, I. (1988). \nMode of action of polygodial, an antifungal sesquiterpene dialdehyde. Agricultural and Biological \nChemistry 6 (52), 1409-1414. \nTarus, P.K., Lang'at-Thoruwa, C.C., Wanyonyi, A.W., and Chhabra, S.C. (2003). Bioactive metabolites \nfrom Trichoderma harzianum  and Trichoderma longibrachiatum . Bulletin of the Chemical Society of \nEthiopia 2 (17), 185-190. \nTorgovnick, A., Heger, J.M., Liaki, V., Isensee, J., Schmitt, A., Knittel, G., Riabinska, A., Beleggia, F., \nLaurien, L., Leeser, U. , et al.  (2018). The Cdkn1aSUPER mouse as a tool to study p53-mediated tumor \nsuppression. Cell Reports 4 (25), 1027-1039.e1026. \nVendrik, C.P.J., Bergers, J.J., De Jong, W.H., and Steerenberg, P.A. (1992). Resistance to cytostatic \ndrugs at the cellular level. Cancer Chemotherapy and Pharmacology 6 (29), 413- 429. \nVermes, A., Guchelaar, H.-J., and Dankert, J. (2000). Flucytosine: a review of its pharmacology, clinical \nindications, pharmacokinetics, toxicity and drug interactions. Journal of Antimicrobial Chemotherapy 2 \n(46), 171-179. \nVicente, M.F., Basilio, A., Cabello, A., and Pel\u00e1ez, F. (2003). Microbial natural products as a source of \nantifungals. Clinical Microbiology and Infection 1 (9), 15-32. \nWani, M.C., Taylor, H.L., Wall, M.E., Coggon, P., and McPhail, A.T. (1971). Plant antitumor agents. VI. \nThe isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia . \nJournal of the American Chemical Society 9 (93), 2325- 2327.  \nWick, J., Heine, D., Lackner, G., Misiek, M., Tauber, J., Jagusch, H., Hertweck, C., and Hoffmeister, D. \n(2016). A fivefold parallelized biosynthetic process secures chlorination o f Armillaria mellea  (honey \nmushroom) toxins. Applied and Environmental Microbiology 4 (82), 1196-1204. \nWilhelm, I., Moln\u00e1r, J., Fazakas, C., Hask\u00f3, J., and Krizbai, I.A. (2013). Role of the blood-brain barrier \nin the formation of brain metastases. International journal of molecular sciences 1 (14), 1383-1411. \nWilliams, R.E.S., C. G., and Wargo, P.M.S., W. H. (1989). Armillaria  root disease. Forest Insect & \nDisease Leaflet 1 (78), 1-8. \nWilson, L., Creswell, K.M., and Chin, D. (1975). Mechanism of action of vinblastine. Binding of [acetyl-\n3H]-vinblastine to embryonic chick brain tubulin and tubulin from sea urchin sperm tail outer doublet \nmicrotubules. Biochemistry 26 (14), 5586-5592. \nWondrousch, D., B\u00f6hme, A., Thaens, D., Ost, N., and Sch\u00fc\u00fcrmann, G. (2010). Local electrophilicity \npredicts the toxicity-relevant reactivity of Michael acceptors. The Journal of Physical Chemistry Letters \n10 (1), 1605-1610. \nWoodward, R.B., Logusch, E., Nambiar, K.P., Sakan, K., Ward, D.E., Au-Yeung, B.W., Balaram, P., \nBrowne, L.J., Card, P.J., and Chen, C.H. (1981). Asymmetric total synthesis of erythromcin. 1. Synthesis \nof an erythronolide A secoacid derivative via asymmetric induction. Journal of the American Chemical \nSociety 11 (103), 3210-3213. \nWu, P., Feldman, A.K., Nugent, A.K., Hawker, C.J., Scheel, A., Voit, B., Pyun, J., Fr\u00e9chet, J.M.J., \nSharpless, K.B., and Fokin, V.V. (2004). Efficiency and fidelity in a click-chemistry route to triazole \ndendrimers by the copper(I)-catalyzed ligation of azides and alkynes. Angewandte Chemie International \nEdition 30 (43), 3928-3932. 9. Literaturverzeichnis   145 \nXiao, \nH., and Zhong, J.-J. (2016). Production of useful terpenoids by higher-fungus cell factory and \nsynthetic biology approaches. Trends in Biotechnology 3 (34), 242-255. \nXu, X., Qiu, G., Ji, L., Ma, R., Dang, Z., Jia, R., and Zhao, B. (2019). Research and development of \nanticancer agents under the guidance of biomarkers. Cancer Translational Medicine 1 (5), 17-21. \nZhang, T., Du, Y., Liu, X., Sun, X., Cai, E., Zhu, H., and Zhao, Y. (2019). Study on antidepressant-like \neffect of protoilludane sesquiterpenoid aromatic esters from Armillaria Mellea . Natural product \nresearch 1-4. \nZhu, J., Wang, M., Wen, W., and Yu, R. (2015). Biosynthesis and regulation of terpenoid indole alkaloids \nin Catharanthus roseus . Pharmacognosy reviews 17 (9), 24-28. \nZonios, D.I., and Bennett, J.E. (2008). Update on azole antifungals. Seminars in Respiratory and Critical \nCare Medicine 02 (29), 198- 210. \n  10. Anhang   146 \n10. Anhang \n10.1.\nEigenst\u00e4ndigkeitserkl\u00e4rung \n \n \nIch versichere hiermit, die vorliegende Dissertation selbstst\u00e4ndig und ohne  Benutzung \nanderer als der angegebenen Quellen und Hilfsmittel  angefertigt zu haben.  \nDie geltende Promotionsordnung der Fakult\u00e4t f\u00fcr Biowissenschaften  der Friedrich-Schiller-\nUniversit\u00e4t \nJena ist mir bekannt.  \nPersonen, die mich bei der Auswahl und Auswertung des Materials sowie der Herstellung \ndes Manuskriptes unterst\u00fctzt  haben,  sind in der Danksagung der Dissert ation oder den \nentsprechenden Manuskripten  genannt.  \nDie Hilfe eines Promotionsberaters wurde nicht in Ansp ruch genommen . Niemand hat \nmittelbar oder unmittelbar geldwerte Leistungen f\u00fcr Arbeiten erhalten, welche im \nZusammenhang mit der vorgelegten schriftlichen Abhandlung stehen.   \nDie Dissertation ist von mir in gleicher oder \u00e4hnlicher Form noch bei keiner anderen \nHochschule eingereicht worden, auch nicht als Pr\u00fcfungsarbeit f\u00fcr eine staatliche oder andere \nwissenschaftliche Pr\u00fcfung. \n \n \n \nJena, den \n \n \n_______________________  \nMaximilian D\u00f6rfer   \n 10.2. Abk\u00fcrzungsverzeichnis   147 \n10.2. Abk\u00fcrzungsv\nerzeichnis \n \n[M+H]+ positiv geladenes Ion der Masse M + 1 \n5-LO 5-Lipoxygenase \nACP Acyl Carrier Protein \nAT Acyltransferase \ncDNA  komplement\u00e4re DNA ohne Introns (complementary DNA) \nDAO  Dihydroarmillylorsellinat \nDC D\u00fcnnschichtchromatografie \nDH Dehydratase \nDNA  Desoxyribonukleins\u00e4ure (desoxyribonucleic acid) \nDMAP 4-(Dimethylamino)-pyridin \nDMAPP Dimethylallylpyrophosphat \n\u03b4 chemische Verschiebung \nE. coli  Escherichia coli  \nER Enoylreduktase \nFLAP  5-Lipoxygenase aktivierendes Protein (5-lipoxygenase activating protein) \ngDNA  genomische DNA (mit Introns)  \nHPLC Hochleistungsfl\u00fcssigchromatografie (high performance liquid chromatography) \nIPP Isopentenylpyrophosphat \nJ Kopplungskonstante \nKR Ketoreduktase \nKS Ketoacylsynthase \nLNKS Lovastatin-nonaketid-synthase \nMALDI  Matrixunterst\u00fctzte Laserdesorption/Ionisation  \n(Matri\nx-assisted laser desorption/ionization)  \nNMR Magnetresonanzspektroskopie (Nuclear Magnetic Resonance) \nNRPS nichtribosomale Peptidsynthetase \nPAGE Polyacrylamid-Gelelektrophorese \nPBS Proteinbiosynthese \nPCR Polymerase Kettenreaktion (polymerase chain reaction) \nPE Phosphatidylethanolamin \nPKS Polyketidsynthase \nPT Produkttemplate \nRNA  Ribonukleins\u00e4ure (ribonucleic acid) \nROS Reaktive Sauerstoff-Spezies (reactive oxygen species) \nSAR Struktur-Aktivit\u00e4ts-Beziehungen (structure-activity-relationships) \nSDS Sodiumdodecylsulfate (Natriumlauryl- bzw. \u2013dodecy lsulfat) \nspp. mehrere Arten einer Gattung ( speci es pluralis ) \nTCM Traditionelle Chinesische Medizin \nTE Thioesterase 10.3. Ver\u00f6ffentlichungen   148 \n10.3. Ver\u00f6ffentlic\nhungen \n10.3.1. Publikationen \nMaximilian D\u00f6rfer , Daniel Heine, Stefanie K\u00f6nig, Sagar Gore, Oliver Werz, Christian \nHertweck, Markus Gressler, Dirk Hoffmeister. (2019) Melleolides impact fungal translation via \nelongation factor 2. Organic & Biomolecular Chemistry, Volume 17 (19), 4906- 4916  \nStefanie K\u00f6nig, Erik Romp, Verena Krauth, Michael R\u00fchl , Maximilian D\u00f6rfer , Stefanie \nLiening, Bettina Hofmann, Ann-Kathrin Hafner, Dieter Steinhilber, Michael Karas, Ulrike \nGarscha, Dirk Hoffmeister, Oliver Werz. (2019) Melleolides from Honey Mushroom Inhibit 5-\nLipoxygenase via Cys159. Cell Chemical Biology, Volume 26 (1), 1- 11 \nMaximilian D\u00f6rfer, Markus Gressler, Dirk Hoffmeister. (2019)  Diversity and bioactivity of \nArmillaria  sesquiterpene aryl ester natural products . Mycological Progress, Volume 18 (8), \n1027- 1037  \nElena Geib, Florian Baldeweg, Maximilian D\u00f6rfer , Markus Nett, Matthias Brock. (2018) Cross-\nChemistry Leads to Product Diversity from Atromentin Synthetases in Aspergilli from Section \nNigri. Cell Chemical Biology, Volume 26 (2), 223- 234 \n10.3.2. Poster \nD\u00f6rfer, M ., Heine, D., Hertweck, C., Hoffmeister, D. \u201eSynthesis of a probe to identify th e \ncellular target of melleolide antibiotics \u201c, Leibniz Wirkstofftage/Leibniz meeting on bioactive \ncompounds, April 2016, Jena. \nD\u00f6rfer, M ., K\u00f6nig, S., Heine, D., Hertweck, C., Werz, O., Hoffmeister, D. \u201eInvestigations on the \ncellular targets of the melleolides \u201c , 30. Irseer Naturstofftage, Februar 2018, Irsee. \n 10.4. Wissenschaftlicher Werdegang   149 \n10.4. W\nissenschaftlicher Werdegang \nD\u00f6rfer, Maximilian \ngeboren am 15.09.1989 in Gera \n \nAkademische Ausbildung \n12/14 \u2013 03/19  Promotionsstudium  \n   Friedrich-Schiller-Universit\u00e4t Jena \nWissenschaftlicher Angestellter in der AG von Herrn Prof. Dr. Dirk Hoffmeister \nam Lehrstuhl f\u00fcr Pharmazeutische Mikrobiologie in Assoziation mit dem \nLeibniz-Institut f\u00fcr Naturstoff-Forschung und Infektionsbiologie, Hans-Kn\u00f6ll-\nInstitut \n12/2014 Approbation als Apotheker  \n12/2014  Diplomarbeit (Dipl. Pharm.) \n\u201eBakterielle Nanocellulose als Wirkstofftr\u00e4ger in zahnmedizinischen \nAnwendungen \u201c \n11/2014  3. Staatsexamen \n   Dritter Abschnitt der Pharmazeutischen Pr\u00fcfung \n02/14 - 12/ 14 Diplomstudium \n   Diplomarbeit am Lehrstuhl f\u00fcr pharmazeutische Technologie des Instituts f\u00fcr  \n   Pharmazie an der Friedrich-Schiller-Universit\u00e4t Jena unter der Leitung von  \n   Frau PD Dr. Dana Kralisch \n03/2013  Wahlpflichtfach Arbeit \n   Aggregation von Erythrozyten unter Einfluss von Polymerbeschichteten  \n   Eisenoxid-Nanopartikeln \n10/09 \u2013 05/13  Studium der Pharmazie   \n   an der Friedrich-Schiller-Universit\u00e4t Jena, erstes und zweites Staatsexamen \n 10.5. Danksagung   150 \n10.5. D\nanksagung \nAm Ende dieser langen Durststrecke, dieser Geduldsprobe aber auch dieser gro\u00dfartigen \nHerausforderung, liegt es mir sehr am Herzen, mich bei all denen zu bedanken, die zum \nGelingen dieser Arbeit beigetragen haben. \nZuerst geht mein Dank an meinen Doktorvater Prof. Dr. Dirk Hoffmeister. Danke f\u00fcr die \nM\u00f6glichkeit, dieses spannende Projekt fortf\u00fchren zu d\u00fcrfen. Du hast mir die anf\u00e4nglichen \nBedenken genommen, dass ein Pharmazeut nicht auch gut chemisch arbeiten kann und bald \ndarauf mein Interesse f\u00fcr Pilze auf ein neues Level angehoben. Vielen Dank f\u00fcr die exzellente \nBetreuung, den regen wissenschaftlichen Austausch und dein Verm\u00f6gen, dieses komplexe, \ninterdisziplin\u00e4re Thema stets aus allen Blickwinkeln zu verstehen oder konstruktiv zu \nhinterfragen. Deine T\u00fcr stand mir immer offen, auch um an schlechteren Tagen wieder neue \nMotivation zu bekommen \nDes Weiteren danke ich Prof. Dr. Oliver Werz, den Mitarbeitern des Lehrstuhles f\u00fcr \npharmazeutische Chemie, vor allem Stefanie K\u00f6nig f\u00fcr die angenehme Zusammenarbeit und \ndie Einf\u00fchrung in die Welt des Target-Fishings. \nEin gro\u00dfes Dankesch\u00f6n geht auch an Dr. Markus Gre\u00dfler, der den Endspurt meiner Arbeit \nbegleitete und mich mit v\u00f6llig neuem Input in der Molekularbiologie versorgte. Danke auch, \ndass du in der Schlussphase noch einmal viele neue Ideen beigesteuert, dich am Ende aber \nauch um die zeitnahe Publikation meiner Ergebnisse mit eingebracht hast. Ohne dich w\u00fcrde \nich jetzt noch an einer Monographie schreiben. \nIch danke allen Mitarbeitern der Arbeitsgruppe Biomolekulare Chemie am HKI in Jena unte r \nder Leitung von Prof. Dr. Christian Hertweck. Die Arbeit am HKI, vor allem im ehemaligen \nLaborhaus 1 f\u00fchlte sich stets an, als sei man in der eigenen Arbeitsgruppe. Einen gro\u00dfen Anteil \ndaran hatte Dr. Daniel Heine. Danke f\u00fcr die Betreuung meiner Synthesen und die Versorgung \nmit chemischem Know-How, aber auch f\u00fcr den Spa\u00df im Labor. Ein weiteres Dankesch\u00f6n an \ndieser Stelle auch an Dr. Florian Meyer, Jan Dworschak und Sabrina Boldt.  \nVielen Dank Heike Heinecke f\u00fcr das Messen meiner NMR-Proben, aber auch f\u00fcr deine \nMotivation und f\u00fcr das ein oder andere Fr\u00fchst\u00fcck. Vielen Dank Andrea Perner f\u00fcr die Messung \nder HPLC- MS-Proben. \nIch danke Prof. Dr. Hans Peter Saluz, und Grit Mrotzek die M\u00f6glichkeit, in der Gruppe f\u00fcr Zell- \nund Molekularbiologie in endlosen Versuchen Ribosomen aufreinigen zu k\u00f6nnen. \nDank geht auch an Dr. Friedemann Gaube f\u00fcr die erneute Einf\u00fchrung ins Pflanzenreich. \nUnsere Praktika waren jedes Jahr aufs Neue eine Bereicherung f\u00fcr mich, der Plant-\nHarvesting-Day immer ein Highlight im Kalender. 10.5. Danksagung   151 \nAu\u00dferdem \nbedanke ich mich nat\u00fcrlich bei den Mitarbeitern der Arbeitsgruppe am Lehrstuhl f\u00fcr \npharmazeutische Mikrobiologie. Dank euch war der Laboralltag nur selten grau \u2013 auch wenn \nes mal nicht so lief. Ein ganz besonderer Dank geht hierbei an Philip Brandt, du hast es dir \nnicht nehmen lassen, mich vom ersten Tag des Studiums bis fast zu meinem letzten an der \nUni als Freund zu begleiten. Wir konnten uns gegenseitig immer wieder Mut machen - die \nMalle-Freitage waren dabei nur d as \u201ei\u201c-T\u00fcpfelchen auf dem gemeinsamen Leidensweg. Auch \ndie interdisziplin\u00e4ren Kaffeepausen mit Eileen Brandenburger, Florian Baldeweg und Jakob \nWurlitzer waren nicht nur pers\u00f6nlich, sondern auch hinsichtlich des Wissenszuwachses meiner \nArbeit eine gro\u00dfe Bereicherung. Auf viele Ideen kommt man einfach nicht am Schreibtisch. \nDanke auch an Tine Steinbach f\u00fcr die super Organisation in der AG und den Durchblick um \nuniversit\u00e4ren B\u00fcrokratie-Dschungel.  \nVielen Dank auch an Sebastian Schober , Johannes Rassbach und Julia Gre\u00dfler, f\u00fcr die Hilfe \nbei der Extraktion der Melleolide. \nIch danke all meinen Freunden in Jena und in der Heimat f\u00fcr euer Interesse an meinem Projekt \nund f\u00fcr den Ausgleich zur h\u00e4ufig doch herausfordernden Arbeit. Danke auch an die Jungs und \nM\u00e4dels vom Schwimmen & Wasserball. Sport war und bleibt immer mein wichtigstes Ventil \nzum Abschalten und Abreagieren. \nDanke f\u00fcr die Unterst\u00fctzung durch meine Schwiegereltern, Eltern und mein Bruderherz. \nLast but not least: Der wohl gr\u00f6\u00dfte Dank geht an meine Frau Juliane. Nachdem du mein \nganzes Studium mit ertragen musstest und dadurch, wie du sagst, selbst zu einem halben \nApotheker geworden bist, kam auch noch die Promotion. Du hast mir immer Freir\u00e4ume \nerk\u00e4mpft vor allem in den letzten Z\u00fcgen meiner Arbeit stets den R\u00fccken freigehalten. Vollzeit \narbeiten, unsere kleine Tochter Ida betreuen, ein Haus sanieren und \u201enebenbei\u201c noch eine \nDissertation schreiben. Ohne dich w\u00e4re mir l\u00e4ngst die Decke auf den Kopf gefallen. ", "language": "PDF", "image": "PDF", "pagetype": "PDF", "links": "PDF"}